[CLS]
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
Me
##as
##ure
the
absolute
ne
##ut
##rop
##hil
count
(
AN
##C
)
before
starting
Fe
##rri
##p
##ro
##x
therapy
and
monitor
the
AN
##C
weekly
on
therapy
.
[SEP]
[CLS]
Monitor
patients
for
signs
and
symptoms
of
pulmonary
toxicity
,
including
cough
and
d
##ys
##p
##nea
.
[SEP]
[CLS]
During
periods
of
stress
,
a
severe
CO
##PD
ex
##ace
##rb
##ation
,
or
a
severe
as
##th
##ma
attack
,
patients
who
have
been
withdrawn
from
systemic
co
##rt
##ico
##ster
##oids
should
be
instructed
to
resume
oral
co
##rt
##ico
##ster
##oids
(
in
large
doses
)
immediately
and
to
contact
their
physicians
for
further
instruction
.
[SEP]
[CLS]
The
treatment
cycle
was
repeated
at
approximately
6
-
week
intervals
up
to
three
additional
times
,
for
a
maximum
of
8
total
injection
procedures
and
4
total
modeling
procedures
[
see
Clinical
Studies
(
14
.
2
)
]
.
[SEP]
[CLS]
5
.
3
H
##y
##po
##gly
##ce
##mia
with
Con
##com
##ita
##nt
Use
of
In
##sul
##in
Secret
##ago
##gues
or
In
##sul
##in
The
risk
of
h
##y
##po
##gly
##ce
##mia
is
increased
when
T
##R
##U
##L
##IC
##IT
##Y
is
used
in
combination
with
insulin
secret
##ago
##gues
(
e
.
g
.
,
su
##lf
##ony
##lu
##rea
##s
)
or
insulin
.
[SEP]
[CLS]
Approximately
one
third
of
the
patients
who
had
eye
examinations
performed
after
approximately
4
years
of
treatment
were
found
to
have
re
##tina
##l
pig
##mentary
abnormal
##ities
.
[SEP]
[CLS]
Inter
##rup
##t
B
##L
##IN
##C
##Y
##TO
if
prolonged
ne
##ut
##rop
##enia
occurs
.
[SEP]
[CLS]
(
N
for
females
:
Place
##bo
=
67
##7
,
FA
##R
##X
##IG
##A
5
mg
=
58
##1
,
FA
##R
##X
##IG
##A
10
mg
=
59
##8
)
.
[SEP]
[CLS]
5
.
2
Corporal
R
##up
##ture
(
Pen
##ile
Fr
##act
##ure
)
or
Other
Ser
##ious
In
##ju
##ry
to
the
Pen
##is
in
the
Treatment
of
P
##ey
##ron
##ie
'
s
Disease
Corporal
r
##up
##ture
was
reported
as
an
adverse
reaction
after
XI
##AF
##LE
##X
injection
##s
in
5
of
104
##4
(
0
.
5
%
)
XI
##AF
##LE
##X
treated
patients
in
the
controlled
and
un
##con
##tro
##lled
clinical
trials
in
P
##ey
##ron
##ie
'
s
disease
.
[SEP]
[CLS]
Eye
disorders
:
Op
##tic
ne
##uri
##tis
,
re
##tina
##l
hem
##or
##r
##hage
,
and
u
##ve
##itis
.
[SEP]
[CLS]
In
these
patients
,
a
comprehensive
evaluation
of
u
##rol
##og
##ic
symptoms
prior
to
and
during
treatment
with
P
##OT
##IG
##A
may
be
appropriate
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Su
##icidal
Be
##ha
##vior
:
Monitor
for
su
##icidal
thoughts
or
behavior
.
[SEP]
[CLS]
Fr
##act
##ures
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
7
)
]
.
[SEP]
[CLS]
Extra
##py
##ram
##idal
symptoms
included
d
##ys
##ton
##ia
,
o
##cu
##logy
##ration
,
d
##ys
##kin
##esi
##a
,
ta
##rdi
##ve
d
##ys
##kin
##esi
##a
,
muscle
rigid
##ity
,
park
##ins
##oni
##sm
,
t
##rem
##or
,
and
extra
##py
##ram
##idal
disorder
(
excluding
aka
##thi
##sia
)
.
[SEP]
[CLS]
The
o
##var
##ies
normally
stop
making
est
##rogen
##s
when
a
woman
is
between
45
and
55
years
old
.
[SEP]
[CLS]
5
.
2
Mali
##gna
##ncies
Mali
##gna
##ncies
in
P
##ediatric
Pat
##ients
Mali
##gna
##ncies
,
some
fatal
,
have
been
reported
among
children
,
adolescent
##s
,
and
young
adults
who
received
treatment
with
T
##NF
-
blocking
agents
(
initiation
of
therapy
<
=
18
years
of
age
)
,
of
which
S
##IM
##PO
##NI
ARIA
is
a
member
.
[SEP]
[CLS]
If
patients
taking
FA
##NA
##P
##T
experience
symptoms
that
could
indicate
the
occurrence
of
cardiac
a
##rr
##hy
##th
##mia
##s
,
e
.
g
.
,
di
##zzi
##ness
,
p
##al
##pit
##ations
,
or
s
##ync
##ope
,
the
pre
##s
##cribe
##r
should
initiate
further
evaluation
,
including
cardiac
monitoring
.
[SEP]
[CLS]
Overall
,
6
p
##ediatric
patients
(
4
.
3
%
)
reported
at
least
one
adverse
reaction
following
D
##OT
##AR
##EM
administration
.
[SEP]
[CLS]
Females
of
reproductive
potential
should
avoid
becoming
pregnant
while
being
treated
.
[SEP]
[CLS]
6
.
2
Clinical
Trials
Experience
in
As
##th
##ma
BR
##E
##O
E
##LL
##IP
##TA
for
the
treatment
of
as
##th
##ma
was
studied
in
18
double
-
blind
,
parallel
-
group
,
controlled
trials
(
11
with
place
##bo
)
of
4
to
76
weeks
'
duration
,
which
enrolled
9
,
96
##9
subjects
with
as
##th
##ma
.
[SEP]
[CLS]
Females
of
reproductive
potential
should
be
advised
to
avoid
becoming
pregnant
while
being
treated
with
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
Table
2
:
Monitor
##ed
Ad
##verse
Re
##actions
-
Application
Site
S
##ym
##pt
##oms
Event
U
##LE
##SF
##IA
(
r
)
Lot
##ion
Vehicle
Application
site
I
##rri
##tation
2
%
(
11
/
47
##8
)
1
%
(
2
/
33
##6
)
Application
site
an
##est
##hesia
2
%
(
10
/
47
##8
)
0
%
(
0
/
33
##6
)
Pain
1
%
(
5
/
47
##8
)
0
%
(
1
/
33
##6
)
The
subset
of
subjects
who
did
not
have
p
##ru
##rit
##us
,
er
##yt
##hem
##a
,
ed
##ema
or
p
##yo
##der
##ma
of
skin
and
scalp
,
or
o
##cular
irritation
prior
to
treatment
were
assessed
for
these
signs
and
symptoms
after
treatment
;
the
results
are
presented
in
Table
3
.
[SEP]
[CLS]
5
.
5
Pre
-
existing
N
##eur
##om
##us
##cular
Di
##sor
##ders
Individuals
with
peripheral
motor
ne
##uro
##pathic
diseases
,
am
##yo
##tro
##phic
lateral
s
##cle
##rosis
or
ne
##uro
##mus
##cular
junction
disorders
(
e
.
g
.
,
my
##ast
##hen
##ia
g
##ra
##vis
or
Lambert
-
Eaton
syndrome
)
should
be
monitored
particularly
closely
when
given
b
##ot
##ulin
##um
to
##xin
.
[SEP]
[CLS]
Elder
##ly
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
treated
with
anti
##psy
##cho
##tic
drugs
are
at
an
increased
risk
of
death
.
[SEP]
[CLS]
Table
2
Ad
##verse
Drug
Re
##actions
##F
##re
##que
##ncies
of
adverse
reactions
are
based
on
all
treatment
-
emerge
##nt
adverse
events
,
attributed
to
study
drugs
.
[SEP]
[CLS]
No
apparent
correlation
of
anti
##body
development
to
clinical
response
or
adverse
events
was
observed
.
[SEP]
[CLS]
Tu
##ber
##cu
##los
##is
Case
##s
of
react
##ivation
of
tuberculosis
or
new
tuberculosis
infections
have
been
observed
in
patients
receiving
T
##NF
-
block
##ers
,
including
patients
who
have
previously
received
treatment
for
late
##nt
or
active
tuberculosis
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
incidence
>
=
10
%
and
>
=
2
%
more
than
place
##bo
)
for
T
##EC
##FI
##DE
##RA
were
flush
##ing
,
abdominal
pain
,
di
##ar
##r
##hea
,
and
nausea
.
[SEP]
[CLS]
The
type
and
frequency
of
adverse
drug
reactions
appeared
to
be
consistent
over
time
.
[SEP]
[CLS]
Pol
##yo
##ma
virus
-
associated
ne
##ph
##rop
##athy
can
lead
to
kidney
g
##raft
loss
;
consider
reduction
in
im
##mu
##nos
##up
##press
##ion
.
[SEP]
[CLS]
B
##lee
##ding
results
from
the
AM
##PL
##IF
##Y
-
E
##XT
study
are
summarized
in
Table
7
.
[SEP]
[CLS]
Do
##ses
ranged
from
18
to
98
Units
/
kg
,
with
a
median
dose
of
49
Units
/
kg
.
[SEP]
[CLS]
(
6
.
1
)
E
##X
##CE
##RP
##T
:
}
}
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Am
##gen
Inc
.
at
1
-
800
-
77
-
AM
##GE
##N
(
1
-
800
-
77
##2
-
64
##36
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Administration
of
Pi
##cat
##o
(
r
)
gel
is
not
recommended
until
skin
is
healed
from
any
previous
drug
or
surgical
treatment
.
[SEP]
[CLS]
Ana
##ly
##ses
of
patients
in
PR
##IS
##TI
##Q
pre
-
marketing
short
-
term
controlled
studies
who
met
criteria
for
sustained
h
##yper
##tens
##ion
revealed
a
consistent
increase
in
the
proportion
of
patients
who
developed
sustained
h
##yper
##tens
##ion
.
[SEP]
[CLS]
T
-
cell
-
de
##ple
##ting
the
##rap
##ies
to
treat
acute
rejection
should
be
used
cautiously
.
[SEP]
[CLS]
Ser
##um
para
##thy
##roid
hormone
levels
and
1
.
25
Vita
##min
D
levels
were
also
higher
in
subjects
receiving
ten
##of
##ov
##ir
D
##F
.
[SEP]
[CLS]
If
an
##aph
##yla
##xi
##s
occurs
,
immediately
disco
##ntin
##ue
the
in
##fusion
(
5
.
2
)
.
[SEP]
[CLS]
d
Includes
sq
##ua
##mous
cell
car
##cin
##oma
of
the
skin
and
k
##era
##to
##aca
##nt
##hom
##a
.
[SEP]
[CLS]
This
product
'
s
label
may
have
been
updated
.
[SEP]
[CLS]
Gas
##tro
##int
##est
##inal
(
G
##I
)
hem
##or
##r
##hage
,
il
##eus
,
enter
##oc
##oli
##tis
,
ne
##ut
##rop
##eni
##c
enter
##oc
##oli
##tis
,
including
fatal
outcome
,
have
been
reported
in
patients
treated
with
J
##E
##V
##TA
##NA
[
see
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
*
Inc
##reased
risk
of
serious
infections
leading
to
hospital
##ization
or
death
including
tuberculosis
(
T
##B
)
,
bacterial
se
##psis
,
invasive
fun
##gal
infections
(
such
as
his
##top
##las
##mos
##is
)
,
and
infections
due
to
other
op
##port
##uni
##stic
path
##ogen
##s
(
5
.
1
)
.
[SEP]
[CLS]
5
.
5
I
##mme
##dia
##te
H
##yper
##sen
##si
##ti
##vity
Re
##actions
I
##mme
##dia
##te
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
,
an
##gio
##ede
##ma
(
including
swelling
of
the
lips
)
,
u
##rt
##ica
##ria
,
r
##ash
,
br
##on
##cho
##sp
##as
##m
,
or
it
##ching
,
have
occurred
after
administration
of
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
.
[SEP]
[CLS]
The
most
common
serious
adverse
reactions
experienced
by
patients
with
s
##AL
##CL
were
se
##ptic
shock
(
3
%
)
,
su
##pra
##vent
##ric
##ular
a
##rr
##hy
##th
##mia
(
3
%
)
,
pain
in
ex
##tre
##mity
(
3
%
)
,
and
u
##rina
##ry
tract
infection
(
3
%
)
.
[SEP]
[CLS]
Me
##as
##ure
serum
AL
##T
,
AS
##T
,
and
bi
##li
##ru
##bin
prior
to
initiation
of
PR
##OM
##AC
##TA
,
every
2
weeks
during
the
dose
adjustment
phase
,
and
monthly
following
establishment
of
a
stable
dose
.
[SEP]
[CLS]
Use
with
caution
in
patients
with
narrow
-
angle
g
##lau
##com
##a
and
ins
##truct
patients
to
consult
a
physician
immediately
if
this
occurs
.
[SEP]
[CLS]
Complete
blood
counts
(
with
white
blood
cell
differential
counts
)
should
be
obtained
at
pre
##tre
##at
##ment
,
and
at
Treatment
Weeks
2
,
4
,
8
,
and
12
,
and
should
be
monitored
closely
at
other
time
points
,
as
clinical
##ly
appropriate
.
[SEP]
[CLS]
5
.
3
Gas
##tro
##int
##est
##inal
Ad
##verse
Re
##actions
Na
##use
##a
,
vomit
##ing
and
severe
di
##ar
##r
##hea
,
at
times
,
may
occur
.
[SEP]
[CLS]
Ad
##verse
reactions
that
led
to
dose
delays
in
more
than
5
%
of
AD
##CE
##TR
##IS
-
treated
patients
in
Study
3
were
ne
##ut
##rop
##enia
(
22
%
)
,
peripheral
sensory
ne
##uro
##pathy
(
16
%
)
,
upper
respiratory
tract
infection
(
6
%
)
,
and
peripheral
motor
ne
##uro
##pathy
(
6
%
)
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
Met
##ab
##olis
##m
and
N
##utrition
Di
##sor
##ders
:
an
##ore
##xia
,
appetite
decreased
,
de
##hy
##dra
##tion
,
diabetes
me
##lli
##tus
,
h
##yper
##cho
##les
##tero
##lem
##ia
,
h
##yper
##gly
##ce
##mia
,
h
##yper
##lip
##ide
##mia
,
h
##yper
##tri
##gly
##cer
##ide
##mia
,
h
##y
##po
##kal
##emia
,
weight
decreased
.
[SEP]
[CLS]
For
patients
at
risk
for
chronic
##ally
reduced
re
##nal
function
(
for
example
,
age
>
60
years
,
h
##yper
##tens
##ion
or
diabetes
)
,
estimate
the
g
##lo
##mer
##ular
fi
##ltration
rate
(
G
##F
##R
)
through
laboratory
testing
(
5
.
1
)
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
SE
##RI
##O
##US
IN
##F
##EC
##TI
##ON
##S
AND
MA
##L
##IG
##NA
##NC
##Y
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
The
risk
appears
lower
for
patients
with
chronic
,
moderate
kidney
disease
(
G
##F
##R
30
to
59
m
##L
/
min
/
1
.
73
##m
2
)
and
little
,
if
any
,
for
patients
with
chronic
,
mild
kidney
disease
(
G
##F
##R
60
to
89
m
##L
/
min
/
1
.
73
##m
2
)
.
[SEP]
[CLS]
You
may
report
side
effects
to
FDA
at
1
-
800
-
FDA
-
108
##8
.
[SEP]
[CLS]
The
most
common
serious
adverse
reactions
experienced
by
patients
with
classical
H
##L
include
peripheral
motor
ne
##uro
##pathy
(
4
%
)
,
abdominal
pain
(
3
%
)
,
pulmonary
em
##bol
##ism
(
2
%
)
,
p
##ne
##um
##oni
##tis
(
2
%
)
,
p
##ne
##um
##oth
##orax
(
2
%
)
,
p
##ye
##lone
##ph
##rit
##is
(
2
%
)
,
and
p
##yre
##xia
(
2
%
)
.
[SEP]
[CLS]
5
.
4
Drug
Inter
##actions
with
C
##YP
##2
##D
##6
Administration
of
Co
##arte
##m
Table
##ts
with
drugs
that
are
meta
##bol
##ized
by
C
##YP
##2
##D
##6
may
significantly
increase
plasma
concentrations
of
the
co
##ad
##mini
##stered
drug
and
increase
the
risk
of
adverse
effects
.
[SEP]
[CLS]
Per
##form
an
op
##ht
##hal
##mo
##logical
evaluation
consisting
of
best
corrected
visual
a
##cu
##ity
,
re
##tina
##l
photographs
,
visual
fields
,
optical
co
##herence
to
##mo
##graphy
(
O
##CT
)
and
other
evaluation
##s
as
appropriate
for
new
onset
of
severe
visual
loss
.
[SEP]
[CLS]
For
additional
information
,
see
Ad
##verse
Re
##actions
(
6
.
1
)
and
consult
the
VI
##RE
##AD
pre
##s
##cribing
information
.
[SEP]
[CLS]
In
a
controlled
trial
in
patients
with
chronic
liver
disease
and
th
##rom
##bo
##cy
##top
##enia
not
related
to
IT
##P
undergoing
elect
##ive
invasive
procedures
(
N
=
29
##2
)
,
the
risk
of
th
##rom
##bot
##ic
events
was
increased
in
patients
treated
with
75
mg
of
PR
##OM
##AC
##TA
once
daily
.
[SEP]
[CLS]
Table
1
:
Per
Pat
##ient
Inc
##iden
##ce
of
Grade
1
and
2
Ad
##verse
Re
##actions
As
##ses
##sed
as
Po
##ssi
##bly
,
Probably
,
or
De
##fin
##ite
##ly
Re
##lated
to
V
##OR
##A
##X
##A
##Z
##E
Ex
##c
##lu
##ding
He
##mat
##olo
##gic
,
He
##pa
##tic
,
or
Ren
##al
Ad
##verse
Re
##actions
1
This
incidence
includes
the
following
terms
:
flush
##ing
,
feeling
hot
,
burning
sensation
.
[SEP]
[CLS]
Counsel
patients
regarding
the
potential
risk
of
M
##TC
and
symptoms
of
thy
##roid
tumors
(
4
.
1
,
5
.
1
)
.
[SEP]
[CLS]
This
was
seen
at
all
doses
with
a
suggestion
of
a
higher
rate
at
400
mg
per
day
.
[SEP]
[CLS]
In
order
to
monitor
the
occurrence
of
ne
##ut
##rop
##enia
,
frequent
blood
cell
counts
should
be
performed
on
all
patients
receiving
J
##E
##V
##TA
##NA
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Bone
ma
##rrow
suppression
(
particularly
ne
##ut
##rop
##enia
)
and
its
clinical
consequences
(
f
##eb
##ril
##e
ne
##ut
##rop
##enia
,
ne
##ut
##rop
##eni
##c
infections
)
:
Monitor
blood
counts
frequently
to
determine
if
dos
##age
modification
or
initiation
of
G
-
CS
##F
is
needed
.
[SEP]
[CLS]
Gamma
G
##lut
##am
##yl
##tra
##ns
##fer
##ase
(
G
##G
##T
)
Inc
##rease
In
the
pool
of
place
##bo
-
controlled
trials
,
the
adverse
event
of
increased
G
##G
##T
occurred
more
frequently
in
the
group
treated
with
T
##AN
##Z
##E
##UM
(
0
.
9
%
and
1
.
5
%
for
place
##bo
versus
T
##AN
##Z
##E
##UM
)
.
[SEP]
[CLS]
Study
2
is
an
ongoing
expanded
access
program
.
[SEP]
[CLS]
He
##pa
##titis
B
V
##ir
##us
Re
##act
##ivation
The
use
of
T
##NF
-
block
##ers
,
of
which
S
##IM
##PO
##NI
ARIA
is
a
member
,
has
been
associated
with
react
##ivation
of
he
##pa
##titis
B
virus
)
in
patients
who
are
chronic
he
##pa
##titis
B
carriers
(
i
.
e
.
,
surface
anti
##gen
positive
)
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
in
Place
##bo
-
Control
##led
Trials
In
the
two
well
-
controlled
studies
demonstrating
effectiveness
,
152
##9
patients
received
T
##EC
##FI
##DE
##RA
with
an
overall
exposure
of
224
##4
person
-
years
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Some
infections
were
fatal
.
[SEP]
[CLS]
CR
##N
##M
=
clinical
##ly
relevant
non
##ma
##jo
##r
.
[SEP]
[CLS]
Use
in
liver
transplant
patients
is
not
recommended
due
to
an
increased
risk
of
g
##raft
loss
and
death
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
.
[SEP]
[CLS]
Table
2
displays
the
frequency
of
adverse
drug
reactions
greater
than
or
equal
to
5
%
of
subjects
in
any
treatment
arm
.
[SEP]
[CLS]
5
.
7
Risk
of
P
##tosis
in
Pat
##ients
T
##reate
##d
with
X
##E
##OM
##IN
for
G
##la
##bella
##r
Lines
Do
not
exceed
the
recommended
dos
##age
and
frequency
of
administration
of
X
##E
##OM
##IN
.
[SEP]
[CLS]
Pat
##ients
with
smaller
neck
muscle
mass
and
patients
who
require
bilateral
injection
##s
into
the
stern
##oc
##le
##ido
##mas
##to
##id
muscles
have
been
reported
to
be
at
greater
risk
of
d
##ys
##pha
##gia
.
[SEP]
[CLS]
In
both
cases
,
the
patients
were
taking
a
1
.
25
mg
dose
of
fin
##gol
##imo
##d
(
higher
than
the
recommended
0
.
5
mg
dose
)
and
had
received
high
-
dose
co
##rt
##ico
##ster
##oid
therapy
to
treat
suspected
MS
re
##lap
##ses
.
[SEP]
[CLS]
These
cases
were
reported
post
-
marketing
and
are
derived
from
a
variety
of
sources
,
including
re
##gis
##tries
and
spontaneous
post
-
marketing
reports
.
[SEP]
[CLS]
FA
##NA
##P
##T
should
be
discontinued
in
patients
who
are
found
to
have
persistent
Q
##T
##c
measurements
>
500
m
##se
##c
.
[SEP]
[CLS]
In
mon
##otherapy
trials
in
patients
with
partial
-
onset
seizure
##s
[
Study
1
and
Study
2
,
see
Clinical
Studies
(
14
.
1
)
]
,
365
patients
received
AP
##TI
##OM
,
of
whom
225
were
treated
for
longer
than
12
months
and
134
for
longer
than
24
months
.
[SEP]
[CLS]
In
MS
place
##bo
-
controlled
trials
,
the
overall
rate
of
infections
(
72
%
)
with
G
##IL
##EN
##Y
##A
was
similar
to
place
##bo
.
[SEP]
[CLS]
The
majority
of
application
site
reactions
were
trans
##ient
and
self
-
limited
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
*
The
most
common
adverse
reactions
occurring
in
>
=
3
%
of
K
##AL
##BI
##TO
##R
-
treated
patients
and
greater
than
place
##bo
are
headache
,
nausea
,
di
##ar
##r
##hea
,
p
##yre
##xia
,
injection
site
reactions
,
and
na
##so
##pha
##ryn
##git
##is
.
[SEP]
[CLS]
As
##sure
good
ve
##nous
access
prior
to
starting
T
##RE
##AN
##DA
in
##fusion
and
monitor
the
in
##tra
##ven
##ous
in
##fusion
site
for
red
##ness
,
swelling
,
pain
,
infection
,
and
ne
##c
##rosis
during
and
after
administration
of
T
##RE
##AN
##DA
.
[SEP]
[CLS]
In
the
pool
##ed
analysis
of
patients
with
moderate
re
##nal
imp
##air
##ment
,
the
incidence
of
re
##nal
-
related
adverse
reactions
was
3
.
7
%
with
place
##bo
,
8
.
9
%
with
IN
##VO
##KA
##NA
100
mg
,
and
9
.
3
%
with
IN
##VO
##KA
##NA
300
mg
.
Disco
##ntin
##uations
due
to
re
##nal
-
related
adverse
events
occurred
in
1
.
0
%
with
place
##bo
,
1
.
2
%
with
IN
##VO
##KA
##NA
100
mg
,
and
1
.
6
%
with
IN
##VO
##KA
##NA
300
mg
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
The
distance
of
a
z
-
score
from
0
represents
the
distance
of
a
percent
##ile
from
the
median
,
measured
in
standard
de
##viation
##s
(
SD
)
.
[SEP]
[CLS]
Table
1
.
[SEP]
[CLS]
No
serious
events
were
reported
through
Year
3
.
[SEP]
[CLS]
General
disorders
and
administration
site
conditions
:
B
##lee
##ding
and
injection
site
reactions
.
[SEP]
[CLS]
Monitor
patients
for
signs
and
symptoms
of
bleeding
.
[SEP]
[CLS]
Anti
-
be
##lat
##ace
##pt
anti
##body
development
was
not
associated
with
altered
clearance
of
be
##lat
##ace
##pt
.
[SEP]
[CLS]
Pat
##ients
may
require
a
lower
dose
of
su
##lf
##ony
##lu
##rea
or
insulin
to
reduce
the
risk
of
h
##y
##po
##gly
##ce
##mia
in
this
setting
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
In
the
event
of
new
or
worse
##ning
pulmonary
symptoms
,
hold
AD
##CE
##TR
##IS
dos
##ing
during
evaluation
and
until
s
##ym
##pt
##oma
##tic
improvement
.
[SEP]
[CLS]
P
##sy
##chia
##tric
disorders
:
br
##ux
##ism
,
depression
,
o
##bs
##ess
##ive
-
com
##pu
##lsive
disorder
.
[SEP]
[CLS]
Since
the
protein
components
in
XI
##AF
##LE
##X
(
AU
##X
-
I
and
AU
##X
-
II
)
have
some
sequence
ho
##mology
with
human
matrix
metal
##lop
##rote
##inas
##es
(
M
##MP
##s
)
,
anti
-
product
antibodies
could
theoretical
##ly
interfere
with
human
M
##MP
##s
.
[SEP]
[CLS]
(
5
.
1
)
*
Live
##r
disease
:
Disco
##ntin
##ue
Nat
##azi
##a
if
j
##au
##ndi
##ce
occurs
.
[SEP]
[CLS]
If
S
##J
##S
or
T
##EN
occurs
,
disco
##ntin
##ue
AD
##CE
##TR
##IS
and
administer
appropriate
medical
therapy
.
[SEP]
[CLS]
Stop
Nat
##azi
##a
at
least
4
weeks
before
and
through
2
weeks
after
major
surgery
.
[SEP]
[CLS]
(
5
.
7
)
5
.
1
Re
##tina
##l
A
##b
##nor
##mal
##ities
and
Po
##ten
##tial
Vision
Loss
P
##OT
##IG
##A
can
cause
abnormal
##ities
of
the
re
##tina
.
[SEP]
[CLS]
1
.
7
2
.
9
3
.
8
Male
g
##eni
##tal
my
##cot
##ic
infections
##G
##eni
##tal
my
##cot
##ic
infections
include
the
following
adverse
reactions
,
listed
in
order
of
frequency
reported
for
males
:
b
##alan
##itis
,
fun
##gal
g
##eni
##tal
infection
,
b
##alan
##itis
can
##di
##da
,
g
##eni
##tal
can
##di
##dia
##sis
,
g
##eni
##tal
infection
male
,
pen
##ile
infection
,
b
##alan
##op
##ost
##hit
##is
,
b
##alan
##op
##ost
##hit
##is
in
##fect
##ive
,
g
##eni
##tal
infection
,
post
##hit
##is
.
[SEP]
[CLS]
Table
1
presents
selected
adverse
reactions
from
Study
1
,
which
occurred
in
at
least
5
%
of
patients
in
the
Y
##ER
##VO
##Y
-
containing
arms
and
with
at
least
5
%
increased
incidence
over
the
control
g
##p
##100
arm
for
all
-
grade
events
and
at
least
1
%
incidence
over
the
control
group
for
Grade
3
-
5
events
.
[SEP]
[CLS]
Case
reports
and
e
##pid
##em
##iol
##ogical
studies
(
case
-
control
and
co
##hor
##t
design
)
have
demonstrated
an
association
between
use
of
drugs
that
interfere
with
se
##rot
##oni
##n
re
##up
##take
and
the
occurrence
of
gas
##tro
##int
##est
##inal
bleeding
.
[SEP]
[CLS]
Approximately
15
%
of
patients
with
re
##tina
##l
pig
##mentary
abnormal
##ities
had
no
such
disco
##lora
##tion
.
[SEP]
[CLS]
In
a
historically
controlled
post
-
marketing
trial
,
the
incidence
of
skin
lace
##ration
(
22
%
)
was
higher
for
subjects
treated
with
two
concurrent
injection
##s
of
XI
##AF
##LE
##X
compared
with
subjects
treated
with
up
to
three
single
injection
##s
in
the
place
##bo
-
controlled
pre
##market
##ing
trials
(
9
%
)
.
[SEP]
[CLS]
Expo
##sure
to
Y
##ER
##VO
##Y
3
mg
/
kg
for
4
doses
given
by
in
##tra
##ven
##ous
in
##fusion
in
previously
treated
patients
with
un
##res
##ec
##table
or
meta
##static
me
##lan
##oma
was
assessed
in
a
random
##ized
,
double
-
blind
clinical
study
(
Study
1
)
.
[SEP]
[CLS]
A
total
of
111
patients
were
treated
with
p
##em
##et
##re
##xed
/
c
##is
##p
##lat
##in
.
[SEP]
[CLS]
Therefore
,
the
possibility
of
an
association
between
neutral
##izing
anti
##body
t
##iter
and
treatment
effect
can
not
be
assessed
.
[SEP]
[CLS]
In
a
pool
##ed
population
of
patients
with
moderate
re
##nal
imp
##air
##ment
(
N
=
108
##5
)
with
base
##line
e
##G
##F
##R
of
30
to
less
than
60
m
##L
/
min
/
1
.
73
m
2
(
mean
base
##line
e
##G
##F
##R
48
m
##L
/
min
/
1
.
73
m
2
)
,
the
overall
incidence
of
these
events
was
lower
than
in
the
dedicated
trial
but
a
dose
-
dependent
increase
in
incident
episodes
of
significant
re
##nal
function
decline
compared
to
place
##bo
was
still
observed
.
[SEP]
[CLS]
These
patients
may
be
at
greater
risk
for
cardiac
complications
[
see
Use
in
S
##pecific
Population
##s
(
8
)
]
.
[SEP]
[CLS]
In
these
pool
##ed
trials
,
the
median
exposure
for
subjects
in
the
IN
##TE
##LE
##NC
##E
(
r
)
arm
and
place
##bo
arm
was
52
.
3
and
51
.
0
weeks
,
respectively
.
[SEP]
[CLS]
Red
##uce
or
with
##hold
dose
as
appropriate
[
see
Do
##sa
##ge
and
Administration
(
2
)
]
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Me
##rc
##k
Sharp
&
Do
##hm
##e
Corp
.
,
a
subsidiary
of
Me
##rc
##k
&
Co
.
,
Inc
.
,
at
1
-
87
##7
-
88
##8
-
42
##31
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Disco
##ntin
##ue
ER
##WI
##NA
##Z
##E
for
severe
or
hem
##or
##r
##ha
##gic
pan
##cre
##ati
##tis
manifest
##ed
by
abdominal
pain
>
72
hours
and
am
##yla
##se
elevation
>
=
2
.
0
x
U
##L
##N
.
[SEP]
[CLS]
V
##ari
##cell
##a
Z
##ost
##er
V
##ir
##us
Anti
##body
Testing
/
V
##ac
##cin
##ation
Pat
##ients
without
a
healthcare
professional
confirmed
history
of
chicken
##pox
or
without
documentation
of
a
full
course
of
v
##ac
##cin
##ation
against
var
##ice
##lla
z
##ost
##er
virus
(
V
##Z
##V
)
should
be
tested
for
antibodies
to
V
##Z
##V
before
in
##iti
##ating
G
##IL
##EN
##Y
##A
.
[SEP]
[CLS]
Approximately
half
the
cases
were
l
##ymph
##oma
##s
,
including
non
-
Ho
##d
##g
##kin
'
s
l
##ymph
##oma
.
[SEP]
[CLS]
When
distant
effects
occur
,
additional
respiratory
muscles
may
be
involved
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Some
patients
who
were
pre
-
treated
with
anti
##his
##tamine
##s
,
anti
##py
##ret
##ics
and
/
or
co
##rt
##ico
##ster
##oids
still
experienced
h
##yper
##sen
##si
##ti
##vity
reactions
.
[SEP]
[CLS]
Pat
##ients
with
ne
##uro
##mus
##cular
disorders
may
be
at
increased
risk
of
clinical
##ly
significant
effects
including
severe
d
##ys
##pha
##gia
and
respiratory
compromise
from
typical
doses
of
D
##Y
##SP
##OR
##T
(
r
)
[
see
##A
##d
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
c
##ime
##ti
##dine
)
was
not
examined
by
clinical
study
,
some
p
##har
##ma
##co
##kin
##etic
interaction
is
expected
,
albeit
less
than
that
observed
with
moderate
C
##YP
##3
##A
##4
inhibitor
##s
[
see
Drug
Inter
##actions
(
7
.
2
)
and
Do
##sa
##ge
and
Administration
(
2
)
]
.
[SEP]
[CLS]
The
median
duration
of
blinded
study
treatment
was
141
days
(
range
19
-
45
##1
days
)
for
patients
receiving
A
##FI
##NI
##TO
##R
and
60
days
(
range
21
-
295
days
)
for
those
receiving
place
##bo
.
[SEP]
[CLS]
5
.
14
Em
##b
##ryo
-
f
##etal
To
##xi
##city
K
##y
##p
##rol
##is
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
based
on
its
mechanism
of
action
and
findings
in
animals
.
[SEP]
[CLS]
Eleven
out
of
163
(
7
%
)
patients
treated
with
600
mg
of
H
##OR
##I
##Z
##AN
##T
discontinued
treatment
due
to
adverse
reactions
compared
with
10
of
the
245
(
4
%
)
patients
who
received
place
##bo
.
[SEP]
[CLS]
Do
##se
adjustments
(
interrupt
##ions
or
reduction
##s
)
due
to
adverse
reactions
occurred
in
52
%
of
A
##FI
##NI
##TO
##R
-
treated
patients
.
[SEP]
[CLS]
A
total
of
70
##1
subjects
received
ST
##RI
##BI
##LD
once
daily
in
these
two
studies
.
[SEP]
[CLS]
(
6
)
6
.
1
Clinical
Trials
Experience
Clinical
trials
are
conducted
under
widely
varying
conditions
and
adverse
reaction
rates
observed
in
the
clinical
trials
of
V
##iza
##my
##l
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Ad
##verse
Re
##action
N
=
290
##n
(
%
)
Pa
##rest
##hesia
##s
7
(
2
%
)
F
##lus
##hing
1
,
2
5
(
2
%
)
Na
##use
##a
/
V
##omi
##ting
5
(
2
%
)
Head
##ache
2
(
1
%
)
H
##y
##pot
##ens
##ion
2
(
1
%
)
Blu
##rred
Vision
1
(
<
1
%
)
Di
##ar
##r
##hea
1
(
<
1
%
)
H
##yper
##sen
##si
##ti
##vity
1
(
<
1
%
)
H
##yper
##tens
##ion
1
(
<
1
%
)
Ra
##sh
1
(
<
1
%
)
T
##hr
##oat
irritation
/
T
##hr
##oat
tight
##ness
1
(
<
1
%
)
T
##rem
##or
1
(
<
1
%
)
6
.
2
I
##mm
##uno
##genic
##ity
As
with
all
therapeutic
proteins
,
there
is
potential
for
im
##mu
##no
##genic
##ity
.
[SEP]
[CLS]
Pat
##ients
in
the
X
##AL
##KO
##RI
arm
(
n
=
171
)
received
X
##AL
##KO
##RI
250
mg
oral
##ly
twice
daily
until
documented
disease
progression
,
into
##ler
##ance
to
therapy
,
or
the
investigator
determined
that
the
patient
was
no
longer
experiencing
clinical
benefit
.
[SEP]
[CLS]
(
5
.
11
)
*
Em
##b
##ryo
-
f
##etal
toxicity
:
Fe
##tal
harm
can
occur
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
5
.
9
Q
##T
Pro
##long
##ation
The
effects
of
SA
##P
##H
##RI
##S
on
the
Q
##T
/
Q
##T
##c
interval
were
evaluated
in
a
dedicated
adult
Q
##T
study
.
[SEP]
[CLS]
e
Case
##s
of
cut
##aneous
sq
##ua
##mous
cell
car
##cin
##oma
were
required
to
be
reported
as
Grade
3
per
protocol
.
[SEP]
[CLS]
Selected
Ad
##verse
Re
##actions
in
Phase
2
/
3
Trials
(
Number
(
%
)
of
Pat
##ients
)
Dal
##ba
##van
##cin
Co
##mp
##ara
##tor
*
(
N
=
1778
)
(
N
=
122
##4
)
Na
##use
##a
98
(
5
.
5
)
78
(
6
.
4
)
V
##omi
##ting
50
(
2
.
8
)
37
(
3
)
Di
##ar
##r
##hea
79
(
4
.
4
)
72
(
5
.
9
)
Head
##ache
83
(
4
.
7
)
59
(
4
.
8
)
Ra
##sh
48
(
2
.
7
)
30
(
2
.
4
)
P
##ru
##rit
##us
38
(
2
.
1
)
41
(
3
.
3
)
*
Co
##mp
##ara
##tors
included
line
##zo
##lid
,
c
##ef
##az
##olin
,
c
##ep
##hale
##xin
,
and
van
##com
##y
##cin
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
>
=
10
%
)
are
fatigue
,
joint
swelling
,
ed
##ema
,
hot
flush
,
di
##ar
##r
##hea
,
vomit
##ing
,
cough
,
h
##yper
##tens
##ion
,
d
##ys
##p
##nea
,
u
##rina
##ry
tract
infection
and
con
##tus
##ion
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
R
##IS
##K
F
##OR
H
##EP
##AT
##IC
DE
##CO
##MP
##EN
##SA
##TI
##ON
IN
PA
##TI
##EN
##TS
W
##IT
##H
CH
##RO
##NI
##C
H
##EP
##AT
##IT
##IS
C
WA
##R
##NI
##NG
:
R
##IS
##K
F
##OR
H
##EP
##AT
##IC
DE
##CO
##MP
##EN
##SA
##TI
##ON
IN
PA
##TI
##EN
##TS
W
##IT
##H
CH
##RO
##NI
##C
H
##EP
##AT
##IT
##IS
C
In
patients
with
chronic
he
##pa
##titis
C
,
PR
##OM
##AC
##TA
(
r
)
in
combination
with
inter
##fer
##on
and
rib
##avi
##rin
may
increase
the
risk
of
he
##pa
##tic
de
##com
##pen
##sation
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
C
##IM
##Z
##IA
is
not
indicated
for
use
in
p
##ediatric
patients
.
[SEP]
[CLS]
Monitor
patients
closely
for
need
of
emergency
card
##ior
##es
##pi
##rator
##y
support
(
5
.
2
)
5
.
1
N
##ep
##hr
##ogenic
System
##ic
Fi
##bro
##sis
(
N
##SF
)
G
##ado
##lini
##um
-
based
contrast
agents
(
GB
##CA
##s
)
increase
the
risk
for
ne
##ph
##rogen
##ic
systemic
fi
##bro
##sis
(
N
##SF
)
among
patients
with
impaired
elimination
of
the
drugs
.
[SEP]
[CLS]
*
For
patients
at
highest
risk
for
N
##SF
,
do
not
exceed
the
recommended
G
##ada
##vist
dose
and
allow
a
sufficient
period
of
time
for
elimination
of
the
drug
from
the
body
prior
to
any
re
-
administration
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
Ser
##ious
h
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
following
Ad
##re
##V
##ie
##w
administration
.
[SEP]
[CLS]
V
##as
##cular
Di
##sor
##ders
:
T
##hr
##omb
##otic
micro
##ang
##io
##pathy
with
acute
re
##nal
failure
.
[SEP]
[CLS]
f
N
##A
=
not
applicable
.
[SEP]
[CLS]
In
animal
reproduction
studies
,
oral
administration
of
c
##riz
##ot
##ini
##b
in
pregnant
rats
during
organ
##ogen
##esis
at
exposure
##s
similar
to
those
observed
with
the
maximum
recommended
human
dose
resulted
in
em
##b
##ryo
##to
##xi
##city
and
f
##eto
##to
##xi
##city
.
[SEP]
[CLS]
Small
increases
in
c
##rea
##tin
##ine
levels
(
about
0
.
1
mg
/
d
##L
)
following
drone
##dar
##one
treatment
initiation
have
been
shown
to
be
a
result
of
in
##hibition
of
c
##rea
##tin
##ine
'
s
tub
##ular
secret
##ion
.
[SEP]
[CLS]
(
5
.
1
)
*
Inc
##rease
##s
in
in
##tra
##oc
##ular
pressure
have
been
seen
within
60
minutes
of
an
in
##tra
##vi
##tre
##al
injection
.
[SEP]
[CLS]
At
the
time
of
data
cut
-
off
,
243
patients
were
enrolled
and
safety
data
was
available
for
141
patients
.
[SEP]
[CLS]
(
5
.
8
)
*
V
##ac
##cin
##ations
:
A
##vo
##id
live
vaccine
##s
and
close
contact
with
those
who
have
received
live
vaccine
##s
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Non
-
infectious
p
##ne
##um
##oni
##tis
:
Monitor
for
clinical
symptoms
or
radio
##logical
changes
;
fatal
cases
have
occurred
.
[SEP]
[CLS]
A
total
of
169
patients
in
the
ch
##em
##otherapy
arm
received
p
##em
##et
##re
##xed
500
mg
/
m
2
in
combination
with
c
##is
##p
##lat
##in
75
mg
/
m
2
(
n
=
91
)
or
car
##bo
##p
##lat
##in
at
a
dose
calculated
to
produce
an
area
under
the
concentration
-
time
curve
(
AU
##C
)
of
5
or
6
mg
?
min
/
m
##L
(
n
=
78
)
.
[SEP]
[CLS]
Eye
disorders
,
including
severe
eye
pain
,
chemical
con
##junct
##iv
##itis
,
corn
##eal
burn
,
eye
##lid
ed
##ema
,
eye
##lid
p
##tosis
,
per
##ior
##bit
##al
ed
##ema
can
occur
after
exposure
[
see
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
2
One
of
these
reactions
was
classified
as
Grade
3
in
severity
.
[SEP]
[CLS]
Most
Common
Ad
##verse
Re
##actions
In
three
random
##ized
,
controlled
clinical
studies
(
Studies
1
,
2
and
3
)
,
which
were
six
to
12
months
in
duration
,
the
following
adverse
reactions
were
reported
by
the
treating
physician
as
related
to
study
drug
.
[SEP]
[CLS]
Events
and
event
rates
include
one
en
##ox
##apa
##rin
-
treated
patient
in
AD
##VA
##NC
##E
-
1
who
also
had
in
##tra
##c
##rani
##al
hem
##or
##r
##hage
.
[SEP]
[CLS]
A
##FI
##NI
##TO
##R
may
be
re
##int
##roduced
at
a
daily
dose
approximately
50
%
lower
than
the
dose
previously
administered
[
see
Table
1
in
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
If
a
severe
h
##yper
##sen
##si
##ti
##vity
reaction
occurs
,
D
##IF
##IC
##ID
(
r
)
should
be
discontinued
and
appropriate
therapy
should
be
instituted
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
GE
Healthcare
at
1
-
800
-
65
##4
-
01
##18
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
5
.
5
Card
##io
##my
##op
##athy
Card
##io
##my
##op
##athy
can
occur
when
T
##AF
##IN
##LA
##R
is
used
in
combination
with
tram
##eti
##ni
##b
and
with
tram
##eti
##ni
##b
as
a
single
agent
[
refer
to
Full
Pre
##s
##cribing
Information
for
tram
##eti
##ni
##b
]
.
[SEP]
[CLS]
Ad
##verse
reactions
related
to
bleeding
occurred
in
219
(
13
.
3
%
)
E
##L
##I
##Q
##UI
##S
-
treated
patients
compared
to
72
(
8
.
7
%
)
place
##bo
-
treated
patients
.
[SEP]
[CLS]
All
adverse
reactions
were
mild
to
moderate
in
severity
and
of
short
duration
.
[SEP]
[CLS]
A
##ppe
##ndi
##ci
##tis
In
the
pool
of
place
##bo
-
and
active
-
controlled
trials
,
serious
events
of
app
##end
##icit
##is
occurred
in
0
.
3
%
of
patients
treated
with
T
##AN
##Z
##E
##UM
compared
with
0
%
among
all
com
##par
##ators
.
[SEP]
[CLS]
Sub
##jects
were
random
##ized
to
receive
O
##TE
##Z
##LA
30
mg
twice
daily
or
place
##bo
twice
daily
.
[SEP]
[CLS]
There
is
evidence
to
suggest
that
some
patients
who
develop
high
sustained
t
##iter
##s
of
anti
-
al
##g
##lu
##cos
##idas
##e
al
##fa
antibodies
may
experience
reduced
clinical
efficacy
to
al
##g
##lu
##cos
##idas
##e
al
##fa
treatment
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
Table
1
presents
the
profile
from
the
9
-
month
double
-
blind
,
random
##ized
,
place
##bo
-
controlled
trial
of
40
treatment
-
naive
patients
(
Trial
1
)
.
[SEP]
[CLS]
Monitor
liver
enzymes
regularly
.
[SEP]
[CLS]
The
duration
of
driving
imp
##air
##ment
after
starting
therapy
with
H
##OR
##I
##Z
##AN
##T
is
unknown
.
[SEP]
[CLS]
These
reactions
can
occur
within
hours
to
weeks
after
injection
with
b
##ot
##ulin
##um
to
##xin
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
,
Ad
##verse
Re
##actions
(
6
.
1
)
,
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
12
-
Week
Trials
Trial
1
was
a
12
-
week
trial
that
evaluated
the
efficacy
of
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
in
adolescent
and
adult
subjects
with
as
##th
##ma
compared
with
flu
##tica
##son
##e
fur
##oat
##e
100
m
##c
##g
and
place
##bo
.
[SEP]
[CLS]
In
Study
1
,
the
incidence
of
Grade
>
=
3
IL
##D
was
1
.
3
%
and
resulted
in
death
in
1
%
of
G
##IL
##OT
##RI
##F
-
treated
patients
.
[SEP]
[CLS]
Inc
##lude
di
##sse
##minated
her
##pet
##ic
infections
in
the
differential
diagnosis
of
patients
who
are
receiving
G
##IL
##EN
##Y
##A
and
present
with
an
at
##y
##pical
MS
re
##lap
##se
or
multi
##or
##gan
failure
.
[SEP]
[CLS]
6
.
1
Clinical
Trial
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
also
may
not
reflect
rates
observed
in
practice
.
[SEP]
[CLS]
*
Con
##com
##ita
##nt
ne
##uro
##mus
##cular
disorders
may
ex
##ace
##rb
##ate
clinical
effects
of
treatment
(
5
.
5
)
.
[SEP]
[CLS]
5
.
7
Em
##b
##ryo
-
Fe
##tal
To
##xi
##city
J
##E
##V
##TA
##NA
is
not
indicated
for
use
in
female
patients
.
[SEP]
[CLS]
[
See
C
on
##tra
##ind
##ica
##tions
(
4
)
,
W
a
##rn
##ings
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Assessment
of
the
incidence
of
anti
##body
formation
is
highly
dependent
on
the
sensitivity
and
specific
##ity
of
the
ass
##ay
.
[SEP]
[CLS]
The
adverse
reactions
presented
in
the
table
below
are
based
on
safety
information
from
76
##9
patients
treated
with
T
##EC
##FI
##DE
##RA
240
mg
twice
a
day
and
77
##1
place
##bo
-
treated
patients
.
[SEP]
[CLS]
(
5
.
5
)
*
Other
Mali
##gna
##ncies
:
ma
##li
##gnant
diseases
have
been
reported
.
[SEP]
[CLS]
*
T
##R
##U
##L
##IC
##IT
##Y
is
con
##tra
##ind
##ica
##ted
in
patients
with
a
personal
or
family
history
of
M
##TC
and
in
patients
with
Multiple
End
##oc
##rine
Neo
##p
##lasia
syndrome
type
2
(
ME
##N
2
)
.
[SEP]
[CLS]
Episode
##s
of
sin
##us
ta
##chy
##card
##ia
,
associated
with
a
con
##com
##ita
##nt
increase
from
base
##line
in
heart
rate
of
>
=
15
beats
per
minute
,
were
reported
in
0
.
7
%
,
1
.
3
%
and
2
.
2
%
of
patient
treated
with
place
##bo
,
T
##R
##U
##L
##IC
##IT
##Y
0
.
75
mg
and
T
##R
##U
##L
##IC
##IT
##Y
1
.
5
mg
,
respectively
.
[SEP]
[CLS]
Ch
##ronic
anti
##psy
##cho
##tic
treatment
should
generally
be
reserved
for
patients
who
suffer
from
a
chronic
illness
that
(
1
)
is
known
to
respond
to
anti
##psy
##cho
##tic
drugs
,
and
(
2
)
for
whom
alternative
,
equally
effective
,
but
potentially
less
harmful
treatments
are
not
available
or
appropriate
.
[SEP]
[CLS]
3
.
7
5
.
7
4
.
3
Back
pain
3
.
2
3
.
1
4
.
2
Inc
##reased
u
##rina
##tion
##I
##nc
##reased
u
##rina
##tion
includes
the
following
adverse
reactions
,
listed
in
order
of
frequency
reported
:
poll
##aki
##uria
,
p
##oly
##uria
,
and
urine
output
increased
.
[SEP]
[CLS]
In
clinical
trials
evaluating
BR
##E
##O
E
##LL
##IP
##TA
in
subjects
with
CO
##PD
or
as
##th
##ma
,
there
was
no
evidence
of
a
treatment
effect
on
serum
glucose
or
potassium
.
[SEP]
[CLS]
Monitor
for
the
development
of
severe
di
##ar
##r
##hea
or
co
##lit
##is
.
[SEP]
[CLS]
Start
Nat
##azi
##a
no
earlier
than
4
weeks
after
delivery
,
in
women
who
are
not
breast
##fe
##eding
.
[SEP]
[CLS]
Half
of
the
patients
in
the
controlled
trials
who
discontinued
P
##OT
##IG
##A
due
to
hall
##uc
##ination
##s
or
ps
##ych
##osis
required
hospital
##ization
.
[SEP]
[CLS]
During
this
period
of
HP
##A
suppression
,
patients
may
exhibit
signs
and
symptoms
of
ad
##rena
##l
ins
##uff
##iciency
when
exposed
to
trauma
,
surgery
,
or
infection
(
particularly
gas
##tro
##enter
##itis
)
or
other
conditions
associated
with
severe
electro
##ly
##te
loss
.
[SEP]
[CLS]
(
6
.
1
)
*
In
p
##ediatric
patients
age
6
years
and
older
with
IT
##P
,
the
most
common
adverse
reactions
(
greater
than
or
equal
to
10
%
and
greater
than
place
##bo
)
were
upper
respiratory
tract
infection
,
na
##so
##pha
##ryn
##git
##is
,
and
r
##hin
##itis
.
[SEP]
[CLS]
However
,
pregnancy
increases
the
risk
of
ve
##nous
th
##rom
##boe
##mbo
##lis
##m
as
much
or
more
than
the
use
of
CO
##Cs
.
[SEP]
[CLS]
Three
of
these
trials
were
active
-
controlled
(
war
##fari
##n
)
(
R
##E
-
CO
##VE
##R
,
R
##E
-
CO
##VE
##R
II
,
and
R
##E
-
ME
##D
##Y
)
,
and
one
study
(
R
##E
-
S
##ON
##AT
##E
)
was
place
##bo
-
controlled
.
[SEP]
[CLS]
Rep
##rod
##uctive
system
and
breast
disorders
:
Men
##st
##ru
##al
disorder
.
[SEP]
[CLS]
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
In
##fect
##ions
:
Monitor
patients
for
signs
or
symptoms
and
treat
appropriately
.
[SEP]
[CLS]
Table
1
shows
common
adverse
reactions
associated
with
the
use
of
FA
##R
##X
##IG
##A
.
[SEP]
[CLS]
Given
these
con
##found
##ers
,
the
relationship
between
at
##y
##pical
anti
##psy
##cho
##tic
use
and
h
##yper
##gly
##ce
##mia
-
related
adverse
events
is
not
completely
understood
.
[SEP]
[CLS]
However
,
some
patients
may
require
treatment
with
FA
##NA
##P
##T
despite
the
presence
of
the
syndrome
.
[SEP]
[CLS]
Two
patients
with
re
##tina
##l
abnormal
##ities
have
had
more
extensive
diagnostic
re
##tina
##l
evaluation
##s
.
[SEP]
[CLS]
Ana
##phy
##lax
##is
,
presenting
as
cough
,
er
##yt
##hem
##a
,
throat
tight
##ness
,
u
##rt
##ica
##ria
,
flush
##ing
,
c
##yan
##osis
,
h
##y
##pot
##ens
##ion
,
r
##ash
,
d
##ys
##p
##nea
,
chest
discomfort
,
and
gas
##tro
##int
##est
##inal
symptoms
in
conjunction
with
u
##rt
##ica
##ria
,
have
been
reported
to
occur
during
in
##fusion
##s
,
regardless
of
duration
of
the
course
of
treatment
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
L
##E
##O
Ph
##arma
Inc
.
at
1
-
87
##7
-
49
##4
-
45
##36
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Pat
##ients
with
moderate
re
##nal
imp
##air
##ment
who
are
taking
medications
that
interfere
with
potassium
ex
##cre
##tion
,
such
as
potassium
-
spa
##ring
di
##ure
##tics
,
or
medications
that
interfere
with
the
re
##nin
-
an
##gio
##tens
##in
-
al
##dos
##tero
##ne
system
are
at
an
increased
risk
of
developing
h
##yper
##kal
##emia
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
In
a
pool
##ed
analysis
of
these
14
controlled
clinical
trials
,
the
overall
incidence
of
adverse
events
was
66
%
in
patients
treated
with
NE
##SI
##NA
25
mg
compared
to
62
%
with
place
##bo
and
70
%
with
active
com
##par
##ator
.
[SEP]
[CLS]
In
a
study
of
45
##50
post
##men
##op
##aus
##al
women
with
o
##ste
##op
##oro
##sis
,
the
mean
change
from
base
##line
in
serum
calcium
level
10
days
after
Pro
##lia
dos
##ing
was
-
5
.
5
%
in
subjects
with
c
##rea
##tin
##ine
clearance
<
30
m
##L
/
min
vs
.
-
3
.
1
%
in
subjects
with
c
##rea
##tin
##ine
clearance
>
=
30
m
##L
/
min
.
[SEP]
[CLS]
End
##oc
##ard
##itis
was
reported
in
no
place
##bo
patients
and
3
patients
receiving
Pro
##lia
.
[SEP]
[CLS]
Five
of
the
9
S
##IR
##TU
##RO
deaths
and
the
2
place
##bo
deaths
were
tuberculosis
-
related
.
[SEP]
[CLS]
5
.
6
Use
in
Pat
##ients
with
He
##pa
##tic
I
##mp
##air
##ment
C
##aba
##zi
##ta
##xe
##l
is
extensively
meta
##bol
##ized
in
the
liver
.
[SEP]
[CLS]
Some
events
occurred
when
T
##RE
##AN
##DA
was
given
in
combination
with
other
anti
##can
##cer
agents
.
[SEP]
[CLS]
Control
##led
Clinical
Studies
Common
Ad
##verse
Re
##actions
Ad
##verse
reactions
occurring
in
>
=
5
%
of
patients
in
the
Q
##ute
##nza
group
and
at
an
incidence
greater
than
in
the
control
group
were
application
site
er
##yt
##hem
##a
,
application
site
pain
,
application
site
p
##ru
##rit
##us
and
application
site
p
##ap
##ules
.
[SEP]
[CLS]
Rare
post
-
marketing
cases
of
he
##pa
##tos
##ple
##nic
T
-
cell
l
##ymph
##oma
(
H
##ST
##CL
)
have
been
reported
in
patients
treated
with
T
##NF
-
blocking
agents
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
E
##ND
##OM
##ET
##RI
##AL
CA
##NC
##ER
,
CA
##RD
##IO
##VA
##SC
##U
##LA
##R
D
##IS
##OR
##DE
##RS
,
AND
PR
##O
##BA
##BL
##E
DE
##ME
##NT
##IA
See
full
pre
##s
##cribing
information
for
complete
Box
##ed
Warning
.
[SEP]
[CLS]
If
serious
and
/
or
immediate
h
##yper
##sen
##si
##ti
##vity
reactions
occur
further
injection
of
X
##E
##OM
##IN
should
be
discontinued
and
appropriate
medical
therapy
immediately
instituted
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
at
an
Inc
##iden
##ce
of
2
%
or
More
in
SA
##P
##H
##RI
##S
-
T
##reate
##d
Pat
##ients
with
Sc
##hi
##zophrenia
:
Ad
##verse
reactions
associated
with
the
use
of
SA
##P
##H
##RI
##S
(
incidence
of
2
%
or
greater
,
rounded
to
the
nearest
percent
,
and
SA
##P
##H
##RI
##S
incidence
greater
than
place
##bo
)
that
occurred
during
acute
therapy
(
up
to
6
-
weeks
in
patients
with
s
##chi
##zophrenia
)
are
shown
in
Table
8
.
[SEP]
[CLS]
Most
patients
(
75
%
)
enrolled
in
the
c
##UT
##I
trial
were
female
,
and
most
patients
(
58
%
)
enrolled
in
the
c
##IA
##I
trial
were
male
.
[SEP]
[CLS]
The
most
common
Grade
3
-
4
laboratory
abnormal
##ity
(
incidence
>
=
3
%
)
was
h
##y
##pop
##hos
##phate
##mia
.
[SEP]
[CLS]
(
5
.
4
)
*
*
H
##yper
##gly
##ce
##mia
and
diabetes
me
##lli
##tus
:
Monitor
patients
for
symptoms
of
h
##yper
##gly
##ce
##mia
including
p
##oly
##di
##ps
##ia
,
p
##oly
##uria
,
p
##oly
##pha
##gia
,
and
weakness
.
[SEP]
[CLS]
5
.
8
Con
##com
##ita
##nt
Administration
with
C
##YP
##3
##A
##4
In
##hibit
##ors
*
Do
##ses
of
To
##via
##z
greater
than
4
mg
are
not
recommended
in
patients
taking
a
potent
C
##YP
##3
##A
##4
inhibitor
(
e
.
g
.
,
k
##eto
##cona
##zo
##le
,
it
##rac
##ona
##zo
##le
,
c
##lar
##ith
##rom
##y
##cin
)
.
[SEP]
[CLS]
Ad
##verse
reactions
observed
in
these
patients
were
similar
to
infant
##ile
-
onset
Po
##mp
##e
disease
patients
who
received
al
##g
##lu
##cos
##idas
##e
al
##fa
in
other
clinical
trials
.
[SEP]
[CLS]
5
.
7
In
##tra
##der
##mal
I
##mm
##une
Re
##action
The
possibility
of
an
immune
reaction
when
injected
in
##tra
##der
##mal
##ly
is
unknown
.
[SEP]
[CLS]
12
-
Month
Trials
Long
-
term
safety
data
is
based
on
two
12
-
month
trials
(
Trials
3
and
4
;
n
=
1
,
63
##3
and
n
=
1
,
62
##2
,
respectively
)
.
[SEP]
[CLS]
Within
each
Me
##d
##DR
##A
system
organ
class
,
the
adverse
reactions
are
presented
in
order
of
decreasing
frequency
.
[SEP]
[CLS]
Since
all
CA
##PS
patients
received
IL
##AR
##IS
in
Part
1
,
there
are
no
controlled
data
on
adverse
events
(
A
##Es
)
.
[SEP]
[CLS]
The
safety
data
described
in
this
section
reflect
exposure
to
B
##L
##IN
##C
##Y
##TO
in
clinical
trials
in
which
212
patients
with
re
##lap
##sed
or
re
##fra
##ctor
##y
AL
##L
received
up
to
28
m
##c
##g
/
day
.
[SEP]
[CLS]
Before
in
##iti
##ating
J
##AR
##DI
##AN
##CE
,
assess
for
volume
contraction
and
correct
volume
status
if
indicated
.
[SEP]
[CLS]
Most
were
Grade
1
or
2
events
.
[SEP]
[CLS]
If
an
##aph
##yla
##ctic
or
other
clinical
##ly
significant
h
##yper
##sen
##si
##ti
##vity
reactions
occur
,
disco
##ntin
##ue
Pi
##cat
##o
(
r
)
immediately
and
institute
appropriate
medical
therapy
.
[SEP]
[CLS]
(
4
)
N
##eu
##tro
##pen
##ia
:
N
##eu
##tro
##pen
##ic
deaths
have
been
reported
.
[SEP]
[CLS]
Ex
##er
##cise
caution
in
the
per
##i
-
surgical
period
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
H
##yper
##sen
##si
##ti
##vity
Re
##actions
Including
Ana
##phy
##lax
##is
:
Ana
##phy
##lax
##is
has
occurred
in
4
%
of
treated
patients
.
[SEP]
[CLS]
(
5
.
4
)
*
Other
serious
infections
:
increased
risk
of
pro
##to
##zo
##al
infections
,
including
op
##port
##uni
##stic
infections
and
tuberculosis
.
[SEP]
[CLS]
One
subject
out
of
76
##1
administered
V
##iza
##my
##l
experienced
a
serious
h
##yper
##sen
##si
##ti
##vity
reaction
with
flush
##ing
,
d
##ys
##p
##nea
and
chest
pressure
within
minutes
following
V
##iza
##my
##l
administration
and
recovered
with
treatment
.
[SEP]
[CLS]
(
5
.
1
,
5
.
3
,
5
.
4
,
5
.
5
)
*
Use
in
liver
transplant
patients
is
not
recommended
due
to
an
increased
risk
of
g
##raft
loss
and
death
.
[SEP]
[CLS]
Three
subjects
on
T
##AN
##Z
##E
##UM
and
one
subject
in
the
all
-
com
##par
##ator
group
experienced
at
least
one
event
of
AL
##T
increase
of
10
-
fold
or
greater
above
the
upper
limit
of
normal
.
[SEP]
[CLS]
During
clinical
development
134
##6
patients
were
exposed
to
Ad
##re
##V
##ie
##w
,
251
patients
with
known
or
suspected
p
##he
##och
##rom
##oc
##yt
##oma
or
ne
##uro
##blast
##oma
,
98
##5
patients
with
heart
failure
,
and
110
control
patients
.
[SEP]
[CLS]
A
random
##ized
,
parallel
-
arm
,
open
-
label
clinical
trial
was
conducted
in
previously
un
##tre
##ated
CH
##C
subjects
with
g
##eno
##type
1
infection
to
compare
use
of
an
E
##SA
versus
rib
##avi
##rin
dose
reduction
for
initial
management
of
an
##emia
during
therapy
with
VI
##CT
##RE
##L
##IS
in
combination
with
p
##eg
##int
##er
##fer
##on
al
##fa
-
2
##b
and
rib
##avi
##rin
.
[SEP]
[CLS]
5
.
6
P
##ul
##mona
##ry
To
##xi
##city
Case
##s
of
inter
##st
##iti
##al
lung
disease
including
p
##ne
##um
##oni
##tis
and
pulmonary
fi
##bro
##sis
have
been
reported
in
patients
treated
with
M
##U
##LT
##A
##Q
in
the
post
-
marketing
setting
[
see
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
Pat
##ients
were
treated
with
al
##g
##lu
##cos
##idas
##e
al
##fa
20
or
40
mg
/
kg
every
other
week
for
periods
ranging
from
1
to
106
weeks
(
mean
:
61
weeks
)
.
[SEP]
[CLS]
SE
##RI
##O
##US
IN
##F
##EC
##TI
##ON
##S
Pat
##ients
treated
with
S
##IM
##PO
##NI
ARIA
are
at
increased
risk
for
developing
serious
infections
that
may
lead
to
hospital
##ization
or
death
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
In
##iti
##ate
treatment
for
late
##nt
tuberculosis
prior
to
S
##IM
##PO
##NI
ARIA
use
.
[SEP]
[CLS]
5
.
7
Fat
Red
##ist
##ri
##but
##ion
buffalo
hum
##p
,
facial
wasting
,
breast
en
##lar
##gement
,
and
`
`
cu
##shing
##oid
appearance
'
'
have
been
observed
in
patients
receiving
anti
##ret
##rov
##ira
##l
therapy
.
[SEP]
[CLS]
Use
of
pro
##coa
##gu
##lant
reversal
agents
such
as
pro
##th
##rom
##bin
complex
concentrate
,
activated
pro
##th
##rom
##bin
complex
concentrate
,
or
re
##comb
##ina
##nt
factor
VII
##a
may
be
considered
but
has
not
been
evaluated
in
clinical
studies
.
[SEP]
[CLS]
Dr
##oned
##aro
##ne
caused
f
##etal
harm
in
animal
studies
at
doses
equivalent
to
recommended
human
doses
.
[SEP]
[CLS]
A
ca
##usal
association
with
single
-
agent
AD
##CE
##TR
##IS
has
not
been
established
.
[SEP]
[CLS]
5
.
5
Re
##c
##rud
##es
##cence
Food
enhance
##s
absorption
of
art
##em
##eth
##er
and
l
##ume
##fant
##rine
following
administration
of
Co
##arte
##m
Table
##ts
.
[SEP]
[CLS]
(
5
.
4
)
*
I
##mme
##dia
##te
h
##yper
##sen
##si
##ti
##vity
reactions
:
Disco
##ntin
##ue
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
at
once
and
consider
alternatives
if
immediate
h
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##gio
##ede
##ma
,
br
##on
##cho
##sp
##as
##m
,
or
an
##aph
##yla
##xi
##s
,
occur
.
[SEP]
[CLS]
*
After
opening
the
foil
pouch
the
D
##U
##AV
##EE
b
##list
##ers
come
in
,
D
##U
##AV
##EE
must
be
used
within
60
days
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
T
##AF
##IN
##LA
##R
and
tram
##eti
##ni
##b
for
all
Grade
4
hem
##or
##r
##ha
##gic
events
and
for
any
Grade
3
hem
##or
##r
##ha
##gic
events
that
do
not
improve
.
[SEP]
[CLS]
Ad
##mini
##ster
K
##AL
##BI
##TO
##R
in
a
setting
equipped
to
manage
an
##aph
##yla
##xi
##s
and
hereditary
an
##gio
##ede
##ma
.
[SEP]
[CLS]
The
majority
of
the
events
were
mild
to
moderate
although
serious
infections
were
observed
.
[SEP]
[CLS]
5
.
3
Development
of
Drug
-
Re
##sist
##ant
Ba
##cter
##ia
Pre
##s
##cribing
D
##IF
##IC
##ID
in
the
absence
of
a
proven
or
strongly
suspected
C
.
di
##ff
##ici
##le
infection
is
unlikely
to
provide
benefit
to
the
patient
and
increases
the
risk
of
the
development
of
drug
-
resistant
bacteria
.
[SEP]
[CLS]
(
4
)
(
5
.
2
)
*
Gas
##tro
##int
##est
##inal
disorders
:
Na
##use
##a
,
vomit
##ing
,
and
di
##ar
##r
##hea
may
occur
.
[SEP]
[CLS]
R
##out
##ine
monitoring
of
serum
ca
##l
##ci
##ton
##in
or
using
thy
##roid
ultra
##sound
monitoring
is
of
uncertain
value
for
early
detection
of
M
##TC
in
patients
treated
with
T
##AN
##Z
##E
##UM
[
see
Con
##tra
##ind
##ica
##tions
(
4
.
1
)
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
All
patients
were
treated
with
IL
##AR
##IS
150
mg
sub
##cut
##aneous
##ly
or
2
mg
/
kg
if
body
weight
was
greater
than
or
equal
to
15
kg
and
less
than
or
equal
to
40
kg
(
see
Table
1
)
.
[SEP]
[CLS]
As
##piration
may
result
from
severe
d
##ys
##pha
##gia
and
is
a
particular
risk
when
treating
patients
in
whom
swallowing
or
respiratory
function
is
already
compromised
.
[SEP]
[CLS]
(
5
.
2
)
*
H
##yper
##sen
##si
##ti
##vity
Re
##actions
,
including
Ana
##phy
##lax
##is
:
Ser
##ious
and
fatal
reactions
have
been
reported
.
[SEP]
[CLS]
These
clinical
trials
excluded
patients
with
diabetes
me
##lli
##tus
,
a
known
risk
factor
for
mac
##ular
ed
##ema
(
see
below
Mac
##ular
Ed
##ema
in
Pat
##ients
with
History
of
U
##ve
##itis
or
Di
##abe
##tes
Mel
##lit
##us
)
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
,
or
if
the
patient
becomes
pregnant
while
taking
this
drug
,
the
patient
should
be
app
##rise
##d
of
the
potential
hazard
to
the
f
##etus
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
5
.
7
Ren
##al
I
##mp
##air
##ment
Do
##ses
of
To
##via
##z
greater
than
4
mg
are
not
recommended
in
patients
with
severe
re
##nal
imp
##air
##ment
[
see
Use
In
S
##pecific
Population
##s
(
8
.
6
)
and
Do
##sa
##ge
and
Administration
(
2
)
]
.
[SEP]
[CLS]
(
all
grades
)
Report
##ed
in
>
=
5
%
of
Sub
##jects
in
Any
Treatment
Arm
in
Studies
102
and
103
(
Week
144
analysis
)
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
>
=
10
%
)
are
:
fatigue
,
headache
,
nausea
,
di
##ar
##r
##hea
,
back
pain
,
pain
in
ex
##tre
##mit
##ies
,
and
upper
abdominal
pain
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Gen
##zy
##me
Corporation
at
1
-
800
-
74
##5
-
44
##47
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Extra
##py
##ram
##idal
symptoms
included
:
d
##ys
##ton
##ia
,
b
##le
##pha
##ros
##pas
##m
,
to
##rt
##ico
##llis
,
d
##ys
##kin
##esi
##a
,
ta
##rdi
##ve
d
##ys
##kin
##esi
##a
,
muscle
rigid
##ity
,
park
##ins
##oni
##sm
,
g
##ait
disturbance
,
masked
f
##ac
##ies
,
and
t
##rem
##or
(
excluding
aka
##thi
##sia
)
.
[SEP]
[CLS]
There
were
no
drug
-
related
adverse
reactions
associated
with
disco
##ntin
##uation
in
patients
treated
with
SA
##P
##H
##RI
##S
at
the
rate
of
at
least
1
%
and
at
least
twice
the
place
##bo
rate
.
[SEP]
[CLS]
None
of
these
6
patients
had
neutral
##izing
antibodies
.
In
a
study
with
ER
##WI
##NA
##Z
##E
treatment
by
in
##tra
##ven
##ous
administration
(
Study
2
)
,
4
of
30
(
13
.
3
%
)
patients
treated
with
ER
##WI
##NA
##Z
##E
developed
anti
-
ER
##WI
##NA
##Z
##E
antibodies
.
[SEP]
[CLS]
Even
in
the
absence
of
T
##NF
-
block
##er
therapy
,
patients
with
r
##he
##uma
##to
##id
art
##hr
##itis
may
be
at
a
higher
risk
(
approximately
2
-
fold
)
than
the
general
population
for
the
development
of
le
##uke
##mia
.
[SEP]
[CLS]
(
5
.
1
)
*
In
##hala
##tion
of
airborne
caps
##aic
##in
can
result
in
coughing
or
s
##nee
##zing
.
[SEP]
[CLS]
J
##E
##V
##TA
##NA
is
con
##tra
##ind
##ica
##ted
in
patients
with
severe
he
##pa
##tic
imp
##air
##ment
(
total
bi
##li
##ru
##bin
>
3
*
U
##L
##N
)
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
At
2
years
,
patients
random
##ized
to
IN
##VO
##KA
##NA
100
mg
and
IN
##VO
##KA
##NA
300
mg
had
place
##bo
-
corrected
decline
##s
in
B
##MD
at
the
total
hip
of
0
.
3
%
and
0
.
7
%
,
respectively
.
[SEP]
[CLS]
In
a
52
-
week
,
double
-
blind
,
com
##par
##ator
-
controlled
trial
that
included
primarily
patients
with
s
##chi
##zophrenia
,
the
mean
decrease
from
base
##line
of
total
ch
##ole
##ster
##ol
was
6
mg
/
d
##L
and
the
mean
decrease
from
base
##line
of
fast
##ing
t
##rig
##ly
##cer
##ides
was
9
.
8
mg
/
d
##L
.
[SEP]
[CLS]
Six
percent
of
patients
receiving
I
##MB
##R
##U
##VI
##CA
in
the
W
##M
trial
discontinued
treatment
due
to
adverse
events
.
[SEP]
[CLS]
Before
starting
F
##U
##L
##Y
##Z
##A
##Q
,
rule
out
infectious
et
##iol
##ogies
of
di
##ar
##r
##hea
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
G
##lax
##o
##S
##mith
##K
##line
at
1
-
88
##8
-
82
##5
-
52
##4
##9
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
with
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
One
hundred
thirty
-
one
patients
(
median
age
57
years
,
60
%
male
)
received
Y
##ER
##VO
##Y
as
a
single
agent
,
380
patients
(
median
age
56
years
,
61
%
male
)
received
Y
##ER
##VO
##Y
with
an
investigation
##al
g
##p
##100
p
##eptide
vaccine
(
g
##p
##100
)
,
and
132
patients
(
median
age
57
years
,
54
%
male
)
received
g
##p
##100
p
##eptide
vaccine
alone
.
[SEP]
[CLS]
The
observed
incidence
of
anti
##body
(
including
neutral
##izing
anti
##body
)
p
##os
##iti
##vity
in
an
ass
##ay
may
be
influenced
by
several
factors
including
ass
##ay
sensitivity
and
specific
##ity
,
ass
##ay
methodology
,
sample
handling
,
timing
of
sample
collection
,
con
##com
##ita
##nt
medications
,
and
underlying
disease
.
[SEP]
[CLS]
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
:
Drug
reaction
with
e
##os
##ino
##phi
##lia
and
systemic
symptoms
(
DR
##ES
##S
syndrome
)
6
.
3
I
##mm
##uno
##genic
##ity
In
clinical
studies
,
1
.
1
%
of
102
##4
e
##val
##ua
##ble
patients
tested
positive
for
binding
antibodies
against
i
##pi
##lim
##uma
##b
in
an
electro
##che
##mi
##lum
##ines
##cent
(
EC
##L
)
based
ass
##ay
.
[SEP]
[CLS]
There
were
no
differences
in
the
occurrence
of
3
+
protein
##uria
(
<
4
%
in
both
studies
)
at
any
time
point
,
and
no
patients
experienced
4
+
protein
##uria
.
[SEP]
[CLS]
5
.
16
H
##y
##po
##kal
##emia
and
H
##yper
##gly
##ce
##mia
Beta
-
ad
##rene
##rg
##ic
ago
##nist
medicines
may
produce
significant
h
##y
##po
##kal
##emia
in
some
patients
,
possibly
through
in
##tra
##cellular
s
##hun
##ting
,
which
has
the
potential
to
produce
adverse
card
##iovascular
effects
.
[SEP]
[CLS]
Table
1
sum
##mar
##izes
the
reactions
reported
at
a
rate
of
at
least
3
%
in
patients
treated
with
C
##IM
##Z
##IA
200
mg
every
other
week
compared
to
place
##bo
(
sa
##line
formulation
)
,
given
con
##com
##ita
##ntly
with
met
##hot
##re
##xa
##te
.
[SEP]
[CLS]
(
5
.
3
)
*
Effects
on
A
##bility
to
Drive
:
Ad
##vise
patients
to
refrain
from
driving
and
engaging
in
hazardous
occupations
or
activities
such
as
operating
heavy
or
potentially
dangerous
machinery
while
B
##L
##IN
##C
##Y
##TO
is
being
administered
.
[SEP]
[CLS]
Disco
##ntin
##ue
CO
##ME
##TR
##I
##Q
for
per
##fo
##ration
or
for
fist
##ula
formation
[
See
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
In
##jection
of
XI
##AF
##LE
##X
into
l
##iga
##ments
of
the
hand
may
result
in
damage
to
those
structures
and
possible
permanent
injury
such
as
tend
##on
r
##up
##ture
or
l
##iga
##ment
damage
.
[SEP]
[CLS]
Rapid
t
##it
##ration
at
greater
than
the
recommended
doses
appeared
to
increase
the
risk
of
ps
##ych
##osis
and
hall
##uc
##ination
##s
.
[SEP]
[CLS]
Inter
##rup
##t
Fe
##rri
##p
##ro
##x
therapy
if
ne
##ut
##rop
##enia
develops
.
[SEP]
[CLS]
Monitor
electro
##card
##io
##gram
##s
and
electro
##ly
##tes
in
patients
with
con
##ges
##tive
heart
failure
,
bra
##dy
##ar
##r
##hy
##th
##mia
##s
,
electro
##ly
##te
abnormal
##ities
,
or
those
who
are
taking
medications
that
are
known
to
pro
##long
the
Q
##T
##c
interval
.
[SEP]
[CLS]
Monitor
he
##pa
##tic
function
prior
to
and
during
treatment
.
[SEP]
[CLS]
The
clinical
significance
of
the
lower
mean
t
##rig
##ly
##cer
##ide
values
in
N
##U
##L
##O
##J
##IX
-
treated
patients
at
one
and
three
years
is
unknown
.
[SEP]
[CLS]
*
He
##pa
##tic
Dec
##om
##pen
##sation
in
Pat
##ients
with
Ch
##ronic
He
##pa
##titis
C
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
He
##pa
##to
##to
##xi
##city
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
T
##hr
##omb
##oe
##mbo
##lic
Co
##mp
##lication
##s
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
Cat
##ara
##cts
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
In
adult
patients
with
IT
##P
,
the
most
common
adverse
reactions
(
greater
than
or
equal
to
5
%
and
greater
than
place
##bo
)
were
:
nausea
,
di
##ar
##r
##hea
,
upper
respiratory
tract
infection
,
vomit
##ing
,
increased
AL
##T
,
my
##al
##gia
,
and
u
##rina
##ry
tract
infection
.
[SEP]
[CLS]
Table
3
shows
adverse
reactions
on
the
Z
##Y
##TI
##GA
arm
in
Study
2
that
occurred
with
a
>
=
2
%
absolute
increase
in
frequency
compared
to
place
##bo
.
[SEP]
[CLS]
In
Study
1
,
patients
were
random
##ized
(
2
:
1
)
to
receive
either
H
##AL
##AV
##EN
(
1
.
4
mg
/
m
2
on
Days
1
and
8
of
a
21
-
day
cycle
)
or
single
agent
treatment
chosen
by
their
physician
(
control
group
)
.
[SEP]
[CLS]
Emergency
re
##sus
##citation
equipment
and
personnel
should
be
immediately
available
.
[SEP]
[CLS]
Table
2
shows
treatment
-
emerge
##nt
adverse
reactions
and
the
category
of
`
`
any
common
adverse
event
'
'
in
E
##SC
##AP
##E
-
1
and
E
##SC
##AP
##E
-
2
where
the
rate
on
C
##lev
##ip
##re
##x
exceeded
the
rate
on
place
##bo
by
at
least
5
%
(
common
adverse
reactions
)
.
[SEP]
[CLS]
Figure
1
Ad
##ju
##dicated
Major
B
##lee
##ding
by
Basel
##ine
Character
##istic
##s
Including
He
##mor
##r
##ha
##gic
St
##roke
T
##reate
##d
Pat
##ients
Note
:
The
figure
above
presents
effects
in
various
subgroup
##s
all
of
which
are
base
##line
characteristics
and
all
of
which
were
pre
-
specified
.
[SEP]
[CLS]
Ad
##vise
females
of
reproductive
potential
of
the
potential
risk
to
a
f
##etus
.
[SEP]
[CLS]
Y
##ER
##VO
##Y
was
discontinued
for
adverse
reactions
in
10
%
of
patients
.
[SEP]
[CLS]
One
case
of
M
##TC
was
reported
in
a
patient
treated
with
T
##R
##U
##L
##IC
##IT
##Y
.
[SEP]
[CLS]
Monitor
clinical
##ly
and
disco
##ntin
##ue
drug
for
severe
reactions
.
[SEP]
[CLS]
Three
active
-
controlled
trials
of
52
weeks
in
duration
were
conducted
in
patients
treated
with
p
##io
##gli
##ta
##zone
and
met
##form
##in
,
in
combination
with
met
##form
##in
and
as
mon
##otherapy
compared
to
g
##lip
##iz
##ide
.
[SEP]
[CLS]
Women
should
be
advised
to
avoid
becoming
pregnant
when
receiving
T
##RE
##AN
##DA
.
[SEP]
[CLS]
In
Phase
2
and
3
place
##bo
-
controlled
trials
combined
,
the
incidence
##s
of
serious
adverse
events
in
patients
receiving
place
##bo
,
To
##via
##z
4
mg
,
and
To
##via
##z
8
mg
were
1
.
9
%
,
3
.
5
%
,
and
2
.
9
%
,
respectively
.
[SEP]
[CLS]
Hospital
##izations
due
to
serious
infections
in
the
abdomen
(
0
.
0
%
place
##bo
vs
.
0
.
1
%
Pro
##lia
)
were
reported
.
[SEP]
[CLS]
Ad
##verse
reactions
are
events
that
occurred
after
the
first
dose
of
study
medication
treatment
and
within
7
days
of
the
last
dose
of
study
medication
or
events
present
at
base
##line
that
increased
in
severity
after
the
start
of
study
medication
treatment
.
[SEP]
[CLS]
In
females
,
disco
##ntin
##uation
due
to
g
##eni
##tal
my
##cot
##ic
infections
occurred
in
0
%
and
0
.
7
%
of
patients
treated
with
place
##bo
and
IN
##VO
##KA
##NA
,
respectively
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
Whether
anti
##psy
##cho
##tic
drug
products
differ
in
their
potential
to
cause
Ta
##rdi
##ve
D
##ys
##kin
##esi
##a
(
TD
)
is
unknown
.
[SEP]
[CLS]
Pat
##ients
>
=
65
years
of
age
are
more
likely
to
experience
certain
adverse
reactions
,
including
ne
##ut
##rop
##enia
and
f
##eb
##ril
##e
ne
##ut
##rop
##enia
[
see
Ad
##verse
Re
##actions
(
6
)
and
Use
in
S
##pecific
Population
##s
(
8
.
5
)
]
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
in
Pat
##ients
with
I
##mat
##ini
##b
-
Re
##sist
##ant
or
-
Into
##ler
##ant
Ph
+
Ch
##ronic
Phase
(
CP
)
,
A
##cc
##ele
##rated
Phase
(
AP
)
,
and
B
##last
Phase
(
BP
)
C
##ML
The
single
-
arm
Phase
1
/
2
clinical
trial
(
Study
1
)
enrolled
patients
with
Ph
+
chronic
,
accelerated
,
or
blast
phase
chronic
my
##elo
##gen
##ous
le
##uke
##mia
(
C
##ML
)
and
with
resistance
or
into
##ler
##ance
to
prior
therapy
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Of
the
255
patients
,
66
%
of
patients
were
female
and
86
%
were
Caucasian
.
[SEP]
[CLS]
5
.
4
D
##ys
##pha
##gia
and
B
##reath
##ing
Di
##ff
##ic
##ult
##ies
in
Treatment
of
Ce
##r
##vic
##al
D
##ys
##ton
##ia
Treatment
with
X
##E
##OM
##IN
and
other
b
##ot
##ulin
##um
to
##xin
products
can
result
in
breathing
difficulties
.
[SEP]
[CLS]
As
##piration
may
result
from
severe
d
##ys
##pha
##gia
and
is
a
particular
risk
when
treating
patients
in
whom
swallowing
or
respiratory
function
is
already
compromised
.
[SEP]
[CLS]
(
5
.
2
)
5
.
1
N
##ep
##hr
##ogenic
System
##ic
Fi
##bro
##sis
G
##ado
##lini
##um
-
based
contrast
agents
(
GB
##CA
##s
)
increase
the
risk
for
ne
##ph
##rogen
##ic
systemic
fi
##bro
##sis
(
N
##SF
)
among
patients
with
impaired
elimination
of
the
drugs
.
[SEP]
[CLS]
The
most
common
(
>
=
20
%
)
adverse
reactions
observed
following
treatment
with
IN
##L
##Y
##TA
were
di
##ar
##r
##hea
,
h
##yper
##tens
##ion
,
fatigue
,
decreased
appetite
,
nausea
,
d
##ys
##phon
##ia
,
hand
-
foot
)
syndrome
,
weight
decreased
,
vomit
##ing
,
as
##the
##nia
,
and
con
##st
##ip
##ation
.
[SEP]
[CLS]
Table
2
:
Ad
##verse
Re
##actions
Report
##ed
in
>
=
2
%
of
Pat
##ients
on
O
##TE
##Z
##LA
30
mg
Twice
Daily
and
>
=
1
%
Than
That
O
##bs
##erve
##d
in
Pat
##ients
on
Place
##bo
for
up
to
Day
112
(
Week
16
)
a
Of
the
reported
gas
##tro
##int
##est
##inal
adverse
reactions
,
1
subject
experienced
a
serious
adverse
reaction
of
nausea
and
vomit
##ing
in
O
##TE
##Z
##LA
30
mg
twice
daily
;
1
subject
treated
with
O
##TE
##Z
##LA
20
mg
twice
daily
experienced
a
serious
adverse
reaction
of
di
##ar
##r
##hea
;
1
patient
treated
with
O
##TE
##Z
##LA
30
mg
twice
daily
experienced
a
serious
adverse
reaction
of
headache
.
[SEP]
[CLS]
Monitor
serum
potassium
and
ma
##gnesium
in
patients
at
risk
for
electro
##ly
##te
disturbance
##s
.
[SEP]
[CLS]
The
rate
of
adverse
reactions
resulting
in
permanent
disco
##ntin
##uation
was
3
.
8
%
in
the
A
##FI
##NI
##TO
##R
-
treated
patients
.
[SEP]
[CLS]
Three
patients
with
anti
-
be
##lim
##uma
##b
antibodies
experienced
mild
in
##fusion
reactions
of
nausea
,
er
##yt
##hem
##ato
##us
r
##ash
,
p
##ru
##rit
##us
,
eye
##lid
ed
##ema
,
headache
,
and
d
##ys
##p
##nea
;
none
of
the
reactions
was
life
-
threatening
.
[SEP]
[CLS]
In
Study
1
,
di
##ar
##r
##hea
occurred
in
96
%
of
patients
treated
with
G
##IL
##OT
##RI
##F
(
n
=
229
)
,
of
which
15
%
was
Grade
3
in
severity
and
occurred
within
the
first
6
weeks
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Trial
2
was
a
12
-
week
trial
that
evaluated
the
efficacy
of
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
,
BR
##E
##O
E
##LL
##IP
##TA
200
/
25
,
and
flu
##tica
##son
##e
fur
##oat
##e
100
m
##c
##g
in
adolescent
and
adult
subjects
with
as
##th
##ma
.
[SEP]
[CLS]
In
Study
1
,
liver
test
abnormal
##ities
of
any
grade
occurred
in
17
.
5
%
of
the
patients
treated
with
G
##IL
##OT
##RI
##F
.
[SEP]
[CLS]
All
patients
received
at
least
one
dose
of
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
(
5
.
1
)
*
I
##mp
##air
##ment
in
re
##nal
function
:
Monitor
re
##nal
function
during
therapy
.
[SEP]
[CLS]
One
(
n
=
106
)
or
2
(
n
=
30
)
doses
of
V
##OR
##A
##X
##A
##Z
##E
were
administered
in
##tra
##ven
##ously
;
the
number
of
doses
was
not
specified
in
13
patients
.
[SEP]
[CLS]
Most
subjects
(
530
,
70
%
)
received
a
dose
of
185
MB
##q
(
5
m
##C
##i
)
.
[SEP]
[CLS]
A
##vo
##id
prolonged
exposure
to
UV
light
and
sunlight
.
[SEP]
[CLS]
A
##vo
##id
accidental
transfer
of
the
drug
into
the
eyes
and
to
the
per
##io
##cular
area
.
[SEP]
[CLS]
5
.
4
W
##orse
##ning
of
U
##rina
##ry
Re
##ten
##tion
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
should
be
used
with
caution
in
patients
with
u
##rina
##ry
retention
.
[SEP]
[CLS]
Pat
##ients
with
low
album
##in
levels
(
less
than
3
.
5
g
/
d
##L
)
or
Model
for
End
-
Stage
Live
##r
Disease
(
ME
##LD
)
score
greater
than
or
equal
to
10
at
base
##line
had
a
greater
risk
for
he
##pa
##tic
de
##com
##pen
##sation
on
the
arm
receiving
treatment
with
PR
##OM
##AC
##TA
plus
anti
##vir
##als
.
[SEP]
[CLS]
He
##pa
##to
##bil
##iary
Di
##sor
##ders
:
ch
##ole
##lit
##hia
##sis
/
ch
##ole
##cy
##st
##itis
,
he
##pa
##tic
s
##te
##ato
##sis
,
he
##pa
##titis
,
he
##pa
##tom
##eg
##aly
.
[SEP]
[CLS]
The
average
age
of
patients
in
Studies
1
and
2
in
the
N
##U
##L
##O
##J
##IX
recommended
dose
and
c
##y
##c
##los
##por
##ine
control
regime
##ns
was
49
years
,
ranging
from
18
to
79
years
.
[SEP]
[CLS]
All
patients
were
monitored
for
adverse
reactions
over
a
24
hour
period
following
Ad
##re
##V
##ie
##w
administration
.
[SEP]
[CLS]
41
.
1
%
were
current
or
previous
smoke
##rs
.
[SEP]
[CLS]
Should
a
stroke
occur
or
be
suspected
,
D
##U
##AV
##EE
should
be
discontinued
immediately
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
Disco
##ntin
##ue
S
##IM
##PO
##NI
ARIA
if
a
patient
develops
a
serious
infection
.
[SEP]
[CLS]
The
elevation
has
a
rapid
onset
,
reaches
a
plateau
after
7
days
and
is
re
##versible
after
disco
##ntin
##uation
.
[SEP]
[CLS]
Pat
##ients
with
his
##top
##las
##mos
##is
or
other
invasive
fun
##gal
infections
may
present
with
di
##sse
##minated
,
rather
than
localized
,
disease
.
[SEP]
[CLS]
The
mechanism
and
long
-
term
consequences
of
these
events
are
currently
unknown
.
[SEP]
[CLS]
Pro
##tamine
su
##lf
##ate
and
vitamin
K
are
not
expected
to
affect
the
anti
##coa
##gu
##lant
activity
of
a
##pi
##xa
##ban
.
[SEP]
[CLS]
The
use
of
SA
##P
##H
##RI
##S
should
be
avoided
in
combination
with
other
drugs
known
to
pro
##long
Q
##T
##c
including
Class
1A
anti
##ar
##r
##hy
##th
##mic
##s
(
e
.
g
.
,
q
##uin
##id
##ine
,
pro
##ca
##ina
##mi
##de
)
or
Class
3
anti
##ar
##r
##hy
##th
##mic
##s
(
e
.
g
.
,
am
##io
##dar
##one
,
so
##tal
##ol
)
,
anti
##psy
##cho
##tic
medications
(
e
.
g
.
,
z
##ip
##ras
##ido
##ne
,
ch
##lor
##p
##roma
##zine
,
th
##ior
##ida
##zine
)
,
and
anti
##biotics
(
e
.
g
.
,
g
##ati
##f
##lo
##xa
##cin
,
m
##ox
##if
##lo
##xa
##cin
)
.
[SEP]
[CLS]
Cat
##ara
##cts
were
observed
in
toxic
##ology
studies
of
el
##trom
##bo
##pa
##g
in
rode
##nts
[
see
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
2
)
]
.
[SEP]
[CLS]
*
In
##vasive
fun
##gal
infections
,
including
his
##top
##las
##mos
##is
,
co
##cci
##dio
##ido
##my
##cos
##is
,
can
##di
##dia
##sis
,
as
##per
##gill
##osis
,
blast
##omy
##cos
##is
and
p
##ne
##um
##oc
##ys
##tosis
.
[SEP]
[CLS]
5
.
3
T
##hr
##omb
##oe
##mbo
##lic
Events
There
is
a
potential
risk
of
art
##erial
th
##rom
##boe
##mbo
##lic
events
(
AT
##Es
)
following
in
##tra
##vi
##tre
##al
use
of
V
##EG
##F
inhibitor
##s
,
including
E
##Y
##LE
##A
.
[SEP]
[CLS]
C
##NS
PT
##LD
,
PM
##L
,
and
other
C
##NS
infections
were
more
frequently
observed
in
association
with
a
N
##U
##L
##O
##J
##IX
regime
##n
of
higher
cumulative
dose
and
more
frequent
dos
##ing
compared
to
the
recommended
regime
##n
;
therefore
,
administration
of
higher
than
the
recommended
doses
and
/
or
more
frequent
dos
##ing
of
N
##U
##L
##O
##J
##IX
is
not
recommended
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
]
.
[SEP]
[CLS]
In
Study
3
,
pulmonary
toxicity
was
reported
in
8
patients
(
5
%
)
in
the
AD
##CE
##TR
##IS
-
treated
arm
and
5
patients
(
3
%
)
in
the
place
##bo
arm
.
[SEP]
[CLS]
5
.
6
He
##pa
##tic
and
Ren
##al
I
##mp
##air
##ment
Co
##arte
##m
Table
##ts
have
not
been
studied
for
efficacy
and
safety
in
patients
with
severe
he
##pa
##tic
and
/
or
re
##nal
imp
##air
##ment
[
see
Do
##sa
##ge
and
Administration
(
2
.
4
)
]
.
[SEP]
[CLS]
In
the
Phase
3
random
##ized
controlled
studies
,
the
incidence
##s
of
ad
##ju
##dicated
AP
##TC
events
per
100
patient
-
years
of
exposure
were
:
Place
##bo
0
(
95
%
C
##I
0
.
00
-
6
.
16
)
,
U
##L
##OR
##IC
40
mg
0
(
95
%
C
##I
0
.
00
-
1
.
08
)
,
U
##L
##OR
##IC
80
mg
1
.
09
(
95
%
C
##I
0
.
44
-
2
.
24
)
,
and
all
##op
##uri
##no
##l
0
.
60
(
95
%
C
##I
0
.
16
-
1
.
53
)
.
[SEP]
[CLS]
Two
percent
demonstrated
a
decrease
in
L
##VE
##F
below
institutional
lower
limits
of
normal
with
an
absolute
decrease
in
L
##VE
##F
of
>
=
20
%
below
base
##line
.
[SEP]
[CLS]
Consider
appropriate
em
##pi
##ric
anti
##fu
##nga
##l
therapy
and
take
into
account
both
the
risk
for
severe
fun
##gal
infection
and
the
risks
of
anti
##fu
##nga
##l
therapy
while
a
diagnostic
work
##up
is
being
performed
.
[SEP]
[CLS]
If
accidental
exposure
occurs
,
flush
eyes
with
water
and
seek
medical
care
.
[SEP]
[CLS]
The
Study
1
population
enrolled
patients
with
a
median
age
of
18
years
(
1
month
to
85
years
)
;
63
%
were
male
,
and
the
underlying
ma
##li
##gna
##ncies
were
o
##ste
##osa
##rc
##oma
/
sa
##rc
##oma
##s
in
32
%
,
and
le
##uke
##mia
or
l
##ymph
##oma
in
63
%
of
patients
.
[SEP]
[CLS]
Consider
anti
-
tuberculosis
therapy
prior
to
initiation
of
S
##IM
##PO
##NI
ARIA
in
patients
with
a
past
history
of
late
##nt
or
active
tuberculosis
in
whom
an
adequate
course
of
treatment
can
not
be
confirmed
,
and
for
patients
with
a
negative
test
for
late
##nt
tuberculosis
but
having
risk
factors
for
tuberculosis
infection
.
[SEP]
[CLS]
In
clinical
trials
,
76
##1
adults
(
36
##7
men
and
39
##4
women
,
91
%
Caucasian
)
with
a
mean
age
of
62
years
(
range
18
-
93
years
)
received
V
##iza
##my
##l
.
[SEP]
[CLS]
Among
the
290
patients
included
in
the
safety
evaluation
of
V
##OR
##A
##X
##A
##Z
##E
,
there
were
8
deaths
within
30
days
of
V
##OR
##A
##X
##A
##Z
##E
exposure
that
were
not
related
to
progressive
disease
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
R
##IS
##K
OF
T
##H
##Y
##RO
##ID
C
-
CE
##LL
T
##UM
##OR
##S
WA
##R
##NI
##NG
:
R
##IS
##K
OF
T
##H
##Y
##RO
##ID
C
-
CE
##LL
T
##UM
##OR
##S
*
Car
##cin
##ogenic
##ity
of
al
##bi
##g
##lut
##ide
could
not
be
assessed
in
rode
##nts
,
but
other
g
##lu
##ca
##gon
-
like
p
##eptide
-
1
(
G
##LP
-
1
)
receptor
ago
##nist
##s
have
caused
thy
##roid
C
-
cell
tumors
in
rode
##nts
at
clinical
##ly
relevant
exposure
##s
.
[SEP]
[CLS]
If
Grade
3
or
4
ne
##ut
##rop
##enia
develops
,
consider
dose
delays
,
reduction
##s
,
disco
##ntin
##uation
,
or
G
-
CS
##F
prop
##hyl
##ax
##is
with
subsequent
doses
(
5
.
3
)
.
[SEP]
[CLS]
In
clinical
trials
with
N
##U
##L
##O
##J
##IX
,
two
cases
of
PM
##L
were
reported
in
patients
receiving
N
##U
##L
##O
##J
##IX
at
higher
cumulative
doses
and
more
frequently
than
the
recommended
regime
##n
,
along
with
my
##co
##phe
##no
##late
m
##of
##eti
##l
(
M
##MF
)
and
co
##rt
##ico
##ster
##oids
;
one
case
occurred
in
a
kidney
transplant
recipient
and
the
second
case
occurred
in
a
liver
transplant
recipient
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
.
[SEP]
[CLS]
A
theoretical
risk
for
transmission
of
C
##re
##utz
##feld
##t
-
Jakob
disease
(
C
##J
##D
)
is
also
considered
extremely
remote
.
[SEP]
[CLS]
They
had
a
mean
age
of
64
years
and
an
average
smoking
history
of
46
pack
-
years
,
with
44
%
identified
as
current
smoke
##rs
.
[SEP]
[CLS]
Disco
##ntin
##ue
T
##I
##VI
##CA
##Y
and
other
suspect
agents
immediately
if
signs
or
symptoms
of
h
##yper
##sen
##si
##ti
##vity
reactions
develop
,
as
a
delay
in
stopping
treatment
may
result
in
a
life
-
threatening
reaction
.
[SEP]
[CLS]
N
##eu
##tral
##izing
antibodies
were
detected
in
3
patients
receiving
B
##EN
##L
##Y
##ST
##A
1
mg
/
kg
.
[SEP]
[CLS]
In
V
##iro
##logical
##ly
-
Su
##pp
##ressed
HIV
-
1
-
In
##fected
Sub
##jects
No
new
adverse
reactions
to
ST
##RI
##BI
##LD
through
Week
48
were
identified
in
58
##4
v
##iro
##logical
##ly
stab
##ly
suppressed
subjects
switching
to
ST
##RI
##BI
##LD
from
a
regime
##n
containing
a
R
##TV
-
boost
##ed
pro
##te
##ase
inhibitor
(
P
##I
)
or
a
non
-
n
##uc
##leo
##side
reverse
trans
##cript
##ase
inhibitor
(
N
##NR
##TI
)
.
[SEP]
[CLS]
The
mean
age
of
treated
patients
was
48
to
50
years
(
range
18
to
92
years
)
,
across
treatment
arms
and
indication
##s
.
[SEP]
[CLS]
This
included
78
##3
patients
who
received
G
##IL
##EN
##Y
##A
0
.
5
mg
in
the
2
-
year
place
##bo
-
controlled
trials
(
Studies
1
and
3
)
and
42
##9
patients
who
received
G
##IL
##EN
##Y
##A
0
.
5
mg
in
the
1
year
active
-
controlled
trial
(
Study
2
)
.
[SEP]
[CLS]
Treatment
of
c
##er
##vic
##al
d
##ys
##ton
##ia
with
b
##ot
##ulin
##um
to
##xin
##s
may
weaken
neck
muscles
that
serve
as
access
##ory
muscles
of
ventilation
.
[SEP]
[CLS]
Ad
##verse
reactions
associated
with
the
use
of
G
##ada
##vist
were
usually
mild
to
moderate
in
severity
and
trans
##ient
in
nature
.
[SEP]
[CLS]
All
serious
adverse
events
were
judged
to
be
not
related
or
unlikely
to
be
related
to
study
medication
by
the
investigator
,
except
for
four
patients
receiving
To
##via
##z
who
reported
one
serious
adverse
event
each
:
an
##gin
##a
,
chest
pain
,
gas
##tro
##enter
##itis
,
and
Q
##T
pro
##long
##ation
on
EC
##G
.
[SEP]
[CLS]
However
,
the
incidence
of
non
##fa
##tal
serious
infections
was
3
.
3
%
in
the
place
##bo
and
4
.
0
%
in
the
Pro
##lia
groups
.
[SEP]
[CLS]
More
frequent
re
##nal
function
monitoring
is
recommended
in
patients
with
an
e
##G
##F
##R
below
60
m
##L
/
min
/
1
.
73
m
2
.
[SEP]
[CLS]
In
rare
instances
severe
an
##aph
##yla
##ct
##oid
reactions
have
occurred
,
particularly
in
the
second
and
subsequent
cycles
of
therapy
.
[SEP]
[CLS]
Ch
##ronic
L
##ymph
##oc
##ytic
Le
##uke
##mia
The
data
described
below
reflect
exposure
to
I
##MB
##R
##U
##VI
##CA
in
an
open
label
clinical
trial
(
Study
1
)
that
included
48
patients
with
previously
treated
C
##LL
and
a
random
##ized
clinical
trial
(
Study
2
)
that
included
39
##1
random
##ized
patients
with
previously
treated
C
##LL
or
SL
##L
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Based
on
Gender
and
Race
No
significant
gender
differences
were
noted
in
the
incidence
of
adverse
reactions
.
[SEP]
[CLS]
At
base
##line
,
the
population
had
diabetes
for
an
average
of
6
years
,
had
a
mean
hem
##og
##lo
##bin
A1
##c
(
H
##b
##A
##1
##c
)
of
8
.
3
%
,
and
21
%
had
established
micro
##vas
##cular
complications
of
diabetes
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
P
##fi
##zer
Inc
.
at
1
-
800
-
43
##8
-
1985
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Because
t
##rough
levels
of
i
##pi
##lim
##uma
##b
interfere
with
the
EC
##L
ass
##ay
results
,
a
subset
analysis
was
performed
in
the
dose
co
##hor
##t
with
the
lowest
t
##rough
levels
.
[SEP]
[CLS]
Monitor
patients
receiving
B
##L
##IN
##C
##Y
##TO
for
signs
and
symptoms
of
ne
##uro
##logical
toxic
##ities
,
and
interrupt
or
disco
##ntin
##ue
B
##L
##IN
##C
##Y
##TO
as
recommended
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
PR
Inter
##val
Pro
##long
##ation
and
Ad
##verse
Re
##actions
of
First
Degree
At
##rio
##vent
##ric
##ular
(
A
##V
)
Block
A
mean
increase
from
base
##line
in
PR
interval
of
2
-
3
mill
##ise
##con
##ds
was
observed
in
T
##R
##U
##L
##IC
##IT
##Y
-
treated
patients
in
contrast
to
a
mean
decrease
of
0
.
9
mill
##ise
##con
##d
in
place
##bo
-
treated
patients
.
[SEP]
[CLS]
U
##rina
##ry
retention
was
generally
reported
within
the
first
6
months
of
treatment
,
but
was
also
observed
later
.
[SEP]
[CLS]
5
.
12
Em
##b
##ryo
-
Fe
##tal
To
##xi
##city
There
are
no
adequate
and
well
-
controlled
studies
of
AD
##CE
##TR
##IS
in
pregnant
women
.
[SEP]
[CLS]
Consequently
,
to
provide
a
meaningful
estimate
of
the
proportion
of
individuals
experiencing
adverse
reactions
,
reactions
were
grouped
in
standardized
categories
using
Me
##d
##DR
##A
terminology
.
[SEP]
[CLS]
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
AG
##RA
##NU
##L
##OC
##Y
##TO
##SI
##S
/
NE
##UT
##RO
##P
##EN
##IA
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
Re
##actions
In
the
R
##E
-
L
##Y
study
,
drug
h
##yper
##sen
##si
##ti
##vity
(
including
u
##rt
##ica
##ria
,
r
##ash
,
and
p
##ru
##rit
##us
)
,
all
##ergic
ed
##ema
,
an
##aph
##yla
##ctic
reaction
,
and
an
##aph
##yla
##ctic
shock
were
reported
in
<
0
.
1
%
of
patients
receiving
PR
##AD
##A
##X
##A
.
[SEP]
[CLS]
*
Fat
##al
and
/
or
serious
he
##pa
##to
##to
##xi
##city
occurred
in
14
%
of
Z
##yd
##eli
##g
-
treated
patients
.
[SEP]
[CLS]
Mu
##s
##cu
##los
##kel
##etal
and
Con
##nect
##ive
T
##iss
##ue
Di
##sor
##ders
:
my
##op
##athy
,
including
r
##hab
##dom
##yo
##lysis
.
[SEP]
[CLS]
Sign
##ificant
##ly
elevated
serum
ca
##l
##ci
##ton
##in
value
may
indicate
M
##TC
and
patients
with
M
##TC
usually
have
ca
##l
##ci
##ton
##in
values
>
50
ng
/
L
.
[SEP]
[CLS]
A
total
of
50
##3
patients
received
H
##AL
##AV
##EN
,
and
247
patients
in
the
control
group
received
therapy
consisting
of
ch
##em
##otherapy
[
total
97
%
(
ant
##hra
##cy
##cline
##s
10
%
,
cape
##ci
##ta
##bine
18
%
,
g
##em
##ci
##ta
##bine
19
%
,
taxa
##nes
15
%
,
v
##ino
##rel
##bine
25
%
,
other
ch
##em
##oth
##era
##pies
10
%
)
]
or
ho
##rmon
##al
therapy
(
3
%
)
.
[SEP]
[CLS]
The
most
frequently
reported
adverse
drug
reactions
(
>
=
25
%
)
in
the
XI
##AF
##LE
##X
clinical
trials
in
patients
with
P
##ey
##ron
##ie
'
s
disease
were
pen
##ile
hem
##ato
##ma
,
pen
##ile
swelling
,
and
pen
##ile
pain
.
[SEP]
[CLS]
H
##AL
##AV
##EN
is
a
micro
##tub
##ule
inhibitor
;
therefore
,
it
is
expected
to
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
When
liver
function
tests
show
sustained
improvement
or
return
to
base
##line
,
initiate
co
##rt
##ico
##ster
##oid
tape
##ring
and
continue
to
tape
##r
over
1
month
.
[SEP]
[CLS]
Table
5
B
##lee
##ding
Events
in
R
##E
-
S
##ON
##AT
##E
T
##reate
##d
Pat
##ients
Note
:
MBE
can
belong
to
more
than
one
criterion
.
[SEP]
[CLS]
Ad
##vise
the
patient
to
r
##ins
##e
his
/
her
mouth
with
water
without
swallowing
following
in
##hala
##tion
to
help
reduce
the
risk
of
or
##op
##har
##yn
##ge
##al
can
##di
##dia
##sis
.
[SEP]
[CLS]
Three
percent
(
3
%
)
of
255
patients
experienced
a
Q
##T
##c
interval
increase
over
base
##line
greater
than
60
m
##se
##c
in
Study
1
.
[SEP]
[CLS]
(
5
.
1
)
*
Fe
##rri
##p
##ro
##x
can
cause
f
##etal
harm
.
[SEP]
[CLS]
(
5
.
6
)
*
N
##eu
##tro
##pen
##ia
:
monitor
blood
counts
.
[SEP]
[CLS]
The
most
common
adverse
drug
reactions
in
at
least
2
%
of
p
##ediatric
subjects
were
r
##ash
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
In
the
non
-
Ho
##d
##g
##kin
'
s
l
##ymph
##oma
study
,
52
%
of
patients
were
male
,
the
median
age
was
55
years
,
and
88
%
of
patients
were
Caucasian
.
[SEP]
[CLS]
Ren
##al
function
should
be
evaluated
prior
to
initiation
of
FA
##R
##X
##IG
##A
and
monitored
periodically
thereafter
.
[SEP]
[CLS]
(
B
)
SP
##IN
##AL
/
EP
##ID
##UR
##AL
H
##EM
##AT
##OM
##A
:
spinal
hem
##ato
##mas
may
occur
in
patients
treated
with
PR
##AD
##A
##X
##A
who
are
receiving
ne
##ura
##xial
an
##est
##hesia
or
undergoing
spinal
pu
##nc
##ture
.
[SEP]
[CLS]
Non
-
G
##I
fist
##ula
##s
were
reported
in
4
%
of
CO
##ME
##TR
##I
##Q
-
treated
patients
.
[SEP]
[CLS]
These
changes
were
not
associated
with
other
abnormal
thy
##roid
function
tests
suggesting
h
##y
##pot
##hy
##roid
##ism
.
[SEP]
[CLS]
A
subset
of
patients
experienced
a
re
##cu
##rrence
of
symptoms
when
restart
##ing
the
same
drug
or
a
different
D
##PP
-
4
inhibitor
.
[SEP]
[CLS]
Ana
##phy
##lax
##is
occurred
as
late
into
treatment
as
the
47
th
in
##fusion
.
[SEP]
[CLS]
If
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
no
longer
controls
the
symptoms
of
br
##on
##cho
##con
##st
##ric
##tion
,
or
the
patient
'
s
inhaled
,
short
-
acting
beta
##2
-
ago
##nist
becomes
less
effective
or
the
patient
needs
more
in
##hala
##tion
of
short
-
acting
beta
##2
-
ago
##nist
than
usual
,
these
may
be
markers
of
de
##ter
##ior
##ation
of
disease
.
[SEP]
[CLS]
At
base
##line
,
the
population
had
diabetes
for
an
average
of
11
years
,
had
a
mean
H
##b
##A
##1
##C
of
8
.
0
%
and
33
%
had
established
micro
##vas
##cular
complications
of
diabetes
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
6
.
1
Re
##tro
##spective
Case
Series
Experience
The
most
common
adverse
reactions
(
occurring
in
>
=
13
%
of
patients
)
,
regardless
of
ca
##usal
##ity
,
are
:
In
##fect
##ions
,
vomit
##ing
,
abdominal
pain
,
p
##yre
##xia
,
tons
##ili
##tis
,
an
##emia
,
ear
infection
,
di
##ar
##r
##hea
,
na
##so
##pha
##ryn
##git
##is
,
and
headache
.
[SEP]
[CLS]
A
##vo
##id
co
-
administration
of
strong
C
##YP
##3
##A
##4
induce
##rs
,
such
as
r
##if
##am
##y
##cin
##s
(
i
.
e
.
,
r
##if
##amp
##in
,
r
##if
##ap
##ent
##ine
and
r
##if
##ab
##uti
##n
)
,
or
moderate
C
##YP
##3
##A
##4
induce
##rs
,
such
as
e
##fa
##vir
##en
##z
,
during
treatment
with
S
##IR
##TU
##RO
[
see
Drug
Inter
##actions
(
7
.
1
)
]
.
[SEP]
[CLS]
Pan
##cre
##ati
##tis
Pan
##cre
##ati
##tis
was
reported
in
1
patient
(
0
.
8
%
)
in
the
place
##bo
group
and
1
patient
(
0
.
8
%
)
in
the
Pro
##lia
group
.
[SEP]
[CLS]
The
time
from
product
administration
to
event
occurrence
was
variable
.
[SEP]
[CLS]
Women
on
thy
##roid
replacement
therapy
may
require
higher
doses
of
thy
##roid
hormone
.
[SEP]
[CLS]
5
.
8
With
##dra
##wal
Se
##iz
##ures
As
with
all
A
##ED
##s
,
when
P
##OT
##IG
##A
is
discontinued
,
it
should
be
withdrawn
gradually
when
possible
to
minimize
the
potential
of
increased
seizure
frequency
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
]
.
[SEP]
[CLS]
The
most
common
adverse
reactions
associated
with
disco
##ntin
##uation
in
subjects
treated
with
SA
##P
##H
##RI
##S
(
rates
at
least
1
%
and
at
least
twice
the
place
##bo
rate
)
were
depression
(
2
.
5
%
)
,
su
##icidal
idea
##tion
(
2
.
5
%
)
,
bi
##pol
##ar
I
disorder
(
1
.
9
%
)
,
ins
##om
##nia
(
1
.
9
%
)
and
de
##pressive
symptoms
(
1
.
3
%
)
.
[SEP]
[CLS]
The
most
common
adverse
reactions
reported
with
Pro
##lia
in
men
with
o
##ste
##op
##oro
##sis
are
back
pain
,
art
##hra
##l
##gia
,
and
na
##so
##pha
##ryn
##git
##is
.
[SEP]
[CLS]
3
##I
##nc
##lude
##s
the
preferred
terms
abdominal
pain
,
abdominal
pain
upper
,
abdominal
pain
lower
,
and
abdominal
discomfort
.
[SEP]
[CLS]
(
5
.
1
)
*
When
treating
patients
with
as
##th
##ma
,
only
pre
##s
##cribe
BR
##E
##O
E
##LL
##IP
##TA
for
patients
not
adequately
controlled
on
a
long
-
term
as
##th
##ma
control
medication
,
such
as
an
I
##CS
,
or
whose
disease
severity
clearly
warrant
##s
initiation
of
treatment
with
both
an
I
##CS
and
a
LA
##BA
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
to
al
##g
##lu
##cos
##idas
##e
al
##fa
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
Table
8
:
Per
##cent
##age
of
EP
##S
Compared
to
Place
##bo
Place
##bo
(
%
)
FA
##NA
##P
##T
10
-
16
mg
/
day
(
%
)
FA
##NA
##P
##T
20
-
24
mg
/
day
(
%
)
Ad
##verse
Event
Te
##rm
(
N
=
58
##7
)
(
N
=
48
##3
)
(
N
=
39
##1
)
All
EP
##S
events
11
.
6
13
.
5
15
.
1
A
##kat
##his
##ia
2
.
7
1
.
7
2
.
3
Brady
##kin
##esi
##a
0
0
.
6
0
.
5
D
##ys
##kin
##esi
##a
1
.
5
1
.
7
1
.
0
D
##ys
##ton
##ia
0
.
7
1
.
0
0
.
8
Parkinson
##ism
0
0
.
2
0
.
3
T
##rem
##or
1
.
9
2
.
5
3
.
1
Ad
##verse
Re
##actions
Associated
with
Disco
##ntin
##uation
of
Treatment
in
Clinical
Trials
Based
on
the
pool
##ed
data
from
4
place
##bo
-
controlled
,
4
-
or
6
-
week
,
fixed
-
or
flexible
-
dose
studies
,
there
was
no
difference
in
the
incidence
of
disco
##ntin
##uation
due
to
adverse
events
between
FA
##NA
##P
##T
-
treated
(
5
%
)
and
place
##bo
-
treated
(
5
%
)
patients
.
[SEP]
[CLS]
Di
##zzi
##ness
led
to
withdrawal
in
2
%
of
patients
receiving
1
,
200
mg
of
H
##OR
##I
##Z
##AN
##T
per
day
compared
with
3
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
5
.
7
A
##cute
Re
##jection
and
Graf
##t
Loss
with
Co
##rt
##ico
##ster
##oid
Mini
##mi
##zation
occurred
in
patients
with
4
to
6
H
##LA
mi
##sma
##tches
.
[SEP]
[CLS]
Because
these
events
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
frequency
or
to
establish
a
ca
##usal
relationship
with
drug
exposure
.
[SEP]
[CLS]
Several
patients
discontinued
G
##IL
##EN
##Y
##A
because
of
une
##x
##plain
##ed
d
##ys
##p
##nea
during
the
extension
(
un
##con
##tro
##lled
)
studies
.
[SEP]
[CLS]
In
the
combined
clinical
trial
experience
with
all
doses
of
fin
##gol
##imo
##d
,
the
rate
of
mac
##ular
ed
##ema
was
approximately
20
%
in
MS
patients
with
a
history
of
u
##ve
##itis
versus
0
.
6
%
in
those
without
a
history
of
u
##ve
##itis
.
[SEP]
[CLS]
Is
##olate
##d
cases
of
as
##per
##gill
##osis
,
her
##pes
z
##ost
##er
)
were
reported
during
IL
##AR
##IS
treatment
.
[SEP]
[CLS]
Because
G
##IL
##EN
##Y
##A
exposure
is
doubled
in
patients
with
severe
he
##pa
##tic
imp
##air
##ment
,
these
patients
should
be
closely
monitored
,
as
the
risk
of
adverse
reactions
is
greater
[
see
Use
in
S
##pecific
Population
##s
(
8
.
6
)
,
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
Currently
available
data
are
inadequate
to
determine
whether
concurrent
use
of
inhaled
co
##rt
##ico
##ster
##oids
or
other
long
-
term
as
##th
##ma
control
drugs
mit
##igate
##s
the
increased
risk
of
as
##th
##ma
-
related
death
from
LA
##BA
.
[SEP]
[CLS]
Rate
##s
of
se
##ro
##con
##version
increased
with
exposure
to
K
##AL
##BI
##TO
##R
over
time
.
[SEP]
[CLS]
Specifically
,
no
##ct
##uria
was
reported
by
0
.
4
%
,
0
.
3
%
,
and
0
.
8
%
of
patients
treated
with
place
##bo
,
J
##AR
##DI
##AN
##CE
10
mg
,
and
J
##AR
##DI
##AN
##CE
25
mg
,
respectively
.
[SEP]
[CLS]
M
##U
##LT
##A
##Q
should
only
be
initiated
in
patients
in
sin
##us
rhythm
who
are
receiving
appropriate
anti
##th
##rom
##bot
##ic
therapy
[
see
Drug
interactions
(
7
.
3
)
]
.
[SEP]
[CLS]
The
Q
##T
##c
##F
was
increased
more
than
60
m
##se
##c
from
base
##line
in
13
%
(
7
/
55
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
and
2
%
(
1
/
53
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
In
a
place
##bo
-
controlled
trial
of
PR
##OM
##AC
##TA
in
patients
with
chronic
liver
disease
##and
th
##rom
##bo
##cy
##top
##enia
not
related
to
IT
##P
,
six
patients
treated
with
PR
##OM
##AC
##TA
and
one
patient
in
the
place
##bo
group
developed
portal
vein
th
##rom
##bos
##es
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
Grade
3
events
were
reported
in
3
of
the
25
patients
treated
with
AD
##CE
##TR
##IS
who
experienced
in
##fusion
-
related
reactions
.
[SEP]
[CLS]
5
.
8
H
##yper
##tri
##gly
##cer
##ide
##mia
In
women
with
pre
-
existing
h
##yper
##tri
##gly
##cer
##ide
##mia
,
treatment
with
est
##rogen
##s
may
be
associated
with
elevations
of
plasma
t
##rig
##ly
##cer
##ides
leading
to
pan
##cre
##ati
##tis
.
[SEP]
[CLS]
In
the
extension
chronic
IT
##P
trial
,
one
additional
patient
had
PR
##OM
##AC
##TA
discontinued
due
to
liver
test
abnormal
##ities
(
less
than
or
equal
to
Grade
3
)
.
[SEP]
[CLS]
(
5
.
2
)
*
He
##pa
##tic
Effects
:
Post
##market
##ing
reports
of
he
##pa
##tic
failure
,
sometimes
fatal
.
[SEP]
[CLS]
Del
##ay
##ed
reactions
can
occur
up
to
several
days
after
E
##O
##VI
##ST
administration
.
[SEP]
[CLS]
These
reactions
may
occur
in
patients
with
no
history
of
prior
exposure
to
V
##iza
##my
##l
.
[SEP]
[CLS]
He
##mat
##uria
:
Ad
##verse
events
of
hem
##at
##uria
,
including
those
requiring
medical
intervention
,
were
more
common
in
J
##E
##V
##TA
##NA
-
treated
patients
.
[SEP]
[CLS]
Prior
to
in
##iti
##ating
im
##mu
##no
##mo
##du
##lator
##y
the
##rap
##ies
,
including
IL
##AR
##IS
,
patients
should
be
evaluated
for
active
and
late
##nt
tuberculosis
infection
.
[SEP]
[CLS]
Because
of
this
,
patients
who
have
conditions
that
might
be
influenced
by
this
factor
,
such
as
cardiac
d
##ys
##function
or
re
##nal
imp
##air
##ment
,
warrant
careful
observation
when
est
##rogen
##s
are
prescribed
.
[SEP]
[CLS]
Of
those
patients
who
developed
new
cu
##SC
##C
,
approximately
33
%
developed
one
or
more
cu
##SC
##C
with
continued
administration
of
T
##AF
##IN
##LA
##R
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
Ex
##clusive
of
an
uncommon
,
mild
injection
site
reaction
,
no
adverse
reactions
to
11
C
-
ch
##olin
##e
have
been
reported
.
[SEP]
[CLS]
Con
##com
##ita
##nt
administration
of
drugs
associated
with
ON
##J
may
increase
the
risk
of
developing
ON
##J
.
[SEP]
[CLS]
Ad
##vise
patients
to
report
symptoms
of
severe
h
##yper
##gly
##ce
##mia
such
as
excessive
thirst
or
any
increase
in
the
volume
or
frequency
of
u
##rina
##tion
.
[SEP]
[CLS]
Graf
##t
loss
in
some
patients
.
[SEP]
[CLS]
5
.
4
Oral
U
##l
##cer
##ation
Mouth
ul
##cer
##s
,
s
##tom
##ati
##tis
,
and
oral
m
##uc
##os
##itis
have
occurred
in
patients
treated
with
A
##FI
##NI
##TO
##R
at
an
incidence
ranging
from
44
%
-
78
%
across
the
clinical
trial
experience
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
IN
##CR
##EA
##SE
##D
M
##OR
##TA
##L
##IT
##Y
IN
E
##LD
##ER
##L
##Y
PA
##TI
##EN
##TS
W
##IT
##H
DE
##ME
##NT
##IA
-
R
##EL
##AT
##ED
PS
##Y
##CH
##OS
##IS
WA
##R
##NI
##NG
:
IN
##CR
##EA
##SE
##D
M
##OR
##TA
##L
##IT
##Y
IN
E
##LD
##ER
##L
##Y
PA
##TI
##EN
##TS
W
##IT
##H
DE
##ME
##NT
##IA
-
R
##EL
##AT
##ED
PS
##Y
##CH
##OS
##IS
Elder
##ly
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
treated
with
anti
##psy
##cho
##tic
drugs
are
at
an
increased
risk
of
death
.
[SEP]
[CLS]
Pat
##ients
ranged
in
age
from
18
to
83
years
,
with
an
overall
median
age
of
51
years
.
[SEP]
[CLS]
Ad
##verse
event
data
collected
from
those
trials
showed
the
following
rates
of
EP
##S
-
related
adverse
events
as
shown
in
Table
8
.
[SEP]
[CLS]
Side
-
by
-
side
ta
##bula
##tion
is
to
si
##mp
##lify
presentation
;
direct
comparisons
across
trials
should
not
be
made
due
to
differing
trial
designs
.
[SEP]
[CLS]
(
5
.
4
)
*
Risk
of
adverse
reactions
or
loss
of
v
##iro
##log
##ic
response
due
to
drug
interactions
:
The
con
##com
##ita
##nt
use
of
ST
##RI
##BI
##LD
and
other
drugs
may
result
in
known
or
potentially
significant
drug
interactions
,
some
of
which
may
lead
to
loss
of
therapeutic
effect
of
ST
##RI
##BI
##LD
and
possible
development
of
resistance
;
and
possible
clinical
##ly
significant
adverse
reactions
from
greater
exposure
##s
of
con
##com
##ita
##nt
drugs
.
[SEP]
[CLS]
There
were
4
suicide
##s
in
drug
-
treated
patients
in
the
trials
and
none
in
place
##bo
-
treated
patients
,
but
the
number
is
too
small
to
allow
any
conclusion
about
drug
effect
on
suicide
.
[SEP]
[CLS]
Treatment
-
emerge
##nt
AD
##R
##s
in
VI
##K
##ING
-
3
were
generally
similar
compared
with
observations
with
the
50
-
mg
once
-
daily
dose
in
adult
Phase
3
trials
.
[SEP]
[CLS]
Other
adverse
reactions
with
a
plausible
relationship
to
treatment
that
have
been
reported
with
an
incidence
of
>
=
0
.
3
%
and
greater
than
place
##bo
in
more
than
330
##0
patients
treated
with
Ed
##ar
##bi
in
controlled
trials
are
listed
below
:
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
:
nausea
General
Di
##sor
##ders
and
Administration
Site
Con
##ditions
:
as
##the
##nia
,
fatigue
Mu
##s
##cu
##los
##kel
##etal
and
Con
##nect
##ive
T
##iss
##ue
Di
##sor
##ders
:
muscle
spa
##sm
N
##er
##vous
System
Di
##sor
##ders
:
di
##zzi
##ness
,
di
##zzi
##ness
post
##ural
Re
##sp
##ira
##tory
,
Thor
##ac
##ic
,
and
Media
##st
##inal
Di
##sor
##ders
:
cough
6
.
2
Clinical
Laboratory
Finding
##s
In
controlled
clinical
trials
,
clinical
##ly
relevant
changes
in
standard
laboratory
parameters
were
uncommon
with
administration
of
Ed
##ar
##bi
.
[SEP]
[CLS]
Use
with
caution
in
patients
with
these
infections
.
[SEP]
[CLS]
E
##stro
##gens
may
increase
the
chances
of
getting
certain
types
of
cancer
##s
,
including
cancer
of
the
breast
or
u
##ter
##us
.
[SEP]
[CLS]
`
`
When
the
est
##rogen
levels
begin
dropping
,
some
women
get
very
uncomfortable
symptoms
,
such
as
feelings
of
warmth
in
the
face
,
neck
,
and
chest
,
or
sudden
intense
episodes
of
heat
and
sweating
(
`
`
hot
flashes
'
'
or
`
`
hot
flush
##es
'
'
)
.
[SEP]
[CLS]
O
##ste
##one
##c
##rosis
of
the
J
##aw
No
cases
of
ON
##J
were
reported
.
[SEP]
[CLS]
The
incidence
of
dip
##lop
##ia
was
greater
with
the
con
##com
##ita
##nt
use
of
AP
##TI
##OM
and
car
##ba
##ma
##ze
##pine
compared
to
the
use
of
AP
##TI
##OM
without
car
##ba
##ma
##ze
##pine
(
up
to
16
%
vs
.
6
%
,
respectively
)
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
Ana
##ly
##ses
of
17
place
##bo
-
controlled
trials
(
m
##oda
##l
duration
of
10
weeks
)
,
largely
in
patients
taking
at
##y
##pical
anti
##psy
##cho
##tic
drugs
,
revealed
a
risk
of
death
in
the
drug
-
treated
patients
of
between
1
.
6
to
1
.
7
times
that
seen
in
place
##bo
-
treated
patients
.
[SEP]
[CLS]
5
.
4
At
##rial
Fi
##bri
##lla
##tion
At
##rial
fi
##bri
##lla
##tion
and
at
##rial
flutter
(
range
,
6
to
9
%
)
have
occurred
in
patients
treated
with
I
##MB
##R
##U
##VI
##CA
,
particularly
in
patients
with
cardiac
risk
factors
,
acute
infections
,
and
a
previous
history
of
at
##rial
fi
##bri
##lla
##tion
.
[SEP]
[CLS]
The
population
was
31
-
84
years
of
age
,
60
%
male
,
and
40
%
female
.
[SEP]
[CLS]
The
incidence
of
Grade
>
=
3
hem
##or
##r
##ha
##gic
events
was
higher
in
CO
##ME
##TR
##I
##Q
-
treated
patients
compared
with
place
##bo
(
3
%
vs
.
1
%
)
.
[SEP]
[CLS]
In
Study
1
,
the
number
of
ER
##WI
##NA
##Z
##E
courses
ranged
from
1
to
9
.
[SEP]
[CLS]
Pat
##ients
who
fail
to
show
substantial
clinical
benefit
after
adequate
t
##it
##ration
should
be
discontinued
from
P
##OT
##IG
##A
.
[SEP]
[CLS]
Women
with
a
tendency
to
ch
##lo
##as
##ma
should
avoid
exposure
to
the
sun
or
ultra
##vio
##let
radiation
while
taking
CO
##Cs
.
[SEP]
[CLS]
5
.
12
Suicide
The
possibility
of
a
suicide
attempt
is
inherent
in
ps
##ych
##otic
illness
,
and
close
supervision
of
high
-
risk
patients
should
accompany
drug
therapy
.
[SEP]
[CLS]
Anti
##body
formation
was
associated
with
lowered
drug
plasma
concentration
and
reduced
efficacy
.
[SEP]
[CLS]
There
were
too
few
cases
to
determine
whether
the
emergence
of
these
events
is
related
to
FA
##R
##X
##IG
##A
.
[SEP]
[CLS]
These
trials
included
83
##2
patients
of
whom
55
##1
and
281
received
XI
##AF
##LE
##X
and
place
##bo
,
respectively
.
[SEP]
[CLS]
Monitor
liver
function
and
modify
,
interrupt
,
or
disco
##ntin
##ue
Z
##Y
##TI
##GA
dos
##ing
as
recommended
.
[SEP]
[CLS]
b
B
##lee
##ding
site
based
on
investigator
assessment
.
[SEP]
[CLS]
Ad
##vise
patients
taking
Fe
##rri
##p
##ro
##x
to
immediately
interrupt
therapy
and
report
to
their
physician
if
they
experience
any
symptoms
in
##dicative
of
infection
.
[SEP]
[CLS]
Em
##b
##ryo
-
f
##etal
toxicity
and
te
##rato
##genic
##ity
occurred
in
rats
that
received
er
##ib
##ulin
me
##sy
##late
at
approximately
half
of
the
recommended
human
dose
based
on
body
surface
area
.
[SEP]
[CLS]
5
.
4
Tu
##mor
L
##ys
##is
S
##yn
##drome
Tu
##mor
l
##ys
##is
syndrome
has
occurred
in
Bel
##eo
##da
##q
-
treated
patients
in
the
clinical
trial
of
patients
with
re
##lap
##sed
or
re
##fra
##ctor
##y
PT
##CL
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Pat
##ients
with
a
history
of
extensive
or
intensive
ch
##em
##otherapy
may
be
at
higher
risk
of
life
threatening
infections
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
5
.
2
Ra
##diation
Risk
N
##eur
##ace
##q
,
similar
to
other
radio
##pha
##rma
##ce
##utical
##s
,
contributes
to
a
patient
'
s
overall
long
-
term
cumulative
radiation
exposure
.
[SEP]
[CLS]
R
##E
-
S
##ON
##AT
##E
was
a
place
##bo
-
controlled
study
in
which
68
##4
patients
received
PR
##AD
##A
##X
##A
150
mg
twice
daily
following
6
to
18
months
of
oral
anti
##coa
##gu
##lant
regime
##n
.
[SEP]
[CLS]
When
medical
##ly
feasible
,
stop
these
drugs
before
Ad
##re
##V
##ie
##w
administration
and
monitor
patients
for
withdrawal
signs
and
symptoms
.
[SEP]
[CLS]
In
the
two
random
##ized
clinical
trials
,
grade
3
to
4
h
##yper
##tens
##ion
occurred
in
2
%
of
patients
,
grade
3
to
4
h
##y
##po
##kal
##emia
in
4
%
of
patients
,
and
grade
3
to
4
ed
##ema
in
1
%
of
patients
treated
with
Z
##Y
##TI
##GA
[
see
##A
##d
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
In
clinical
trials
of
T
##NF
block
##ers
,
including
C
##IM
##Z
##IA
,
in
patients
with
RA
,
some
patients
have
developed
AN
##A
.
[SEP]
[CLS]
To
reduce
the
potential
risk
of
bleeding
associated
with
the
concurrent
use
of
da
##bi
##gat
##ran
and
e
##pid
##ural
or
spinal
an
##est
##hesia
/
anal
##ges
##ia
or
spinal
pu
##nc
##ture
,
consider
the
p
##har
##ma
##co
##kin
##etic
profile
of
da
##bi
##gat
##ran
[
see
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
As
##piration
pneumonia
is
a
common
cause
of
m
##or
##bid
##ity
and
mortality
in
elderly
patients
,
in
particular
those
with
advanced
Alzheimer
'
s
dem
##ent
##ia
.
[SEP]
[CLS]
About
25
%
of
patients
were
from
the
United
States
and
75
%
from
other
countries
.
[SEP]
[CLS]
The
combination
of
trans
##ami
##nas
##e
elevations
and
elevated
bi
##li
##ru
##bin
without
evidence
of
o
##bs
##truction
is
generally
recognized
as
an
important
predict
##or
of
severe
liver
injury
.
[SEP]
[CLS]
B
##EP
##RE
##VE
should
not
be
used
to
treat
contact
lens
-
related
irritation
.
[SEP]
[CLS]
(
5
.
1
)
*
Inter
##st
##iti
##al
Lu
##ng
Disease
(
IL
##D
)
/
P
##ne
##um
##oni
##tis
:
O
##cc
##ur
##red
in
2
.
9
%
of
patients
.
[SEP]
[CLS]
In
this
setting
,
a
re
-
evaluation
of
the
patient
and
the
CO
##PD
treatment
regime
##n
should
be
undertaken
at
once
.
[SEP]
[CLS]
Pan
##cre
##ati
##tis
Pan
##cre
##ati
##tis
was
reported
in
4
patients
(
0
.
1
%
)
in
the
place
##bo
and
8
patients
(
0
.
2
%
)
in
the
Pro
##lia
groups
.
[SEP]
[CLS]
Record
the
specific
GB
##CA
and
the
dose
administered
to
a
patient
.
[SEP]
[CLS]
Ser
##ious
adverse
events
were
reported
in
60
%
of
the
patients
in
the
K
##R
##d
arm
and
54
%
of
the
patients
in
the
Rd
arm
.
[SEP]
[CLS]
In
other
women
,
symptoms
can
be
more
severe
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Associated
with
Disco
##ntin
##uation
of
Treatment
:
Approximately
16
%
(
25
/
158
)
of
SA
##P
##H
##RI
##S
-
treated
patients
discontinued
treatment
due
to
an
adverse
reaction
,
compared
with
about
11
%
(
18
/
166
)
on
place
##bo
.
[SEP]
[CLS]
Pro
##la
##ct
##in
:
In
short
-
term
,
place
##bo
-
controlled
adult
s
##chi
##zophrenia
trials
,
the
mean
decreases
in
pro
##la
##ct
##in
levels
were
6
.
5
ng
/
m
##L
for
SA
##P
##H
##RI
##S
-
treated
patients
compared
to
10
.
7
ng
/
m
##L
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
*
To
##via
##z
should
be
administered
with
caution
to
patients
with
clinical
##ly
significant
bladder
outlet
o
##bs
##truction
because
of
the
risk
of
u
##rina
##ry
retention
.
[SEP]
[CLS]
Because
H
##OR
##I
##Z
##AN
##T
is
a
pro
##dr
##ug
of
g
##aba
##pent
##in
,
H
##OR
##I
##Z
##AN
##T
also
increases
this
risk
.
[SEP]
[CLS]
Treatment
with
ST
##RI
##BI
##LD
should
be
suspended
in
any
patient
who
develops
clinical
or
laboratory
findings
suggest
##ive
of
la
##ctic
acid
##osis
or
pronounced
he
##pa
##to
##to
##xi
##city
(
which
may
include
he
##pa
##tom
##eg
##aly
and
s
##te
##ato
##sis
even
in
the
absence
of
marked
trans
##ami
##nas
##e
elevations
)
.
[SEP]
[CLS]
Monitor
thy
##roid
function
tests
and
clinical
chemist
##ries
at
the
start
of
treatment
,
before
each
dose
,
and
as
clinical
##ly
indicated
based
on
symptoms
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
that
led
to
disco
##ntin
##uation
in
G
##IL
##OT
##RI
##F
-
treated
patients
were
di
##ar
##r
##hea
(
1
.
3
%
)
,
IL
##D
(
0
.
9
%
)
,
and
par
##ony
##chia
(
0
.
9
%
)
.
[SEP]
[CLS]
The
incidence
of
adverse
events
leading
to
study
drug
disco
##ntin
##uation
for
C
##lev
##ip
##re
##x
in
severe
h
##yper
##tens
##ion
was
4
.
8
%
.
[SEP]
[CLS]
5
.
5
Post
##eri
##or
Rev
##ers
##ible
En
##ce
##pha
##lop
##athy
S
##yn
##drome
There
have
been
rare
cases
of
posterior
re
##versible
en
##ce
##pha
##lop
##athy
syndrome
(
PR
##ES
)
reported
in
patients
receiving
G
##IL
##EN
##Y
##A
.
[SEP]
[CLS]
5
.
4
O
##ste
##one
##c
##rosis
of
the
J
##aw
O
##ste
##one
##c
##rosis
of
the
jaw
(
ON
##J
)
,
which
can
occur
spontaneous
##ly
,
is
generally
associated
with
tooth
extraction
and
/
or
local
infection
with
delayed
healing
.
[SEP]
[CLS]
5
.
7
Live
##r
In
##ju
##ry
El
##eva
##tions
of
liver
enzymes
may
occur
in
patients
receiving
G
##IL
##EN
##Y
##A
.
[SEP]
[CLS]
Blood
G
##lu
##cos
##e
and
Li
##pid
##s
H
##yper
##gly
##ce
##mia
,
h
##yper
##lip
##ide
##mia
,
and
h
##yper
##tri
##gly
##cer
##ide
##mia
have
been
reported
in
patients
taking
A
##FI
##NI
##TO
##R
[
see
Ad
##verse
Re
##actions
(
6
.
1
,
6
.
2
,
6
.
3
,
6
.
4
,
6
.
5
)
]
.
[SEP]
[CLS]
Twenty
-
two
(
6
%
)
patients
discontinued
J
##E
##V
##TA
##NA
treatment
due
to
ne
##ut
##rop
##enia
,
f
##eb
##ril
##e
ne
##ut
##rop
##enia
,
infection
,
or
se
##psis
.
[SEP]
[CLS]
5
.
2
A
##cute
Re
##sp
##ira
##tory
Di
##st
##ress
S
##yn
##drome
(
AR
##DS
)
A
##cute
respiratory
distress
syndrome
(
AR
##DS
)
can
occur
in
patients
receiving
human
g
##ran
##ulo
##cy
##te
colony
-
s
##ti
##mulating
factors
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Ba
##us
##ch
&
Lo
##mb
Incorporated
.
[SEP]
[CLS]
R
##iba
##vir
##in
therapy
should
not
be
started
unless
a
report
of
a
negative
pregnancy
test
has
been
obtained
immediately
prior
to
initiation
of
therapy
.
[SEP]
[CLS]
c
Includes
the
following
terms
:
r
##ash
,
r
##ash
generalized
,
r
##ash
p
##ru
##ritic
,
r
##ash
er
##yt
##hem
##ato
##us
,
r
##ash
p
##ap
##ular
,
r
##ash
ve
##si
##cular
,
r
##ash
mac
##ular
,
and
r
##ash
mac
##ulo
-
p
##ap
##ular
.
[SEP]
[CLS]
Pre
##scription
##s
for
SA
##P
##H
##RI
##S
should
be
written
for
the
smallest
quantity
of
tablets
consistent
with
good
patient
management
in
order
to
reduce
the
risk
of
over
##dos
##e
.
[SEP]
[CLS]
In
Study
3
,
in
##fusion
-
related
reactions
were
reported
in
25
patients
(
15
%
)
in
the
AD
##CE
##TR
##IS
-
treated
arm
and
3
patients
(
2
%
)
in
the
place
##bo
arm
.
[SEP]
[CLS]
(
5
.
8
,
2
.
3
)
*
H
##yper
##gly
##ce
##mia
:
Monitor
serum
glucose
levels
in
patients
with
pre
-
existing
diabetes
or
h
##yper
##gly
##ce
##mia
.
[SEP]
[CLS]
If
examination
reveals
p
##ap
##ille
##de
##ma
or
re
##tina
##l
vascular
lesions
,
D
##U
##AV
##EE
should
be
permanently
discontinued
.
[SEP]
[CLS]
During
the
four
week
lead
-
in
period
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
in
subjects
treated
with
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
,
28
/
126
##3
(
2
%
)
subjects
experienced
adverse
reactions
leading
to
disco
##ntin
##uation
of
treatment
.
[SEP]
[CLS]
If
such
reactions
occur
,
disco
##ntin
##ue
further
administration
of
C
##IM
##Z
##IA
and
institute
appropriate
therapy
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Poole
##d
Phase
3
Clinical
Trials
(
four
trials
,
two
in
ABS
##SS
##I
and
two
in
CA
##B
##P
)
Te
##f
##lar
##o
(
N
=
1300
)
Poole
##d
Co
##mp
##ara
##tors
a
(
N
=
129
##7
)
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
Di
##ar
##r
##hea
5
%
3
%
Na
##use
##a
4
%
4
%
Con
##st
##ip
##ation
2
%
2
%
V
##omi
##ting
2
%
2
%
Laboratory
Investigation
##s
Inc
##reased
trans
##ami
##nas
##es
2
%
3
%
Met
##ab
##olis
##m
and
N
##utrition
disorders
H
##y
##po
##kal
##emia
2
%
3
%
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
Ra
##sh
3
%
2
%
V
##as
##cular
Di
##sor
##ders
Ph
##le
##bit
##is
2
%
1
%
Other
Ad
##verse
Re
##actions
O
##bs
##erve
##d
During
Clinical
Trials
of
Te
##f
##lar
##o
Following
is
a
list
of
additional
adverse
reactions
reported
by
the
1740
patients
who
received
Te
##f
##lar
##o
in
any
clinical
trial
with
incidence
##s
less
than
2
%
.
[SEP]
[CLS]
Eleven
patients
(
26
%
)
were
treated
for
greater
than
6
months
and
7
patients
(
16
%
)
were
treated
for
greater
than
1
year
.
[SEP]
[CLS]
In
Study
3
,
67
%
of
patients
treated
with
AD
##CE
##TR
##IS
experienced
any
grade
of
ne
##uro
##pathy
.
[SEP]
[CLS]
Disco
##ntin
##ue
for
into
##ler
##able
Grade
2
,
or
Grade
3
or
4
r
##ash
not
improving
within
3
weeks
despite
interrupt
##ion
of
T
##AF
##IN
##LA
##R
.
[SEP]
[CLS]
In
Studies
1
and
2
,
the
most
common
adverse
reactions
(
>
=
2
%
)
associated
with
in
##fusion
-
related
reactions
were
chill
##s
(
4
%
)
,
nausea
(
3
%
)
,
d
##ys
##p
##nea
(
3
%
)
,
p
##ru
##rit
##us
(
3
%
)
,
p
##yre
##xia
(
2
%
)
,
and
cough
(
2
%
)
.
[SEP]
[CLS]
5
.
2
Ser
##oto
##nin
S
##yn
##drome
The
development
of
a
potentially
life
-
threatening
se
##rot
##oni
##n
syndrome
has
been
reported
with
S
##NR
##I
##s
and
SSR
##I
##s
,
including
PR
##IS
##TI
##Q
,
alone
but
particularly
with
con
##com
##ita
##nt
use
of
other
se
##rot
##one
##rg
##ic
drugs
(
including
trip
##tan
##s
,
t
##ric
##yclic
anti
##de
##press
##ants
,
f
##ent
##any
##l
,
lit
##hium
,
tram
##ado
##l
,
try
##pt
##op
##han
,
bus
##pi
##rone
,
and
St
.
John
'
s
W
##ort
)
,
and
with
drugs
that
imp
##air
metabolism
of
se
##rot
##oni
##n
(
in
particular
,
MA
##O
##I
##s
,
both
those
intended
to
treat
psychiatric
disorders
and
also
others
,
such
as
line
##zo
##lid
and
in
##tra
##ven
##ous
met
##hyl
##ene
blue
)
.
[SEP]
[CLS]
It
is
not
possible
to
determine
whether
these
events
are
related
directly
to
the
use
of
PD
##E
##5
inhibitor
##s
or
to
other
factors
[
see
##A
##d
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
For
p
##ediatric
patients
with
SE
##GA
that
do
not
require
immediate
treatment
,
complete
the
recommended
childhood
series
of
live
virus
v
##ac
##cin
##ations
according
to
American
Council
on
I
##mm
##uni
##zation
Practice
##s
(
AC
##IP
)
guidelines
prior
to
the
start
of
therapy
.
[SEP]
[CLS]
*
Ser
##oto
##nin
S
##yn
##drome
:
Ser
##oto
##nin
syndrome
has
been
reported
with
SSR
##I
##s
and
S
##NR
##I
##s
,
including
with
PR
##IS
##TI
##Q
,
both
when
taken
alone
,
but
especially
when
co
-
administered
with
other
se
##rot
##one
##rg
##ic
agents
(
including
trip
##tan
##s
,
t
##ric
##yclic
anti
##de
##press
##ants
,
f
##ent
##any
##l
,
lit
##hium
,
tram
##ado
##l
,
try
##pt
##op
##han
,
bus
##pi
##rone
,
and
St
.
John
'
s
W
##ort
)
.
[SEP]
[CLS]
In
##fect
##ions
,
in
some
instances
serious
,
have
been
reported
with
IL
##AR
##IS
.
[SEP]
[CLS]
Co
##ad
##mini
##stra
##tion
of
IL
##AR
##IS
with
T
##NF
inhibitor
##s
is
not
recommended
because
this
may
increase
the
risk
of
serious
infections
[
see
Drug
Inter
##actions
(
7
.
1
)
]
.
[SEP]
[CLS]
Monitor
##ing
of
fast
##ing
serum
glucose
and
lip
##id
profile
is
recommended
prior
to
the
start
of
A
##FI
##NI
##TO
##R
therapy
and
periodically
thereafter
as
well
as
management
with
appropriate
medical
therapy
.
[SEP]
[CLS]
ch
##em
##otherapy
,
co
##rt
##ico
##ster
##oids
,
an
##gio
##genesis
inhibitor
##s
)
,
poor
oral
h
##ygiene
,
and
co
-
m
##or
##bid
disorders
(
e
.
g
.
[SEP]
[CLS]
*
*
Fat
##al
bleeding
is
an
ad
##ju
##dicated
death
with
the
primary
cause
of
death
as
in
##tra
##c
##rani
##al
bleeding
or
non
-
in
##tra
##c
##rani
##al
bleeding
during
the
on
-
treatment
period
.
[SEP]
[CLS]
The
two
cases
of
PT
##LD
were
reported
among
the
140
E
##B
##V
se
##rop
##os
##itive
patients
(
1
.
4
%
)
.
[SEP]
[CLS]
There
is
limited
experience
with
short
-
duration
therapy
with
beta
-
block
##ers
as
a
treatment
for
C
##lev
##ip
##re
##x
-
induced
ta
##chy
##card
##ia
.
[SEP]
[CLS]
(
5
.
1
)
*
Live
vaccine
##s
should
not
be
given
concurrently
with
IL
##AR
##IS
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
P
##OT
##EN
##TI
##AL
R
##IS
##K
OF
M
##Y
##OC
##AR
##DI
##AL
IN
##FA
##RC
##TI
##ON
W
##IT
##H
L
##ON
##G
-
T
##ER
##M
US
##E
:
F
##OR
SH
##OR
##T
-
T
##ER
##M
H
##OS
##PI
##TA
##L
US
##E
ON
##L
##Y
WA
##R
##NI
##NG
:
P
##OT
##EN
##TI
##AL
R
##IS
##K
OF
M
##Y
##OC
##AR
##DI
##AL
IN
##FA
##RC
##TI
##ON
W
##IT
##H
L
##ON
##G
-
T
##ER
##M
US
##E
:
F
##OR
SH
##OR
##T
-
T
##ER
##M
H
##OS
##PI
##TA
##L
US
##E
ON
##L
##Y
There
was
a
greater
incidence
of
my
##oc
##ard
##ial
in
##far
##ction
in
al
##vi
##mo
##pan
-
treated
patients
compared
to
place
##bo
-
treated
patients
in
a
12
-
month
clinical
trial
,
although
a
ca
##usal
relationship
has
not
been
established
.
[SEP]
[CLS]
Consider
the
diagnosis
of
PM
##L
in
any
patient
presenting
with
new
-
onset
or
de
##ter
##ior
##ating
ne
##uro
##logical
signs
and
symptoms
and
consult
with
a
ne
##uro
##logist
or
other
appropriate
specialist
as
clinical
##ly
indicated
.
[SEP]
[CLS]
Disco
##ntin
##ue
G
##IL
##OT
##RI
##F
if
IL
##D
is
diagnosed
.
[SEP]
[CLS]
Table
1
lists
adverse
reactions
that
occurred
in
>
=
1
%
of
G
##IL
##EN
##Y
##A
-
treated
patients
and
>
=
1
%
higher
rate
than
for
place
##bo
.
[SEP]
[CLS]
The
proportion
of
p
##ediatric
patients
with
AL
##T
elevations
>
=
3
times
upper
limit
of
normal
(
U
##L
##N
)
was
2
.
4
%
for
patients
treated
with
SA
##P
##H
##RI
##S
10
mg
twice
daily
versus
none
for
the
other
SA
##P
##H
##RI
##S
dose
groups
and
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Table
8
:
Grade
3
-
4
Laboratory
A
##b
##nor
##mal
##ities
(
>
10
%
)
(
Mon
##otherapy
)
Ad
##verse
Re
##action
K
##y
##p
##rol
##is
(
N
=
59
##8
)
Dec
##reased
Plate
##lets
184
(
31
%
)
Dec
##reased
L
##ymph
##ocytes
151
(
25
%
)
Dec
##reased
He
##mo
##g
##lo
##bin
132
(
22
%
)
Dec
##reased
Total
White
Blood
Cell
Count
71
(
12
%
)
Dec
##reased
So
##dium
69
(
12
%
)
Dec
##reased
A
##bs
##ol
##ute
N
##eu
##tro
##phi
##l
Count
67
(
11
%
)
6
.
2
Post
-
marketing
Experience
The
following
adverse
reactions
were
reported
in
the
post
-
marketing
experience
with
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
The
use
of
clinical
information
in
the
interpretation
of
Amy
##vid
images
has
not
been
evaluated
and
may
lead
to
errors
.
[SEP]
[CLS]
In
some
women
,
the
symptoms
are
mild
,
and
they
will
not
need
to
take
medicines
.
[SEP]
[CLS]
Among
the
factors
that
may
increase
the
risk
for
N
##SF
are
repeated
or
higher
than
recommended
doses
of
a
GB
##CA
and
the
degree
of
re
##nal
imp
##air
##ment
at
the
time
of
exposure
.
[SEP]
[CLS]
(
5
.
5
)
*
Po
##ten
##tial
worse
##ning
of
infections
)
.
[SEP]
[CLS]
A
dose
decrease
is
recommended
when
administer
##ing
IN
##L
##Y
##TA
to
patients
with
moderate
he
##pa
##tic
imp
##air
##ment
(
Child
-
P
##ugh
class
B
)
.
[SEP]
[CLS]
Der
##mat
##olo
##gic
Re
##actions
der
##mal
adverse
events
(
such
as
der
##mat
##itis
,
e
##cz
##ema
,
and
r
##ash
##es
)
were
reported
in
4
patients
(
3
.
3
%
)
in
the
place
##bo
group
and
5
patients
(
4
.
2
%
)
in
the
Pro
##lia
group
.
[SEP]
[CLS]
est
##rad
##iol
,
may
be
decreased
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
B
##io
##M
##ari
##n
at
1
-
86
##6
-
90
##6
-
610
##0
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
I
##mp
##air
##ment
in
Ren
##al
Fun
##ction
IN
##VO
##KA
##NA
is
associated
with
a
dose
-
dependent
increase
in
serum
c
##rea
##tin
##ine
and
a
con
##com
##ita
##nt
fall
in
estimated
G
##F
##R
(
Table
3
)
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
in
patients
with
IL
##D
/
p
##ne
##um
##oni
##tis
.
[SEP]
[CLS]
If
an
an
##aph
##yla
##ctic
or
other
clinical
##ly
significant
all
##ergic
reaction
occurs
,
initiate
appropriate
therapy
and
disco
##ntin
##ue
further
use
of
Pro
##lia
[
see
Con
##tra
##ind
##ica
##tions
(
4
.
3
)
,
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
Monitor
patients
closely
and
take
appropriate
pre
##ca
##ution
##s
in
patients
at
risk
for
tumor
l
##ys
##is
syndrome
(
e
.
g
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
reactions
have
occurred
as
early
as
30
minutes
from
the
start
of
in
##fusion
but
as
late
as
six
days
after
in
##fusion
.
[SEP]
[CLS]
FA
##NA
##P
##T
and
other
anti
##psy
##cho
##tic
drugs
should
be
used
cautiously
in
patients
at
risk
for
as
##piration
pneumonia
[
see
Box
##ed
Warning
]
.
[SEP]
[CLS]
Four
patients
out
of
2
,
36
##7
patients
treated
with
C
##IM
##Z
##IA
in
RA
clinical
studies
developed
clinical
signs
suggest
##ive
of
a
l
##up
##us
-
like
syndrome
.
[SEP]
[CLS]
Pre
##gna
##ncy
should
be
ruled
out
in
the
event
of
am
##eno
##rr
##hea
occurring
in
two
or
more
consecutive
cycles
.
[SEP]
[CLS]
P
##OT
##IG
##A
should
only
be
used
in
patients
who
have
responded
inadequate
##ly
to
several
alternative
treatments
and
for
whom
the
benefits
out
##wei
##gh
the
potential
risk
of
vision
loss
.
[SEP]
[CLS]
Monitor
patients
frequently
for
signs
and
symptoms
of
ne
##uro
##logical
imp
##air
##ment
and
if
observed
,
treat
urgent
##ly
.
[SEP]
[CLS]
Most
patients
who
developed
these
infections
were
taking
con
##com
##ita
##nt
im
##mu
##nos
##up
##press
##ants
such
as
met
##hot
##re
##xa
##te
or
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
(
5
.
4
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Se
##vere
cut
##aneous
reactions
:
Monitor
patients
for
the
development
of
severe
cut
##aneous
reactions
and
disco
##ntin
##ue
Z
##yd
##eli
##g
.
[SEP]
[CLS]
Have
an
##aph
##yla
##ctic
and
h
##yper
##sen
##si
##ti
##vity
treatment
measures
available
prior
to
Ad
##re
##V
##ie
##w
administration
[
see
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
Con
##ges
##tive
Heart
F
##ail
##ure
Many
commonly
used
card
##iovascular
,
pulmonary
,
and
ne
##uro
##psy
##chia
##tric
medications
interfere
with
Ad
##re
##V
##ie
##w
imaging
(
see
above
)
.
[SEP]
[CLS]
In
patients
receiving
the
recommended
C
##IM
##Z
##IA
dos
##age
of
200
mg
every
other
week
with
con
##com
##ita
##nt
M
##T
##X
,
the
AC
##R
##20
response
was
lower
among
anti
##body
positive
patients
than
among
anti
##body
-
negative
patients
(
Study
RA
-
I
,
48
%
versus
60
%
;
Study
RA
-
II
35
%
versus
59
%
,
respectively
)
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
5
%
)
reported
in
patients
receiving
E
##Y
##LE
##A
were
con
##junct
##ival
hem
##or
##r
##hage
,
eye
pain
,
cat
##ara
##ct
,
v
##it
##re
##ous
float
##ers
,
in
##tra
##oc
##ular
pressure
increased
,
and
v
##it
##re
##ous
detachment
.
[SEP]
[CLS]
(
5
.
1
,
5
.
2
)
*
With
##dra
##wal
:
S
##ym
##pt
##oms
may
occur
with
rapid
dose
reduction
or
disco
##ntin
##uation
.
[SEP]
[CLS]
In
pool
##ed
clinical
trials
,
the
incidence
of
a
##gra
##nu
##loc
##yt
##osis
was
1
.
7
%
of
patients
.
[SEP]
[CLS]
Con
##current
Administration
with
V
##em
##ura
##fen
##ib
In
a
dose
-
finding
trial
,
Grade
3
increases
in
trans
##ami
##nas
##es
with
or
without
con
##com
##ita
##nt
increases
in
total
bi
##li
##ru
##bin
occurred
in
6
of
10
patients
who
received
concurrent
Y
##ER
##VO
##Y
(
3
mg
/
kg
)
and
ve
##mura
##fen
##ib
(
96
##0
mg
B
##ID
or
720
mg
B
##ID
)
.
[SEP]
[CLS]
(
5
.
2
)
5
.
1
A
##gra
##nu
##loc
##yt
##osis
/
N
##eu
##tro
##pen
##ia
Fat
##al
a
##gra
##nu
##loc
##yt
##osis
can
occur
with
Fe
##rri
##p
##ro
##x
use
.
[SEP]
[CLS]
a
Pat
##ients
with
at
least
one
MBE
.
[SEP]
[CLS]
There
was
also
an
increased
incidence
of
pneumonia
##s
resulting
in
hospital
##ization
.
[SEP]
[CLS]
Do
not
administer
Bel
##eo
##da
##q
to
patients
with
an
active
infection
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Reg
##ener
##on
at
1
-
85
##5
-
395
-
32
##48
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Use
caution
and
monitor
for
symptoms
and
signs
of
ad
##ren
##oc
##ort
##ical
ins
##uff
##iciency
,
particularly
if
patients
are
withdrawn
from
pre
##dn
##ison
##e
,
have
pre
##dn
##ison
##e
dose
reduction
##s
,
or
experience
unusual
stress
.
[SEP]
[CLS]
A
##vo
##id
concurrent
use
of
Z
##yd
##eli
##g
with
other
drugs
that
may
cause
liver
toxicity
.
[SEP]
[CLS]
(
5
.
1
)
*
Ad
##ren
##oc
##ort
##ical
ins
##uff
##iciency
:
Monitor
for
symptoms
and
signs
of
ad
##ren
##oc
##ort
##ical
ins
##uff
##iciency
.
[SEP]
[CLS]
In
general
,
in
clinical
trials
,
r
##ash
was
mild
to
moderate
,
occurred
primarily
in
the
second
week
of
therapy
,
and
was
in
##f
##re
##quent
after
Week
4
.
[SEP]
[CLS]
The
median
time
to
onset
of
moderate
,
severe
,
or
life
-
threatening
immune
-
mediated
der
##mat
##itis
was
3
.
1
weeks
and
ranged
up
to
17
.
3
weeks
from
the
initiation
of
Y
##ER
##VO
##Y
.
[SEP]
[CLS]
An
additional
13
(
2
.
5
%
)
patients
experienced
moderate
he
##pa
##to
##to
##xi
##city
manifest
##ed
by
liver
function
test
abnormal
##ities
(
AL
##T
elevations
of
more
than
2
.
5
times
but
not
more
than
5
times
the
upper
limit
of
normal
or
total
bi
##li
##ru
##bin
elevation
of
more
than
1
.
5
times
but
not
more
than
3
times
the
upper
limit
of
normal
;
Grade
2
)
.
[SEP]
[CLS]
For
ne
##ut
##rop
##enia
(
AN
##C
<
1
.
5
x
10
9
/
L
and
>
0
.
5
x
10
9
/
L
)
:
In
##st
##ru
##ct
the
patient
to
immediately
disco
##ntin
##ue
Fe
##rri
##p
##ro
##x
and
all
other
medications
with
a
potential
to
cause
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
Disco
##ntin
##ue
for
ne
##ph
##rot
##ic
syndrome
.
[SEP]
[CLS]
5
.
11
D
##ys
##pha
##gia
E
##so
##pha
##ge
##al
d
##ys
##mot
##ility
and
as
##piration
have
been
associated
with
anti
##psy
##cho
##tic
drug
use
.
[SEP]
[CLS]
S
##ym
##pt
##oma
##tic
h
##y
##pot
##ens
##ion
can
occur
after
in
##iti
##ating
FA
##R
##X
##IG
##A
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
particularly
in
patients
with
impaired
re
##nal
function
(
e
##G
##F
##R
less
than
60
m
##L
/
min
/
1
.
73
m
2
)
,
elderly
patients
,
or
patients
on
loop
di
##ure
##tics
.
[SEP]
[CLS]
5
.
7
Palma
##r
-
Plant
##ar
E
##ry
##th
##rod
##ys
##est
##hesia
S
##yn
##drome
Palma
##r
-
plant
##ar
er
##yt
##hr
##ody
##ses
##the
##sia
syndrome
(
PP
##ES
)
occurred
in
50
%
of
patients
treated
with
CO
##ME
##TR
##I
##Q
and
was
severe
(
>
=
Grade
3
)
in
13
%
of
patients
.
[SEP]
[CLS]
The
proportion
of
patients
who
discontinued
treatment
due
to
adverse
reactions
was
13
%
for
the
recommended
N
##U
##L
##O
##J
##IX
regime
##n
and
19
%
for
the
c
##y
##c
##los
##por
##ine
control
arm
through
three
years
of
treatment
.
[SEP]
[CLS]
Drugs
with
alpha
-
ad
##rene
##rg
##ic
blocking
effects
have
been
reported
to
induce
p
##ria
##pis
##m
.
[SEP]
[CLS]
The
overall
safety
profile
of
K
##AL
##Y
##DE
##CO
is
based
on
pool
##ed
data
from
three
place
##bo
-
controlled
clinical
trials
conducted
in
35
##3
patients
6
years
of
age
and
older
with
CF
who
had
a
G
##55
##1
##D
mutation
in
the
CF
##TR
gene
(
Trials
1
and
2
)
or
were
ho
##mo
##zy
##go
##us
for
the
F
##50
##8
##del
mutation
(
Trial
3
)
.
[SEP]
[CLS]
If
at
##rial
fi
##bri
##lla
##tion
per
##sist
##s
,
consider
the
risks
and
benefits
of
I
##MB
##R
##U
##VI
##CA
treatment
and
dose
modification
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
The
pre
##ser
##vat
##ive
in
B
##EP
##RE
##VE
,
ben
##zal
##kon
##ium
chloride
,
may
be
absorbed
by
soft
contact
lenses
.
[SEP]
[CLS]
New
ma
##li
##gna
##ncies
related
to
the
breast
(
0
.
6
%
place
##bo
vs
.
0
.
9
%
Pro
##lia
)
were
reported
.
[SEP]
[CLS]
5
.
10
I
##mm
##uni
##zation
##s
Pat
##ients
treated
with
C
##IM
##Z
##IA
may
receive
v
##ac
##cin
##ations
,
except
for
live
or
live
at
##ten
##uated
vaccine
##s
.
[SEP]
[CLS]
The
most
common
serious
adverse
reactions
(
>
2
%
)
were
pneumonia
,
p
##yre
##xia
,
infection
,
an
##emia
,
increased
c
##rea
##tin
##ine
,
th
##rom
##bo
##cy
##top
##enia
,
and
multi
-
organ
failure
.
[SEP]
[CLS]
The
mean
age
of
the
population
was
56
years
and
3
%
were
older
than
75
years
of
age
.
[SEP]
[CLS]
In
Studies
1
and
2
,
the
most
common
adverse
reactions
(
>
=
20
%
)
,
regardless
of
ca
##usal
##ity
,
were
ne
##ut
##rop
##enia
,
peripheral
sensory
ne
##uro
##pathy
,
fatigue
,
nausea
,
an
##emia
,
upper
respiratory
tract
infection
,
di
##ar
##r
##hea
,
p
##yre
##xia
,
r
##ash
,
th
##rom
##bo
##cy
##top
##enia
,
cough
,
and
vomit
##ing
.
[SEP]
[CLS]
If
any
bleeding
requires
medical
intervention
,
temporarily
interrupt
the
IN
##L
##Y
##TA
dose
.
[SEP]
[CLS]
Table
11
:
Ad
##verse
Re
##actions
Report
##ed
in
2
%
or
More
of
Adult
Pat
##ients
In
Any
SA
##P
##H
##RI
##S
-
Do
##se
Group
and
Which
O
##cc
##ur
##red
at
Greater
Inc
##iden
##ce
Than
in
the
Place
##bo
Group
at
3
Weeks
in
Ad
##junct
##ive
B
##ip
##olar
Man
##ia
Trials
*
SA
##P
##H
##RI
##S
5
mg
to
10
mg
twice
daily
with
flexible
dos
##ing
.
[SEP]
[CLS]
D
##U
##AV
##EE
is
not
for
use
in
children
.
[SEP]
[CLS]
Pain
in
ex
##tre
##mity
and
m
##us
##cu
##los
##kel
##etal
pain
have
also
been
reported
in
clinical
trials
.
[SEP]
[CLS]
(
5
.
7
)
*
I
##mm
##une
re
##con
##st
##itution
syndrome
:
May
ne
##cess
##itate
further
evaluation
and
treatment
.
[SEP]
[CLS]
In
AT
##H
##EN
##A
,
the
maximum
follow
-
up
was
30
months
.
[SEP]
[CLS]
6
.
1
Clinical
Study
Experience
in
Advanced
Ho
##rmon
##e
Re
##ceptor
-
Po
##sitive
,
H
##ER
##2
-
N
##eg
##ative
B
##rea
##st
Cancer
The
efficacy
and
safety
of
A
##FI
##NI
##TO
##R
(
10
mg
/
day
)
plus
ex
##em
##esta
##ne
(
25
mg
/
day
)
(
n
=
48
##5
)
versus
place
##bo
plus
ex
##em
##esta
##ne
(
25
mg
/
day
)
(
n
=
239
)
was
evaluated
in
a
random
##ized
,
controlled
trial
in
patients
with
advanced
or
meta
##static
hormone
receptor
-
positive
,
H
##ER
##2
-
negative
breast
cancer
.
[SEP]
[CLS]
WA
##R
##NI
##NG
:
P
##OT
##EN
##TI
##AL
R
##IS
##K
OF
M
##Y
##OC
##AR
##DI
##AL
IN
##FA
##RC
##TI
##ON
W
##IT
##H
L
##ON
##G
-
T
##ER
##M
US
##E
:
F
##OR
SH
##OR
##T
-
T
##ER
##M
H
##OS
##PI
##TA
##L
US
##E
ON
##L
##Y
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
Treatment
-
emerge
##nt
AD
##R
##s
of
moderate
to
severe
intensity
observed
in
at
least
2
%
of
subjects
in
either
treatment
arm
in
SP
##RI
##NG
-
2
and
S
##ING
##LE
trials
are
provided
in
Table
2
.
[SEP]
[CLS]
In
a
long
-
term
(
52
-
week
)
,
double
-
blind
,
com
##par
##ator
-
controlled
adult
trial
that
included
primarily
patients
with
s
##chi
##zophrenia
,
the
mean
decrease
in
pro
##la
##ct
##in
from
base
##line
for
SA
##P
##H
##RI
##S
-
treated
patients
was
26
.
9
ng
/
m
##L
.
[SEP]
[CLS]
(
2
.
3
,
5
.
4
)
*
Ke
##rat
##itis
:
O
##cc
##urs
in
0
.
8
%
of
patients
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
establish
a
ca
##usal
relationship
to
drug
exposure
.
[SEP]
[CLS]
5
.
3
Dec
##reased
Gas
##tro
##int
##est
##inal
Mo
##tility
To
##via
##z
,
like
other
anti
##mus
##car
##ini
##c
drugs
,
should
be
used
with
caution
in
patients
with
decreased
gas
##tro
##int
##est
##inal
m
##ot
##ility
,
such
as
those
with
severe
con
##st
##ip
##ation
.
[SEP]
[CLS]
Of
the
58
##6
subjects
,
59
%
were
female
and
84
%
were
white
;
the
mean
age
was
46
years
.
[SEP]
[CLS]
Additionally
,
the
observed
incidence
of
anti
##body
(
including
neutral
##izing
anti
##body
)
p
##os
##iti
##vity
in
an
ass
##ay
may
be
influenced
by
several
factors
,
including
ass
##ay
methodology
,
sample
handling
,
timing
of
sample
collection
,
con
##com
##ita
##nt
medications
,
and
underlying
disease
.
[SEP]
[CLS]
Inter
##rup
##tion
of
Pro
##lia
therapy
should
be
considered
,
pending
a
risk
/
benefit
assessment
,
on
an
individual
basis
.
[SEP]
[CLS]
*
Inc
##reased
risk
of
su
##icidal
thinking
in
children
,
adolescent
##s
and
young
adults
taking
anti
##de
##press
##ants
(
5
.
1
)
.
[SEP]
[CLS]
Disco
##ntin
##ue
G
##RA
##NI
##X
if
suspected
(
5
.
2
)
*
All
##ergic
reactions
(
an
##gion
##eur
##otic
ed
##ema
,
der
##mat
##itis
all
##ergic
,
drug
h
##yper
##sen
##si
##ti
##vity
,
h
##yper
##sen
##si
##ti
##vity
,
r
##ash
,
p
##ru
##ritic
r
##ash
and
u
##rt
##ica
##ria
)
(
5
.
3
)
*
Sick
##le
cell
crisis
:
Se
##vere
and
sometimes
fatal
crisis
can
occur
.
[SEP]
[CLS]
N
##ep
##hr
##otic
syndrome
secondary
to
me
##mb
##rano
##us
g
##lo
##mer
##ulon
##ep
##hr
##itis
was
observed
in
some
Po
##mp
##e
disease
patients
treated
with
al
##g
##lu
##cos
##idas
##e
al
##fa
who
had
persistent
##ly
positive
anti
-
r
##h
##GA
##A
I
##g
##G
anti
##body
t
##iter
##s
.
[SEP]
[CLS]
Co
##arte
##m
Table
##ts
should
be
avoided
in
patients
:
*
with
con
##gen
##ital
pro
##long
##ation
of
the
Q
##T
interval
(
e
.
g
.
,
long
Q
##T
syndrome
)
or
any
other
clinical
condition
known
to
pro
##long
the
Q
##T
##c
interval
such
as
patients
with
a
history
of
s
##ym
##pt
##oma
##tic
cardiac
a
##rr
##hy
##th
##mia
##s
,
with
clinical
##ly
relevant
bra
##dy
##card
##ia
or
with
severe
cardiac
disease
.
[SEP]
[CLS]
In
the
pool
##ed
Phase
3
CA
##B
##P
trials
,
51
/
520
(
9
.
8
%
)
of
Te
##f
##lar
##o
-
treated
patients
compared
to
24
/
53
##4
(
4
.
5
%
)
of
c
##ef
##tri
##ax
##one
-
treated
patients
se
##ro
##con
##verted
from
a
negative
to
a
positive
direct
Co
##omb
##s
'
test
result
.
[SEP]
[CLS]
In
this
clinical
context
,
if
the
patient
is
found
to
have
abnormal
liver
tests
(
AL
##T
greater
than
three
times
the
upper
limit
of
the
reference
range
)
,
U
##L
##OR
##IC
treatment
should
be
interrupted
and
investigation
done
to
establish
the
probable
cause
.
[SEP]
[CLS]
Treatment
-
related
Ad
##verse
Re
##actions
(
>
=
3
%
)
from
Extension
Trial
in
Adults
with
Ch
##ronic
I
##mm
##une
(
I
##dio
##pathic
)
T
##hr
##omb
##oc
##yt
##ope
##nia
Ad
##verse
Re
##action
PR
##OM
##AC
##TA
50
mg
n
=
29
##9
(
%
)
Head
##ache
10
H
##yper
##bil
##ir
##ubi
##ne
##mia
6
AL
##T
increased
6
Cat
##ara
##ct
5
AS
##T
increased
4
Fat
##ig
##ue
4
Na
##use
##a
4
In
the
three
controlled
chronic
IT
##P
trials
,
serum
liver
test
abnormal
##ities
(
predominantly
Grade
2
or
less
in
severity
)
were
reported
in
11
%
and
7
%
of
patients
for
PR
##OM
##AC
##TA
and
place
##bo
,
respectively
.
[SEP]
[CLS]
Therefore
,
the
use
of
such
combinations
is
not
recommended
.
[SEP]
[CLS]
If
the
decision
has
been
made
to
disco
##ntin
##ue
treatment
,
medication
should
be
tape
##red
,
as
rapidly
as
is
feasible
,
but
with
recognition
that
abrupt
disco
##ntin
##uation
can
be
associated
with
certain
symptoms
[
see
Do
##sa
##ge
and
Administration
(
2
.
4
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
7
)
for
a
description
of
the
risks
of
disco
##ntin
##uation
of
PR
##IS
##TI
##Q
]
.
[SEP]
[CLS]
It
is
uncertain
whether
the
occurrence
of
H
##ST
##CL
is
related
to
use
of
a
T
##NF
block
##er
or
a
T
##NF
block
##er
in
combination
with
these
other
im
##mu
##nos
##up
##press
##ants
.
[SEP]
[CLS]
For
patients
at
highest
risk
for
N
##SF
,
do
not
exceed
the
recommended
E
##O
##VI
##ST
dose
and
allow
a
sufficient
period
of
time
for
elimination
of
the
drug
prior
to
any
re
-
administration
.
[SEP]
[CLS]
The
range
of
time
to
diagnosis
of
cu
##SC
##C
was
136
to
##19
##7
days
in
the
combination
arm
and
was
9
to
197
days
in
the
arm
receiving
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
5
.
1
I
##maging
E
##rro
##rs
I
##maging
errors
have
been
reported
with
11
C
-
ch
##olin
##e
P
##ET
and
P
##ET
/
CT
imaging
.
[SEP]
[CLS]
Disco
##ntin
##ue
G
##RA
##NI
##X
if
suspected
(
5
.
4
)
*
Cap
##illa
##ry
Lea
##k
S
##yn
##drome
:
Monitor
if
symptoms
develop
and
administer
standard
s
##ym
##pt
##oma
##tic
treatment
(
5
.
5
)
5
.
1
S
##ple
##nic
R
##up
##ture
S
##ple
##nic
r
##up
##ture
,
including
fatal
cases
,
can
occur
following
administration
of
human
g
##ran
##ulo
##cy
##te
colony
-
s
##ti
##mulating
factors
.
[SEP]
[CLS]
Pat
##ients
who
are
suspected
of
having
or
who
develop
ON
##J
while
on
Pro
##lia
should
receive
care
by
a
den
##tist
or
an
oral
surgeon
.
[SEP]
[CLS]
Anti
-
e
##cal
##lant
##ide
I
##g
##E
antibodies
were
detected
at
a
rate
of
4
.
7
%
for
tested
patients
,
and
anti
-
P
.
pastor
##is
I
##g
##E
antibodies
were
also
detected
at
a
rate
of
20
.
2
%
.
[SEP]
[CLS]
If
PR
##ES
is
suspected
,
G
##IL
##EN
##Y
##A
should
be
discontinued
.
[SEP]
[CLS]
In
addition
,
two
cases
of
PT
##LD
involving
the
liver
all
##og
##raft
(
one
fatal
)
and
one
fatal
case
of
PM
##L
were
observed
among
the
147
patients
random
##ized
to
N
##U
##L
##O
##J
##IX
.
[SEP]
[CLS]
5
.
6
Ser
##ious
In
##fect
##ions
In
a
clinical
trial
of
over
78
##00
women
with
post
##men
##op
##aus
##al
o
##ste
##op
##oro
##sis
,
serious
infections
leading
to
hospital
##ization
were
reported
more
frequently
in
the
Pro
##lia
group
than
in
the
place
##bo
group
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
He
##mat
##olo
##gic
Para
##meter
##s
Dec
##reased
hem
##og
##lo
##bin
have
been
reported
in
patients
taking
A
##FI
##NI
##TO
##R
[
see
Ad
##verse
Re
##actions
(
6
.
1
,
6
.
2
,
6
.
3
,
6
.
4
,
6
.
5
)
]
.
[SEP]
[CLS]
These
adverse
reactions
were
not
present
at
base
##line
,
occurred
more
commonly
on
T
##AN
##Z
##E
##UM
than
on
place
##bo
,
and
occurred
in
at
least
5
%
of
patients
treated
with
T
##AN
##Z
##E
##UM
.
[SEP]
[CLS]
(
5
.
3
)
*
Do
not
administer
le
##uc
##ovo
##rin
within
2
hours
before
or
after
a
dose
of
V
##OR
##A
##X
##A
##Z
##E
.
[SEP]
[CLS]
5
.
2
E
.
A
.
S
.
E
.
[SEP]
[CLS]
In
post
##market
##ing
experience
with
al
##g
##lu
##cos
##idas
##e
al
##fa
,
serious
adverse
reactions
have
been
reported
,
including
an
##aph
##yla
##xi
##s
[
see
##B
##ox
##ed
Warning
##and
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
[
See
Clinical
Ph
##arma
##cology
(
12
.
3
)
.
]
[SEP]
[CLS]
Grade
1
-
4
elevations
in
bi
##li
##ru
##bin
occurred
in
3
%
of
patients
treated
with
X
##TA
##ND
##I
(
0
.
1
%
Grade
3
-
4
)
and
2
%
of
patients
treated
with
place
##bo
(
no
Grade
3
-
4
)
.
[SEP]
[CLS]
The
most
common
adverse
reactions
leading
to
disco
##ntin
##uation
of
Pro
##lia
in
patients
with
post
##men
##op
##aus
##al
o
##ste
##op
##oro
##sis
are
back
pain
and
con
##st
##ip
##ation
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Leading
to
Disco
##ntin
##uation
of
Treatment
:
A
total
of
6
.
7
%
(
7
/
104
)
of
patients
treated
with
SA
##P
##H
##RI
##S
2
.
5
mg
twice
daily
,
5
.
1
%
(
5
/
99
)
of
patients
treated
with
SA
##P
##H
##RI
##S
5
mg
twice
daily
,
and
5
.
1
%
(
5
/
99
)
of
patients
treated
with
SA
##P
##H
##RI
##S
10
mg
twice
daily
discontinued
treatment
due
to
adverse
reactions
compared
to
4
%
(
4
/
101
)
on
place
##bo
.
[SEP]
[CLS]
5
.
3
V
##eno
##us
T
##hr
##omb
##oe
##mbo
##lic
Events
In
clinical
trials
,
ve
##nous
th
##rom
##boe
##mbo
##lic
events
have
been
reported
,
including
deaths
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Image
interpretation
errors
(
especially
false
negative
##s
)
have
been
observed
(
5
.
1
)
.
[SEP]
[CLS]
X
##E
##OM
##IN
-
treated
patients
were
22
to
79
years
of
age
(
mean
62
years
)
,
predominantly
female
(
65
%
)
,
Caucasian
(
79
%
)
,
and
had
a
mean
time
since
diagnosis
of
approximately
5
years
.
[SEP]
[CLS]
Pat
##ients
received
place
##bo
(
N
=
99
##5
)
,
J
##AR
##DI
##AN
##CE
10
mg
(
N
=
99
##9
)
,
or
J
##AR
##DI
##AN
##CE
25
mg
(
N
=
97
##7
)
once
daily
.
[SEP]
[CLS]
In
cases
of
s
##ym
##pt
##oma
##tic
bra
##dy
##card
##ia
that
is
not
life
-
threatening
,
hold
X
##AL
##KO
##RI
until
recovery
to
as
##ym
##pt
##oma
##tic
bra
##dy
##card
##ia
or
to
a
heart
rate
of
60
b
##pm
or
above
,
re
-
evaluate
the
use
of
con
##com
##ita
##nt
medications
,
and
adjust
the
dose
of
X
##AL
##KO
##RI
.
[SEP]
[CLS]
Because
of
the
potential
for
h
##yper
##sen
##si
##ti
##vity
reactions
,
administer
anti
##his
##tamine
##s
with
or
without
anti
##py
##ret
##ics
prior
to
in
##fusion
.
[SEP]
[CLS]
5
.
4
Use
with
Me
##dication
##s
Known
to
Cause
H
##y
##po
##gly
##ce
##mia
In
##sul
##in
and
insulin
secret
##ago
##gues
,
such
as
su
##lf
##ony
##lu
##rea
##s
,
are
known
to
cause
h
##y
##po
##gly
##ce
##mia
.
[SEP]
[CLS]
The
majority
of
these
immune
-
mediated
reactions
initially
manifest
##ed
during
treatment
;
however
,
a
minority
occurred
weeks
to
months
after
disco
##ntin
##uation
of
Y
##ER
##VO
##Y
.
[SEP]
[CLS]
5
.
9
CO
##C
Use
Before
or
During
Early
Pre
##gna
##ncy
Ex
##tensive
e
##pid
##em
##iol
##ogical
studies
have
revealed
no
increased
risk
of
birth
defects
in
women
who
have
used
oral
con
##tra
##ceptive
##s
prior
to
pregnancy
.
[SEP]
[CLS]
For
invasive
dental
procedures
,
with
##hold
CO
##ME
##TR
##I
##Q
treatment
for
at
least
28
days
prior
to
scheduled
surgery
,
if
possible
.
[SEP]
[CLS]
Women
on
thy
##roid
hormone
replacement
therapy
may
need
increased
doses
of
thy
##roid
hormone
because
serum
concentrations
of
thy
##roid
-
binding
g
##lo
##bul
##in
increase
with
use
of
CO
##Cs
[
see
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
If
con
##tra
##ceptive
methods
are
being
considered
,
use
effective
con
##tra
##ception
during
treatment
,
and
for
at
least
1
month
after
the
last
dose
of
Z
##yd
##eli
##g
[
see
Use
in
S
##pecific
Population
##s
(
8
.
6
)
]
.
[SEP]
[CLS]
At
base
##line
,
2
.
5
%
of
the
population
reported
re
##tino
##pathy
.
[SEP]
[CLS]
5
.
2
Car
##cin
##oma
of
the
B
##rea
##sts
and
Rep
##rod
##uctive
Organ
##s
Women
who
currently
have
or
have
had
breast
cancer
should
not
use
Nat
##azi
##a
because
breast
cancer
is
a
ho
##rmon
##ally
-
sensitive
tumor
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
,
or
if
the
patient
becomes
pregnant
while
taking
this
drug
,
the
patient
should
be
app
##rise
##d
of
potential
hazard
to
the
f
##etus
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
Inc
##reased
dos
##age
of
co
##rt
##ico
##ster
##oids
may
be
indicated
before
,
during
and
after
stress
##ful
situations
.
[SEP]
[CLS]
5
.
3
N
##utrition
##al
Management
Since
h
##yper
##am
##mon
##emia
is
the
result
of
protein
cat
##ab
##olis
##m
,
complete
protein
restriction
is
recommended
to
be
maintained
for
24
to
48
hours
and
ca
##lor
##ic
supplement
##ation
should
be
ma
##xi
##mized
to
reverse
cat
##ab
##olis
##m
and
nitrogen
turnover
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
-
approval
use
of
C
##IM
##Z
##IA
.
[SEP]
[CLS]
Women
who
are
not
pregnant
and
use
Nat
##azi
##a
,
may
experience
am
##eno
##rr
##hea
.
[SEP]
[CLS]
Monitor
plasma
zinc
,
and
supplement
in
the
event
of
a
deficiency
.
[SEP]
[CLS]
Pat
##ients
using
BR
##E
##O
E
##LL
##IP
##TA
should
not
use
another
medicine
containing
a
LA
##BA
(
e
.
g
.
,
sa
##lm
##eter
##ol
,
form
##oter
##ol
f
##uma
##rate
,
a
##rf
##orm
##oter
##ol
ta
##rt
##rate
,
in
##da
##cate
##rol
)
for
any
reason
.
[SEP]
[CLS]
(
5
.
8
)
*
Rev
##ers
##ible
posterior
le
##uk
##oe
##nce
##pha
##lop
##athy
syndrome
(
R
##PL
##S
)
:
Disco
##ntin
##ue
CO
##ME
##TR
##I
##Q
.
[SEP]
[CLS]
Doc
##ume
##nted
s
##ym
##pt
##oma
##tic
h
##y
##po
##gly
##ce
##mia
occurred
in
39
%
and
40
%
of
patients
when
T
##R
##U
##L
##IC
##IT
##Y
0
.
75
mg
and
1
.
5
mg
,
respectively
,
was
co
-
administered
with
a
su
##lf
##ony
##lu
##rea
.
[SEP]
[CLS]
In
addition
,
it
is
recommended
to
avoid
use
of
XI
##AF
##LE
##X
in
patients
with
co
##agu
##lation
disorders
,
including
patients
receiving
con
##com
##ita
##nt
anti
##coa
##gu
##lants
(
except
for
low
-
dose
as
##pi
##rin
)
.
[SEP]
[CLS]
Rev
##ers
##al
of
Anti
##coa
##gu
##lant
Effect
:
A
specific
reversal
agent
for
da
##bi
##gat
##ran
is
not
available
.
[SEP]
[CLS]
FA
##NA
##P
##T
shares
this
p
##har
##ma
##co
##log
##ic
activity
.
[SEP]
[CLS]
(
5
.
4
)
*
Inc
##reased
L
##D
##L
-
C
:
Monitor
and
treat
per
standard
of
care
.
[SEP]
[CLS]
5
.
4
H
##yper
##sen
##si
##ti
##vity
Re
##actions
,
Including
Ana
##phy
##lax
##is
In
the
controlled
portions
of
the
clinical
trials
in
Du
##pu
##yt
##ren
'
s
contract
##ure
(
Studies
1
and
2
)
,
a
greater
proportion
of
XI
##AF
##LE
##X
-
treated
patients
(
15
%
)
compared
to
place
##bo
-
treated
patients
(
1
%
)
had
mild
all
##ergic
reactions
(
p
##ru
##rit
##us
)
after
up
to
3
injection
##s
.
[SEP]
[CLS]
Ad
##vise
females
of
reproductive
potential
to
use
effective
con
##tra
##ception
during
treatment
with
Z
##Y
##KA
##DI
##A
and
for
at
least
2
weeks
following
completion
of
therapy
[
see
Use
in
S
##pecific
Population
##s
(
8
.
7
)
]
.
[SEP]
[CLS]
Post
-
Trans
##p
##lant
L
##ymph
##op
##rol
##ifer
##ative
Di
##sor
##der
Report
##ed
cases
of
post
-
transplant
l
##ymph
##op
##rol
##ifer
##ative
disorder
(
PT
##LD
)
up
to
36
months
post
transplant
were
obtained
for
N
##U
##L
##O
##J
##IX
by
pool
##ing
both
dos
##age
regime
##ns
of
N
##U
##L
##O
##J
##IX
in
Studies
1
and
2
(
80
##4
patients
)
with
data
from
a
third
study
in
kidney
transplant
##ation
(
Study
3
,
145
patients
)
which
evaluated
two
N
##U
##L
##O
##J
##IX
dos
##age
regime
##ns
similar
,
but
slightly
different
,
from
those
of
Studies
1
and
2
(
see
Table
2
)
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
I
##MM
##UN
##E
-
ME
##DI
##AT
##ED
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
WA
##R
##NI
##NG
:
I
##MM
##UN
##E
-
ME
##DI
##AT
##ED
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
Y
##ER
##VO
##Y
can
result
in
severe
and
fatal
immune
-
mediated
adverse
reactions
due
to
T
-
cell
activation
and
proliferation
.
[SEP]
[CLS]
Before
in
##iti
##ating
FA
##R
##X
##IG
##A
in
patients
with
one
or
more
of
these
characteristics
,
volume
status
should
be
assessed
and
corrected
.
[SEP]
[CLS]
Pat
##ients
who
develop
a
##rr
##hy
##th
##mic
symptoms
(
e
.
g
.
,
p
##al
##pit
##ations
,
light
##headed
##ness
)
or
new
onset
d
##ys
##p
##nea
should
have
an
EC
##G
performed
.
[SEP]
[CLS]
The
reporting
rate
of
these
reactions
associated
with
o
##x
##car
##ba
##ze
##pine
use
exceeds
the
background
incidence
rate
estimates
by
a
factor
of
3
-
to
10
-
fold
.
[SEP]
[CLS]
There
are
no
adequate
and
well
-
controlled
studies
in
pregnant
women
using
IN
##L
##Y
##TA
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
clinical
monitoring
for
S
##IR
##TU
##RO
-
related
adverse
reactions
is
recommended
.
[SEP]
[CLS]
A
ca
##usal
relationship
to
drug
exposure
has
not
been
established
.
[SEP]
[CLS]
Additional
signs
may
include
elevated
c
##rea
##tine
p
##hos
##ph
##oki
##nas
##e
,
my
##og
##lo
##bin
##uria
(
r
##hab
##dom
##yo
##lysis
)
,
and
acute
re
##nal
failure
.
[SEP]
[CLS]
*
Record
the
date
you
open
the
foil
pouch
in
the
space
provided
on
the
b
##list
##er
package
label
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
reactions
are
discussed
in
greater
detail
in
other
sections
of
the
label
##ing
.
[SEP]
[CLS]
Common
adverse
events
(
>
=
5
%
in
any
X
##E
##OM
##IN
treatment
group
)
observed
in
patients
who
received
X
##E
##OM
##IN
(
120
Units
or
240
Units
)
included
d
##ys
##pha
##gia
,
neck
pain
,
muscle
weakness
,
injection
site
pain
,
and
m
##us
##cu
##los
##kel
##etal
pain
.
[SEP]
[CLS]
He
##mo
##g
##lo
##bin
/
He
##mat
##oc
##rit
Low
hem
##og
##lo
##bin
were
observed
in
0
.
2
%
,
0
.
4
%
,
and
0
.
3
%
of
Ed
##ar
##bi
-
treated
subjects
,
respectively
.
[SEP]
[CLS]
The
data
below
reflect
exposure
to
AD
##CE
##TR
##IS
as
mon
##otherapy
in
32
##7
patients
with
classical
Ho
##d
##g
##kin
l
##ymph
##oma
(
H
##L
)
and
systemic
an
##ap
##lastic
large
cell
l
##ymph
##oma
(
s
##AL
##CL
)
,
including
160
patients
in
two
un
##con
##tro
##lled
single
-
arm
trials
(
Studies
1
and
2
)
and
167
patients
in
one
place
##bo
-
controlled
random
##ized
trial
(
Study
3
)
.
[SEP]
[CLS]
These
consisted
mainly
of
d
##ys
##p
##nea
.
[SEP]
[CLS]
No
data
are
available
on
the
secondary
transmission
of
infection
from
persons
receiving
live
vaccine
##s
to
patients
receiving
B
##EN
##L
##Y
##ST
##A
or
the
effect
of
B
##EN
##L
##Y
##ST
##A
on
new
im
##mu
##ni
##zation
##s
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
with
SA
##P
##H
##RI
##S
at
an
Inc
##iden
##ce
of
2
%
or
More
in
SA
##P
##H
##RI
##S
-
treated
B
##ip
##olar
Pat
##ients
:
Ad
##verse
reactions
associated
with
the
use
of
SA
##P
##H
##RI
##S
(
incidence
of
>
=
2
%
in
any
SA
##P
##H
##RI
##S
dose
group
and
greater
than
place
##bo
)
that
occurred
during
acute
therapy
are
shown
in
Table
10
.
[SEP]
[CLS]
*
have
unusual
v
##agi
##nal
bleeding
.
[SEP]
[CLS]
The
majority
of
the
reports
of
eye
##lid
p
##tosis
were
mild
to
moderate
in
severity
and
resolved
over
several
weeks
.
[SEP]
[CLS]
(
r
)
)
Program
.
[SEP]
[CLS]
Through
96
weeks
,
the
rate
of
adverse
events
leading
to
disco
##ntin
##uation
was
2
%
in
both
treatment
arms
.
[SEP]
[CLS]
In
those
patients
treated
with
H
##OR
##I
##Z
##AN
##T
who
reported
di
##zzi
##ness
,
symptoms
persisted
during
treatment
in
about
20
%
.
[SEP]
[CLS]
Di
##zzi
##ness
,
ta
##chy
##card
##ia
,
and
weight
increased
were
at
least
twice
as
common
on
20
to
24
mg
/
day
as
on
10
to
16
mg
/
day
.
[SEP]
[CLS]
6
.
3
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
approval
use
of
al
##g
##lu
##cos
##idas
##e
al
##fa
.
[SEP]
[CLS]
In
##fect
##ions
resulting
in
death
occurred
in
0
.
3
%
(
4
/
1
,
45
##8
)
of
patients
treated
with
B
##EN
##L
##Y
##ST
##A
and
in
0
.
1
%
(
1
/
67
##5
)
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
With
##hold
G
##IL
##OT
##RI
##F
for
k
##era
##titis
evaluation
.
[SEP]
[CLS]
Following
resolution
of
trans
##ami
##nas
##e
elevations
,
consider
the
benefits
and
risks
of
re
##suming
K
##AL
##Y
##DE
##CO
dos
##ing
.
[SEP]
[CLS]
WA
##R
##NI
##NG
:
R
##IS
##K
OF
AN
##AP
##H
##Y
##LA
##X
##IS
,
H
##YP
##ER
##SE
##NS
##IT
##I
##VI
##TY
AND
I
##MM
##UN
##E
-
ME
##DI
##AT
##ED
R
##EA
##CT
##ION
##S
,
and
R
##IS
##K
OF
CA
##RD
##IO
##RE
##SP
##IR
##AT
##OR
##Y
FA
##IL
##UR
##E
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
See
Table
3
and
Table
4
for
other
potentially
significant
drug
interactions
[
see
Drug
Inter
##actions
(
7
.
1
)
]
.
[SEP]
[CLS]
An
increase
in
the
A
##FI
##NI
##TO
##R
dose
is
recommended
when
co
-
administered
with
a
strong
C
##YP
##3
##A
##4
/
P
##g
##P
induce
##r
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
,
2
.
5
)
and
Drug
Inter
##actions
(
7
.
2
)
]
.
[SEP]
[CLS]
The
population
had
a
mean
age
of
39
(
range
:
18
to
75
)
,
94
%
were
female
,
and
52
%
were
Caucasian
.
[SEP]
[CLS]
Administration
of
IL
##AR
##IS
should
be
discontinued
if
a
patient
develops
a
serious
infection
.
[SEP]
[CLS]
The
rate
of
treatment
disco
##ntin
##uation
due
to
u
##rina
##ry
tract
infections
was
0
.
1
%
,
0
.
2
%
,
and
0
.
1
%
for
place
##bo
,
J
##AR
##DI
##AN
##CE
10
mg
,
and
J
##AR
##DI
##AN
##CE
25
mg
,
respectively
.
[SEP]
[CLS]
Ser
##ious
Ad
##verse
Events
and
Disco
##ntin
##uation
-
Per
##io
##per
##ative
H
##yper
##tens
##ion
Studies
The
incidence
of
adverse
events
leading
to
study
drug
disco
##ntin
##uation
in
patients
with
per
##io
##per
##ative
h
##yper
##tens
##ion
receiving
C
##lev
##ip
##re
##x
was
5
.
9
%
versus
3
.
2
%
for
all
active
com
##par
##ators
.
[SEP]
[CLS]
(
5
.
3
)
*
Con
##tin
##ue
h
##yd
##ration
and
al
##kal
##ini
##zation
of
the
urine
as
indicated
.
[SEP]
[CLS]
Episode
##s
vary
in
frequency
,
severity
and
may
be
life
-
threatening
if
treatment
is
delayed
.
[SEP]
[CLS]
Healthcare
professionals
should
be
aware
of
the
similarity
of
symptoms
between
h
##yper
##sen
##si
##ti
##vity
reactions
and
hereditary
an
##gio
##ede
##ma
and
patients
should
be
monitored
closely
.
[SEP]
[CLS]
Spin
##al
/
e
##pid
##ural
an
##est
##hesia
or
pu
##nc
##ture
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
>
1
%
)
are
related
to
bleeding
.
[SEP]
[CLS]
*
W
##orse
##ning
Ren
##al
I
##mp
##air
##ment
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
In
the
controlled
and
un
##con
##tro
##lled
portions
through
approximately
92
weeks
,
the
incidence
of
ma
##li
##gna
##ncies
per
100
patient
-
years
,
other
than
l
##ymph
##oma
and
N
##MS
##C
,
in
S
##IM
##PO
##NI
ARIA
-
treated
patients
was
0
.
31
(
C
##I
:
0
.
06
,
0
.
92
)
and
the
incidence
of
N
##MS
##C
was
0
.
1
(
95
%
C
##I
:
0
.
00
,
0
.
58
)
.
[SEP]
[CLS]
In
v
##it
##ro
studies
with
human
plate
##lets
indicate
that
ST
##EN
##DR
##A
potent
##iate
##s
the
anti
-
aggregator
##y
effect
of
sodium
ni
##tro
##p
##russ
##ide
(
a
ni
##tric
oxide
[
NO
]
donor
)
.
[SEP]
[CLS]
(
5
.
3
,
7
.
2
,
7
.
3
)
5
.
1
Pro
##long
##ation
of
the
Q
##T
Inter
##val
Some
anti
##mal
##aria
##ls
(
e
.
g
.
,
ha
##lo
##fant
##rine
,
q
##uin
##ine
,
q
##uin
##id
##ine
)
including
Co
##arte
##m
Table
##ts
have
been
associated
with
pro
##long
##ation
of
the
Q
##T
interval
on
the
electro
##card
##io
##gram
.
[SEP]
[CLS]
*
H
##yper
##sen
##si
##ti
##vity
reactions
:
an
##aph
##yla
##xi
##s
,
u
##rt
##ica
##ria
,
an
##gio
##ede
##ma
,
and
serious
skin
reactions
(
bull
##ous
eruption
)
have
been
reported
.
[SEP]
[CLS]
The
small
number
of
patients
positive
for
antibodies
to
S
##IM
##PO
##NI
ARIA
limits
the
ability
to
draw
definitive
conclusions
regarding
the
relationship
between
antibodies
to
go
##lim
##uma
##b
and
clinical
efficacy
or
safety
measures
.
[SEP]
[CLS]
5
.
5
Live
##r
In
##ju
##ry
*
He
##pa
##to
##cellular
liver
injury
,
including
acute
liver
failure
requiring
transplant
,
has
been
reported
in
patients
treated
with
M
##U
##LT
##A
##Q
in
the
post
##market
##ing
setting
.
[SEP]
[CLS]
The
data
above
reflect
the
percentage
of
patients
whose
test
results
were
considered
positive
for
antibodies
to
S
##IM
##PO
##NI
ARIA
in
an
E
##L
##IS
##A
ass
##ay
.
[SEP]
[CLS]
5
.
2
Risk
for
Image
Mi
##sin
##ter
##p
##reta
##tion
and
Other
E
##rro
##rs
E
##rro
##rs
may
occur
while
using
V
##iza
##my
##l
P
##ET
images
to
estimate
brain
ne
##uri
##tic
plaque
density
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Administration
Re
##actions
In
the
controlled
phase
of
Trial
1
through
Week
24
,
1
.
1
%
of
S
##IM
##PO
##NI
ARIA
in
##fusion
##s
were
associated
with
an
in
##fusion
reaction
compared
with
0
.
2
%
of
in
##fusion
##s
in
the
control
group
.
[SEP]
[CLS]
Disco
##ntin
##ue
medication
pending
examination
if
there
is
sudden
partial
or
complete
loss
of
vision
,
or
a
sudden
onset
of
prop
##tosis
,
dip
##lop
##ia
,
or
mi
##gra
##ine
.
[SEP]
[CLS]
*
receiving
medications
that
are
meta
##bol
##ized
by
the
c
##yt
##och
##rome
enzyme
C
##YP
##2
##D
##6
which
also
have
cardiac
effects
(
e
.
g
.
,
fl
##eca
##ini
##de
,
im
##ip
##ram
##ine
,
am
##it
##rip
##ty
##line
,
c
##lo
##mi
##pra
##mine
)
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
,
Drug
Inter
##actions
(
7
.
6
)
,
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
Post
##market
##ing
cases
of
he
##pa
##tos
##ple
##nic
T
-
cell
l
##ymph
##oma
(
H
##ST
##CL
)
,
a
rare
type
of
T
-
cell
l
##ymph
##oma
that
has
a
very
aggressive
disease
course
and
is
usually
fatal
,
have
been
reported
in
patients
treated
with
T
##NF
block
##ers
,
including
C
##IM
##Z
##IA
.
[SEP]
[CLS]
There
are
no
data
on
the
risks
of
using
C
##IM
##Z
##IA
in
patients
who
have
experienced
a
severe
h
##yper
##sen
##si
##ti
##vity
reaction
towards
another
T
##NF
block
##er
;
in
these
patients
caution
is
needed
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
B
##lee
##ding
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
?
[SEP]
[CLS]
Table
4
lists
adverse
reactions
occurring
in
>
=
2
%
of
patients
receiving
Te
##f
##lar
##o
in
the
pool
##ed
Phase
3
clinical
trials
.
[SEP]
[CLS]
S
##ym
##pt
##oms
reported
included
sudden
onset
of
severe
headache
,
altered
mental
status
,
visual
disturbance
##s
,
and
seizure
.
[SEP]
[CLS]
The
incidence
of
Grade
3
h
##yper
##gly
##ce
##mia
based
on
laboratory
values
was
6
%
(
12
/
187
)
in
patients
treated
with
T
##AF
##IN
##LA
##R
compared
with
none
of
the
da
##car
##ba
##zine
-
treated
patients
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
Ser
##ious
All
##ergic
Re
##actions
Ser
##ious
all
##ergic
reactions
occurred
in
less
than
1
%
of
patients
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
NE
##UT
##RO
##P
##EN
##IA
AND
H
##YP
##ER
##SE
##NS
##IT
##I
##VI
##TY
WA
##R
##NI
##NG
:
NE
##UT
##RO
##P
##EN
##IA
AND
H
##YP
##ER
##SE
##NS
##IT
##I
##VI
##TY
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
NE
##UT
##RO
##P
##EN
##IA
AND
H
##YP
##ER
##SE
##NS
##IT
##I
##VI
##TY
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
In
short
-
term
,
place
##bo
-
controlled
bi
##pol
##ar
man
##ia
adult
trials
,
the
mean
increase
in
pro
##la
##ct
##in
levels
was
4
.
9
ng
/
m
##L
for
SA
##P
##H
##RI
##S
-
treated
patients
compared
to
a
decrease
of
0
.
2
ng
/
m
##L
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
*
Life
-
threatening
an
##aph
##yla
##ctic
reactions
and
severe
h
##yper
##sen
##si
##ti
##vity
reactions
have
occurred
in
some
patients
during
and
after
al
##g
##lu
##cos
##idas
##e
al
##fa
in
##fusion
##s
.
[SEP]
[CLS]
5
.
4
I
##mm
##une
-
mediated
N
##eur
##op
##ath
##ies
In
Study
1
,
1
case
of
fatal
G
##uil
##lain
-
Barr
##e
syndrome
and
1
case
of
severe
(
Grade
3
)
peripheral
motor
ne
##uro
##pathy
were
reported
.
[SEP]
[CLS]
Do
not
place
D
##U
##AV
##EE
in
pill
boxes
or
pill
organizers
.
[SEP]
[CLS]
Extra
##py
##ram
##idal
S
##ym
##pt
##oms
(
EP
##S
)
in
Clinical
Trials
Poole
##d
data
from
the
4
place
##bo
-
controlled
,
4
-
or
6
-
week
,
fixed
-
or
flexible
-
dose
studies
provided
information
regarding
treatment
-
emerge
##nt
EP
##S
.
[SEP]
[CLS]
(
6
.
4
)
SE
##GA
with
T
##SC
:
Most
common
adverse
reactions
(
incidence
>
=
30
%
)
are
s
##tom
##ati
##tis
and
respiratory
tract
infection
.
[SEP]
[CLS]
The
incidence
of
adverse
reactions
below
is
based
upon
two
double
-
blind
,
place
##bo
-
controlled
,
48
-
week
clinical
trials
(
Trials
1
and
2
)
in
a
total
of
213
patients
with
CF
ages
6
to
53
who
have
a
G
##55
##1
##D
mutation
in
the
CF
##TR
gene
and
who
were
treated
with
K
##AL
##Y
##DE
##CO
150
mg
oral
##ly
or
place
##bo
twice
daily
.
[SEP]
[CLS]
Ad
##mini
##ster
co
##rt
##ico
##ster
##oid
eye
drops
to
patients
who
develop
u
##ve
##itis
,
i
##rit
##is
,
or
e
##pis
##cle
##rit
##is
.
[SEP]
[CLS]
The
median
time
to
onset
of
moderate
to
severe
immune
-
mediated
end
##oc
##rino
##pathy
was
11
weeks
and
ranged
up
to
19
.
3
weeks
after
the
initiation
of
Y
##ER
##VO
##Y
.
[SEP]
[CLS]
*
help
reduce
your
chances
of
developing
o
##ste
##op
##oro
##sis
(
thin
,
weak
bones
)
If
you
use
D
##U
##AV
##EE
only
to
prevent
o
##ste
##op
##oro
##sis
due
to
men
##op
##aus
##e
,
talk
with
your
healthcare
provider
about
whether
a
different
treatment
or
medicine
without
est
##rogen
##s
might
be
better
for
you
.
D
##U
##AV
##EE
should
be
taken
for
the
shortest
time
possible
and
only
for
as
long
as
treatment
is
needed
.
[SEP]
[CLS]
The
median
time
to
onset
from
last
dose
of
D
##Y
##SP
##OR
##T
(
r
)
was
approximately
one
week
,
and
the
median
duration
was
approximately
three
weeks
.
[SEP]
[CLS]
5
.
7
I
##mm
##uni
##zation
Live
vaccine
##s
should
not
be
given
for
30
days
before
or
concurrently
with
B
##EN
##L
##Y
##ST
##A
as
clinical
safety
has
not
been
established
.
[SEP]
[CLS]
The
risk
of
symptoms
is
probably
greatest
in
children
treated
for
spa
##stic
##ity
but
symptoms
can
also
occur
in
adults
treated
for
spa
##stic
##ity
and
other
conditions
,
particularly
in
those
patients
who
have
underlying
conditions
that
would
pre
##dis
##pose
them
to
these
symptoms
.
[SEP]
[CLS]
These
reactions
were
of
mild
to
moderate
severity
.
[SEP]
[CLS]
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
has
not
been
studied
in
patients
with
acute
##ly
de
##ter
##ior
##ating
CO
##PD
.
[SEP]
[CLS]
In
the
pool
of
eight
clinical
trials
,
the
incidence
rate
of
pan
##cre
##ati
##tis
(
acute
)
was
0
.
9
,
2
.
7
,
and
0
.
9
per
1000
patient
-
years
of
exposure
to
com
##par
##ator
,
IN
##VO
##KA
##NA
100
mg
,
and
IN
##VO
##KA
##NA
300
mg
,
respectively
.
[SEP]
[CLS]
O
##bt
##ain
serum
potassium
,
calcium
,
and
ma
##gnesium
at
base
##line
and
correct
if
abnormal
.
[SEP]
[CLS]
*
A
24
-
week
place
##bo
-
controlled
trial
(
Trial
5
)
involving
69
patients
between
the
ages
of
6
and
68
years
with
an
R
##11
##7
##H
mutation
in
the
CF
##TR
gene
.
[SEP]
[CLS]
At
the
recommended
dose
of
50
mg
,
the
disco
##ntin
##uation
rate
due
to
an
adverse
reaction
for
PR
##IS
##TI
##Q
(
4
.
1
%
)
was
similar
to
the
rate
for
place
##bo
(
3
.
8
%
)
.
[SEP]
[CLS]
(
5
.
1
,
5
.
2
,
5
.
3
,
5
.
4
,
5
.
5
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
Y
##ER
##VO
##Y
can
result
in
severe
and
fatal
immune
-
mediated
reactions
due
to
T
-
cell
activation
and
proliferation
.
[SEP]
[CLS]
Information
on
selected
significant
adverse
reactions
observed
during
clinical
trials
is
summarized
below
.
[SEP]
[CLS]
The
administration
of
oral
con
##tra
##ceptive
##s
to
induce
withdrawal
bleeding
should
not
be
used
as
a
test
for
pregnancy
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
The
incidence
of
XI
##AF
##LE
##X
-
associated
p
##ru
##rit
##us
increased
after
more
XI
##AF
##LE
##X
injection
##s
in
patients
with
Du
##pu
##yt
##ren
'
s
contract
##ure
.
[SEP]
[CLS]
There
is
no
evidence
of
increased
risk
of
infections
with
continued
exposure
over
time
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Con
##duct
periodic
monitoring
with
electro
##card
##io
##gram
##s
(
EC
##G
##s
)
and
electro
##ly
##tes
in
patients
with
con
##ges
##tive
heart
failure
,
bra
##dy
##ar
##r
##hy
##th
##mia
##s
,
electro
##ly
##te
abnormal
##ities
,
or
those
who
are
taking
medications
that
are
known
to
pro
##long
the
Q
##T
##c
interval
.
[SEP]
[CLS]
c
Con
##fi
##dence
interval
Pat
##ients
Major
bleeding
event
a
B
##lee
##ding
sites
for
MBE
b
Clinical
##ly
relevant
non
-
major
bleeding
Any
bleeding
In
the
R
##E
-
ME
##D
##Y
study
,
the
rate
of
any
gas
##tro
##int
##est
##inal
bleed
##s
in
patients
receiving
PR
##AD
##A
##X
##A
150
mg
was
3
.
1
%
(
2
.
2
%
on
war
##fari
##n
)
.
[SEP]
[CLS]
There
were
insufficient
numbers
of
patients
with
bio
##psy
-
proven
he
##pa
##titis
to
character
##ize
the
clinical
course
of
this
event
.
[SEP]
[CLS]
Inc
##reased
dos
##age
of
co
##rt
##ico
##ster
##oids
may
be
indicated
before
,
during
and
after
stress
##ful
situations
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
One
patient
with
base
##line
h
##yper
##uri
##ce
##mia
and
bulk
##y
disease
experienced
Grade
4
tumor
l
##ys
##is
syndrome
during
the
first
cycle
of
treatment
and
died
due
to
multi
-
organ
failure
.
[SEP]
[CLS]
Monitor
patients
frequently
for
signs
and
symptoms
of
ne
##uro
##logical
imp
##air
##ment
.
[SEP]
[CLS]
Because
these
events
are
reported
voluntarily
from
a
population
of
unknown
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
.
[SEP]
[CLS]
The
most
common
serious
adverse
reactions
reported
in
patients
receiving
H
##AL
##AV
##EN
were
f
##eb
##ril
##e
ne
##ut
##rop
##enia
(
4
%
)
and
ne
##ut
##rop
##enia
(
2
%
)
.
[SEP]
[CLS]
Although
some
past
studies
have
suggested
that
CO
##Cs
might
increase
the
incidence
of
breast
cancer
,
more
recent
studies
have
not
confirmed
such
findings
.
[SEP]
[CLS]
The
adverse
reactions
were
predominantly
of
mild
to
moderate
intensity
.
[SEP]
[CLS]
Do
not
resume
Fe
##rri
##p
##ro
##x
in
patients
who
have
developed
a
##gra
##nu
##loc
##yt
##osis
unless
potential
benefits
out
##wei
##gh
potential
risks
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Ex
##eli
##xi
##s
,
Inc
.
at
1
-
85
##5
-
500
-
39
##35
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Other
adverse
reactions
seen
frequently
in
one
or
more
studies
included
as
##the
##nia
,
fatigue
,
ma
##lai
##se
,
and
weakness
;
dry
mouth
;
so
##m
##no
##len
##ce
;
cough
;
con
##st
##ip
##ation
;
headache
;
m
##uc
##osa
##l
inflammation
and
s
##tom
##ati
##tis
.
[SEP]
[CLS]
Across
clinical
trials
(
n
=
166
##9
)
,
49
X
##AL
##KO
##RI
-
treated
patients
(
2
.
9
%
)
had
IL
##D
of
any
grade
,
18
patients
(
1
.
1
%
)
had
Grade
3
or
4
IL
##D
,
and
8
patients
(
0
.
5
%
)
had
fatal
IL
##D
.
[SEP]
[CLS]
Of
the
total
8
,
39
##4
patients
exposed
to
at
least
one
dose
of
PR
##IS
##TI
##Q
;
2
,
116
were
exposed
to
PR
##IS
##TI
##Q
for
6
months
,
representing
1
,
65
##8
patient
-
years
of
exposure
,
and
42
##1
were
exposed
for
one
year
,
representing
41
##6
patient
-
years
of
exposure
.
[SEP]
[CLS]
Ad
##vise
women
of
the
potential
risk
to
a
f
##etus
and
to
avoid
pregnancy
while
taking
the
drug
(
5
.
7
)
.
[SEP]
[CLS]
(
5
.
8
)
*
Q
##T
Pro
##long
##ation
:
Inc
##rease
##s
in
Q
##T
interval
;
avoid
use
with
drugs
that
also
increase
the
Q
##T
interval
and
in
patients
with
risk
factors
for
prolonged
Q
##T
interval
.
[SEP]
[CLS]
5
.
4
I
##mme
##dia
##te
H
##yper
##sen
##si
##ti
##vity
Re
##actions
I
##mme
##dia
##te
h
##yper
##sen
##si
##ti
##vity
reactions
may
occur
after
administration
of
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
.
[SEP]
[CLS]
Table
1
Su
##mma
##ry
of
Treatment
Expo
##sure
in
R
##E
-
L
##Y
PR
##AD
##A
##X
##A
110
mg
twice
daily
PR
##AD
##A
##X
##A
150
mg
twice
daily
War
##fari
##n
Total
number
treated
59
##8
##3
60
##5
##9
59
##9
##8
Expo
##sure
>
12
months
49
##36
49
##39
51
##9
##3
>
24
months
238
##7
240
##5
247
##0
Mean
exposure
(
months
)
20
.
5
20
.
3
21
.
3
Total
patient
-
years
10
,
242
10
,
261
10
,
65
##9
Drug
Disco
##ntin
##uation
in
R
##E
-
L
##Y
The
rates
of
adverse
reactions
leading
to
treatment
disco
##ntin
##uation
were
21
%
for
PR
##AD
##A
##X
##A
150
mg
and
16
%
for
war
##fari
##n
.
[SEP]
[CLS]
as
rescue
therapy
for
the
treatment
of
acute
episodes
of
br
##on
##cho
##sp
##as
##m
.
[SEP]
[CLS]
Only
use
S
##IR
##TU
##RO
when
an
effective
treatment
regime
##n
can
not
otherwise
be
provided
[
see
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
5
.
6
Disco
##ntin
##uation
of
H
##OR
##I
##Z
##AN
##T
When
disco
##ntin
##uing
H
##OR
##I
##Z
##AN
##T
,
patients
with
R
##LS
receiving
600
mg
or
less
once
daily
can
disco
##ntin
##ue
the
drug
without
tape
##ring
.
[SEP]
[CLS]
DR
##ES
##S
typically
,
although
not
exclusively
,
presents
with
fever
,
r
##ash
,
and
/
or
l
##ymph
##ade
##no
##pathy
,
in
association
with
other
organ
system
involvement
,
such
as
he
##pa
##titis
,
ne
##ph
##rit
##is
,
hem
##ato
##logical
abnormal
##ities
,
my
##oc
##ard
##itis
,
or
my
##os
##itis
sometimes
resembling
an
acute
viral
infection
.
[SEP]
[CLS]
All
serious
adverse
events
were
assessed
as
unrelated
to
study
drug
.
[SEP]
[CLS]
Pat
##ients
receiving
B
##EN
##L
##Y
##ST
##A
should
be
instructed
to
contact
their
healthcare
provider
if
they
experience
new
or
worse
##ning
depression
,
su
##icidal
thoughts
,
or
other
mood
changes
.
[SEP]
[CLS]
Report
any
diagnosis
of
N
##SF
following
D
##OT
##AR
##EM
administration
to
G
##uer
##bet
LLC
(
1
-
87
##7
-
72
##9
-
66
##7
##9
)
or
FDA
(
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
)
.
[SEP]
[CLS]
On
Day
1
,
the
maximum
decline
in
heart
rate
generally
occurs
within
6
hours
and
recover
##s
,
although
not
to
base
##line
levels
,
by
8
to
10
hours
post
##dos
##e
.
[SEP]
[CLS]
Falls
were
not
associated
with
loss
of
consciousness
or
seizure
.
[SEP]
[CLS]
If
an
an
##aph
##yla
##ctic
or
other
serious
all
##ergic
reaction
occurs
,
administration
of
S
##IM
##PO
##NI
ARIA
should
be
discontinued
immediately
and
appropriate
therapy
instituted
.
[SEP]
[CLS]
(
5
.
6
)
*
Live
##r
injury
:
liver
enzyme
results
should
be
available
before
initiation
.
[SEP]
[CLS]
The
incidence
of
Grade
1
-
4
th
##rom
##bo
##cy
##top
##enia
was
6
%
of
patients
treated
with
X
##TA
##ND
##I
(
0
.
3
%
Grade
3
-
4
)
and
5
%
of
patients
treated
with
place
##bo
(
0
.
5
%
Grade
3
-
4
)
.
[SEP]
[CLS]
5
.
7
T
##hy
##roid
D
##ys
##function
In
a
controlled
clinical
study
with
IN
##L
##Y
##TA
for
the
treatment
of
patients
with
RC
##C
,
h
##y
##pot
##hy
##roid
##ism
was
reported
in
69
/
35
##9
patients
(
19
%
)
receiving
IN
##L
##Y
##TA
and
29
/
35
##5
patients
(
8
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
Ser
##ious
in
##fusion
reactions
(
excluding
h
##yper
##sen
##si
##ti
##vity
reactions
)
were
reported
in
0
.
5
%
of
patients
receiving
B
##EN
##L
##Y
##ST
##A
and
0
.
4
%
of
patients
receiving
place
##bo
and
included
bra
##dy
##card
##ia
,
my
##al
##gia
,
headache
,
r
##ash
,
u
##rt
##ica
##ria
,
and
h
##y
##pot
##ens
##ion
.
[SEP]
[CLS]
Data
from
a
large
place
##bo
-
controlled
US
trial
that
compared
the
safety
of
another
LA
##BA
(
sa
##lm
##eter
##ol
)
with
place
##bo
added
to
usual
as
##th
##ma
therapy
showed
an
increase
in
as
##th
##ma
-
related
deaths
in
subjects
receiving
sa
##lm
##eter
##ol
.
[SEP]
[CLS]
The
safety
of
re
##ini
##tia
##ting
IN
##L
##Y
##TA
therapy
in
patients
previously
experiencing
R
##PL
##S
is
not
known
.
[SEP]
[CLS]
Card
##iac
Di
##sor
##ders
Pa
##l
##pit
##ations
,
ta
##chy
##card
##ia
.
[SEP]
[CLS]
If
appropriate
,
initiation
of
anti
-
he
##pa
##titis
B
therapy
may
be
warrant
##ed
.
[SEP]
[CLS]
A
ca
##usal
relationship
with
al
##vi
##mo
##pan
with
long
-
term
use
has
not
been
established
.
[SEP]
[CLS]
Because
patients
with
moderate
to
severe
re
##nal
imp
##air
##ment
(
C
##r
##C
##l
<
=
50
##m
##L
/
min
)
would
require
a
dose
lower
than
10
mg
twice
daily
and
no
strength
smaller
than
10
mg
is
available
,
AM
##P
##Y
##RA
is
con
##tra
##ind
##ica
##ted
in
these
patients
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
Consul
##tation
with
a
specialist
(
e
.
g
.
,
ne
##uro
##logist
and
/
or
infectious
disease
)
should
be
considered
for
any
suspected
or
confirmed
cases
of
PM
##L
.
[SEP]
[CLS]
B
##lee
##ding
events
were
counted
during
treatment
or
within
2
days
of
stopping
study
treatment
(
on
-
treatment
period
)
.
[SEP]
[CLS]
These
wound
-
related
complications
may
require
surgical
intervention
.
[SEP]
[CLS]
There
has
been
a
long
-
standing
concern
,
however
,
that
anti
##de
##press
##ants
may
have
a
role
in
in
##ducing
worse
##ning
of
depression
and
the
emergence
of
su
##icidal
##ity
in
certain
patients
during
the
early
phases
of
treatment
.
[SEP]
[CLS]
Complete
treatment
of
pre
-
existing
invasive
fun
##gal
infections
prior
to
starting
treatment
with
A
##FI
##NI
##TO
##R
.
[SEP]
[CLS]
(
5
.
3
)
*
V
##eno
##us
T
##hr
##omb
##oe
##mbo
##lis
##m
:
Deep
vein
th
##rom
##bos
##is
and
pulmonary
em
##bol
##ism
can
occur
in
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
The
types
of
AR
resulting
in
withdrawal
from
the
study
varied
considerably
.
[SEP]
[CLS]
In
Trial
1
,
cut
##aneous
sq
##ua
##mous
cell
car
##cin
##oma
##s
and
k
##era
##to
##aca
##nt
##hom
##as
(
cu
##SC
##C
)
occurred
in
7
%
(
14
/
187
)
of
patients
treated
with
T
##AF
##IN
##LA
##R
and
in
none
of
the
patients
treated
with
da
##car
##ba
##zine
.
[SEP]
[CLS]
Three
percent
of
subjects
receiving
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
had
plate
##let
counts
of
less
than
50
*
10
9
per
L
compared
to
1
%
of
subjects
receiving
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
.
[SEP]
[CLS]
Su
##mma
##ry
of
Clinical
Trial
Experience
in
Classical
H
##L
Post
-
auto
-
H
##SC
##T
Con
##sol
##ida
##tion
(
Study
3
)
AD
##CE
##TR
##IS
was
studied
in
32
##9
patients
with
classical
H
##L
at
high
risk
of
re
##lap
##se
or
progression
post
-
auto
-
H
##SC
##T
in
a
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
clinical
trial
in
which
the
recommended
starting
dose
and
schedule
was
1
.
8
mg
/
kg
of
AD
##CE
##TR
##IS
administered
in
##tra
##ven
##ously
over
30
minutes
every
3
weeks
or
place
##bo
for
up
to
16
cycles
.
[SEP]
[CLS]
Clinical
surveillance
of
all
women
taking
D
##U
##AV
##EE
is
important
.
[SEP]
[CLS]
I
##mm
##uno
##genic
##ity
Anti
##bo
##dies
to
S
##IM
##PO
##NI
ARIA
were
detected
in
13
(
3
%
)
go
##lim
##uma
##b
-
treated
patients
following
IV
administration
of
S
##IM
##PO
##NI
ARIA
in
combination
with
M
##T
##X
through
Week
24
of
Trial
1
.
[SEP]
[CLS]
(
5
.
2
)
*
Direct
Co
##omb
##s
'
test
se
##ro
##con
##version
has
been
reported
with
Te
##f
##lar
##o
.
[SEP]
[CLS]
The
size
of
the
control
group
and
limited
duration
of
the
controlled
portions
of
the
studies
pre
##c
##lude
##s
the
ability
to
draw
firm
conclusions
.
[SEP]
[CLS]
Most
adverse
reactions
were
mild
,
did
not
lead
to
disco
##ntin
##uation
of
study
medication
,
and
resolved
.
[SEP]
[CLS]
5
.
5
Mac
##rop
##hage
Act
##ivation
S
##yn
##drome
Mac
##rop
##hage
activation
syndrome
(
MA
##S
)
is
a
known
,
life
-
threatening
disorder
that
may
develop
in
patients
with
r
##he
##umatic
conditions
,
in
particular
S
##J
##IA
,
and
should
be
aggressively
treated
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
fluid
and
electro
##ly
##te
management
,
protein
supplement
##ation
,
anti
##biotic
treatment
of
C
.
di
##ff
##ici
##le
,
and
surgical
evaluation
should
be
instituted
as
clinical
##ly
indicated
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
6
.
2
Post
Marketing
Experience
H
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
rarely
during
the
post
-
marketing
use
of
B
##EP
##RE
##VE
.
[SEP]
[CLS]
Test
patients
for
H
##B
##V
infection
before
in
##iti
##ating
treatment
with
C
##IM
##Z
##IA
.
[SEP]
[CLS]
In
patients
with
end
-
stage
re
##nal
failure
,
he
##pa
##tic
contrast
was
marked
##ly
reduced
and
was
attributed
to
elevated
serum
f
##er
##rit
##in
levels
.
[SEP]
[CLS]
*
with
known
disturbance
##s
of
electro
##ly
##te
balance
,
e
.
g
.
,
h
##y
##po
##kal
##emia
or
h
##y
##po
##ma
##gne
##se
##mia
.
[SEP]
[CLS]
Per
##cent
##ages
calculated
with
the
number
of
male
subjects
in
each
group
as
den
##omi
##nat
##or
:
place
##bo
(
N
=
51
##4
)
,
J
##AR
##DI
##AN
##CE
10
mg
(
N
=
55
##6
)
,
J
##AR
##DI
##AN
##CE
25
mg
(
N
=
55
##7
)
.
[SEP]
[CLS]
One
case
of
AN
##C
less
than
0
.
5
##x
##10
9
/
L
was
observed
in
the
IL
##AR
##IS
group
and
none
in
the
place
##bo
group
.
[SEP]
[CLS]
El
##eva
##tions
5
-
fold
the
U
##L
##N
or
greater
occurred
in
4
.
5
%
of
patients
on
G
##IL
##EN
##Y
##A
and
1
%
of
patients
on
place
##bo
.
[SEP]
[CLS]
6
.
1
Clinical
Studies
Experience
in
Pat
##ients
with
Du
##pu
##yt
##ren
'
s
Con
##tract
##ure
Because
clinical
studies
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
studies
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
studies
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Pat
##ients
received
B
##EN
##L
##Y
##ST
##A
at
doses
of
1
mg
/
kg
(
N
=
67
##3
)
,
4
mg
/
kg
(
N
=
111
;
Trial
1
only
)
,
or
10
mg
/
kg
(
N
=
67
##4
)
or
place
##bo
(
N
=
67
##5
)
in
##tra
##ven
##ously
over
a
1
-
hour
period
on
Days
0
,
14
,
28
,
and
then
every
28
days
.
[SEP]
[CLS]
Physicians
should
also
consider
the
risk
that
reduced
im
##mu
##nos
##up
##press
##ion
represents
to
the
functioning
all
##og
##raft
.
[SEP]
[CLS]
The
pool
##ed
mean
maximum
dose
in
these
studies
was
10
mg
/
hour
and
the
mean
duration
of
treatment
was
8
hours
.
[SEP]
[CLS]
In
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
,
the
median
time
to
initial
onset
of
fever
was
30
days
compared
with
19
days
in
patients
treated
with
T
##AF
##IN
##LA
##R
as
a
single
agent
;
the
median
duration
of
fever
was
6
days
with
the
combination
compared
with
4
days
with
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
5
.
2
Ren
##al
I
##mp
##air
##ment
AM
##P
##Y
##RA
is
eliminated
through
the
kidney
##s
primarily
as
unchanged
drug
[
see
Clinical
Ph
##arma
##cology
(
12
.
4
)
]
.
[SEP]
[CLS]
Use
cautiously
in
patients
with
seizure
disorder
(
5
.
8
)
.
[SEP]
[CLS]
The
incidence
of
op
##port
##uni
##stic
infections
was
similar
between
place
##bo
and
Pro
##lia
groups
,
and
the
overall
incidence
of
infections
was
similar
between
the
treatment
groups
.
[SEP]
[CLS]
There
was
one
death
due
to
pulmonary
em
##bol
##ism
on
the
place
##bo
arm
.
[SEP]
[CLS]
He
##pa
##tic
function
should
be
monitored
closely
in
these
patients
.
[SEP]
[CLS]
With
##hold
Y
##ER
##VO
##Y
dos
##ing
in
patients
with
moderate
to
severe
signs
and
symptoms
.
[SEP]
[CLS]
*
In
##fant
##ile
-
onset
Po
##mp
##e
disease
patients
with
compromised
cardiac
or
respiratory
function
may
be
at
risk
of
serious
acute
ex
##ace
##rb
##ation
of
their
cardiac
or
respiratory
compromise
due
to
fluid
over
##load
,
and
require
additional
monitoring
(
5
.
3
)
.
[SEP]
[CLS]
These
events
have
been
chosen
for
inclusion
due
to
either
their
serious
##ness
,
frequency
of
reporting
,
or
ca
##usal
connection
to
BR
##E
##O
E
##LL
##IP
##TA
or
a
combination
of
these
factors
.
[SEP]
[CLS]
In
those
patients
treated
with
H
##OR
##I
##Z
##AN
##T
who
reported
so
##m
##no
##len
##ce
,
the
so
##m
##no
##len
##ce
persisted
during
treatment
in
about
30
%
.
[SEP]
[CLS]
5
.
10
Pro
##tein
##uria
In
a
controlled
clinical
study
with
IN
##L
##Y
##TA
for
the
treatment
of
patients
with
RC
##C
,
protein
##uria
was
reported
in
39
/
35
##9
patients
(
11
%
)
receiving
IN
##L
##Y
##TA
and
26
/
35
##5
patients
(
7
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
The
most
frequent
serious
adverse
reactions
reported
in
patients
treated
with
G
##IL
##OT
##RI
##F
were
di
##ar
##r
##hea
(
6
.
6
%
)
;
vomit
##ing
(
4
.
8
%
)
;
and
d
##ys
##p
##nea
,
fatigue
,
and
h
##y
##po
##kal
##emia
(
1
.
7
%
each
)
.
[SEP]
[CLS]
Two
patients
(
2
%
)
on
place
##bo
and
1
patient
(
0
.
5
%
)
on
K
##AL
##Y
##DE
##CO
permanently
discontinued
treatment
for
elevated
trans
##ami
##nas
##es
,
all
>
8
*
U
##L
##N
.
[SEP]
[CLS]
Do
##se
reduction
##s
due
to
adverse
reactions
occurred
in
59
%
of
patients
treated
with
Z
##Y
##KA
##DI
##A
.
[SEP]
[CLS]
When
pregnancy
is
detected
,
disco
##ntin
##ue
Ed
##ar
##bi
as
soon
as
possible
[
see
##U
##se
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
D
##IS
##TA
##NT
SP
##RE
##AD
OF
TO
##X
##IN
E
##FF
##EC
##T
WA
##R
##NI
##NG
:
D
##IS
##TA
##NT
SP
##RE
##AD
OF
TO
##X
##IN
E
##FF
##EC
##T
Post
##market
##ing
reports
indicate
that
the
effects
of
X
##E
##OM
##IN
and
all
b
##ot
##ulin
##um
to
##xin
products
may
spread
from
the
area
of
injection
to
produce
symptoms
consistent
with
b
##ot
##ulin
##um
to
##xin
effects
.
[SEP]
[CLS]
(
5
.
5
)
*
Dec
##rease
in
pulmonary
function
tests
)
:
O
##bt
##ain
P
##FT
when
clinical
##ly
indicated
.
[SEP]
[CLS]
Less
Common
Ad
##verse
Re
##actions
In
a
pool
##ed
analysis
of
clinical
studies
,
adverse
reactions
with
an
incidence
of
less
than
2
%
reported
in
D
##Y
##SP
##OR
##T
(
r
)
treatment
groups
included
d
##ys
##pha
##gia
0
.
5
%
,
g
##ait
disturbance
0
.
5
%
,
h
##yper
##ton
##ia
0
.
5
%
,
and
sensation
of
he
##avi
##ness
0
.
3
%
.
[SEP]
[CLS]
If
an
##aph
##yla
##xi
##s
or
severe
h
##yper
##sen
##si
##ti
##vity
reactions
occur
,
immediately
disco
##ntin
##ue
administration
of
al
##g
##lu
##cos
##idas
##e
al
##fa
,
and
initiate
appropriate
medical
treatment
.
[SEP]
[CLS]
Other
than
injection
site
reactions
,
most
adverse
reactions
became
noticeable
about
one
week
after
treatment
and
lasted
several
weeks
.
[SEP]
[CLS]
Monitor
glucose
levels
in
patients
at
base
##line
and
periodically
during
treatment
.
[SEP]
[CLS]
At
base
##line
,
57
%
of
the
population
had
diabetes
more
than
5
years
and
had
a
mean
hem
##og
##lo
##bin
A1
##c
(
H
##b
##A
##1
##c
)
of
8
%
.
[SEP]
[CLS]
Table
2
sum
##mar
##izes
the
adverse
reactions
regardless
of
ca
##usal
##ity
from
the
trial
in
patients
with
re
##lap
##sed
or
re
##fra
##ctor
##y
PT
##CL
.
[SEP]
[CLS]
Table
##s
5
and
6
sum
##mar
##ize
common
adverse
reactions
and
laboratory
abnormal
##ities
in
X
##AL
##KO
##RI
-
treated
patients
.
[SEP]
[CLS]
Pat
##ients
with
a
pre
-
existing
low
white
blood
cell
count
(
W
##BC
)
or
a
history
of
le
##uk
##ope
##nia
/
ne
##ut
##rop
##enia
should
have
their
complete
blood
count
(
CBC
)
monitored
frequently
during
the
first
few
months
of
therapy
and
SA
##P
##H
##RI
##S
should
be
discontinued
at
the
first
sign
of
a
decline
in
W
##BC
in
the
absence
of
other
ca
##usa
##tive
factors
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
,
or
if
a
patient
becomes
pregnant
while
receiving
this
drug
,
the
patient
should
be
app
##rise
##d
of
the
potential
hazard
to
the
f
##etus
[
see
##U
##se
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
If
signs
suggesting
all
##ergic
reactions
(
in
particular
,
difficulties
in
breathing
or
swallowing
,
swelling
of
tongue
,
lips
and
face
,
u
##rt
##ica
##ria
,
skin
r
##ash
)
occur
,
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
should
be
discontinued
immediately
and
alternative
therapy
instituted
.
[SEP]
[CLS]
With
##holding
treatment
should
be
considered
in
patients
with
serious
infections
until
the
infection
(
s
)
is
resolved
.
[SEP]
[CLS]
Events
related
to
di
##zzi
##ness
and
disturbance
in
g
##ait
were
more
often
serious
in
AP
##TI
##OM
-
treated
patients
than
in
place
##bo
-
treated
patients
(
2
%
vs
.
0
%
)
,
and
more
often
led
to
study
withdrawal
in
AP
##TI
##OM
-
treated
patients
than
in
place
##bo
-
treated
patients
(
9
%
vs
.
0
.
7
%
)
.
[SEP]
[CLS]
Management
of
h
##yper
##sen
##si
##ti
##vity
reactions
should
be
based
on
the
severity
of
the
reaction
and
include
slowing
or
temporary
interrupt
##ion
of
the
in
##fusion
and
/
or
administration
of
additional
anti
##his
##tamine
##s
,
anti
##py
##ret
##ics
,
and
/
or
co
##rt
##ico
##ster
##oids
for
mild
reactions
.
[SEP]
[CLS]
Eva
##lu
##ate
patients
with
thigh
or
groin
pain
to
rule
out
a
f
##em
##oral
fracture
(
5
.
5
)
*
Ser
##ious
infections
including
skin
infections
:
May
occur
,
including
those
leading
to
hospital
##ization
.
[SEP]
[CLS]
(
5
.
1
)
*
B
##EP
##RE
##VE
should
not
be
used
to
treat
contact
lens
-
related
irritation
.
[SEP]
[CLS]
d
Includes
fatigue
,
as
##the
##nia
,
ma
##lai
##se
.
[SEP]
[CLS]
Disco
##ntin
##ue
PR
##AD
##A
##X
##A
in
patients
with
active
path
##ological
bleeding
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
Inc
##rease
in
Ser
##um
In
##or
##gan
##ic
Ph
##os
##phorus
In
the
pool
of
13
place
##bo
-
controlled
studies
,
increases
from
base
##line
in
mean
serum
p
##hos
##phorus
levels
were
reported
at
Week
24
in
FA
##R
##X
##IG
##A
-
treated
patients
compared
with
place
##bo
-
treated
patients
(
mean
increase
of
0
.
13
versus
-
0
.
04
mg
/
d
##L
,
respectively
)
.
[SEP]
[CLS]
Institute
hormone
replacement
therapy
as
needed
.
[SEP]
[CLS]
Pre
##s
##cribe
##rs
should
monitor
patients
for
so
##m
##no
##len
##ce
and
se
##dation
,
particularly
with
con
##com
##ita
##nt
use
of
other
central
nervous
system
de
##press
##ants
.
[SEP]
[CLS]
The
most
common
adverse
reaction
resulting
in
disco
##ntin
##uation
of
H
##AL
##AV
##EN
was
peripheral
ne
##uro
##pathy
(
5
%
)
.
[SEP]
[CLS]
There
is
substantial
evidence
that
CO
##Cs
do
not
increase
the
incidence
of
breast
cancer
.
[SEP]
[CLS]
Pat
##ients
with
p
##ne
##um
##oni
##tis
thought
to
be
caused
by
Z
##yd
##eli
##g
have
been
treated
with
disco
##ntin
##uation
of
Z
##yd
##eli
##g
and
administration
of
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
5
.
2
Det
##eri
##oration
of
Disease
and
A
##cute
Episode
##s
BR
##E
##O
E
##LL
##IP
##TA
should
not
be
initiated
in
patients
during
rapidly
de
##ter
##ior
##ating
or
potentially
life
-
threatening
episodes
of
CO
##PD
or
as
##th
##ma
.
[SEP]
[CLS]
(
5
.
12
)
*
As
##ses
##s
for
decrease
in
bone
mineral
density
initially
and
periodically
thereafter
.
[SEP]
[CLS]
If
ne
##uro
##logical
compromise
is
noted
,
urgent
treatment
is
necessary
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
Consider
the
benefits
and
risks
before
ne
##ura
##xial
intervention
in
patients
anti
##coa
##gu
##lated
or
to
be
anti
##coa
##gu
##lated
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
5
.
2
The
##rap
##eu
##tic
Monitor
##ing
P
##las
##ma
am
##monia
levels
should
be
maintained
within
normal
range
for
age
via
individual
dose
adjustment
.
[SEP]
[CLS]
c
Con
##fi
##dence
interval
Pat
##ients
Major
bleeding
event
a
Clinical
##ly
relevant
non
-
major
bleeding
Any
bleeding
In
the
R
##E
-
S
##ON
##AT
##E
study
,
the
rate
of
any
gas
##tro
##int
##est
##inal
bleed
##s
in
patients
receiving
PR
##AD
##A
##X
##A
150
mg
was
0
.
7
%
(
0
.
3
%
on
place
##bo
)
.
[SEP]
[CLS]
Factor
##s
that
can
increase
the
risk
of
developing
e
##pid
##ural
or
spinal
hem
##ato
##mas
in
these
patients
include
:
use
of
in
##d
##well
##ing
e
##pid
##ural
cat
##he
##ters
con
##com
##ita
##nt
use
of
other
drugs
that
affect
hem
##ost
##asis
,
such
as
non
-
s
##tero
##idal
anti
-
inflammatory
drugs
(
NSA
##ID
##s
)
,
plate
##let
inhibitor
##s
,
other
anti
##coa
##gu
##lants
a
history
of
traumatic
or
repeated
e
##pid
##ural
or
spinal
pu
##nc
##tures
a
history
of
spinal
def
##orm
##ity
or
spinal
surgery
optimal
timing
between
the
administration
of
PR
##AD
##A
##X
##A
and
ne
##ura
##xial
procedures
is
not
known
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
Based
on
the
severity
of
the
adverse
drug
reaction
,
with
##hold
Z
##Y
##KA
##DI
##A
until
h
##yper
##gly
##ce
##mia
is
adequately
controlled
,
then
resume
Z
##Y
##KA
##DI
##A
at
a
reduced
dose
as
described
in
Table
1
.
[SEP]
[CLS]
Disco
##ntin
##ue
Z
##yd
##eli
##g
permanently
in
patients
who
experience
in
##test
##inal
per
##fo
##ration
.
[SEP]
[CLS]
Pat
##ients
taking
Z
##yd
##eli
##g
who
present
with
pulmonary
symptoms
such
as
cough
,
d
##ys
##p
##nea
,
h
##y
##pox
##ia
,
inter
##st
##iti
##al
in
##fi
##lt
##rates
on
a
radio
##log
##ic
exam
,
or
a
decline
by
more
than
5
%
in
oxygen
sat
##uration
should
be
evaluated
for
p
##ne
##um
##oni
##tis
.
[SEP]
[CLS]
[
See
Do
##sa
##ge
and
Administration
(
2
.
1
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
.
]
[SEP]
[CLS]
For
patients
whose
se
##ra
tested
positive
in
the
screening
im
##mu
##no
##ass
##ay
,
an
in
v
##it
##ro
biological
ass
##ay
was
performed
to
detect
neutral
##izing
antibodies
.
[SEP]
[CLS]
Among
the
28
patients
with
Grade
2
enter
##oc
##oli
##tis
,
79
%
experienced
complete
resolution
,
11
%
improved
,
and
11
%
did
not
improve
.
[SEP]
[CLS]
The
detection
of
anti
-
b
##lina
##tum
##oma
##b
anti
##body
formation
is
highly
dependent
on
the
sensitivity
and
specific
##ity
of
the
ass
##ay
.
[SEP]
[CLS]
At
base
##line
,
5
.
2
%
of
the
population
reported
re
##tino
##pathy
.
[SEP]
[CLS]
5
.
6
N
##eur
##ological
Ad
##verse
Re
##actions
Di
##zzi
##ness
and
Di
##st
##ur
##ban
##ce
in
G
##ait
and
Co
##ordination
AP
##TI
##OM
causes
dose
-
related
increases
in
adverse
reactions
related
to
di
##zzi
##ness
and
disturbance
in
g
##ait
(
di
##zzi
##ness
,
at
##ax
##ia
,
ve
##rt
##igo
,
balance
disorder
,
g
##ait
disturbance
,
n
##ys
##tag
##mus
,
and
abnormal
coordination
)
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
5
.
1
He
##mor
##r
##hage
Fat
##al
bleeding
events
have
occurred
in
patients
treated
with
I
##MB
##R
##U
##VI
##CA
.
[SEP]
[CLS]
5
.
3
Spin
##al
or
Ce
##r
##vic
##al
Co
##rd
Co
##mp
##ression
Spin
##al
or
c
##er
##vic
##al
cord
compression
(
SC
##C
)
is
a
known
and
serious
com
##plication
of
MP
##S
IV
##A
and
may
occur
as
part
of
the
natural
history
of
the
disease
.
[SEP]
[CLS]
The
mean
duration
of
exposure
to
IN
##VO
##KA
##NA
was
38
weeks
with
1832
individuals
exposed
to
IN
##VO
##KA
##NA
for
greater
than
50
weeks
.
[SEP]
[CLS]
All
men
were
instructed
to
take
at
least
1000
mg
of
calcium
and
800
I
##U
of
vitamin
D
supplement
##ation
per
day
.
[SEP]
[CLS]
It
is
not
known
if
D
##U
##AV
##EE
passes
into
your
breast
milk
.
[SEP]
[CLS]
Laboratory
A
##b
##nor
##mal
##ities
Table
6
describes
Grade
3
-
4
laboratory
abnormal
##ities
reported
at
a
rate
of
>
=
10
%
in
the
K
##R
##d
arm
for
patients
who
received
combination
therapy
.
[SEP]
[CLS]
It
is
recommended
that
therapeutic
infectious
agents
not
be
given
concurrently
with
S
##IM
##PO
##NI
ARIA
.
[SEP]
[CLS]
(
5
.
10
)
*
Use
with
caution
in
patients
with
card
##iovascular
disorders
because
of
beta
-
ad
##rene
##rg
##ic
stimulation
.
[SEP]
[CLS]
(
5
.
8
)
*
Blood
pressure
(
BP
)
:
Monitor
BP
during
treatment
.
[SEP]
[CLS]
In
##fect
##ions
In
Study
1
,
1
%
of
patients
treated
with
X
##TA
##ND
##I
compared
to
0
.
3
%
of
patients
treated
with
place
##bo
died
from
infections
or
se
##psis
.
[SEP]
[CLS]
Testing
was
performed
in
patients
who
experienced
moderate
to
severe
or
h
##yper
##sen
##si
##ti
##vity
reactions
,
for
which
mast
-
cell
activation
was
suspected
.
[SEP]
[CLS]
5
.
2
Weight
Dec
##rease
During
the
controlled
period
of
the
studies
in
ps
##oria
##tic
art
##hr
##itis
(
P
##s
##A
)
,
weight
decrease
between
5
%
-
10
%
of
body
weight
was
reported
in
10
%
(
49
/
49
##7
)
of
subjects
treated
with
O
##TE
##Z
##LA
30
mg
twice
daily
compared
to
3
.
3
%
(
16
/
49
##5
)
treated
with
place
##bo
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
LA
##CT
##IC
AC
##ID
##OS
##IS
/
SE
##VE
##RE
H
##EP
##AT
##OM
##EG
##AL
##Y
W
##IT
##H
ST
##EA
##TO
##SI
##S
and
P
##OS
##T
T
##RE
##AT
##ME
##NT
AC
##UT
##E
E
##X
##AC
##ER
##BA
##TI
##ON
OF
H
##EP
##AT
##IT
##IS
B
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
pre
##dn
##ison
##e
)
at
the
time
of
fracture
.
[SEP]
[CLS]
5
.
16
Laboratory
Tests
Ser
##um
f
##oll
##icle
s
##ti
##mulating
hormone
(
F
##S
##H
)
and
est
##rad
##iol
levels
have
not
been
shown
to
be
useful
in
the
management
of
moderate
to
severe
v
##as
##omo
##tor
symptoms
.
[SEP]
[CLS]
SA
##P
##H
##RI
##S
is
not
indicated
for
the
treatment
of
dem
##ent
##ia
-
related
ps
##ych
##osis
,
and
should
not
be
used
in
patients
at
risk
for
as
##piration
pneumonia
[
see
also
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
These
events
are
notable
because
of
their
serious
##ness
,
severity
,
or
increased
frequency
in
subjects
who
received
VI
##CT
##RE
##L
##IS
in
combination
with
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
compared
with
subjects
who
received
only
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
.
[SEP]
[CLS]
PR
##IS
##TI
##Q
should
be
discontinued
before
in
##iti
##ating
treatment
with
the
MA
##O
##I
[
see
Con
##tra
##ind
##ica
##tions
(
4
.
2
)
and
Do
##sa
##ge
and
Administration
(
2
.
6
)
]
.
[SEP]
[CLS]
Women
taking
D
##U
##AV
##EE
should
not
take
additional
est
##rogen
##s
as
this
may
increase
the
risk
of
end
##ome
##tri
##al
h
##yper
##p
##lasia
.
[SEP]
[CLS]
In
the
event
of
an
erection
that
per
##sist
##s
longer
than
4
hours
,
the
patient
should
seek
immediate
medical
assistance
.
[SEP]
[CLS]
There
is
evidence
to
suggest
that
some
patients
who
develop
high
and
sustained
I
##g
##G
anti
##body
t
##iter
##s
may
experience
reduced
clinical
efficacy
to
al
##g
##lu
##cos
##idas
##e
al
##fa
treatment
,
such
as
loss
of
motor
function
,
vent
##ila
##tor
dependence
,
or
death
.
[SEP]
[CLS]
In
addition
,
because
IL
##AR
##IS
may
interfere
with
normal
immune
response
to
new
anti
##gens
,
v
##ac
##cin
##ations
may
not
be
effective
in
patients
receiving
IL
##AR
##IS
.
[SEP]
[CLS]
Sub
##group
analyses
of
women
50
to
59
years
of
age
suggest
a
statistical
##ly
non
-
significant
reduction
in
CH
##D
events
(
CE
[
0
.
625
mg
]
-
alone
compared
to
place
##bo
)
in
women
with
less
than
10
years
since
men
##op
##aus
##e
(
8
versus
16
per
10
,
000
women
-
years
)
.
[SEP]
[CLS]
In
controlled
studies
of
C
##IM
##Z
##IA
for
C
##ro
##hn
'
s
disease
and
other
investigation
##al
uses
,
there
was
one
case
of
l
##ymph
##oma
among
2
,
65
##7
C
##im
##zia
-
treated
patients
and
one
case
of
Ho
##d
##g
##kin
'
s
l
##ymph
##oma
among
1
,
31
##9
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Co
##rona
##ry
Heart
Disease
In
the
W
##H
##I
est
##rogen
-
alone
sub
##st
##ud
##y
,
no
overall
effect
on
co
##rona
##ry
heart
disease
(
CH
##D
)
events
(
defined
as
non
##fa
##tal
my
##oc
##ard
##ial
in
##far
##ction
,
silent
my
##oc
##ard
##ial
in
##far
##ction
,
or
CH
##D
death
)
was
reported
in
women
receiving
est
##rogen
-
alone
compared
to
place
##bo
[
see
Clinical
Studies
(
14
.
5
)
]
.
[SEP]
[CLS]
Physicians
should
be
at
##ten
##tive
to
symptoms
of
infection
or
worse
##ning
of
S
##J
##IA
,
as
these
are
known
trigger
##s
for
MA
##S
.
[SEP]
[CLS]
If
con
##com
##ita
##nt
use
of
PR
##IS
##TI
##Q
with
other
se
##rot
##one
##rg
##ic
drugs
,
including
trip
##tan
##s
,
t
##ric
##yclic
anti
##de
##press
##ants
,
f
##ent
##any
##l
,
lit
##hium
,
tram
##ado
##l
,
bus
##pi
##rone
,
try
##pt
##op
##han
,
and
St
.
John
'
s
W
##ort
is
clinical
##ly
warrant
##ed
,
patients
should
be
made
aware
of
a
potential
increased
risk
for
se
##rot
##oni
##n
syndrome
,
particularly
during
treatment
initiation
and
dose
increases
.
[SEP]
[CLS]
The
con
##com
##ita
##nt
use
of
AD
##CE
##TR
##IS
with
b
##leo
##my
##cin
is
con
##tra
##ind
##ica
##ted
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
After
an
average
follow
-
up
of
5
.
2
years
,
28
women
in
the
est
##rogen
-
alone
group
and
19
women
in
the
place
##bo
group
were
diagnosed
with
probable
dem
##ent
##ia
.
[SEP]
[CLS]
The
safety
of
D
##IF
##IC
##ID
200
mg
tablets
taken
twice
a
day
for
10
days
was
evaluated
in
56
##4
patients
with
CD
##AD
in
two
active
-
com
##par
##ator
controlled
trials
with
86
.
7
%
of
patients
receiving
a
full
course
of
treatment
.
[SEP]
[CLS]
Short
-
term
studies
did
not
show
an
increase
in
the
risk
of
su
##icidal
##ity
with
anti
##de
##press
##ants
compared
to
place
##bo
in
adults
beyond
age
24
;
there
was
a
reduction
with
anti
##de
##press
##ants
compared
to
place
##bo
in
adults
aged
65
and
older
.
[SEP]
[CLS]
The
safety
of
V
##OR
##A
##X
##A
##Z
##E
is
based
on
data
from
290
patients
who
were
treated
in
2
single
-
arm
,
open
-
label
,
multi
##cent
##er
trials
en
##roll
##ing
patients
who
had
marked
##ly
delayed
met
##hot
##re
##xa
##te
clearance
secondary
to
re
##nal
d
##ys
##function
.
[SEP]
[CLS]
In
addition
to
the
term
injection
site
reaction
(
see
Table
1
)
,
the
following
other
types
of
injection
site
reactions
also
occurred
more
frequently
on
T
##AN
##Z
##E
##UM
:
injection
site
hem
##ato
##ma
(
1
.
9
%
versus
2
.
1
%
for
place
##bo
versus
T
##AN
##Z
##E
##UM
)
,
injection
site
er
##yt
##hem
##a
(
0
.
4
%
versus
1
.
7
%
for
place
##bo
versus
T
##AN
##Z
##E
##UM
)
,
injection
site
r
##ash
(
0
%
versus
1
.
4
%
for
place
##bo
versus
T
##AN
##Z
##E
##UM
)
,
injection
site
h
##yper
##sen
##si
##ti
##vity
(
0
%
versus
0
.
8
%
for
place
##bo
versus
T
##AN
##Z
##E
##UM
)
,
and
injection
site
hem
##or
##r
##hage
(
0
.
6
%
versus
0
.
7
%
for
place
##bo
versus
T
##AN
##Z
##E
##UM
)
.
[SEP]
[CLS]
5
.
2
I
##mm
##uno
##su
##pp
##ression
The
impact
of
treatment
with
anti
-
inter
##le
##uki
##n
-
1
(
IL
-
1
)
therapy
on
the
development
of
ma
##li
##gna
##ncies
is
not
known
.
[SEP]
[CLS]
(
6
.
2
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
G
##lax
##o
##S
##mith
##K
##line
at
1
-
88
##8
-
82
##5
-
52
##4
##9
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
E
##NT
##ER
##EG
R
##EM
##S
Program
that
restrict
##s
use
to
enrolled
hospitals
because
of
the
potential
risk
of
my
##oc
##ard
##ial
in
##far
##ction
with
long
-
term
use
of
E
##NT
##ER
##EG
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
*
If
you
miss
a
dose
of
D
##U
##AV
##EE
,
take
it
as
soon
as
you
remember
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
Y
##ER
##VO
##Y
in
patients
with
severe
ne
##uro
##pathy
(
interfering
with
daily
activities
)
such
as
G
##uil
##lain
-
Barr
##e
-
like
syndrome
##s
.
[SEP]
[CLS]
The
AD
##R
##s
observed
in
FL
##AM
##ING
##O
were
generally
consistent
with
those
seen
in
SP
##RI
##NG
-
2
and
S
##ING
##LE
.
[SEP]
[CLS]
Ad
##verse
laboratory
and
EC
##G
effects
are
presented
separately
in
Table
2
.
[SEP]
[CLS]
A
total
of
64
%
of
patients
on
G
##IL
##OT
##RI
##F
and
67
%
of
p
##em
##et
##re
##xed
/
c
##is
##p
##lat
##in
patients
were
female
.
[SEP]
[CLS]
En
##sure
safe
handling
to
protect
patients
and
health
care
workers
from
un
##int
##ent
##ional
radiation
exposure
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
]
.
[SEP]
[CLS]
Ad
##verse
reactions
are
adverse
events
in
which
there
is
some
basis
to
believe
there
is
a
ca
##usal
relationship
between
the
drug
and
the
occurrence
of
the
adverse
event
.
[SEP]
[CLS]
IN
##L
##Y
##TA
has
not
been
studied
in
patients
who
have
evidence
of
un
##tre
##ated
brain
meta
##sta
##sis
or
recent
active
gas
##tro
##int
##est
##inal
bleeding
and
should
not
be
used
in
those
patients
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
G
##lax
##o
##S
##mith
##K
##line
at
1
-
88
##8
-
82
##5
-
52
##4
##9
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
C
##aut
##ion
should
be
exercised
when
administer
##ing
al
##g
##lu
##cos
##idas
##e
al
##fa
to
patients
susceptible
to
fluid
volume
over
##load
.
[SEP]
[CLS]
Ad
##mini
##ster
insulin
therapy
as
necessary
in
patients
with
h
##yper
##gly
##ce
##mia
.
[SEP]
[CLS]
H
##OR
##I
##Z
##AN
##T
is
a
pro
##dr
##ug
of
g
##aba
##pent
##in
.
[SEP]
[CLS]
The
risk
of
su
##icidal
thoughts
was
generally
consistent
among
drugs
in
the
data
analyzed
.
[SEP]
[CLS]
Pat
##ients
treated
with
any
A
##ED
for
any
indication
should
be
monitored
for
the
emergence
or
worse
##ning
of
depression
,
su
##icidal
thoughts
or
behavior
,
and
/
or
any
unusual
changes
in
mood
or
behavior
.
[SEP]
[CLS]
O
##bt
##ain
an
EC
##G
before
initiation
of
treatment
,
and
at
least
2
,
12
,
and
24
weeks
after
starting
treatment
with
S
##IR
##TU
##RO
.
[SEP]
[CLS]
Most
of
these
reactions
may
have
been
the
consequence
of
the
surgical
procedure
.
[SEP]
[CLS]
5
.
5
Para
##dox
##ical
B
##ron
##cho
##sp
##as
##m
As
with
other
inhaled
beta
##2
-
ago
##nist
##s
,
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
may
produce
para
##dox
##ical
br
##on
##cho
##sp
##as
##m
that
may
be
life
-
threatening
.
[SEP]
[CLS]
Table
5
.
[SEP]
[CLS]
If
a
patient
develops
a
der
##mat
##olo
##gic
reaction
while
taking
AP
##TI
##OM
,
disco
##ntin
##ue
AP
##TI
##OM
use
,
unless
the
reaction
is
clearly
not
drug
-
related
.
[SEP]
[CLS]
A
total
of
1
,
86
##7
subjects
were
included
in
two
clinical
phase
3
studies
with
a
treatment
duration
up
to
28
cycles
with
Nat
##azi
##a
as
an
oral
con
##tra
##ceptive
and
264
subjects
in
the
two
phase
3
clinical
trials
with
a
treatment
duration
of
7
cycles
evaluating
Nat
##azi
##a
in
the
treatment
of
heavy
,
prolonged
,
and
/
or
frequent
men
##st
##ru
##al
bleeding
in
women
without
organic
path
##ology
.
[SEP]
[CLS]
The
h
##yper
##sen
##si
##ti
##vity
reactions
include
it
##ching
,
body
r
##ash
,
and
swelling
of
lips
.
[SEP]
[CLS]
Consider
as
a
possible
cause
for
severe
joint
pain
and
disco
##ntin
##ue
drug
if
appropriate
.
[SEP]
[CLS]
Pat
##ients
treated
with
con
##com
##ita
##nt
im
##mu
##nos
##up
##press
##ants
had
a
lower
rate
of
anti
##body
development
than
patients
not
taking
im
##mu
##nos
##up
##press
##ants
at
base
##line
(
3
%
and
11
%
,
respectively
)
.
[SEP]
[CLS]
The
im
##mu
##no
##genic
##ity
of
B
##L
##IN
##C
##Y
##TO
has
been
evaluated
using
either
an
electro
##che
##mi
##lum
##ines
##cence
detection
technology
(
EC
##L
)
or
an
enzyme
-
linked
im
##mu
##nos
##or
##bent
ass
##ay
(
E
##L
##IS
##A
)
screening
im
##mu
##no
##ass
##ay
for
the
detection
of
binding
anti
-
b
##lina
##tum
##oma
##b
antibodies
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
incidence
1
%
or
greater
)
are
:
systemic
h
##yper
##sen
##si
##ti
##vity
,
h
##yper
##gly
##ce
##mia
,
trans
##ami
##nas
##es
abnormal
,
fever
,
pan
##cre
##ati
##tis
,
local
reactions
,
vomit
##ing
,
nausea
,
th
##rom
##bos
##is
,
h
##yper
##bil
##ir
##ubi
##ne
##mia
,
abdominal
pain
,
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
Table
4
shows
the
number
of
patients
experiencing
bleeding
events
in
the
study
.
[SEP]
[CLS]
N
##eur
##op
##athy
lasting
more
than
one
year
occurred
in
5
%
(
26
/
50
##3
)
of
patients
.
[SEP]
[CLS]
Ad
##verse
reactions
that
occurred
with
a
frequency
>
1
%
were
associated
with
the
injection
site
(
1
.
3
%
)
,
problems
.
[SEP]
[CLS]
If
signs
or
symptoms
suggest
S
##J
##S
/
T
##EN
,
use
of
this
drug
should
not
be
resumed
and
alternative
therapy
should
be
considered
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
With
##hold
Z
##yd
##eli
##g
if
the
AL
##T
or
AS
##T
is
greater
than
5
times
the
upper
limit
of
normal
,
and
continue
to
monitor
AS
##T
,
AL
##T
and
total
bi
##li
##ru
##bin
weekly
until
the
abnormal
##ity
is
resolved
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
Women
with
a
history
of
CO
##C
-
related
ch
##ole
##sta
##sis
may
have
the
condition
re
##cu
##r
with
subsequent
CO
##C
use
.
[SEP]
[CLS]
With
##dra
##wal
symptoms
(
e
.
g
.
,
con
##vu
##ls
##ions
,
ps
##ych
##osis
,
hall
##uc
##ination
##s
,
behavioral
disorder
,
t
##rem
##or
,
and
anxiety
)
have
been
reported
following
abrupt
disco
##ntin
##uan
##ce
of
ben
##zo
##dia
##ze
##pine
##s
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
reactions
have
uncommon
##ly
been
reported
during
the
post
##market
##ing
use
of
Ad
##re
##V
##ie
##w
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
The
safety
profile
for
subjects
who
completed
48
weeks
of
treatment
was
similar
to
the
safety
profile
for
subjects
who
completed
24
weeks
of
treatment
.
[SEP]
[CLS]
Women
with
h
##yper
##tri
##gly
##cer
##ide
##mia
,
or
a
family
history
thereof
,
may
be
at
an
increased
risk
of
pan
##cre
##ati
##tis
when
using
CO
##Cs
.
[SEP]
[CLS]
The
incidence
of
h
##yper
##tens
##ion
increases
with
increasing
concentration
of
pro
##ges
##tin
.
[SEP]
[CLS]
Pat
##ients
with
a
history
of
g
##eni
##tal
my
##cot
##ic
infections
were
more
likely
to
have
a
g
##eni
##tal
my
##cot
##ic
infection
during
the
study
than
those
with
no
prior
history
(
10
.
0
%
,
23
.
1
%
,
and
25
.
0
%
versus
0
.
8
%
,
5
.
9
%
,
and
5
.
0
%
on
place
##bo
,
FA
##R
##X
##IG
##A
5
mg
,
and
FA
##R
##X
##IG
##A
10
mg
,
respectively
)
.
[SEP]
[CLS]
Two
(
1
%
)
of
these
were
fatal
.
[SEP]
[CLS]
Non
-
me
##lan
##oma
skin
cancer
was
reported
in
1
.
5
%
(
6
/
401
)
of
patients
treated
with
the
recommended
N
##U
##L
##O
##J
##IX
regime
##n
and
in
3
.
7
%
(
15
/
405
)
of
patients
treated
with
c
##y
##c
##los
##por
##ine
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
Eva
##lu
##ate
at
each
visit
for
signs
and
symptoms
of
end
##oc
##rino
##pathy
.
[SEP]
[CLS]
P
##OT
##IG
##A
was
associated
with
dose
-
related
weight
gain
,
with
mean
weight
increasing
by
0
.
2
kg
,
1
.
2
kg
,
1
.
6
kg
,
and
2
.
7
kg
in
the
place
##bo
,
600
mg
per
day
,
900
mg
per
day
,
and
1
,
200
mg
per
day
groups
,
respectively
.
[SEP]
[CLS]
5
.
3
Cy
##top
##enia
##s
Treatment
-
emerge
##nt
Grade
3
or
4
c
##yt
##ope
##nia
##s
including
ne
##ut
##rop
##enia
(
range
,
19
to
29
%
)
,
th
##rom
##bo
##cy
##top
##enia
(
range
,
5
to
17
%
)
,
and
an
##emia
(
range
,
0
to
9
%
)
occurred
in
patients
treated
with
I
##MB
##R
##U
##VI
##CA
.
[SEP]
[CLS]
5
.
3
He
##pa
##tic
Effects
There
have
been
post
##market
##ing
reports
of
fatal
and
non
##fa
##tal
he
##pa
##tic
failure
in
patients
taking
NE
##SI
##NA
,
although
some
of
the
reports
contain
insufficient
information
necessary
to
establish
the
probable
cause
[
see
##A
##d
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
X
##AL
##KO
##RI
in
patients
who
develop
Q
##T
##c
greater
than
500
m
##s
or
greater
than
or
equal
to
60
m
##s
change
from
base
##line
with
Tor
##sad
##e
de
point
##es
or
p
##oly
##morphic
vent
##ric
##ular
ta
##chy
##card
##ia
or
signs
/
symptoms
of
serious
a
##rr
##hy
##th
##mia
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
Ad
##verse
reactions
associated
with
op
##ht
##hal
##mic
s
##tero
##ids
include
elevated
in
##tra
##oc
##ular
pressure
,
which
may
be
associated
with
op
##tic
nerve
damage
,
visual
a
##cu
##ity
and
field
defects
,
posterior
sub
##cap
##sul
##ar
cat
##ara
##ct
formation
;
secondary
o
##cular
infection
,
and
per
##fo
##ration
of
the
globe
where
there
is
thin
##ning
of
the
corn
##ea
or
s
##cle
##ra
.
[SEP]
[CLS]
Table
3
.
[SEP]
[CLS]
In
addition
,
beta
-
ago
##nist
##s
have
been
reported
to
produce
EC
##G
changes
,
such
as
flat
##ten
##ing
of
the
T
wave
,
pro
##long
##ation
of
the
Q
##T
##c
interval
,
and
ST
segment
depression
,
although
the
clinical
significance
of
these
findings
is
unknown
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
most
serious
adverse
reactions
reported
with
PR
##AD
##A
##X
##A
were
related
to
bleeding
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
The
em
##tric
##ita
##bine
and
ten
##of
##ov
##ir
D
##F
components
of
ST
##RI
##BI
##LD
are
primarily
ex
##cre
##ted
by
the
kidney
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
medical
support
,
including
card
##io
##pu
##lm
##ona
##ry
re
##sus
##citation
equipment
,
should
be
readily
available
when
al
##g
##lu
##cos
##idas
##e
al
##fa
is
administered
.
[SEP]
[CLS]
The
median
onset
time
for
h
##yper
##tens
##ion
(
s
##ys
##to
##lic
blood
pressure
>
150
mm
##H
##g
or
di
##ast
##olic
blood
pressure
>
100
mm
##H
##g
)
was
within
the
first
month
of
the
start
of
IN
##L
##Y
##TA
treatment
and
blood
pressure
increases
have
been
observed
as
early
as
4
days
after
starting
IN
##L
##Y
##TA
.
[SEP]
[CLS]
b
Per
##ip
##her
##al
ne
##uro
##path
##ies
NE
##C
includes
the
preferred
terms
under
H
##LT
peripheral
ne
##uro
##path
##ies
NE
##C
.
[SEP]
[CLS]
Se
##vere
acute
ex
##ace
##rb
##ations
of
he
##pa
##titis
B
have
been
reported
in
patients
who
are
coin
##fected
with
H
##B
##V
and
human
im
##mu
##no
##de
##ficiency
virus
-
1
(
HIV
-
1
)
and
have
discontinued
E
##MT
##RI
##VA
or
VI
##RE
##AD
,
which
are
components
of
ST
##RI
##BI
##LD
.
[SEP]
[CLS]
Cause
##s
of
death
on
the
A
##FI
##NI
##TO
##R
arm
included
one
case
of
each
of
the
following
:
acute
re
##nal
failure
,
acute
respiratory
distress
,
cardiac
arrest
,
death
(
cause
unknown
)
,
he
##pa
##tic
failure
,
pneumonia
,
and
se
##psis
.
[SEP]
[CLS]
(
5
.
9
)
5
.
1
Ang
##io
##ede
##ma
Ang
##io
##ede
##ma
of
the
face
has
been
reported
with
f
##es
##oter
##od
##ine
.
[SEP]
[CLS]
Pat
##ients
on
the
place
##bo
arm
could
cross
over
to
open
-
label
A
##FI
##NI
##TO
##R
upon
disease
progression
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
Y
##ER
##VO
##Y
in
patients
with
Stevens
-
Johnson
syndrome
,
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
,
or
r
##ash
complicated
by
full
thickness
der
##mal
ul
##cer
##ation
,
or
ne
##c
##rot
##ic
,
bull
##ous
,
or
hem
##or
##r
##ha
##gic
manifest
##ations
.
[SEP]
[CLS]
Four
place
##bo
-
controlled
add
-
on
combination
therapy
trials
of
26
weeks
duration
were
also
conducted
:
with
met
##form
##in
,
with
a
su
##lf
##ony
##lu
##rea
,
with
a
th
##ia
##zo
##lid
##ined
##ione
and
with
insulin
.
[SEP]
[CLS]
Ch
##ronic
L
##ymph
##oc
##ytic
Le
##uke
##mia
The
data
described
below
reflect
exposure
to
T
##RE
##AN
##DA
in
153
patients
with
C
##LL
studied
in
an
active
-
controlled
,
random
##ized
trial
.
[SEP]
[CLS]
Ad
##e
##qua
##te
data
are
not
available
on
the
safety
or
efficacy
of
treating
patients
who
are
carriers
of
H
##B
##V
with
anti
-
viral
therapy
in
conjunction
with
T
##NF
block
##er
therapy
to
prevent
H
##B
##V
react
##ivation
.
[SEP]
[CLS]
At
base
##line
,
21
%
of
the
population
reported
peripheral
ne
##uro
##pathy
and
5
%
reported
re
##tino
##pathy
.
[SEP]
[CLS]
The
risk
of
seizure
##s
in
patients
with
e
##pile
##pt
##iform
activity
on
an
E
##EG
is
unknown
,
and
could
be
substantially
higher
than
that
observed
in
AM
##P
##Y
##RA
clinical
studies
.
[SEP]
[CLS]
5
.
8
Use
with
Biological
Disease
-
Mo
##di
##fying
Anti
##r
##he
##umatic
Drugs
(
Biological
D
##MA
##RD
##s
)
Ser
##ious
infections
were
seen
in
clinical
studies
with
concurrent
use
of
an
##aki
##n
##ra
(
an
inter
##le
##uki
##n
-
1
antagonist
)
and
another
T
##NF
block
##er
,
et
##ane
##rc
##ept
,
with
no
added
benefit
compared
to
et
##ane
##rc
##ept
alone
.
[SEP]
[CLS]
During
its
development
for
the
ad
##junct
##ive
treatment
of
seizure
##s
associated
with
L
##GS
,
ON
##FI
was
administered
to
333
healthy
volunteers
and
300
patients
with
a
current
or
prior
diagnosis
of
L
##GS
,
including
197
patients
treated
for
12
months
or
more
.
[SEP]
[CLS]
The
range
of
mean
base
##line
L
##D
##L
-
C
levels
was
90
.
3
to
90
.
6
mg
/
d
##L
across
treatment
groups
.
[SEP]
[CLS]
Each
EC
##L
##IP
##SE
study
compared
C
##lev
##ip
##re
##x
(
n
=
75
##2
)
to
an
active
com
##par
##ator
:
ni
##tro
##gly
##cer
##in
(
N
##T
##G
,
n
=
278
)
,
sodium
ni
##tro
##p
##russ
##ide
(
S
##NP
,
n
=
28
##3
)
,
or
ni
##card
##ip
##ine
(
N
##IC
,
n
=
193
)
.
[SEP]
[CLS]
5
.
3
Con
##tin
##uation
and
Tim
##ing
of
Le
##uc
##ovo
##rin
Rescue
Con
##tin
##ue
to
administer
le
##uc
##ovo
##rin
after
V
##OR
##A
##X
##A
##Z
##E
.
[SEP]
[CLS]
Other
factors
associated
with
hem
##at
##uria
were
well
-
balanced
between
arms
and
do
not
account
for
the
increased
rate
of
hem
##at
##uria
on
the
J
##E
##V
##TA
##NA
arm
.
[SEP]
[CLS]
The
greatest
risk
appears
associated
with
prolonged
use
,
with
increased
risks
of
15
-
to
24
-
fold
for
5
to
10
years
or
more
of
treatment
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
H
##yper
##sen
##si
##ti
##vity
Re
##actions
Ser
##ious
and
occasionally
fatal
an
##aph
##yla
##ctic
)
reactions
and
serious
skin
reactions
have
been
reported
in
patients
receiving
beta
-
la
##ct
##am
anti
##ba
##cter
##ial
drugs
.
[SEP]
[CLS]
During
clinical
trials
,
no
an
##aph
##yla
##ctic
reactions
have
been
reported
.
[SEP]
[CLS]
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
D
##ys
##ge
##us
##ia
(
alter
##ation
of
taste
)
was
an
adverse
event
reported
at
an
increased
frequency
in
subjects
receiving
VI
##CT
##RE
##L
##IS
in
combination
with
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
compared
with
subjects
receiving
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
alone
(
Table
3
)
.
[SEP]
[CLS]
It
should
be
noted
that
PR
##IS
##TI
##Q
is
not
approved
for
use
in
treating
bi
##pol
##ar
depression
.
[SEP]
[CLS]
In
HIV
-
1
-
In
##fected
Sub
##jects
With
No
Anti
##ret
##rov
##ira
##l
Treatment
History
The
safety
assessment
of
ST
##RI
##BI
##LD
is
based
on
the
Week
144
pool
##ed
data
from
140
##8
subjects
in
two
random
##ized
,
double
-
blind
,
active
-
controlled
clinical
trials
,
Study
102
and
Study
103
,
in
anti
##ret
##rov
##ira
##l
treatment
-
naive
HIV
-
1
infected
adult
subjects
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Ser
##ious
an
##aph
##yla
##ctic
)
reactions
have
been
reported
with
beta
-
la
##ct
##am
anti
##ba
##cter
##ial
drugs
,
including
Te
##f
##lar
##o
.
[SEP]
[CLS]
*
In
those
patients
already
taking
an
op
##ti
##mized
dose
of
a
PD
##E
##5
inhibitor
,
alpha
-
block
##er
therapy
should
be
initiated
at
the
lowest
dose
.
[SEP]
[CLS]
(
5
.
4
,
2
.
3
)
*
Card
##io
##my
##op
##athy
:
As
##ses
##s
L
##VE
##F
before
treatment
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
,
after
one
month
of
treatment
,
then
every
2
to
3
months
thereafter
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
an
unknown
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
.
[SEP]
[CLS]
(
5
.
9
)
*
G
##lu
##cos
##e
-
6
-
Ph
##os
##phate
De
##hy
##dr
##ogen
##ase
De
##ficiency
:
Close
##ly
monitor
for
hem
##oly
##tic
an
##emia
.
[SEP]
[CLS]
It
should
be
recognized
that
symptoms
of
the
underlying
disease
being
treated
may
be
similar
to
symptoms
of
h
##yper
##sen
##si
##ti
##vity
.
[SEP]
[CLS]
Individuals
who
have
already
experienced
N
##A
##ION
are
at
increased
risk
of
N
##A
##ION
re
##cu
##rrence
.
[SEP]
[CLS]
Pat
##ients
who
experience
reduced
clinical
response
may
also
be
tested
for
inhibitor
##y
anti
##body
activity
.
[SEP]
[CLS]
This
risk
has
been
shown
to
per
##sist
for
at
least
8
to
15
years
after
est
##rogen
therapy
is
discontinued
.
[SEP]
[CLS]
Of
the
32
##9
enrolled
patients
,
32
##7
(
167
br
##ent
##ux
##ima
##b
ve
##do
##tin
,
160
place
##bo
)
received
at
least
one
dose
of
study
treatment
.
[SEP]
[CLS]
If
PM
##L
is
diagnosed
,
consideration
should
be
given
to
reduction
or
withdrawal
of
im
##mu
##nos
##up
##press
##ion
taking
into
account
the
risk
to
the
all
##og
##raft
.
[SEP]
[CLS]
Pat
##ients
on
con
##com
##ita
##nt
im
##mu
##nos
##up
##press
##ant
agents
or
with
impaired
immune
systems
may
be
at
increased
risk
for
serious
infections
.
[SEP]
[CLS]
Pat
##ients
should
be
evaluated
for
tuberculosis
and
tested
for
late
##nt
infection
prior
to
in
##iti
##ating
N
##U
##L
##O
##J
##IX
.
[SEP]
[CLS]
With
##hold
T
##AF
##IN
##LA
##R
,
and
tram
##eti
##ni
##b
if
used
in
combination
,
for
into
##ler
##able
or
severe
skin
toxicity
.
[SEP]
[CLS]
Established
micro
##vas
##cular
complications
of
diabetes
at
base
##line
included
di
##abe
##tic
ne
##ph
##rop
##athy
(
7
%
)
,
re
##tino
##pathy
(
8
%
)
,
or
ne
##uro
##pathy
(
16
%
)
.
[SEP]
[CLS]
Suicide
is
a
known
risk
of
depression
and
certain
other
psychiatric
disorders
,
and
these
disorders
themselves
are
the
strongest
predict
##ors
of
suicide
.
[SEP]
[CLS]
5
.
6
I
##mp
##aire
##d
W
##ou
##nd
He
##aling
Ever
##oli
##mus
delays
wound
healing
and
increases
the
occurrence
of
wound
-
related
complications
like
wound
de
##his
##cence
,
wound
infection
,
in
##cision
##al
her
##nia
,
l
##ymph
##oc
##ele
,
and
se
##roma
.
[SEP]
[CLS]
Bone
pain
was
the
most
frequent
treatment
-
emerge
##nt
adverse
reaction
that
occurred
in
at
least
1
%
or
greater
in
patients
treated
with
G
##RA
##NI
##X
at
the
recommended
dose
and
was
numerical
##ly
two
times
more
frequent
than
in
the
place
##bo
group
.
[SEP]
[CLS]
Ad
##vise
patients
not
to
drive
or
operate
heavy
machinery
until
they
know
how
To
##via
##z
affects
them
(
5
.
5
)
*
To
##via
##z
should
be
used
with
caution
in
patients
with
my
##ast
##hen
##ia
g
##ra
##vis
,
a
disease
characterized
by
decreased
ch
##olin
##ergic
activity
at
the
ne
##uro
##mus
##cular
junction
.
[SEP]
[CLS]
Two
place
##bo
-
controlled
mon
##otherapy
trials
of
12
and
26
weeks
of
duration
were
conducted
in
patients
treated
with
NE
##SI
##NA
12
.
5
mg
daily
,
NE
##SI
##NA
25
mg
daily
and
place
##bo
.
[SEP]
[CLS]
Mu
##s
##cu
##los
##kel
##etal
Di
##sor
##ders
:
My
##os
##itis
.
[SEP]
[CLS]
All
5
patients
had
maximum
AS
##T
levels
>
8
*
U
##L
##N
,
which
returned
to
base
##line
levels
following
interrupt
##ion
of
K
##AL
##Y
##DE
##CO
dos
##ing
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
at
an
Inc
##iden
##ce
of
2
%
or
More
among
FA
##NA
##P
##T
-
T
##reate
##d
Pat
##ients
and
More
Fr
##e
##quent
than
Place
##bo
Table
7
en
##ume
##rates
the
pool
##ed
incidence
##s
of
treatment
-
emerge
##nt
adverse
reactions
that
were
spontaneous
##ly
reported
in
four
place
##bo
-
controlled
,
4
-
or
6
-
week
,
fixed
-
or
flexible
-
dose
studies
,
listing
those
reactions
that
occurred
in
2
%
or
more
of
patients
treated
with
FA
##NA
##P
##T
in
any
of
the
dose
groups
,
and
for
which
the
incidence
in
FA
##NA
##P
##T
-
treated
patients
in
any
dose
group
was
greater
than
the
incidence
in
patients
treated
with
place
##bo
.
[SEP]
[CLS]
If
une
##x
##plain
##ed
or
clinical
##ly
significant
weight
loss
occurs
,
weight
loss
should
be
evaluated
,
and
disco
##ntin
##uation
of
O
##TE
##Z
##LA
should
be
considered
.
[SEP]
[CLS]
In
some
cases
of
an
##aph
##yla
##xi
##s
,
e
##pine
##ph
##rine
has
been
administered
.
[SEP]
[CLS]
D
##ys
##ton
##ic
symptoms
include
:
spa
##sm
of
the
neck
muscles
,
sometimes
progress
##ing
to
tight
##ness
of
the
throat
,
swallowing
difficulty
,
difficulty
breathing
,
and
/
or
pro
##trusion
of
the
tongue
.
[SEP]
[CLS]
In
addition
to
cases
of
gas
##tro
##int
##est
##inal
per
##fo
##ration
were
reported
in
4
/
71
##5
patients
(
1
%
)
.
[SEP]
[CLS]
The
most
common
adverse
reactions
leading
to
withdrawal
in
patients
receiving
P
##OT
##IG
##A
were
di
##zzi
##ness
(
6
%
)
,
confusion
##al
state
(
4
%
)
,
fatigue
(
3
%
)
,
and
so
##m
##no
##len
##ce
(
3
%
)
.
[SEP]
[CLS]
Treatment
of
Bone
Loss
in
Pat
##ients
Re
##ceiving
And
##rogen
De
##p
##ri
##vation
Therapy
for
Pro
##state
Cancer
or
Ad
##ju
##vant
A
##roma
##tase
In
##hibit
##or
Therapy
for
B
##rea
##st
Cancer
The
safety
of
Pro
##lia
in
the
treatment
of
bone
loss
in
men
with
non
##met
##ast
##atic
pro
##state
cancer
receiving
and
##rogen
de
##p
##ri
##vation
therapy
(
AD
##T
)
was
assessed
in
a
3
-
year
,
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
,
multinational
study
of
146
##8
men
aged
48
to
97
years
.
[SEP]
[CLS]
A
total
of
120
women
were
exposed
to
place
##bo
and
129
women
were
exposed
to
Pro
##lia
administered
once
every
6
months
as
a
single
60
mg
sub
##cut
##aneous
dose
.
[SEP]
[CLS]
In
random
##ized
controlled
studies
,
AL
##T
)
elevations
greater
than
three
times
the
upper
limit
of
normal
(
U
##L
##N
)
were
observed
:
1
.
3
%
in
al
##og
##lip
##tin
-
treated
patients
and
1
.
5
%
in
all
com
##par
##ator
-
treated
patients
.
[SEP]
[CLS]
5
.
5
H
##y
##po
##nat
##rem
##ia
Clinical
##ly
significant
h
##y
##po
##nat
##rem
##ia
(
sodium
<
125
m
##E
##q
/
L
)
can
develop
in
patients
taking
AP
##TI
##OM
.
[SEP]
[CLS]
(
5
.
2
)
5
.
1
Con
##tam
##ination
of
T
##ip
and
Sol
##ution
To
minimize
con
##tam
##inating
the
drop
##per
tip
and
solution
,
care
should
be
taken
not
to
touch
the
eyelids
or
surrounding
areas
with
the
drop
##per
tip
of
the
bottle
.
[SEP]
[CLS]
Monitor
patients
for
fever
and
infections
and
evaluate
promptly
.
[SEP]
[CLS]
I
##mm
##une
-
mediated
end
##oc
##rino
##path
##ies
:
Monitor
thy
##roid
function
tests
and
clinical
chemist
##ries
prior
to
each
dose
.
[SEP]
[CLS]
Other
Mali
##gna
##ncies
Mali
##gna
##ncies
,
excluding
non
-
me
##lan
##oma
skin
cancer
and
PT
##LD
,
were
reported
in
Study
1
and
Study
2
in
3
.
5
%
(
14
/
401
)
of
patients
treated
with
the
recommended
N
##U
##L
##O
##J
##IX
regime
##n
and
3
.
7
%
(
15
/
405
)
of
patients
treated
with
the
c
##y
##c
##los
##por
##ine
control
regime
##n
.
[SEP]
[CLS]
Ma
##mma
##ry
g
##land
pro
##life
##rative
changes
and
increases
in
serum
pro
##la
##ct
##in
were
seen
in
mice
and
rats
treated
with
FA
##NA
##P
##T
[
see
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
1
)
]
.
[SEP]
[CLS]
Rare
cases
of
op
##port
##uni
##stic
infections
have
also
been
reported
in
these
clinical
trials
.
[SEP]
[CLS]
FA
##R
##X
##IG
##A
can
increase
the
risk
of
h
##y
##po
##gly
##ce
##mia
when
combined
with
insulin
or
an
insulin
secret
##ago
##gue
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
A
pen
##ile
modeling
procedure
was
performed
at
the
study
site
on
patients
1
to
3
days
after
the
second
injection
of
the
cycle
.
[SEP]
[CLS]
If
anti
##coa
##gu
##lation
with
PR
##AD
##A
##X
##A
is
discontinued
for
a
reason
other
than
path
##ological
bleeding
or
completion
of
a
course
of
therapy
,
consider
coverage
with
another
anti
##coa
##gu
##lant
[
see
Do
##sa
##ge
and
Administration
(
2
.
4
,
2
.
5
,
2
.
6
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Ph
##eo
##ch
##rom
##oc
##yt
##oma
and
N
##eur
##ob
##last
##oma
Drugs
which
interfere
with
nor
##ep
##ine
##ph
##rine
up
##take
in
ne
##uro
##end
##oc
##rine
tumors
may
lead
to
false
negative
imaging
results
.
[SEP]
[CLS]
Over
95
%
of
XI
##AF
##LE
##X
-
treated
patients
had
an
adverse
reaction
of
the
injected
ex
##tre
##mity
after
up
to
3
injection
##s
.
[SEP]
[CLS]
5
.
3
He
##pa
##to
##to
##xi
##city
Bel
##eo
##da
##q
can
cause
fatal
he
##pa
##to
##to
##xi
##city
and
liver
function
test
abnormal
##ities
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
An
estimate
of
the
at
##tri
##but
##able
risk
is
3
.
3
cases
/
100
,
000
CO
##C
users
.
[SEP]
[CLS]
(
5
.
1
)
*
Drugs
which
block
nor
##ep
##ine
##ph
##rine
up
##take
or
de
##ple
##te
nor
##ep
##ine
##ph
##rine
stores
may
decrease
Ad
##re
##V
##ie
##w
up
##take
.
[SEP]
[CLS]
Disco
##ntin
##uations
due
to
Ad
##verse
Re
##actions
Twenty
-
five
patients
(
19
.
4
%
)
discontinued
treatment
with
Bel
##eo
##da
##q
due
to
adverse
reactions
.
[SEP]
[CLS]
These
hem
##ato
##mas
may
result
in
permanent
.
[SEP]
[CLS]
Do
not
re
##chal
##len
##ge
patients
who
develop
ne
##ut
##rop
##enia
with
Fe
##rri
##p
##ro
##x
unless
potential
benefits
out
##wei
##gh
potential
risks
.
[SEP]
[CLS]
Based
on
the
severity
of
the
laboratory
abnormal
##ities
,
with
##hold
Z
##Y
##KA
##DI
##A
with
re
##sumption
at
a
reduced
dose
as
described
in
Table
1
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
5
.
2
Po
##ten
##tia
##tion
of
Se
##dation
from
Con
##com
##ita
##nt
Use
with
Central
N
##er
##vous
System
De
##press
##ants
Since
ON
##FI
has
a
central
nervous
system
(
C
##NS
)
de
##press
##ant
effect
,
patients
or
their
care
##gi
##vers
should
be
caution
##ed
against
simultaneous
use
with
other
C
##NS
de
##press
##ant
drugs
or
alcohol
,
and
caution
##ed
that
the
effects
of
other
C
##NS
de
##press
##ant
drugs
or
alcohol
may
be
potent
##iated
.
[SEP]
[CLS]
There
are
insufficient
data
to
determine
whether
FA
##R
##X
##IG
##A
has
an
effect
on
pre
-
existing
bladder
tumors
.
[SEP]
[CLS]
Ra
##sh
(
greater
than
or
equal
to
Grade
2
)
occurred
in
15
%
of
p
##ediatric
subjects
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
approval
use
of
PR
##AD
##A
##X
##A
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
I
##MM
##UN
##E
-
ME
##DI
##AT
##ED
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
X
##E
##OM
##IN
-
treated
patients
were
18
to
79
years
old
(
mean
53
years
)
,
and
were
predominantly
female
(
66
%
)
and
Caucasian
(
91
%
)
.
[SEP]
[CLS]
This
,
in
turn
,
may
in
##hibit
reproductive
function
by
imp
##air
##ing
go
##na
##dal
##ster
##oid
##ogen
##esis
in
both
female
and
male
patients
.
[SEP]
[CLS]
Disco
##ntin
##uation
from
study
due
to
g
##eni
##tal
infection
occurred
in
0
%
of
place
##bo
-
treated
patients
and
0
.
2
%
of
patients
treated
with
FA
##R
##X
##IG
##A
10
mg
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Eli
Lilly
and
Company
at
1
-
800
-
Lilly
##R
##x
(
1
-
800
-
54
##5
-
59
##7
##9
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Consider
the
risks
and
benefits
of
re
-
administer
##ing
V
##im
##iz
##im
following
a
severe
reaction
.
[SEP]
[CLS]
[
See
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
3
%
.
[SEP]
[CLS]
5
.
2
Contact
Len
##s
Use
Pat
##ients
should
be
advised
not
to
wear
a
contact
lens
if
their
eye
is
red
.
[SEP]
[CLS]
A
higher
percentage
of
AP
##TI
##OM
-
treated
patients
(
5
.
1
%
)
than
place
##bo
-
treated
patients
(
0
.
7
%
)
experienced
decreases
in
sodium
values
of
more
than
10
m
##E
##q
/
L
.
[SEP]
[CLS]
These
18
patients
experienced
26
an
##aph
##yla
##ctic
reactions
during
in
##fusion
with
signs
and
symptoms
including
cough
,
er
##yt
##hem
##a
,
throat
tight
##ness
,
u
##rt
##ica
##ria
,
flush
##ing
,
c
##yan
##osis
,
h
##y
##pot
##ens
##ion
,
r
##ash
,
d
##ys
##p
##nea
,
chest
discomfort
,
and
gas
##tro
##int
##est
##inal
symptoms
(
e
.
g
.
,
nausea
,
abdominal
pain
,
re
##tch
##ing
,
and
vomit
##ing
)
in
conjunction
with
u
##rt
##ica
##ria
.
[SEP]
[CLS]
Ex
##c
##lude
other
potential
causes
of
IL
##D
/
p
##ne
##um
##oni
##tis
,
and
permanently
disco
##ntin
##ue
X
##AL
##KO
##RI
in
patients
diagnosed
with
drug
-
related
IL
##D
/
p
##ne
##um
##oni
##tis
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
5
.
7
Em
##b
##ryo
-
Fe
##tal
To
##xi
##city
Based
on
findings
in
animals
,
I
##MB
##R
##U
##VI
##CA
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
Because
post
##market
##ing
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
>
25
%
)
are
nausea
,
fatigue
,
p
##yre
##xia
,
an
##emia
,
and
vomit
##ing
.
[SEP]
[CLS]
Al
##co
##hol
and
other
he
##pa
##to
##to
##xi
##c
drugs
should
be
avoided
while
on
S
##IR
##TU
##RO
,
especially
in
patients
with
impaired
he
##pa
##tic
function
.
[SEP]
[CLS]
Disco
##ntin
##ue
if
evidence
of
liver
injury
.
[SEP]
[CLS]
Trans
##ami
##nas
##e
elevations
generally
occurred
within
the
first
2
months
of
treatment
.
[SEP]
[CLS]
The
incidence
of
serious
adverse
events
was
9
.
2
%
in
the
place
##bo
group
and
14
.
7
%
in
the
Pro
##lia
group
.
[SEP]
[CLS]
SA
##P
##H
##RI
##S
is
not
approved
for
the
treatment
of
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
.
[SEP]
[CLS]
In
the
single
-
arm
Phase
1
/
2
clinical
trial
in
54
##6
patients
with
C
##ML
treated
with
prior
therapy
,
severe
fluid
retention
was
reported
in
14
patients
(
3
%
)
.
[SEP]
[CLS]
Basel
##ine
re
##nal
function
was
normal
or
mildly
impaired
(
mean
e
##G
##F
##R
88
m
##L
/
min
/
1
.
73
m
2
)
.
[SEP]
[CLS]
The
useful
##ness
of
hem
##od
##ial
##ys
##is
in
the
prevention
of
N
##SF
is
unknown
[
see
Do
##sa
##ge
and
Administration
(
2
)
and
Clinical
Ph
##arma
##cology
(
12
)
]
.
[SEP]
[CLS]
Pat
##ients
,
their
care
##gi
##vers
,
and
families
should
be
informed
that
H
##OR
##I
##Z
##AN
##T
increases
the
risk
of
su
##icidal
thoughts
and
behavior
and
should
be
advised
of
the
need
to
be
alert
for
the
emergence
or
worse
##ning
of
the
signs
and
symptoms
of
depression
,
any
unusual
changes
in
mood
or
behavior
,
or
the
emergence
of
su
##icidal
thoughts
,
behavior
,
or
thoughts
about
self
-
harm
.
[SEP]
[CLS]
In
the
case
of
mild
pan
##cre
##ati
##tis
,
hold
ER
##WI
##NA
##Z
##E
until
the
signs
and
symptoms
sub
##side
and
am
##yla
##se
levels
return
to
normal
.
[SEP]
[CLS]
Approximately
57
%
of
the
patients
were
male
.
[SEP]
[CLS]
Trans
##ami
##nas
##e
elevations
were
more
common
in
patients
with
a
history
of
trans
##ami
##nas
##e
elevations
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
To
en
##roll
in
the
E
.
A
.
S
.
E
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
Trans
##ami
##nas
##e
(
AL
##T
or
AS
##T
)
El
##eva
##tions
El
##eva
##ted
trans
##ami
##nas
##es
have
been
reported
in
patients
with
CF
receiving
K
##AL
##Y
##DE
##CO
.
[SEP]
[CLS]
Al
##g
##lu
##cos
##idas
##e
al
##fa
-
treated
patients
who
experience
a
decrease
in
motor
function
should
be
tested
for
the
presence
of
inhibitor
##y
antibodies
that
neutral
##ize
enzyme
up
##take
or
activity
.
[SEP]
[CLS]
Disco
##ntin
##uation
of
therapy
in
G
##IL
##OT
##RI
##F
-
treated
patients
for
adverse
reactions
was
14
.
0
%
.
[SEP]
[CLS]
Anti
##fu
##nga
##l
agents
should
not
be
used
unless
fun
##gal
infection
has
been
diagnosed
[
see
Drug
Inter
##actions
(
7
.
1
)
]
.
[SEP]
[CLS]
More
patients
on
T
##AN
##Z
##E
##UM
than
on
place
##bo
:
discontinued
due
to
an
injection
site
reaction
(
2
%
versus
0
.
2
%
)
,
experienced
more
than
2
reactions
(
38
%
versus
20
%
)
,
had
a
reaction
judged
by
investigators
to
be
`
`
moderate
'
'
or
`
`
severe
'
'
(
27
%
versus
6
%
)
and
required
local
or
systemic
treatment
for
the
reactions
(
36
%
versus
11
%
)
.
[SEP]
[CLS]
5
.
3
Li
##pid
In
##take
C
##lev
##ip
##re
##x
contains
approximately
0
.
2
g
of
lip
##id
per
m
##L
(
2
.
0
k
##cal
)
.
[SEP]
[CLS]
It
is
unknown
whether
the
su
##icidal
##ity
risk
extends
to
longer
-
term
use
,
i
.
e
.
,
beyond
several
months
.
[SEP]
[CLS]
Pro
##phy
##lax
##is
for
P
##JP
should
be
considered
when
con
##com
##ita
##nt
use
of
co
##rt
##ico
##ster
##oids
or
other
im
##mu
##nos
##up
##pressive
agents
are
required
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
or
if
the
patient
becomes
pregnant
while
taking
this
drug
,
the
patient
should
be
app
##rise
##d
of
the
potential
hazard
to
a
f
##etus
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
Table
1
:
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
at
>
=
3
%
and
Higher
than
Place
##bo
in
2
Place
##bo
Control
##led
Clinical
Trials
in
Pat
##ients
with
H
##A
##E
T
##reate
##d
with
K
##AL
##BI
##TO
##R
a
Pat
##ients
experiencing
more
than
1
event
with
the
same
preferred
term
are
counted
only
once
for
that
preferred
term
.
[SEP]
[CLS]
These
infections
may
lead
to
serious
,
including
fatal
,
outcomes
[
see
Box
##ed
Warning
and
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
with
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Pol
##yo
##ma
V
##ir
##us
N
##ep
##hr
##op
##athy
In
addition
to
cases
of
J
##C
virus
-
associated
PM
##L
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
,
cases
of
p
##oly
##oma
virus
-
associated
ne
##ph
##rop
##athy
(
P
##VA
##N
)
,
mostly
due
to
B
##K
virus
infection
,
have
been
reported
.
[SEP]
[CLS]
They
may
be
bilateral
and
many
patients
report
pro
##dr
##oma
##l
pain
in
the
affected
area
,
usually
presenting
as
dull
,
aching
thigh
pain
,
weeks
to
months
before
a
complete
fracture
occurs
.
[SEP]
[CLS]
In
the
C
##IM
##Z
##IA
RA
clinical
trials
(
place
##bo
-
controlled
and
open
label
)
a
total
of
three
cases
of
l
##ymph
##oma
were
observed
among
2
,
36
##7
patients
.
[SEP]
[CLS]
Individuals
with
`
`
crowded
'
'
op
##tic
disc
are
also
considered
at
greater
risk
for
N
##A
##ION
compared
to
the
general
population
,
however
,
evidence
is
insufficient
to
support
screening
of
prospective
users
of
PD
##E
##5
inhibitor
##s
,
including
ST
##EN
##DR
##A
,
for
this
uncommon
condition
.
[SEP]
[CLS]
H
##yper
##to
##xin
-
producing
strains
of
C
.
di
##ff
##ici
##le
cause
increased
m
##or
##bid
##ity
and
mortality
,
as
these
infections
can
be
re
##fra
##ctor
##y
to
anti
##mic
##ro
##bial
therapy
and
may
require
co
##lect
##omy
.
[SEP]
[CLS]
This
component
reduces
the
risk
of
end
##ome
##tri
##al
h
##yper
##p
##lasia
that
can
occur
with
the
con
##ju
##gated
est
##rogen
##s
component
.
[SEP]
[CLS]
When
Co
##arte
##m
Table
##ts
are
co
##ad
##mini
##stered
with
induce
##rs
of
C
##YP
##3
##A
##4
it
may
result
in
decreased
concentrations
of
art
##em
##eth
##er
and
/
or
l
##ume
##fant
##rine
and
loss
of
anti
##mal
##aria
##l
efficacy
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Drug
Inter
##actions
(
7
)
]
.
[SEP]
[CLS]
Case
##s
of
T
##B
included
extra
##pu
##lm
##ona
##ry
T
##B
.
[SEP]
[CLS]
SA
##P
##H
##RI
##S
has
not
been
evaluated
in
patients
with
a
recent
history
of
my
##oc
##ard
##ial
in
##far
##ction
or
unstable
heart
disease
.
[SEP]
[CLS]
He
##pa
##tic
:
Live
##r
In
##ju
##ry
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
Re
##sp
##ira
##tory
:
Inter
##st
##iti
##al
lung
disease
including
p
##ne
##um
##oni
##tis
and
pulmonary
fi
##bro
##sis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
I
##mm
##une
:
Ana
##phy
##la
##ctic
reactions
including
an
##gio
##ede
##ma
V
##as
##cular
:
V
##as
##cu
##lit
##is
,
including
le
##uk
##oc
##yt
##oc
##lastic
v
##as
##cu
##lit
##is
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
IN
##CR
##EA
##SE
##D
R
##IS
##K
OF
DE
##AT
##H
,
ST
##RO
##KE
AND
H
##EA
##RT
FA
##IL
##UR
##E
IN
PA
##TI
##EN
##TS
W
##IT
##H
DE
##CO
##MP
##EN
##SA
##TE
##D
H
##EA
##RT
FA
##IL
##UR
##E
OR
P
##ER
##MA
##NE
##NT
AT
##RI
##AL
F
##IB
##RI
##LL
##AT
##ION
WA
##R
##NI
##NG
:
IN
##CR
##EA
##SE
##D
R
##IS
##K
OF
DE
##AT
##H
,
ST
##RO
##KE
AND
H
##EA
##RT
FA
##IL
##UR
##E
IN
PA
##TI
##EN
##TS
W
##IT
##H
DE
##CO
##MP
##EN
##SA
##TE
##D
H
##EA
##RT
FA
##IL
##UR
##E
OR
P
##ER
##MA
##NE
##NT
AT
##RI
##AL
F
##IB
##RI
##LL
##AT
##ION
In
patients
with
s
##ym
##pt
##oma
##tic
heart
failure
and
recent
de
##com
##pen
##sation
requiring
hospital
##ization
or
NY
##HA
Class
IV
heart
failure
;
M
##U
##LT
##A
##Q
doubles
the
risk
of
death
.
[SEP]
[CLS]
Pat
##ients
with
these
di
##ag
##nose
##s
were
excluded
from
pre
-
marketing
clinical
trials
.
[SEP]
[CLS]
Long
-
term
cumulative
radiation
exposure
is
associated
with
an
increased
risk
of
cancer
.
[SEP]
[CLS]
T
##AF
##IN
##LA
##R
may
render
ho
##rmon
##al
con
##tra
##ceptive
##s
less
effective
and
an
alternative
method
of
con
##tra
##ception
should
be
used
.
[SEP]
[CLS]
Based
on
the
clinical
trial
experience
,
IL
##AR
##IS
does
not
appear
to
increase
the
incidence
of
MA
##S
in
S
##J
##IA
patients
,
but
no
definitive
conclusion
can
be
made
.
[SEP]
[CLS]
However
,
treatment
with
im
##mu
##nos
##up
##press
##ants
,
including
IL
##AR
##IS
,
may
result
in
an
increase
in
the
risk
of
ma
##li
##gna
##ncies
.
[SEP]
[CLS]
Live
##r
enzymes
should
be
monitored
in
patients
who
develop
symptoms
suggest
##ive
of
he
##pa
##tic
d
##ys
##function
,
such
as
une
##x
##plain
##ed
nausea
,
vomit
##ing
,
abdominal
pain
,
fatigue
,
an
##ore
##xia
,
or
j
##au
##ndi
##ce
and
/
or
dark
urine
.
[SEP]
[CLS]
P
##VA
##N
is
associated
with
serious
outcomes
;
including
de
##ter
##ior
##ating
re
##nal
function
and
kidney
g
##raft
loss
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
An
accelerated
v
##ac
##cin
##ation
schedule
may
be
appropriate
.
[SEP]
[CLS]
In
patients
treated
with
T
##AF
##IN
##LA
##R
,
the
median
time
to
initial
onset
of
fever
(
any
severity
)
was
11
days
(
range
:
1
to
202
days
)
and
the
median
duration
of
fever
was
3
days
(
range
:
1
to
129
days
)
.
[SEP]
[CLS]
Do
not
administer
IL
##AR
##IS
to
patients
during
an
active
infection
requiring
medical
intervention
.
[SEP]
[CLS]
Some
of
the
patients
who
tested
positive
for
al
##g
##lu
##cos
##idas
##e
al
##fa
-
specific
I
##g
##E
antibodies
experienced
an
##aph
##yla
##ctic
reactions
[
see
##B
##ox
##ed
Warning
##and
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
O
##bs
##er
##vation
##al
studies
suggest
that
,
similar
to
at
##y
##pical
anti
##psy
##cho
##tic
drugs
,
treatment
with
conventional
anti
##psy
##cho
##tic
drugs
may
increase
mortality
.
[SEP]
[CLS]
ST
##RI
##BI
##LD
is
not
approved
for
the
treatment
of
chronic
H
##B
##V
infection
and
the
safety
and
efficacy
of
ST
##RI
##BI
##LD
have
not
been
established
in
patients
coin
##fected
with
H
##B
##V
and
HIV
-
1
.
[SEP]
[CLS]
Monitor
serum
p
##hos
##phorus
in
patients
at
risk
for
re
##nal
imp
##air
##ment
.
[SEP]
[CLS]
These
events
have
been
included
because
of
their
serious
##ness
and
assessment
of
potential
ca
##usal
relationship
.
[SEP]
[CLS]
Program
,
an
authorized
hospital
representative
must
acknowledge
that
:
*
hospital
staff
who
pre
##s
##cribe
,
di
##spense
,
or
administer
E
##NT
##ER
##EG
have
been
provided
the
educational
materials
on
the
need
to
limit
use
of
E
##NT
##ER
##EG
to
short
-
term
,
in
##patient
use
;
*
patients
will
not
receive
more
than
15
doses
of
E
##NT
##ER
##EG
;
and
*
E
##NT
##ER
##EG
will
not
be
di
##spense
##d
to
patients
after
they
have
been
discharged
from
the
hospital
.
[SEP]
[CLS]
Monitor
patients
for
signs
and
symptoms
of
der
##mat
##itis
such
as
r
##ash
and
p
##ru
##rit
##us
.
[SEP]
[CLS]
Se
##vere
pan
##cre
##ati
##tis
is
a
con
##tra
##ind
##ica
##tion
to
additional
as
##par
##agi
##nas
##e
administration
.
[SEP]
[CLS]
One
patient
experienced
disturbance
in
attention
,
eye
##lid
disorder
,
feeling
abnormal
and
headache
,
and
one
patient
experienced
d
##ys
##pha
##gia
.
[SEP]
[CLS]
Disco
##ntin
##uation
of
IN
##L
##Y
##TA
treatment
due
to
h
##yper
##tens
##ion
occurred
in
1
/
35
##9
patients
(
<
1
%
)
receiving
IN
##L
##Y
##TA
and
none
of
the
patients
receiving
so
##ra
##fen
##ib
[
see
##A
##d
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
I
##mm
##une
-
mediated
ne
##uro
##path
##ies
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
Four
serious
adverse
events
occurred
in
two
place
##bo
-
treated
subjects
.
[SEP]
[CLS]
(
5
.
3
)
*
Mac
##ular
ed
##ema
:
Per
##form
an
examination
of
the
fund
##us
including
the
mac
##ula
before
and
3
-
4
months
after
treatment
initiation
.
[SEP]
[CLS]
Table
5
reflects
exposure
to
D
##Y
##SP
##OR
##T
(
r
)
in
39
##8
patients
19
to
75
years
of
age
who
were
evaluated
in
the
random
##ized
,
place
##bo
-
controlled
clinical
studies
that
assessed
the
use
of
D
##Y
##SP
##OR
##T
(
r
)
for
the
temporary
improvement
in
the
appearance
of
g
##la
##bella
##r
lines
[
see
##C
##lini
##cal
Studies
(
14
)
]
.
[SEP]
[CLS]
If
you
think
you
may
be
pregnant
,
you
should
have
a
pregnancy
test
and
know
the
results
.
[SEP]
[CLS]
*
Drugs
that
act
directly
on
the
re
##nin
-
an
##gio
##tens
##in
system
can
cause
death
to
the
developing
f
##etus
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Most
of
these
adverse
reactions
were
mild
to
moderate
in
intensity
and
occurred
during
the
t
##it
##ration
phase
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
A
24
-
week
,
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
clinical
trial
of
V
##im
##iz
##im
was
conducted
in
176
patients
with
MP
##S
IV
##A
,
ages
5
to
57
years
old
.
[SEP]
[CLS]
The
risk
did
not
vary
substantially
by
age
(
5
to
100
years
)
in
the
clinical
trials
analyzed
.
[SEP]
[CLS]
In
patients
pre
##dis
##posed
to
h
##y
##po
##cal
##ce
##mia
and
disturbance
##s
of
mineral
metabolism
(
e
.
g
.
[SEP]
[CLS]
5
.
3
Q
##T
Inter
##val
Pro
##long
##ation
Q
##T
##c
pro
##long
##ation
can
occur
in
patients
treated
with
X
##AL
##KO
##RI
.
[SEP]
[CLS]
The
data
presented
below
are
based
on
information
collected
from
Study
1
,
a
single
-
arm
,
multi
-
center
,
open
-
label
,
safety
and
clinical
p
##har
##ma
##cology
trial
(
in
##tra
##mus
##cular
administration
)
,
the
ER
##WI
##NA
##Z
##E
Master
Treatment
Protocol
(
E
##MT
##P
)
,
an
expanded
access
program
(
both
in
##tra
##mus
##cular
,
in
##tra
##ven
##ous
,
and
other
or
unknown
administration
)
,
and
Study
2
,
a
single
-
arm
,
multi
-
center
,
open
-
label
,
p
##har
##ma
##co
##kin
##etic
(
P
##K
)
study
trial
of
in
##tra
##ven
##ous
administration
of
ER
##WI
##NA
##Z
##E
.
Study
1
enrolled
58
patients
treated
on
National
Cancer
Institute
(
NC
##I
)
-
sponsored
cooperative
group
AL
##L
protocols
who
were
unable
to
continue
to
receive
p
##eg
##as
##par
##gas
##e
due
to
h
##yper
##sen
##si
##ti
##vity
reactions
.
[SEP]
[CLS]
Neither
clinical
studies
nor
e
##pid
##em
##iol
##og
##ic
studies
conducted
to
date
have
shown
an
association
between
chronic
administration
of
this
class
of
drugs
and
tumor
##ige
##nes
##is
in
humans
;
the
available
evidence
is
considered
too
limited
to
be
con
##clusive
at
this
time
.
[SEP]
[CLS]
H
##yper
##p
##rol
##act
##ine
##mia
may
suppress
h
##y
##pot
##hala
##mic
G
##n
##R
##H
,
resulting
in
reduced
pit
##uit
##ary
go
##nado
##tro
##pin
secret
##ion
.
[SEP]
[CLS]
No
cases
of
PM
##L
were
reported
in
patients
treated
with
the
recommended
N
##U
##L
##O
##J
##IX
regime
##n
or
the
control
regime
##n
in
these
trials
.
[SEP]
[CLS]
Additionally
,
the
observed
incidence
of
anti
##body
(
including
neutral
##izing
anti
##body
)
p
##os
##iti
##vity
in
an
ass
##ay
may
be
influenced
by
several
factors
,
including
ass
##ay
methodology
,
sample
handling
,
timing
of
sample
collection
,
con
##com
##ita
##nt
medications
,
and
underlying
disease
.
[SEP]
[CLS]
Some
patients
with
Du
##pu
##yt
##ren
'
s
contract
##ure
developed
I
##g
##E
-
anti
-
drug
antibodies
in
greater
proportions
and
higher
t
##iter
##s
with
successive
XI
##AF
##LE
##X
injection
##s
.
[SEP]
[CLS]
5
.
2
g
##eno
##to
##xi
##city
in
animal
studies
,
Fe
##rri
##p
##ro
##x
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
The
increased
risk
of
as
##th
##ma
-
related
death
is
considered
a
class
effect
of
LA
##BA
,
including
v
##ila
##nter
##ol
,
one
of
the
active
ingredients
in
BR
##E
##O
E
##LL
##IP
##TA
.
[SEP]
[CLS]
Pat
##ients
with
tuberculosis
have
frequently
presented
with
di
##sse
##minated
disease
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
Re
##actions
In
the
4
pivotal
studies
,
drug
h
##yper
##sen
##si
##ti
##vity
(
including
u
##rt
##ica
##ria
,
r
##ash
,
and
p
##ru
##rit
##us
)
,
all
##ergic
ed
##ema
,
an
##aph
##yla
##ctic
reaction
,
and
an
##aph
##yla
##ctic
shock
were
reported
in
0
.
1
%
of
patients
receiving
PR
##AD
##A
##X
##A
.
[SEP]
[CLS]
Consequently
,
FA
##R
##X
##IG
##A
should
not
be
used
in
patients
with
active
bladder
cancer
.
[SEP]
[CLS]
Pre
##s
##cribe
##rs
should
caution
patients
against
engaging
in
hazardous
activities
requiring
mental
alert
##ness
,
such
as
operating
dangerous
machinery
or
motor
vehicles
,
until
the
effect
of
ON
##FI
is
known
.
[SEP]
[CLS]
Monitor
L
##D
##L
-
C
and
treat
per
standard
of
care
after
in
##iti
##ating
FA
##R
##X
##IG
##A
.
[SEP]
[CLS]
Have
an
##aph
##yla
##ctic
and
h
##yper
##sen
##si
##ti
##vity
treatment
measures
available
prior
to
Ad
##re
##V
##ie
##w
administration
.
[SEP]
[CLS]
R
##up
##ture
of
he
##pa
##tic
ad
##eno
##mas
may
cause
death
through
in
##tra
-
abdominal
hem
##or
##r
##hage
.
[SEP]
[CLS]
5
.
4
Q
##T
Pro
##long
##ation
In
an
un
##con
##tro
##lled
open
-
label
EC
##G
study
in
26
patients
,
Q
##T
pro
##long
##ation
was
observed
on
Day
8
,
independent
of
er
##ib
##ulin
concentration
,
with
no
Q
##T
pro
##long
##ation
observed
on
Day
1
.
[SEP]
[CLS]
Pat
##ients
whose
base
##line
AL
##T
or
AS
##T
were
elevated
were
more
likely
to
experience
liver
test
elevation
than
those
beginning
with
normal
values
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
to
establish
a
ca
##usal
relationship
to
drug
exposure
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
C
##IG
##AR
##ET
##TE
SM
##OK
##ING
AND
SE
##RI
##O
##US
CA
##RD
##IO
##VA
##SC
##U
##LA
##R
E
##VE
##NT
##S
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
Disco
##ntin
##uation
of
therapy
due
to
adverse
reactions
occurred
in
10
%
of
patients
treated
with
Z
##Y
##KA
##DI
##A
.
[SEP]
[CLS]
The
desired
therapeutic
response
was
achieved
at
doses
of
4
-
6
mg
/
hour
.
[SEP]
[CLS]
The
mean
time
to
na
##dir
was
13
days
and
the
mean
time
to
recovery
from
severe
ne
##ut
##rop
##enia
(
<
500
/
mm
3
)
was
8
days
.
[SEP]
[CLS]
5
.
4
Ba
##cter
##ial
In
##fect
##ions
Pro
##long
##ed
use
of
co
##rt
##ico
##ster
##oids
may
suppress
the
host
response
and
thus
increase
the
hazard
of
secondary
o
##cular
infections
.
[SEP]
[CLS]
New
-
On
##set
Di
##abe
##tes
After
Trans
##p
##lant
##ation
The
incidence
of
new
-
onset
diabetes
after
transplant
##ation
(
NO
##DA
##T
)
was
defined
in
Studies
1
and
2
as
use
of
an
anti
##dia
##bet
##ic
agent
for
>
=
30
days
or
>
=
2
fast
##ing
plasma
glucose
values
>
=
126
mg
/
d
##L
(
7
.
0
mm
##ol
/
L
)
post
-
transplant
##ation
.
[SEP]
[CLS]
Because
of
the
observed
op
##ht
##hal
##mo
##log
##ic
adverse
reactions
,
P
##OT
##IG
##A
should
only
be
used
in
patients
who
have
responded
inadequate
##ly
to
several
alternative
treatments
and
for
whom
the
benefits
out
##wei
##gh
the
risk
of
re
##tina
##l
abnormal
##ities
and
potential
vision
loss
.
[SEP]
[CLS]
C
##aus
##ality
can
not
be
excluded
.
[SEP]
[CLS]
Ad
##junct
##ive
Therapy
Control
##led
Trials
In
the
controlled
ad
##junct
##ive
therapy
e
##pile
##psy
trials
(
Study
3
,
Study
4
,
and
Study
5
)
,
the
rate
of
disco
##ntin
##uation
as
a
result
of
any
adverse
reaction
was
14
%
for
the
800
mg
dose
,
25
%
for
the
1200
mg
dose
,
and
7
%
in
subjects
random
##ized
to
place
##bo
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
Ana
##phy
##lax
##is
and
Ang
##io
##ede
##ma
T
##EC
##FI
##DE
##RA
can
cause
an
##aph
##yla
##xi
##s
and
an
##gio
##ede
##ma
after
the
first
dose
or
at
any
time
during
treatment
.
[SEP]
[CLS]
Gas
##tro
##int
##est
##inal
disorders
Di
##ar
##r
##hea
37
0
Na
##use
##a
21
0
St
##oma
##titis
16
0
Gas
##tro
##es
##op
##hage
##al
re
##f
##lux
disease
13
0
Skin
and
sub
##cut
##aneous
tissue
disorders
Ra
##sh
22
0
B
##ruising
16
0
P
##ru
##rit
##us
11
0
General
disorders
and
administrative
site
conditions
Fat
##ig
##ue
21
0
Mu
##s
##cu
##los
##kel
##etal
and
connect
##ive
tissue
disorders
Mu
##s
##cle
spa
##sm
##s
21
0
Art
##hr
##op
##athy
13
0
In
##fect
##ions
and
in
##fest
##ations
Upper
respiratory
tract
infection
19
0
Sin
##us
##itis
19
0
P
##ne
##um
##onia
14
6
Skin
infection
14
2
Re
##sp
##ira
##tory
,
th
##ora
##ci
##c
and
media
##st
##inal
disorders
E
##pis
##ta
##xi
##s
19
0
Co
##ugh
13
0
N
##er
##vous
system
disorders
Di
##zzi
##ness
14
0
Head
##ache
13
0
Neo
##p
##las
##ms
ben
##ign
,
ma
##li
##gnant
,
and
un
##sp
##ec
##ified
(
including
c
##ys
##ts
and
p
##oly
##ps
)
Skin
cancer
11
0
Table
8
:
Treatment
-
Em
##er
##gent
##B
##ase
##d
on
laboratory
measurements
.
[SEP]
[CLS]
The
safety
of
IN
##L
##Y
##TA
has
been
evaluated
in
71
##5
patients
in
mon
##otherapy
studies
,
which
included
53
##7
patients
with
advanced
RC
##C
.
[SEP]
[CLS]
Ren
##al
function
abnormal
##ities
can
occur
after
in
##iti
##ating
IN
##VO
##KA
##NA
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Q
##T
Pro
##long
##ation
*
Q
##T
pro
##long
##ation
can
occur
with
S
##IR
##TU
##RO
.
[SEP]
[CLS]
Anti
##psy
##cho
##tic
treatment
,
itself
,
however
,
may
suppress
(
or
partially
suppress
)
the
signs
and
symptoms
of
the
syndrome
and
thereby
may
possibly
mask
the
underlying
process
.
[SEP]
[CLS]
This
rare
type
of
T
-
cell
l
##ymph
##oma
has
a
very
aggressive
disease
course
and
is
usually
fatal
.
[SEP]
[CLS]
Table
1
Table
2
6
.
2
I
##mm
##uno
##genic
##ity
As
with
most
therapeutic
proteins
,
patients
may
develop
anti
-
drug
antibodies
(
AD
##A
)
to
ER
##WI
##NA
##Z
##E
.
In
a
study
with
ER
##WI
##NA
##Z
##E
treatment
by
in
##tra
##mus
##cular
administration
(
Study
1
)
,
6
of
56
(
11
%
)
patients
treated
with
ER
##WI
##NA
##Z
##E
developed
antibodies
to
ER
##WI
##NA
##Z
##E
.
[SEP]
[CLS]
Me
##rk
##el
cell
car
##cin
##oma
has
been
reported
in
patients
treated
with
T
##NF
-
blocking
agents
.
[SEP]
[CLS]
Case
##s
of
s
##ync
##ope
were
also
reported
after
the
first
dose
of
G
##IL
##EN
##Y
##A
.
[SEP]
[CLS]
So
##m
##no
##len
##ce
includes
the
following
events
:
so
##m
##no
##len
##ce
,
se
##dation
,
and
h
##yper
##so
##m
##nia
.
[SEP]
[CLS]
If
h
##yper
##tens
##ion
can
not
be
adequately
controlled
,
with
##hold
K
##y
##p
##rol
##is
and
evaluate
.
[SEP]
[CLS]
5
.
6
Em
##b
##ryo
##fe
##tal
To
##xi
##city
Based
on
its
mechanism
of
action
,
G
##IL
##OT
##RI
##F
can
cause
f
##etal
harm
when
administered
to
a
pregnant
woman
.
[SEP]
[CLS]
(
5
.
2
)
*
H
##OR
##I
##Z
##AN
##T
is
not
interchange
##able
with
other
g
##aba
##pent
##in
products
.
[SEP]
[CLS]
In
##form
patients
of
the
risk
and
of
symptoms
and
to
contact
a
physician
immediately
if
symptoms
of
an
in
##fusion
reaction
occur
[
see
Pat
##ient
Counsel
##ing
Information
(
17
)
]
.
[SEP]
[CLS]
Although
the
overall
incidence
of
F
##D
&
C
Yellow
No
.
[SEP]
[CLS]
The
data
described
below
reflect
D
##OT
##AR
##EM
exposure
in
281
##3
patients
,
representing
26
##7
##2
adults
and
141
p
##ediatric
patients
.
[SEP]
[CLS]
In
the
clinical
trials
,
2
subjects
who
received
place
##bo
committed
suicide
compared
to
none
in
O
##TE
##Z
##LA
-
treated
subjects
.
[SEP]
[CLS]
Pat
##ients
with
ne
##uro
##mus
##cular
disorders
may
be
at
increased
risk
of
clinical
##ly
significant
effects
including
severe
d
##ys
##pha
##gia
and
respiratory
compromise
from
typical
doses
of
X
##E
##OM
##IN
[
See
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Some
patients
had
residual
visual
a
##cu
##ity
loss
even
after
resolution
of
mac
##ular
ed
##ema
.
[SEP]
[CLS]
In
2
-
year
,
double
-
blind
,
place
##bo
-
controlled
studies
in
patients
with
multiple
s
##cle
##rosis
,
mac
##ular
ed
##ema
with
or
without
visual
symptoms
occurred
in
1
.
5
%
of
patients
(
11
/
79
##9
)
treated
with
fin
##gol
##imo
##d
1
.
25
mg
,
0
.
5
%
of
patients
(
4
/
78
##3
)
treated
with
G
##IL
##EN
##Y
##A
0
.
5
mg
and
0
.
4
%
of
patients
(
3
/
77
##3
)
treated
with
place
##bo
.
[SEP]
[CLS]
In
##fect
##ions
,
s
##tom
##ati
##tis
,
and
p
##ne
##um
##oni
##tis
were
the
most
common
reasons
for
treatment
delay
or
dose
reduction
.
[SEP]
[CLS]
Mean
percentage
decreases
in
B
##MD
from
base
##line
to
Week
144
in
the
ST
##RI
##BI
##LD
group
were
comparable
to
the
AT
##V
+
R
##TV
+
T
##R
##U
##VA
##DA
group
at
the
l
##umba
##r
spine
(
-
1
.
43
%
versus
-
3
.
68
%
,
respectively
)
and
at
the
hip
(
-
2
.
83
%
versus
-
3
.
77
%
,
respectively
)
.
[SEP]
[CLS]
5
.
3
Local
Skin
Re
##actions
Se
##vere
skin
reactions
in
the
treated
area
,
can
occur
after
topic
##al
application
of
Pi
##cat
##o
(
r
)
gel
[
see
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
Treatment
of
S
##J
##IA
A
total
of
201
S
##J
##IA
patients
aged
2
to
less
than
20
years
have
received
IL
##AR
##IS
in
clinical
trials
.
[SEP]
[CLS]
The
adverse
drug
reactions
associated
with
IL
##AR
##IS
treatment
in
S
##J
##IA
patients
were
infections
,
abdominal
pain
,
and
injection
site
reactions
.
[SEP]
[CLS]
5
.
6
Drug
Inter
##actions
See
Table
2
for
a
listing
of
drugs
that
are
con
##tra
##ind
##ica
##ted
for
use
with
VI
##CT
##RE
##L
##IS
due
to
potentially
life
-
threatening
adverse
events
,
significant
drug
interactions
or
loss
of
v
##iro
##log
##ic
activity
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
In
several
cases
,
these
reactions
occurred
after
the
first
dose
.
[SEP]
[CLS]
Consider
the
risks
and
benefits
of
treatment
prior
to
in
##iti
##ating
S
##IM
##PO
##NI
ARIA
in
patients
:
*
with
chronic
or
re
##current
infection
;
*
who
have
been
exposed
to
tuberculosis
;
*
with
a
history
of
an
op
##port
##uni
##stic
infection
;
*
who
have
resided
or
traveled
in
areas
of
endemic
tuberculosis
or
endemic
my
##cos
##es
,
such
as
his
##top
##las
##mos
##is
,
co
##cci
##dio
##ido
##my
##cos
##is
,
or
blast
##omy
##cos
##is
;
or
*
with
underlying
conditions
that
may
pre
##dis
##pose
them
to
infection
.
[SEP]
[CLS]
The
following
events
occurred
in
less
than
1
%
of
patients
in
the
three
place
##bo
-
controlled
3
-
month
clinical
trials
and
/
or
the
open
-
label
,
long
-
term
extension
study
lasting
12
months
.
[SEP]
[CLS]
5
.
2
Inc
##rease
in
In
##tra
##oc
##ular
Press
##ure
A
##cute
increases
in
in
##tra
##oc
##ular
pressure
have
been
seen
within
60
minutes
of
in
##tra
##vi
##tre
##al
injection
,
including
with
E
##Y
##LE
##A
[
see
##A
##d
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Case
##s
of
M
##TC
in
patients
treated
with
l
##ira
##g
##lut
##ide
,
another
G
##LP
-
1
receptor
ago
##nist
,
have
been
reported
in
the
post
##market
##ing
period
;
the
data
in
these
reports
are
insufficient
to
establish
or
exclude
a
ca
##usal
relationship
between
M
##TC
and
G
##LP
-
1
receptor
ago
##nist
use
in
humans
.
[SEP]
[CLS]
With
the
interventions
used
for
an
##emia
management
in
the
clinical
trials
,
the
average
additional
decrease
of
hem
##og
##lo
##bin
was
approximately
1
g
per
d
##L
.
[SEP]
[CLS]
He
##mo
##dial
##ys
##is
does
not
appear
to
have
a
substantial
impact
on
a
##pi
##xa
##ban
exposure
[
see
##C
##lini
##cal
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
Table
4
:
Ad
##verse
Re
##actions
Report
##ed
by
>
=
2
%
of
Pat
##ients
T
##reate
##d
with
ST
##EN
##DR
##A
in
a
Place
##bo
-
Control
##led
Clinical
Trial
Last
##ing
2
Month
##s
to
Det
##er
##mine
the
Time
to
On
##set
of
Effect
(
Study
3
)
Ad
##verse
Re
##action
Place
##bon
=
143
ST
##EN
##DR
##A
100
mg
##n
=
146
ST
##EN
##DR
##A
200
mg
##n
=
146
Head
##ache
0
.
7
%
1
.
4
%
8
.
9
%
Na
##sal
congestion
0
.
0
%
0
.
7
%
4
.
1
%
Gas
##tro
##enter
##itis
viral
0
.
0
%
0
.
0
%
2
.
1
%
Across
all
trials
with
any
ST
##EN
##DR
##A
dose
,
1
subject
reported
a
change
in
color
vision
.
[SEP]
[CLS]
Across
8
Phase
III
clinical
trials
[
see
Clinical
Studies
(
14
)
]
,
pan
##cre
##ati
##tis
ad
##ju
##dicated
as
likely
related
to
therapy
occurred
more
frequently
in
patients
receiving
T
##AN
##Z
##E
##UM
(
6
of
2
,
365
[
0
.
3
%
]
)
than
in
patients
receiving
place
##bo
(
0
of
46
##8
[
0
%
]
)
or
active
com
##par
##ators
(
2
of
2
,
06
##5
[
0
.
1
%
]
)
.
[SEP]
[CLS]
Tu
##ber
##cu
##los
##is
should
be
strongly
considered
in
patients
who
develop
a
new
infection
during
C
##IM
##Z
##IA
treatment
,
especially
in
patients
who
have
previously
or
recently
traveled
to
countries
with
a
high
prevalence
of
tuberculosis
,
or
who
have
had
close
contact
with
a
person
with
active
tuberculosis
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
##ap
##p
##rov
##al
use
of
drug
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
.
[SEP]
[CLS]
If
you
would
like
more
information
,
talk
with
your
healthcare
provider
.
[SEP]
[CLS]
6
.
3
I
##mm
##uno
##genic
##ity
Pat
##ients
with
classical
H
##L
and
s
##AL
##CL
in
Studies
1
and
2
[
see
Clinical
Studies
(
14
)
]
were
tested
for
antibodies
to
br
##ent
##ux
##ima
##b
ve
##do
##tin
every
3
weeks
using
a
sensitive
electro
##che
##mi
##lum
##ines
##cent
im
##mu
##no
##ass
##ay
.
[SEP]
[CLS]
The
population
studied
had
a
mean
age
of
49
years
(
3
%
of
subjects
were
older
than
65
years
of
age
)
,
39
%
were
female
,
82
%
were
white
and
15
%
were
black
.
[SEP]
[CLS]
In
such
patients
,
consider
disco
##ntin
##uation
of
SA
##P
##H
##RI
##S
at
the
first
sign
of
a
clinical
##ly
significant
decline
in
W
##BC
in
the
absence
of
other
ca
##usa
##tive
factors
.
[SEP]
[CLS]
In
##fect
##ions
:
PM
##L
[
see
Box
##ed
Warning
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
9
)
]
,
serious
infections
and
op
##port
##uni
##stic
infections
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
.
[SEP]
[CLS]
The
im
##mu
##no
##genic
##ity
data
reflect
the
percentage
of
patients
whose
test
results
were
considered
positive
for
antibodies
to
E
##Y
##LE
##A
in
im
##mu
##no
##ass
##ays
.
[SEP]
[CLS]
The
protocol
specified
that
patients
continue
receiving
in
##tra
##ven
##ous
h
##yd
##ration
,
u
##rina
##ry
al
##kal
##ini
##zation
and
le
##uc
##ovo
##rin
,
and
that
le
##uc
##ovo
##rin
administration
be
adjusted
to
ensure
that
it
was
not
administered
within
two
hours
before
or
after
V
##OR
##A
##X
##A
##Z
##E
.
[SEP]
[CLS]
The
most
commonly
reported
adverse
reactions
(
occurring
in
at
least
1
%
of
subjects
)
in
V
##iza
##my
##l
-
treated
subjects
are
shown
in
Table
2
.
[SEP]
[CLS]
(
Box
##ed
Warning
,
4
,
5
.
1
,
5
.
6
)
*
Other
ma
##li
##gna
##ncies
:
increased
risk
with
all
im
##mu
##nos
##up
##press
##ants
;
appears
related
to
intensity
and
duration
of
use
.
[SEP]
[CLS]
5
.
2
T
##hy
##roid
A
##cc
##um
##ulation
The
Da
##T
##sca
##n
injection
may
contain
up
to
6
%
of
free
i
##od
##ide
(
i
##od
##ine
123
)
.
[SEP]
[CLS]
If
experiencing
Grade
>
=
3
di
##ar
##r
##hea
,
dos
##age
should
be
modified
.
[SEP]
[CLS]
The
use
of
PR
##AD
##A
##X
##A
for
the
prop
##hyl
##ax
##is
of
th
##rom
##boe
##mbo
##lic
events
in
patients
with
at
##rial
fi
##bri
##lla
##tion
in
the
setting
of
other
forms
of
v
##al
##vu
##lar
heart
disease
,
including
the
presence
of
a
bio
##p
##ros
##the
##tic
heart
valve
,
has
not
been
studied
and
is
not
recommended
.
[SEP]
[CLS]
In
CA
##PS
Study
1
,
no
pattern
was
observed
for
any
type
or
frequency
of
adverse
events
throughout
the
three
study
periods
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
The
most
common
adverse
reactions
leading
to
disco
##ntin
##uation
for
subjects
taking
O
##TE
##Z
##LA
were
nausea
(
1
.
6
%
)
,
di
##ar
##r
##hea
(
1
.
0
%
)
,
and
headache
(
0
.
8
%
)
.
[SEP]
[CLS]
In
Studies
102
and
103
,
bone
fracture
##s
occurred
in
27
subjects
(
3
.
9
%
)
in
the
ST
##RI
##BI
##LD
group
,
8
subjects
(
2
.
3
%
)
in
the
AT
##RI
##PL
##A
group
,
and
19
subjects
(
5
.
4
%
)
in
the
AT
##V
+
R
##TV
+
T
##R
##U
##VA
##DA
group
.
[SEP]
[CLS]
(
5
.
1
)
*
Ser
##ious
In
##fect
##ions
:
Ser
##ious
and
sometimes
fatal
infections
have
been
reported
in
patients
receiving
im
##mu
##nos
##up
##pressive
agents
,
including
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
Table
5
lists
treatment
-
emerge
##nt
adverse
reactions
that
occurred
in
>
=
2
%
of
patients
with
P
##H
##N
treated
with
H
##OR
##I
##Z
##AN
##T
1
,
200
mg
/
day
and
numerical
##ly
greater
than
place
##bo
.
[SEP]
[CLS]
Stop
K
##y
##p
##rol
##is
for
Grade
3
or
4
d
##ys
##p
##nea
until
resolved
or
returned
to
base
##line
.
[SEP]
[CLS]
One
patient
with
a
history
of
Wolff
-
Parkinson
-
White
syndrome
experienced
a
serious
adverse
reaction
of
su
##pra
##vent
##ric
##ular
ta
##chy
##card
##ia
.
[SEP]
[CLS]
All
second
degree
A
##V
blocks
on
place
##bo
were
Mo
##bit
##z
Type
I
and
occurred
after
the
first
12
hours
post
##dos
##e
.
[SEP]
[CLS]
During
the
initial
phase
of
combination
anti
##ret
##rov
##ira
##l
treatment
,
patients
whose
immune
systems
respond
may
develop
an
inflammatory
response
to
in
##do
##lent
or
residual
op
##port
##uni
##stic
infections
(
such
as
My
##co
##ba
##cter
##ium
a
##vi
##um
infection
,
c
##yt
##ome
##gal
##ov
##ir
##us
,
P
##ne
##um
##oc
##ys
##tis
ji
##rove
##ci
##i
pneumonia
[
PC
##P
]
,
or
tuberculosis
)
,
which
may
ne
##cess
##itate
further
evaluation
and
treatment
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
5
%
or
greater
in
either
indication
)
occurring
in
patients
receiving
Z
##ER
##BA
##X
##A
were
nausea
,
di
##ar
##r
##hea
,
headache
,
and
p
##yre
##xia
.
[SEP]
[CLS]
The
incidence
of
Grade
3
or
greater
non
-
hem
##ato
##log
##ic
,
non
-
infectious
adverse
reactions
occurring
with
ER
##WI
##NA
##Z
##E
in
Study
1
,
Study
2
and
E
##MT
##P
trial
is
provided
in
Table
2
.
[SEP]
[CLS]
In
controlled
clinical
studies
,
98
%
of
patients
completed
>
=
90
%
of
the
intended
patch
application
duration
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
that
led
to
permanent
disco
##ntin
##uation
in
X
##AL
##KO
##RI
-
treated
patients
were
elevated
trans
##ami
##nas
##es
(
1
.
2
%
)
,
he
##pa
##to
##to
##xi
##city
(
1
.
2
%
)
,
and
IL
##D
(
1
.
2
%
)
.
[SEP]
[CLS]
Fat
##al
adverse
reactions
in
X
##AL
##KO
##RI
-
treated
patients
in
Study
2
occurred
in
9
(
5
%
)
patients
,
consisting
of
:
acute
respiratory
distress
syndrome
,
a
##rr
##hy
##th
##mia
,
d
##ys
##p
##nea
,
pneumonia
,
p
##ne
##um
##oni
##tis
,
pulmonary
em
##bol
##ism
,
IL
##D
,
respiratory
failure
and
se
##psis
.
[SEP]
[CLS]
During
the
clinical
trial
,
the
patient
experienced
prolonged
l
##ymph
##ope
##nia
(
l
##ymph
##oc
##yte
counts
predominantly
<
0
.
5
##x
##10
9
/
L
for
3
.
5
years
)
while
taking
T
##EC
##FI
##DE
##RA
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
Consider
interrupt
##ion
of
T
##EC
##FI
##DE
##RA
if
l
##ymph
##oc
##yte
counts
<
0
.
5
x
10
9
/
L
per
##sist
for
more
than
six
months
.
[SEP]
[CLS]
(
6
.
1
)
E
##X
##CE
##RP
##T
:
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
G
##lax
##o
##S
##mith
##K
##line
at
1
-
88
##8
-
82
##5
-
52
##4
##9
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
are
discussed
below
and
elsewhere
in
label
##ing
:
*
Di
##stant
S
##p
##read
of
To
##xin
Effect
[
see
##B
##ox
##ed
Warning
]
*
Lac
##k
of
Inter
##chang
##ea
##bility
between
Bo
##tu
##lin
##um
To
##xin
Products
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
S
##p
##read
of
Effects
from
To
##xin
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
D
##ys
##pha
##gia
and
B
##reath
##ing
Di
##ff
##ic
##ult
##ies
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
F
##ac
##ial
Anatomy
in
the
Treatment
of
G
##la
##bella
##r
Lines
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
Pre
-
existing
N
##eur
##om
##us
##cular
Di
##sor
##ders
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
*
Human
Album
##in
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
*
In
##tra
##der
##mal
I
##mm
##une
Re
##action
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
[SEP]
[CLS]
Pre
-
existing
h
##yper
##tens
##ion
should
be
controlled
before
in
##iti
##ating
treatment
with
PR
##IS
##TI
##Q
.
[SEP]
[CLS]
Use
of
o
##cular
s
##tero
##ids
may
pro
##long
the
course
and
may
ex
##ace
##rb
##ate
the
severity
of
many
viral
infections
of
the
eye
)
.
[SEP]
[CLS]
Other
immune
-
mediated
adverse
reactions
,
including
o
##cular
manifest
##ations
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
.
[SEP]
[CLS]
Of
the
patients
who
developed
tuberculosis
through
3
years
,
all
but
one
N
##U
##L
##O
##J
##IX
patient
lived
in
countries
with
a
high
prevalence
of
tuberculosis
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
Of
these
29
patients
,
5
(
17
%
)
required
cat
##he
##ter
##ization
,
with
post
-
void
##ing
residual
##s
of
up
to
1
,
500
m
##L
.
[SEP]
[CLS]
N
##eu
##tral
##izing
antibodies
to
AU
##X
-
I
or
AU
##X
-
II
,
were
detected
in
10
%
and
21
%
,
respectively
,
of
patients
treated
with
XI
##AF
##LE
##X
.
[SEP]
[CLS]
D
##ys
##lip
##ide
##mia
Mean
values
of
total
ch
##ole
##ster
##ol
,
HD
##L
,
L
##D
##L
,
and
t
##rig
##ly
##cer
##ides
were
reported
in
Studies
1
and
2
.
[SEP]
[CLS]
Pat
##ients
should
be
closely
monitored
during
treatment
for
the
emergence
of
possible
bacterial
,
fun
##gal
,
or
viral
infections
.
[SEP]
[CLS]
Fat
##al
adverse
reactions
in
patients
treated
with
Z
##Y
##KA
##DI
##A
occurred
in
5
%
of
patients
,
consisting
of
:
pneumonia
(
4
patients
)
,
respiratory
failure
,
IL
##D
/
p
##ne
##um
##oni
##tis
,
p
##ne
##um
##oth
##orax
,
gas
##tric
hem
##or
##r
##hage
,
general
physical
health
de
##ter
##ior
##ation
,
pulmonary
tuberculosis
,
cardiac
ta
##mpo
##na
##de
,
and
se
##psis
(
1
patient
each
)
.
[SEP]
[CLS]
There
have
been
reports
of
an
##aph
##yla
##ctic
reactions
in
patients
with
severe
milk
protein
all
##er
##gy
after
in
##hala
##tion
of
other
powder
medications
containing
la
##ct
##ose
;
therefore
,
patients
with
severe
milk
protein
all
##er
##gy
should
not
use
BR
##E
##O
E
##LL
##IP
##TA
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
reactions
including
Drug
Ra
##sh
with
E
##os
##ino
##phi
##lia
and
System
##ic
S
##ym
##pt
##oms
(
DR
##ES
##S
)
have
also
been
reported
and
were
characterized
by
r
##ash
,
constitutional
findings
,
and
sometimes
organ
d
##ys
##function
,
including
he
##pa
##tic
failure
.
[SEP]
[CLS]
5
.
11
H
##yper
##sen
##si
##ti
##vity
Re
##actions
,
Including
Ana
##phy
##lax
##is
H
##yper
##sen
##si
##ti
##vity
reactions
such
as
an
##aph
##yla
##xi
##s
,
an
##gio
##ede
##ma
,
r
##ash
,
and
u
##rt
##ica
##ria
may
occur
after
administration
of
BR
##E
##O
E
##LL
##IP
##TA
.
[SEP]
[CLS]
Monitor
closely
and
take
appropriate
measures
.
[SEP]
[CLS]
Se
##vere
pen
##ile
hem
##ato
##ma
was
also
reported
as
an
adverse
reaction
in
39
of
104
##4
(
3
.
7
%
)
XI
##AF
##LE
##X
-
treated
patients
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
The
most
common
adverse
drug
reactions
(
>
=
10
%
)
reported
in
the
two
random
##ized
clinical
trials
that
occurred
more
commonly
(
>
2
%
)
in
the
a
##bir
##ater
##one
ace
##tate
arm
were
fatigue
,
joint
swelling
,
ed
##ema
,
hot
flush
,
di
##ar
##r
##hea
,
vomit
##ing
,
cough
,
h
##yper
##tens
##ion
,
d
##ys
##p
##nea
,
u
##rina
##ry
tract
infection
and
con
##tus
##ion
.
[SEP]
[CLS]
The
most
common
reasons
for
dose
reduction
##s
were
elevated
trans
##ami
##nas
##es
,
di
##ar
##r
##hea
or
co
##lit
##is
,
and
r
##ash
.
[SEP]
[CLS]
In
Study
5
,
treatment
of
re
##current
contract
##ures
with
XI
##AF
##LE
##X
resulted
in
similar
im
##mu
##no
##genic
##ity
results
as
seen
in
Studies
1
and
2
.
[SEP]
[CLS]
5
.
5
V
##ira
##l
In
##fect
##ions
Employment
of
a
co
##rt
##ico
##ster
##oid
medication
in
the
treatment
of
patients
with
a
history
of
her
##pes
simple
##x
requires
great
caution
.
[SEP]
[CLS]
#
Most
her
##pes
infections
were
non
-
serious
and
1
led
to
treatment
disco
##ntin
##uation
.
[SEP]
[CLS]
The
mean
age
of
the
population
was
59
years
and
4
%
were
older
than
75
years
.
[SEP]
[CLS]
Treatment
with
PR
##IS
##TI
##Q
and
any
con
##com
##ita
##nt
se
##rot
##one
##rg
##ic
agents
should
be
discontinued
immediately
if
the
above
events
occur
and
supportive
s
##ym
##pt
##oma
##tic
treatment
should
be
initiated
.
[SEP]
[CLS]
In
patients
receiving
B
##L
##IN
##C
##Y
##TO
in
clinical
trials
,
Grade
3
or
greater
elevations
in
liver
enzymes
occurred
in
approximately
6
%
of
patients
outside
the
setting
of
CR
##S
and
resulted
in
treatment
disco
##ntin
##uation
in
less
than
1
%
of
patients
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
.
[SEP]
[CLS]
The
system
organ
class
and
individual
AD
##R
terms
are
sorted
in
descending
frequency
order
in
the
I
##MB
##R
##U
##VI
##CA
arm
.
[SEP]
[CLS]
(
5
.
1
)
*
Progressive
multi
##fo
##cal
le
##uk
##oe
##nce
##pha
##lop
##athy
(
PM
##L
)
:
With
##hold
T
##EC
##FI
##DE
##RA
at
the
first
sign
or
s
##ym
##pt
##om
suggest
##ive
of
PM
##L
.
[SEP]
[CLS]
In
the
single
-
arm
Phase
1
/
2
clinical
trial
,
the
median
time
to
onset
for
di
##ar
##r
##hea
(
all
grades
)
was
2
days
and
the
median
duration
per
event
was
1
day
.
[SEP]
[CLS]
In
##hala
##tion
of
airborne
caps
##aic
##in
can
result
in
coughing
or
s
##nee
##zing
.
[SEP]
[CLS]
Only
use
S
##IR
##TU
##RO
when
an
effective
treatment
regime
##n
can
not
otherwise
be
provided
.
[SEP]
[CLS]
Across
all
controlled
and
un
##con
##tro
##lled
trials
,
more
than
1
,
600
patients
have
received
Q
##ute
##nza
.
[SEP]
[CLS]
The
6
-
dose
Co
##arte
##m
Table
##ts
population
was
patients
with
malaria
between
ages
2
months
and
71
years
:
67
%
(
1
,
33
##2
)
were
16
years
and
younger
and
33
%
(
64
##7
)
were
older
than
16
years
.
[SEP]
[CLS]
When
distant
effects
occur
,
additional
respiratory
muscles
may
be
involved
[
See
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
5
.
1
S
##p
##read
of
To
##xin
Effect
Post
##market
##ing
safety
data
from
X
##E
##OM
##IN
and
other
approved
b
##ot
##ulin
##um
to
##xin
##s
suggest
that
b
##ot
##ulin
##um
to
##xin
effects
may
,
in
some
cases
,
be
observed
beyond
the
site
of
local
injection
.
[SEP]
[CLS]
Post
##market
##ing
Experience
In
the
post
##market
##ing
setting
,
third
-
degree
A
##V
block
and
A
##V
block
with
junction
##al
escape
have
been
observed
during
the
first
-
dose
6
-
hour
observation
period
with
G
##IL
##EN
##Y
##A
.
[SEP]
[CLS]
Monitor
patients
closely
for
need
of
emergency
card
##ior
##es
##pi
##rator
##y
support
.
[SEP]
[CLS]
In
an
ex
##p
##lora
##tory
clinical
trial
evaluating
the
use
of
the
sub
##cut
##aneous
formulation
of
go
##lim
##uma
##b
in
patients
with
severe
persistent
as
##th
##ma
,
more
patients
treated
with
go
##lim
##uma
##b
reported
ma
##li
##gna
##ncies
compared
with
control
patients
.
[SEP]
[CLS]
5
.
6
D
##ys
##p
##nea
D
##ys
##p
##nea
was
reported
in
28
%
of
patients
treated
with
K
##y
##p
##rol
##is
and
was
Grade
3
or
greater
in
4
%
of
patients
.
[SEP]
[CLS]
Care
##ful
consideration
should
be
given
to
this
potential
risk
prior
to
in
##iti
##ating
therapy
in
patients
with
these
conditions
.
[SEP]
[CLS]
If
su
##pine
h
##yper
##tens
##ion
is
not
well
-
managed
,
NO
##RT
##H
##ER
##A
may
increase
the
risk
of
card
##iovascular
events
.
[SEP]
[CLS]
6
.
2
Ad
##verse
Events
Associated
With
G
##aba
##pent
##in
The
following
adverse
events
have
been
reported
in
patients
receiving
g
##aba
##pent
##in
,
either
in
clinical
trials
or
post
##market
##ing
:
breast
en
##lar
##gement
,
g
##yne
##com
##ast
##ia
,
and
elevated
c
##rea
##tine
kinase
.
[SEP]
[CLS]
Monitor
blood
pressure
regularly
in
all
patients
.
[SEP]
[CLS]
Two
patients
receiving
al
##g
##lu
##cos
##idas
##e
al
##fa
discontinued
the
trial
due
to
an
##aph
##yla
##ctic
reactions
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
laboratory
testing
prior
to
in
##iti
##ating
therapy
and
monitoring
for
he
##pa
##to
##to
##xi
##city
during
therapy
with
T
##I
##VI
##CA
##Y
is
recommended
in
patients
with
underlying
he
##pa
##tic
disease
such
as
he
##pa
##titis
B
or
C
.
(
5
.
2
)
*
accumulation
of
body
fat
and
immune
re
##con
##st
##itution
syndrome
have
been
reported
in
patients
treated
with
combination
anti
##ret
##rov
##ira
##l
therapy
.
[SEP]
[CLS]
E
##NT
##ER
##EG
is
not
recommended
for
use
in
these
patients
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
i
##rre
##spective
of
ca
##usal
##ity
)
leading
to
treatment
disco
##ntin
##uation
were
p
##ne
##um
##oni
##tis
and
d
##ys
##p
##nea
.
[SEP]
[CLS]
Table
4
:
Ad
##verse
Re
##actions
Report
##ed
>
=
10
%
of
Pat
##ients
with
Advanced
P
##NE
##T
G
##rading
according
to
CT
##CA
##E
Version
3
.
0
a
Includes
s
##tom
##ati
##tis
,
a
##ph
##th
##ous
s
##tom
##ati
##tis
,
g
##ing
##ival
pain
,
g
##loss
##itis
,
g
##loss
##ody
##nia
,
lip
ul
##cer
##ation
,
mouth
ul
##cer
##ation
,
tongue
ul
##cer
##ation
,
and
m
##uc
##osa
##l
inflammation
.
[SEP]
[CLS]
5
.
6
Co
##rne
##al
Expo
##sure
,
Co
##rne
##al
U
##l
##cer
##ation
,
and
E
##ct
##rop
##ion
in
Pat
##ients
T
##reate
##d
with
X
##E
##OM
##IN
for
B
##le
##pha
##ros
##pas
##m
Red
##uce
##d
blinking
from
injection
of
b
##ot
##ulin
##um
to
##xin
products
in
the
or
##bic
##ular
##is
muscle
can
lead
to
corn
##eal
exposure
and
corn
##eal
ul
##cer
##ation
,
especially
in
patients
with
VII
nerve
disorders
.
[SEP]
[CLS]
The
incidence
of
adverse
reactions
associated
with
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
and
BR
##E
##O
E
##LL
##IP
##TA
200
/
25
is
shown
in
Table
3
.
[SEP]
[CLS]
Expo
##sure
to
sunlight
and
ultra
##vio
##let
(
UV
)
light
should
be
limited
by
wearing
protective
clothing
and
using
a
sun
##screen
with
a
high
protection
factor
.
[SEP]
[CLS]
Of
the
total
population
across
the
three
trials
,
229
patients
received
a
dose
of
125
mg
twice
a
day
for
a
mean
duration
of
141
days
,
69
patients
received
a
dose
of
250
mg
twice
a
day
for
a
mean
duration
of
139
days
,
102
patients
received
a
dose
of
250
mg
four
times
a
day
for
a
mean
duration
of
14
days
,
54
patients
received
a
dose
of
500
mg
twice
a
day
for
a
mean
duration
of
146
days
,
and
242
patients
received
a
dose
of
500
mg
four
times
a
day
for
a
mean
duration
of
14
days
.
[SEP]
[CLS]
Neo
##nate
##s
(
i
.
e
.
[SEP]
[CLS]
(
5
.
5
)
*
I
##mp
##aire
##d
wound
healing
:
Inc
##reased
risk
of
wound
-
related
complications
.
[SEP]
[CLS]
Physicians
should
consider
PT
##LD
in
patients
reporting
new
or
worse
##ning
ne
##uro
##logical
,
cognitive
,
or
behavioral
signs
or
symptoms
.
[SEP]
[CLS]
Fat
##al
outcomes
have
been
observed
.
[SEP]
[CLS]
*
Progressive
multi
##fo
##cal
le
##uk
##oe
##nce
##pha
##lop
##athy
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
*
b
In
this
trial
,
no
documented
s
##ym
##pt
##oma
##tic
or
severe
h
##y
##po
##gly
##ce
##mia
were
reported
for
T
##AN
##Z
##E
##UM
50
mg
and
these
data
are
omitted
from
the
table
.
[SEP]
[CLS]
B
##ip
##olar
I
Di
##sor
##der
(
3
-
weeks
)
Place
##bo
SA
##P
##H
##RI
##S
##2
.
5
mg
##t
##wi
##ce
daily
SA
##P
##H
##RI
##S
##5
mg
##t
##wi
##ce
daily
SA
##P
##H
##RI
##S
##10
mg
##t
##wi
##ce
daily
Change
from
Basel
##ine
(
kg
)
(
N
*
)
0
.
5
(
89
)
1
.
7
(
92
)
1
.
6
(
90
)
1
.
4
(
87
)
Pro
##port
##ion
of
Sub
##jects
with
a
>
=
7
%
Inc
##rease
in
Body
Weight
%
with
>
=
7
%
increase
in
body
weight
1
.
1
%
12
.
0
%
8
.
9
%
8
.
0
%
5
.
6
H
##yper
##sen
##si
##ti
##vity
Re
##actions
H
##yper
##sen
##si
##ti
##vity
reactions
have
been
observed
in
patients
treated
with
SA
##P
##H
##RI
##S
.
[SEP]
[CLS]
Pat
##ients
greater
than
65
years
of
age
,
patients
with
co
-
m
##or
##bid
conditions
,
and
/
or
patients
taking
con
##com
##ita
##nt
im
##mu
##nos
##up
##press
##ants
(
e
.
g
.
[SEP]
[CLS]
Most
,
but
not
all
,
of
these
patients
had
underlying
an
##ato
##mic
or
vascular
risk
factors
for
developing
N
##A
##ION
,
including
but
not
necessarily
limited
to
:
low
cup
to
disc
ratio
(
`
`
crowded
disc
'
'
)
,
age
over
50
,
diabetes
,
h
##yper
##tens
##ion
,
co
##rona
##ry
artery
disease
,
h
##yper
##lip
##ide
##mia
,
and
smoking
.
[SEP]
[CLS]
Report
##ed
infections
with
T
##NF
-
block
##ers
,
of
which
S
##IM
##PO
##NI
ARIA
is
a
member
,
include
:
*
Active
tuberculosis
,
including
react
##ivation
of
late
##nt
tuberculosis
.
[SEP]
[CLS]
trans
##fusion
)
if
clinical
##ly
indicated
.
[SEP]
[CLS]
(
5
.
1
)
*
Rapid
in
##tra
##ven
##ous
in
##fusion
of
g
##ly
##cope
##pt
##ide
anti
##ba
##cter
##ial
agents
can
cause
reactions
.
[SEP]
[CLS]
SA
##P
##H
##RI
##S
should
also
be
avoided
in
patients
with
a
history
of
cardiac
a
##rr
##hy
##th
##mia
##s
and
in
other
circumstances
that
may
increase
the
risk
of
the
occurrence
of
to
##rsa
##de
de
point
##es
and
/
or
sudden
death
in
association
with
the
use
of
drugs
that
pro
##long
the
Q
##T
##c
interval
,
including
bra
##dy
##card
##ia
;
h
##y
##po
##kal
##emia
or
h
##y
##po
##ma
##gne
##se
##mia
;
and
presence
of
con
##gen
##ital
pro
##long
##ation
of
the
Q
##T
interval
.
[SEP]
[CLS]
Certain
adverse
reactions
consistent
with
symptoms
of
an
##emia
,
such
as
d
##ys
##p
##nea
,
ex
##ert
##ional
d
##ys
##p
##nea
,
di
##zzi
##ness
and
s
##ync
##ope
were
reported
more
frequently
in
subjects
who
received
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
than
in
those
treated
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
The
increase
in
risk
was
demonstrated
in
year
1
and
persisted
[
see
Clinical
Studies
(
14
.
5
)
]
.
[SEP]
[CLS]
The
disco
##ntin
##uation
rate
due
to
adverse
reactions
for
patients
treated
with
ST
##EN
##DR
##A
50
mg
,
100
mg
,
or
200
mg
was
1
.
4
%
,
2
.
0
%
,
and
2
.
0
%
,
respectively
,
compared
to
1
.
7
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
If
this
occurs
,
treatment
with
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
should
be
stopped
and
other
treatments
considered
.
[SEP]
[CLS]
(
8
.
4
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Ser
##ious
infections
-
do
not
start
C
##IM
##Z
##IA
during
an
active
infection
.
[SEP]
[CLS]
Pat
##ients
in
S
##J
##IA
Study
1
received
a
single
dose
of
IL
##AR
##IS
4
mg
/
kg
(
n
=
43
)
or
place
##bo
(
n
=
41
)
via
sub
##cut
##aneous
injection
and
were
assessed
at
Day
15
for
the
efficacy
end
##points
and
had
a
safety
analysis
up
to
Day
29
.
[SEP]
[CLS]
The
development
of
p
##ne
##um
##oni
##tis
has
been
reported
even
at
a
reduced
dose
.
[SEP]
[CLS]
(
5
.
5
)
(
6
)
(
8
.
5
)
*
He
##pa
##tic
imp
##air
##ment
:
Red
##uce
the
J
##E
##V
##TA
##NA
dose
to
20
mg
/
m
2
in
patients
with
mild
he
##pa
##tic
imp
##air
##ment
and
to
15
mg
/
m
2
in
patients
with
moderate
he
##pa
##tic
imp
##air
##ment
.
[SEP]
[CLS]
Consider
a
diagnosis
of
non
-
infectious
p
##ne
##um
##oni
##tis
in
patients
presenting
with
non
-
specific
respiratory
signs
and
symptoms
such
as
h
##y
##pox
##ia
,
p
##le
##ural
e
##ff
##usion
,
cough
,
or
d
##ys
##p
##nea
,
and
in
whom
infectious
,
neo
##p
##lastic
,
and
other
causes
have
been
excluded
by
means
of
appropriate
investigations
.
[SEP]
[CLS]
R
##out
##ine
op
##ht
##hal
##mo
##logical
examination
detected
mac
##ular
ed
##ema
in
some
patients
with
no
visual
symptoms
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
NO
##RT
##H
##ER
##A
can
cause
su
##pine
h
##yper
##tens
##ion
and
may
increase
card
##iovascular
risk
if
su
##pine
h
##yper
##tens
##ion
is
not
well
-
managed
(
5
.
1
)
.
[SEP]
[CLS]
Care
##ful
testing
of
corn
##eal
sensation
in
eyes
previously
operated
upon
,
avoid
##ance
of
injection
into
the
lower
lid
area
to
avoid
e
##ct
##rop
##ion
,
and
vigorous
treatment
of
any
e
##pit
##hel
##ial
defect
should
be
employed
.
[SEP]
[CLS]
Laboratory
A
##b
##nor
##mal
##ities
The
frequency
of
laboratory
abnormal
##ities
(
Grades
3
-
4
)
occurring
in
at
least
2
%
of
subjects
receiving
ST
##RI
##BI
##LD
in
Studies
102
and
103
are
presented
in
Table
3
.
[SEP]
[CLS]
Per
##form
an
examination
of
the
fund
##us
including
the
mac
##ula
in
all
patients
before
starting
treatment
,
again
3
-
4
months
after
starting
treatment
,
and
again
at
any
time
after
a
patient
reports
visual
disturbance
##s
while
on
G
##IL
##EN
##Y
##A
therapy
.
[SEP]
[CLS]
The
reported
frequency
for
the
group
receiving
10
mg
/
kg
may
under
##est
##imate
the
actual
frequency
due
to
lower
ass
##ay
sensitivity
in
the
presence
of
high
drug
concentrations
.
[SEP]
[CLS]
5
.
2
H
##yper
##py
##re
##xia
and
Con
##fusion
Post
-
marketing
cases
of
a
s
##ym
##pt
##om
complex
resembling
ne
##uro
##le
##ptic
ma
##li
##gnant
syndrome
(
N
##MS
)
have
been
reported
with
NO
##RT
##H
##ER
##A
use
during
post
-
marketing
surveillance
in
Japan
.
[SEP]
[CLS]
(
5
.
3
,
5
.
4
)
5
.
1
H
##yper
##sen
##si
##ti
##vity
Re
##actions
H
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
and
were
characterized
by
r
##ash
,
constitutional
findings
,
and
sometimes
organ
d
##ys
##function
,
including
liver
injury
.
[SEP]
[CLS]
(
5
.
3
)
*
Ta
##rdi
##ve
d
##ys
##kin
##esi
##a
:
Disco
##ntin
##ue
if
clinical
##ly
appropriate
.
[SEP]
[CLS]
di
##ff
##ici
##le
.
[SEP]
[CLS]
5
.
4
All
##ergic
Re
##actions
This
product
contains
F
##D
&
C
Yellow
No
.
[SEP]
[CLS]
The
most
common
adverse
reaction
reported
for
A
##FI
##NI
##TO
##R
(
incidence
>
=
30
%
)
was
s
##tom
##ati
##tis
.
[SEP]
[CLS]
The
symptoms
are
consistent
with
the
mechanism
of
action
of
b
##ot
##ulin
##um
to
##xin
and
may
include
as
##the
##nia
,
generalized
muscle
weakness
,
dip
##lop
##ia
,
blurred
vision
,
p
##tosis
,
d
##ys
##pha
##gia
,
d
##ys
##phon
##ia
,
d
##ys
##art
##hr
##ia
,
u
##rina
##ry
in
##con
##tine
##nce
and
breathing
difficulties
.
[SEP]
[CLS]
The
percentage
of
patients
who
withdrew
from
treatment
due
to
adverse
reactions
was
7
.
5
%
in
the
D
##U
##AV
##EE
group
and
10
.
0
%
in
the
place
##bo
group
.
[SEP]
[CLS]
(
5
.
10
)
*
Live
##r
enzyme
elevation
has
been
observed
during
treatment
with
IN
##L
##Y
##TA
.
[SEP]
[CLS]
For
the
6
-
dose
regime
##n
,
Co
##arte
##m
Table
##ts
was
studied
in
active
-
controlled
(
36
##6
patients
)
and
non
-
controlled
,
open
-
label
trials
(
1
,
61
##3
patients
)
.
[SEP]
[CLS]
A
total
of
39
##4
patients
received
more
than
one
treatment
application
and
27
##4
patients
were
followed
for
48
weeks
or
longer
.
[SEP]
[CLS]
F
##lus
##h
eyes
and
m
##uc
##ous
membrane
##s
with
cool
water
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
AS
##TH
##MA
-
R
##EL
##AT
##ED
DE
##AT
##H
WA
##R
##NI
##NG
:
AS
##TH
##MA
-
R
##EL
##AT
##ED
DE
##AT
##H
L
on
##g
-
acting
beta
2
-
ad
##rene
##rg
##ic
ago
##nist
s
(
LA
##BA
)
increase
the
risk
of
as
##th
##ma
-
related
death
.
[SEP]
[CLS]
T
##AB
##LE
2
:
Changes
in
Fast
##ing
G
##lu
##cos
##e
in
P
##ediatric
Sub
##jects
B
##ip
##olar
I
Di
##sor
##der
(
3
-
weeks
)
Place
##bo
SA
##P
##H
##RI
##S
##2
.
5
mg
##t
##wi
##ce
daily
SA
##P
##H
##RI
##S
##5
mg
##t
##wi
##ce
daily
SA
##P
##H
##RI
##S
##10
mg
##t
##wi
##ce
daily
Mean
Change
from
Basel
##ine
in
Fast
##ing
G
##lu
##cos
##e
at
End
##point
Change
from
Basel
##ine
(
mg
/
d
##L
)
(
N
*
)
-
2
.
24
(
56
)
1
.
43
(
51
)
-
0
.
45
(
57
)
0
.
34
(
52
)
Pro
##port
##ion
of
Sub
##jects
with
Shi
##fts
from
Basel
##ine
to
End
##point
Normal
to
High
>
45
&
<
100
to
>
=
126
mg
/
d
##L
0
%
0
%
1
.
8
%
0
%
(
n
/
N
*
)
(
0
/
56
)
(
0
/
51
)
(
1
/
57
)
(
0
/
52
)
D
##ys
##lip
##ide
##mia
Un
##des
##ira
##ble
alterations
in
lip
##ids
have
been
observed
in
patients
treated
with
at
##y
##pical
anti
##psy
##cho
##tics
.
[SEP]
[CLS]
Inc
##rease
##s
in
He
##mo
##g
##lo
##bin
In
the
pool
of
four
place
##bo
-
controlled
trials
,
mean
changes
(
percent
changes
)
from
base
##line
in
hem
##og
##lo
##bin
were
-
0
.
18
g
/
d
##L
(
-
1
.
1
%
)
with
place
##bo
,
0
.
47
g
/
d
##L
(
3
.
5
%
)
with
IN
##VO
##KA
##NA
100
mg
,
and
0
.
51
g
/
d
##L
(
3
.
8
%
)
with
IN
##VO
##KA
##NA
300
mg
.
[SEP]
[CLS]
As
with
all
anti
##de
##press
##ants
,
PR
##IS
##TI
##Q
should
be
used
cautiously
in
patients
with
a
history
or
family
history
of
man
##ia
or
h
##y
##po
##mani
##a
.
[SEP]
[CLS]
Rest
##less
Le
##gs
S
##yn
##drome
:
The
exposure
to
H
##OR
##I
##Z
##AN
##T
in
1
,
201
patients
with
R
##LS
included
61
##3
exposed
for
at
least
6
months
and
37
##1
exposed
for
at
least
1
year
.
[SEP]
[CLS]
It
is
unknown
whether
T
##R
##U
##L
##IC
##IT
##Y
causes
thy
##roid
C
-
cell
tumors
,
including
me
##du
##llar
##y
thy
##roid
car
##cin
##oma
(
M
##TC
)
,
in
humans
as
the
human
relevance
of
du
##lag
##lut
##ide
-
induced
rode
##nt
thy
##roid
C
-
cell
tumors
has
not
been
determined
(
5
.
1
,
13
.
1
)
.
[SEP]
[CLS]
5
.
9
H
##y
##po
##nat
##rem
##ia
H
##y
##po
##nat
##rem
##ia
may
occur
as
a
result
of
treatment
with
SSR
##I
##s
and
S
##NR
##I
##s
,
including
PR
##IS
##TI
##Q
.
[SEP]
[CLS]
Data
from
a
place
##bo
-
controlled
,
4
-
week
,
fixed
-
dose
study
,
in
which
fast
##ing
blood
samples
were
drawn
,
in
adult
subjects
with
s
##chi
##zophrenia
are
presented
in
Table
3
.
[SEP]
[CLS]
The
safety
data
described
below
are
based
on
one
,
random
##ized
,
double
-
blind
,
controlled
Phase
3
trial
in
patients
with
RA
receiving
S
##IM
##PO
##NI
ARIA
by
in
##tra
##ven
##ous
in
##fusion
(
Trial
1
)
.
[SEP]
[CLS]
In
place
##bo
-
controlled
trials
in
patients
with
e
##pile
##psy
,
di
##zzi
##ness
was
reported
in
23
%
of
patients
treated
with
P
##OT
##IG
##A
and
9
%
of
patients
treated
with
place
##bo
.
[SEP]
[CLS]
*
Fe
##rri
##p
##ro
##x
can
cause
a
##gra
##nu
##loc
##yt
##osis
that
can
lead
to
serious
infections
and
death
.
[SEP]
[CLS]
Long
-
term
cumulative
radiation
exposure
is
associated
with
an
increased
risk
for
cancer
.
[SEP]
[CLS]
Ch
##roma
##tur
##ia
(
reddish
/
brown
disco
##lora
##tion
of
the
urine
)
is
a
result
of
the
ex
##cre
##tion
of
the
iron
in
the
urine
.
[SEP]
[CLS]
c
##D
##ef
##ined
as
bleeding
accompanied
by
one
or
more
of
the
following
:
a
decrease
in
hem
##og
##lo
##bin
of
>
=
2
g
/
d
##L
,
a
trans
##fusion
of
2
or
more
units
of
packed
red
blood
cells
,
bleeding
at
a
critical
site
or
with
fatal
outcome
.
[SEP]
[CLS]
Immediately
disco
##ntin
##ue
treatment
if
severe
h
##yper
##sen
##si
##ti
##vity
,
severe
r
##ash
or
r
##ash
with
systemic
symptoms
or
liver
trans
##ami
##nas
##e
elevations
develops
and
monitor
clinical
status
,
including
liver
trans
##ami
##nas
##es
closely
.
[SEP]
[CLS]
5
.
6
Inc
##reased
To
##xi
##city
in
the
Pre
##sen
##ce
of
Se
##vere
Ren
##al
I
##mp
##air
##ment
The
frequency
of
>
=
Grade
3
adverse
reactions
and
deaths
was
greater
in
patients
with
severe
re
##nal
imp
##air
##ment
compared
to
patients
with
normal
re
##nal
function
.
[SEP]
[CLS]
If
a
h
##yper
##sen
##si
##ti
##vity
reaction
occurs
,
the
patient
should
disco
##ntin
##ue
T
##R
##U
##L
##IC
##IT
##Y
and
promptly
seek
medical
advice
.
[SEP]
[CLS]
c
not
applicable
;
(
g
##rading
system
does
not
specify
>
Grade
2
for
al
##ope
##cia
)
.
[SEP]
[CLS]
H
##yper
##tens
##ion
Blood
pressure
and
use
of
anti
##hy
##pert
##ens
##ive
medications
were
reported
in
Studies
1
and
2
.
[SEP]
[CLS]
5
.
2
Fat
Red
##ist
##ri
##but
##ion
buffalo
hum
##p
,
facial
wasting
,
breast
en
##lar
##gement
,
and
`
`
cu
##shing
##oid
appearance
'
'
have
been
observed
in
patients
receiving
anti
##ret
##rov
##ira
##l
therapy
.
[SEP]
[CLS]
Major
bleeding
events
within
each
sub
##cate
##gor
##y
were
counted
once
per
patient
,
but
patients
may
have
contributed
events
to
multiple
sub
##cate
##gor
##ies
.
[SEP]
[CLS]
Pre
##med
##ica
##tion
may
include
ace
##tam
##ino
##phe
##n
,
an
anti
##his
##tamine
,
and
a
co
##rt
##ico
##ster
##oid
.
[SEP]
[CLS]
Card
##iac
disorders
:
at
##rial
fi
##bri
##lla
##tion
,
cardiac
failure
.
[SEP]
[CLS]
*
Pan
##cre
##ati
##tis
:
Has
been
reported
in
clinical
trials
.
[SEP]
[CLS]
(
6
.
1
)
*
P
##H
##N
:
Most
common
adverse
reactions
(
>
=
10
%
and
greater
than
place
##bo
)
were
di
##zzi
##ness
,
so
##m
##no
##len
##ce
,
and
headache
.
[SEP]
[CLS]
[
See
Do
##sa
##ge
and
Administration
(
2
.
3
)
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Pat
##ients
who
can
not
be
monitored
should
usually
not
be
treated
with
P
##OT
##IG
##A
.
[SEP]
[CLS]
In
##fusion
Re
##actions
There
were
no
reports
of
an
##aph
##yla
##xi
##s
or
drug
h
##yper
##sen
##si
##ti
##vity
in
patients
treated
with
N
##U
##L
##O
##J
##IX
in
Studies
1
and
2
through
three
years
.
[SEP]
[CLS]
The
patient
was
also
not
taking
any
im
##mu
##nos
##up
##pressive
or
im
##mu
##no
##mo
##du
##lator
##y
medications
con
##com
##ita
##ntly
.
[SEP]
[CLS]
When
treating
p
##ediatric
patients
,
weight
gain
should
be
monitored
and
assessed
against
that
expected
for
normal
growth
.
[SEP]
[CLS]
These
included
infections
,
sub
##du
##ral
hem
##ato
##mas
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
R
##IS
##K
OF
AN
##AP
##H
##Y
##LA
##X
##IS
WA
##R
##NI
##NG
:
R
##IS
##K
OF
AN
##AP
##H
##Y
##LA
##X
##IS
Life
-
threatening
an
##aph
##yla
##ctic
reactions
have
occurred
in
some
patients
during
V
##im
##iz
##im
in
##fusion
##s
.
[SEP]
[CLS]
In
such
cases
,
promptly
disco
##ntin
##ue
NE
##SI
##NA
,
assess
for
other
potential
causes
,
institute
appropriate
monitoring
and
treatment
and
initiate
alternative
treatment
for
diabetes
.
[SEP]
[CLS]
The
most
common
cause
of
death
as
reported
by
the
investigator
was
T
##B
(
9
subjects
)
.
[SEP]
[CLS]
D
##AL
##VA
##NC
##E
was
discontinued
due
to
an
adverse
reaction
in
53
/
1778
(
3
%
)
patients
and
the
com
##par
##ator
was
discontinued
due
to
an
adverse
reaction
in
35
/
122
##4
(
2
.
8
%
)
patients
.
[SEP]
[CLS]
The
median
duration
of
study
treatment
was
7
.
1
months
for
patients
who
received
X
##AL
##KO
##RI
and
2
.
8
months
for
patients
who
received
ch
##em
##otherapy
.
[SEP]
[CLS]
(
5
.
4
,
5
.
5
)
5
.
1
Eye
and
Mu
##co
##us
Me
##mb
##rane
Expo
##sure
Do
not
apply
Q
##ute
##nza
to
the
face
or
scalp
to
avoid
risk
of
exposure
to
the
eyes
or
m
##uc
##ous
membrane
##s
.
[SEP]
[CLS]
In
##st
##ru
##ct
patients
receiving
G
##IL
##EN
##Y
##A
to
report
symptoms
of
infections
to
a
physician
.
[SEP]
[CLS]
In
un
##ap
##p
##roved
uses
,
including
spa
##stic
##ity
in
children
and
in
approved
indication
##s
,
symptoms
consistent
with
spread
of
to
##xin
effect
have
been
reported
at
doses
comparable
to
or
lower
than
the
maximum
recommended
total
dose
.
[SEP]
[CLS]
Ad
##mini
##ster
this
product
in
a
setting
with
re
##sus
##citation
equipment
and
other
agents
necessary
to
treat
an
##aph
##yla
##xi
##s
.
[SEP]
[CLS]
*
B
##ip
##olar
Di
##sor
##der
Adults
(
Ad
##junct
##ive
)
:
so
##m
##no
##len
##ce
,
oral
h
##y
##po
##est
##hesia
.
[SEP]
[CLS]
The
most
common
Grade
3
-
4
adverse
reactions
(
incidence
>
=
3
%
)
were
infections
,
d
##ys
##p
##nea
,
fatigue
,
s
##tom
##ati
##tis
,
de
##hy
##dra
##tion
,
p
##ne
##um
##oni
##tis
,
abdominal
pain
,
and
as
##the
##nia
.
[SEP]
[CLS]
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
was
studied
in
2
,
36
##9
subjects
and
BR
##E
##O
E
##LL
##IP
##TA
200
/
25
was
studied
in
95
##6
subjects
.
[SEP]
[CLS]
Ser
##um
Li
##pid
##s
:
In
the
clinical
trials
of
ST
##RI
##BI
##LD
,
a
similar
percentage
of
subjects
receiving
ST
##RI
##BI
##LD
,
AT
##RI
##PL
##A
,
and
AT
##V
+
R
##TV
+
T
##R
##U
##VA
##DA
were
on
lip
##id
lowering
agents
at
base
##line
(
12
%
,
12
%
,
and
13
%
,
respectively
)
.
[SEP]
[CLS]
E
##cc
##hy
##mos
##is
easily
occurs
in
the
soft
tissues
of
the
eye
##lid
.
[SEP]
[CLS]
Con
##tin
##uation
of
G
##IL
##EN
##Y
##A
in
patients
who
develop
mac
##ular
ed
##ema
has
not
been
evaluated
.
[SEP]
[CLS]
Some
events
have
been
fatal
.
[SEP]
[CLS]
Pat
##ients
should
be
advised
to
el
##eva
##te
the
head
of
the
bed
when
resting
or
sleeping
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
Dec
##reased
E
##ff
##ica
##cy
in
Pat
##ients
with
Basel
##ine
C
##rea
##tin
##ine
Clear
##ance
of
30
to
<
=
50
m
##L
/
min
In
a
subgroup
analysis
of
a
Phase
3
c
##IA
##I
trial
,
clinical
cure
rates
were
lower
in
patients
with
base
##line
c
##rea
##tin
##ine
clearance
(
C
##r
##C
##l
)
of
30
to
<
=
50
m
##L
/
min
compared
to
those
with
C
##r
##C
##l
>
=
50
m
##L
/
min
(
Table
4
)
.
[SEP]
[CLS]
Table
8
:
Ad
##verse
Re
##actions
Report
##ed
in
>
=
10
%
of
A
##FI
##NI
##TO
##R
-
treated
Pat
##ients
with
Ren
##al
Ang
##io
##my
##oli
##po
##ma
G
##rading
according
to
CT
##CA
##E
Version
3
.
0
a
Includes
s
##tom
##ati
##tis
,
a
##ph
##th
##ous
s
##tom
##ati
##tis
,
mouth
ul
##cer
##ation
,
g
##ing
##ival
pain
,
g
##loss
##itis
,
and
g
##loss
##ody
##nia
.
[SEP]
[CLS]
T
##hr
##omb
##oc
##yt
##ope
##nia
was
reported
in
approximately
40
%
of
patients
in
clinical
trials
with
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
(
5
.
2
)
5
.
1
H
##yper
##sen
##si
##ti
##vity
Re
##actions
H
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
following
Da
##T
##sca
##n
administration
[
see
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
General
disorders
and
administration
site
conditions
-
As
##the
##nia
.
[SEP]
[CLS]
More
cases
of
pneumonia
in
the
group
receiving
T
##AN
##Z
##E
##UM
were
serious
(
0
.
4
%
for
T
##AN
##Z
##E
##UM
versus
0
.
1
%
for
all
com
##par
##ators
)
.
[SEP]
[CLS]
A
total
of
108
subjects
treated
with
Pi
##cat
##o
(
r
)
gel
on
the
face
/
scalp
and
38
subjects
treated
on
the
trunk
/
ex
##tre
##mit
##ies
were
followed
for
12
months
.
[SEP]
[CLS]
To
decrease
thy
##roid
accumulation
of
i
##od
##ine
123
,
block
the
thy
##roid
g
##land
before
administration
of
Da
##T
##sca
##n
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
If
diagnosed
,
with
##hold
T
##AF
##IN
##LA
##R
for
up
to
6
weeks
until
u
##ve
##itis
/
i
##rit
##is
resolve
##s
to
Grade
0
-
1
.
[SEP]
[CLS]
5
.
6
O
##cular
To
##xi
##ci
##ties
Re
##tina
##l
Pig
##ment
E
##pit
##hel
##ial
Detachment
(
R
##P
##ED
)
:
Re
##tina
##l
pig
##ment
e
##pit
##hel
##ial
detachment
##s
(
R
##P
##ED
)
can
occur
when
T
##AF
##IN
##LA
##R
is
used
in
combination
with
tram
##eti
##ni
##b
and
with
tram
##eti
##ni
##b
as
a
single
agent
[
refer
to
Full
Pre
##s
##cribing
Information
for
tram
##eti
##ni
##b
]
.
[SEP]
[CLS]
An
increased
risk
of
stroke
and
D
##V
##T
has
been
reported
with
est
##rogen
-
alone
therapy
.
[SEP]
[CLS]
The
proportion
of
subjects
who
received
an
E
##SA
was
43
%
in
those
treated
with
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
compared
to
24
%
in
those
treated
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
.
[SEP]
[CLS]
Eva
##lu
##ate
if
di
##ar
##r
##hea
occurs
.
[SEP]
[CLS]
Monitor
##ing
Pat
##ients
should
be
closely
monitored
for
the
development
of
signs
and
symptoms
of
infection
during
and
after
treatment
with
C
##IM
##Z
##IA
,
including
the
development
of
tuberculosis
in
patients
who
tested
negative
for
late
##nt
tuberculosis
infection
prior
to
in
##iti
##ating
therapy
.
[SEP]
[CLS]
Five
of
the
six
patients
in
the
group
that
received
PR
##OM
##AC
##TA
experienced
a
th
##rom
##bot
##ic
com
##plication
within
30
days
of
completing
treatment
with
PR
##OM
##AC
##TA
and
at
a
plate
##let
count
above
200
x
10
9
/
L
.
[SEP]
[CLS]
Consider
the
diagnosis
of
pan
##cre
##ati
##tis
for
patients
presenting
with
severe
abdominal
pain
.
[SEP]
[CLS]
As
with
other
PD
##E
##5
inhibitor
##s
ST
##EN
##DR
##A
has
systemic
v
##as
##od
##ila
##tory
properties
and
may
au
##gment
the
blood
pressure
-
lowering
effect
of
other
anti
-
h
##yper
##tensive
medications
.
[SEP]
[CLS]
5
.
7
Or
##th
##ost
##atic
H
##y
##pot
##ens
##ion
,
S
##ync
##ope
,
and
Other
He
##mo
##dynamic
Effects
SA
##P
##H
##RI
##S
may
induce
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
and
s
##ync
##ope
in
some
patients
,
especially
early
in
treatment
,
because
of
its
alpha
##1
-
ad
##rene
##rg
##ic
antagonist
activity
.
[SEP]
[CLS]
5
.
1
Ser
##ious
In
##fect
##ions
Pat
##ients
treated
with
S
##IM
##PO
##NI
ARIA
are
at
increased
risk
for
developing
serious
infections
involving
various
organ
systems
and
sites
that
may
lead
to
hospital
##ization
or
death
.
[SEP]
[CLS]
6
.
1
Clinical
Studies
Experience
The
data
described
below
primarily
derive
from
two
random
##ized
,
active
-
controlled
three
-
year
trials
of
N
##U
##L
##O
##J
##IX
in
de
no
##vo
kidney
transplant
patients
.
[SEP]
[CLS]
AL
##T
elevations
were
re
##versible
in
all
subjects
.
[SEP]
[CLS]
Higher
than
recommended
dos
##ing
or
repeated
dos
##ing
appears
to
increase
the
risk
(
5
.
1
)
*
H
##yper
##sen
##si
##ti
##vity
:
h
##yper
##sen
##si
##ti
##vity
reactions
with
cut
##aneous
manifest
##ations
,
ranging
from
mild
to
severe
reactions
including
shock
can
occur
.
[SEP]
[CLS]
SA
##P
##H
##RI
##S
should
be
used
with
caution
in
(
1
)
patients
with
known
card
##iovascular
disease
(
history
of
my
##oc
##ard
##ial
in
##far
##ction
or
is
##che
##mic
heart
disease
,
heart
failure
or
conduct
##ion
abnormal
##ities
)
,
c
##ere
##bro
##vas
##cular
disease
,
or
conditions
which
would
pre
##dis
##pose
patients
to
h
##y
##pot
##ens
##ion
(
de
##hy
##dra
##tion
,
h
##y
##po
##vo
##lem
##ia
,
and
treatment
with
anti
##hy
##pert
##ens
##ive
medications
)
;
and
(
2
)
in
the
elderly
.
[SEP]
[CLS]
(
6
)
The
most
common
adverse
events
occurring
in
at
least
20
%
of
patients
treated
with
K
##y
##p
##rol
##is
in
the
combination
therapy
trial
:
decreased
l
##ymph
##ocytes
,
decreased
absolute
ne
##ut
##rop
##hil
count
,
decreased
p
##hos
##phorus
,
an
##emia
,
ne
##ut
##rop
##enia
,
decreased
total
white
blood
cell
count
,
decreased
plate
##lets
,
di
##ar
##r
##hea
,
fatigue
,
th
##rom
##bo
##cy
##top
##enia
,
p
##yre
##xia
,
muscle
spa
##sm
,
cough
,
upper
respiratory
tract
infection
,
decreased
hem
##og
##lo
##bin
,
h
##y
##po
##kal
##emia
.
[SEP]
[CLS]
In
short
-
term
s
##chi
##zophrenia
adult
trials
,
s
##ync
##ope
was
reported
in
0
.
2
%
(
1
/
57
##2
)
of
patients
treated
with
therapeutic
doses
(
5
mg
or
10
mg
twice
daily
)
of
SA
##P
##H
##RI
##S
,
compared
to
0
.
3
%
(
1
/
37
##8
)
of
patients
treated
with
place
##bo
.
[SEP]
[CLS]
If
pan
##cre
##ati
##tis
is
suspected
,
promptly
disco
##ntin
##ue
T
##AN
##Z
##E
##UM
.
[SEP]
[CLS]
(
5
.
5
)
*
Mac
##rov
##as
##cular
Out
##come
##s
:
There
have
been
no
clinical
trials
establishing
con
##clusive
evidence
of
mac
##rov
##as
##cular
risk
reduction
with
T
##AN
##Z
##E
##UM
or
any
other
anti
##dia
##bet
##ic
drug
.
[SEP]
[CLS]
S
##ym
##pt
##oms
of
P
##V
##T
included
abdominal
pain
,
nausea
,
vomit
##ing
,
and
di
##ar
##r
##hea
.
[SEP]
[CLS]
During
adult
pre
-
marketing
clinical
trials
with
SA
##P
##H
##RI
##S
,
including
long
-
term
trials
without
comparison
to
place
##bo
,
seizure
##s
were
reported
in
0
.
3
%
(
5
/
1953
)
of
patients
treated
with
SA
##P
##H
##RI
##S
.
[SEP]
[CLS]
Factor
##s
that
can
increase
the
risk
of
developing
spinal
hem
##ato
##mas
in
these
patients
include
:
*
?
use
of
in
##d
##well
##ing
e
##pid
##ural
cat
##he
##ters
*
?
con
##com
##ita
##nt
use
of
other
drugs
that
affect
hem
##ost
##asis
,
such
as
non
##ster
##oid
##al
anti
-
inflammatory
drugs
(
NSA
##ID
##s
)
,
plate
##let
inhibitor
##s
,
other
anti
##coa
##gu
##lants
*
?
a
history
of
traumatic
or
repeated
e
##pid
##ural
or
spinal
pu
##nc
##tures
*
?
a
history
of
spinal
def
##orm
##ity
or
spinal
surgery
*
?
optimal
timing
between
the
administration
of
E
##L
##I
##Q
##UI
##S
and
ne
##ura
##xial
procedures
is
not
known
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
Monitor
patients
frequently
for
signs
and
symptoms
of
ne
##uro
##logical
imp
##air
##ment
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
incidence
>
=
3
%
)
are
upper
respiratory
tract
infection
,
br
##on
##chi
##tis
,
cough
,
flat
##ule
##nce
and
increased
bi
##li
##ru
##bin
.
[SEP]
[CLS]
A
##vo
##id
the
use
of
Po
##tas
##sium
I
##od
##ide
Oral
Sol
##ution
or
Lu
##gol
'
s
Sol
##ution
in
patients
who
are
sensitive
to
such
products
.
[SEP]
[CLS]
Monitor
##ing
of
complete
blood
counts
is
essential
on
a
weekly
basis
during
cycle
1
and
before
each
treatment
cycle
thereafter
so
that
the
dose
can
be
adjusted
,
if
needed
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
The
reactions
have
generally
consisted
of
skin
er
##yt
##hem
##a
and
p
##ru
##rit
##is
and
have
either
resolved
spontaneous
##ly
or
following
the
administration
of
co
##rt
##ico
##ster
##oids
and
anti
-
his
##tamine
##s
.
[SEP]
[CLS]
*
H
##yper
##py
##re
##xia
and
confusion
(
5
.
2
)
*
May
ex
##ace
##rb
##ate
symptoms
in
patients
with
existing
is
##che
##mic
heart
disease
(
5
.
3
)
*
All
##ergic
reactions
(
5
.
4
)
5
.
1
Su
##pine
H
##yper
##tens
##ion
NO
##RT
##H
##ER
##A
therapy
may
cause
or
ex
##ace
##rb
##ate
su
##pine
h
##yper
##tens
##ion
in
patients
with
NO
##H
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
GB
##CA
##s
have
been
associated
with
a
risk
for
N
##SF
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Mac
##ular
ed
##ema
has
also
been
reported
in
patients
taking
G
##IL
##EN
##Y
##A
0
.
5
mg
in
the
post
##market
##ing
setting
,
usually
within
the
first
6
months
of
treatment
.
[SEP]
[CLS]
Sometimes
both
o
##var
##ies
are
removed
during
an
operation
before
natural
men
##op
##aus
##e
takes
place
.
[SEP]
[CLS]
(
5
.
1
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
For
All
In
##dication
##s
:
*
The
pot
##ency
Units
of
X
##E
##OM
##IN
are
not
interchange
##able
with
other
preparations
of
b
##ot
##ulin
##um
to
##xin
products
.
[SEP]
[CLS]
In
addition
,
a
two
-
week
dose
-
ranging
trial
was
conducted
in
51
##1
adult
patients
with
mild
persistent
as
##th
##ma
taking
inhaled
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
With
##hold
,
dose
reduce
,
or
disco
##ntin
##ue
B
##OS
##U
##L
##IF
.
[SEP]
[CLS]
Monitor
blood
pressure
periodically
during
the
treatment
and
provide
adequate
support
for
treatment
related
pain
.
[SEP]
[CLS]
Prior
to
the
initiation
of
the
next
cycle
of
therapy
,
the
AN
##C
should
be
>
=
1
x
10
9
/
L
and
the
plate
##let
count
should
be
>
=
75
x
10
9
/
L
.
[SEP]
[CLS]
Di
##zzi
##ness
,
nausea
,
so
##m
##no
##len
##ce
,
and
fatigue
were
all
reported
at
lower
incidence
##s
during
the
A
##ED
With
##dra
##wal
Phase
and
Mon
##otherapy
Phase
compared
with
the
T
##it
##ration
Phase
.
[SEP]
[CLS]
The
data
described
in
the
Warning
##s
and
Pre
##ca
##ution
##s
section
and
below
reflect
exposure
to
T
##AF
##IN
##LA
##R
as
a
single
agent
and
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
The
onset
tends
to
be
within
the
first
treatment
cycle
of
T
##RE
##AN
##DA
and
,
without
intervention
,
may
lead
to
acute
re
##nal
failure
and
death
.
[SEP]
[CLS]
Clinical
monitoring
of
weight
is
recommended
.
[SEP]
[CLS]
Because
of
the
increased
risk
of
u
##rina
##ry
retention
on
P
##OT
##IG
##A
,
u
##rol
##og
##ic
symptoms
should
be
carefully
monitored
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
most
serious
adverse
reactions
were
:
*
Ser
##ious
In
##fect
##ions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
Mali
##gna
##ncies
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
incidence
>
=
3
%
)
are
:
upper
respiratory
tract
infection
,
viral
infection
,
br
##on
##chi
##tis
,
h
##yper
##tens
##ion
,
and
r
##ash
(
6
.
1
)
.
[SEP]
[CLS]
c
Under
##lying
et
##iology
not
established
.
[SEP]
[CLS]
Case
##s
of
elevated
blood
pressure
requiring
immediate
treatment
have
been
reported
with
PR
##IS
##TI
##Q
.
[SEP]
[CLS]
(
6
.
1
)
E
##X
##CE
##RP
##T
:
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
X
##eno
##P
##ort
at
1
-
87
##7
-
X
##EN
##OP
##RT
(
1
-
87
##7
-
93
##6
-
67
##7
##8
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Table
displays
adverse
reactions
that
were
reported
in
greater
than
5
%
of
patients
in
the
NO
##RT
##H
##ER
##A
group
and
with
at
least
a
3
%
greater
incidence
in
the
NO
##RT
##H
##ER
##A
group
than
in
the
place
##bo
group
.
[SEP]
[CLS]
5
.
8
H
##yper
##cor
##tic
##ism
and
Ad
##rena
##l
Su
##pp
##ression
In
##hale
##d
flu
##tica
##son
##e
fur
##oat
##e
is
absorbed
into
the
circulation
and
can
be
systemic
##ally
active
.
[SEP]
[CLS]
Con
##gen
##ital
,
f
##ami
##lial
and
genetic
disorders
:
h
##y
##po
##sp
##adia
##s
.
[SEP]
[CLS]
5
.
7
Inc
##reased
To
##xi
##city
in
the
Pre
##sen
##ce
of
Mode
##rate
or
Se
##vere
He
##pa
##tic
I
##mp
##air
##ment
The
frequency
of
>
=
Grade
3
adverse
reactions
and
deaths
was
greater
in
patients
with
moderate
and
severe
he
##pa
##tic
imp
##air
##ment
compared
to
patients
with
normal
he
##pa
##tic
function
.
[SEP]
[CLS]
There
were
no
treatment
disco
##ntin
##uations
and
one
death
due
to
cardiac
failure
in
the
place
##bo
group
.
[SEP]
[CLS]
With
##hold
if
not
re
##sp
##ons
##ive
to
anti
-
em
##etics
or
anti
-
di
##ar
##r
##hea
##ls
,
then
dose
reduce
Z
##Y
##KA
##DI
##A
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
Because
clinical
studies
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
studies
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
studies
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Pat
##ients
requiring
oral
co
##rt
##ico
##ster
##oids
should
be
we
##ane
##d
slowly
from
systemic
co
##rt
##ico
##ster
##oid
use
after
transferring
to
BR
##E
##O
E
##LL
##IP
##TA
.
[SEP]
[CLS]
2
Post
##market
##ing
Experience
The
following
adverse
drug
reactions
have
been
identified
during
post
-
approval
of
H
##AL
##AV
##EN
.
[SEP]
[CLS]
The
median
duration
of
treatment
with
Z
##Y
##TI
##GA
was
8
months
.
[SEP]
[CLS]
Hold
AD
##CE
##TR
##IS
dos
##ing
for
any
suspected
case
of
PM
##L
and
disco
##ntin
##ue
AD
##CE
##TR
##IS
dos
##ing
if
a
diagnosis
of
PM
##L
is
confirmed
.
[SEP]
[CLS]
In
v
##it
##ro
studies
showed
no
evidence
of
cross
-
react
##ivity
between
anti
-
drug
-
anti
##body
positive
patient
se
##ra
and
a
series
of
relevant
M
##MP
##s
.
[SEP]
[CLS]
After
five
years
more
than
90
percent
of
patients
remained
se
##rop
##os
##itive
for
anti
-
AU
##X
-
I
and
anti
-
AU
##X
-
II
anti
##body
(
Study
4
)
.
[SEP]
[CLS]
Gas
##tro
##int
##est
##inal
disorders
:
enter
##oc
##oli
##tis
,
re
##ct
##al
hem
##or
##r
##hage
,
gas
##tric
ul
##cer
,
pan
##cre
##ati
##tis
,
par
##ot
##id
g
##land
en
##lar
##gement
.
[SEP]
[CLS]
5
.
10
Para
##dox
##ical
B
##ron
##cho
##sp
##as
##m
As
with
other
inhaled
medicines
,
BR
##E
##O
E
##LL
##IP
##TA
can
produce
para
##dox
##ical
br
##on
##cho
##sp
##as
##m
,
which
may
be
life
threatening
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
events
(
incidence
>
=
2
%
and
at
a
rate
greater
than
the
place
##bo
rate
)
for
AM
##P
##Y
##RA
were
u
##rina
##ry
tract
infection
,
ins
##om
##nia
,
di
##zzi
##ness
,
headache
,
nausea
,
as
##the
##nia
,
back
pain
,
balance
disorder
,
multiple
s
##cle
##rosis
re
##lap
##se
,
par
##est
##hesia
,
na
##so
##pha
##ryn
##git
##is
,
con
##st
##ip
##ation
,
d
##ys
##pe
##ps
##ia
,
and
p
##har
##yn
##gol
##ary
##nge
##al
pain
(
6
.
1
)
.
[SEP]
[CLS]
This
risk
increases
with
age
,
particularly
in
women
over
35
years
of
age
,
and
with
the
number
of
cigarettes
smoked
.
[SEP]
[CLS]
By
Year
3
,
one
or
more
anti
##hy
##pert
##ens
##ive
medications
were
used
in
85
%
of
N
##U
##L
##O
##J
##IX
-
treated
patients
and
92
%
of
c
##y
##c
##los
##por
##ine
-
treated
patients
.
[SEP]
[CLS]
Of
56
patients
who
tested
negative
for
antibodies
during
treatment
and
re
##ass
##essed
approximately
7
half
-
lives
after
disco
##ntin
##uation
of
N
##U
##L
##O
##J
##IX
,
1
tested
anti
##body
positive
.
[SEP]
[CLS]
[
See
Use
in
S
##pecific
Population
##s
(
8
.
4
)
.
]
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
reactions
are
described
in
more
detail
in
the
Warning
##s
and
Pre
##ca
##ution
##s
section
of
the
label
:
*
So
##m
##no
##len
##ce
/
se
##dation
and
di
##zzi
##ness
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
*
R
##LS
:
Most
common
adverse
reactions
(
>
=
10
%
and
at
least
2
times
the
rate
of
place
##bo
)
were
so
##m
##no
##len
##ce
/
se
##dation
and
di
##zzi
##ness
.
[SEP]
[CLS]
For
patients
who
experience
a
sustained
increase
in
blood
pressure
while
receiving
PR
##IS
##TI
##Q
,
either
dose
reduction
or
disco
##ntin
##uation
should
be
considered
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
The
overall
trial
population
had
a
median
age
of
61
years
;
61
%
of
patients
in
the
G
##IL
##OT
##RI
##F
arm
and
60
%
of
patients
in
the
p
##em
##et
##re
##xed
/
c
##is
##p
##lat
##in
arm
were
younger
than
65
years
.
[SEP]
[CLS]
The
ca
##usa
##tive
organisms
for
these
reactions
are
identified
when
provided
by
the
physician
.
[SEP]
[CLS]
The
adverse
reaction
profile
of
T
##EC
##FI
##DE
##RA
in
the
un
##con
##tro
##lled
clinical
studies
was
consistent
with
the
experience
in
the
place
##bo
-
controlled
clinical
trials
.
[SEP]
[CLS]
At
the
first
sign
or
s
##ym
##pt
##om
suggest
##ive
of
PM
##L
,
with
##hold
T
##EC
##FI
##DE
##RA
and
perform
an
appropriate
diagnostic
evaluation
.
[SEP]
[CLS]
H
##yper
##gly
##ce
##mia
and
Di
##abe
##tes
Mel
##lit
##us
H
##yper
##gly
##ce
##mia
,
in
some
cases
extreme
and
associated
with
k
##eto
##ac
##ido
##sis
or
h
##yper
##os
##mo
##lar
coma
or
death
,
has
been
reported
in
patients
treated
with
at
##y
##pical
anti
##psy
##cho
##tics
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
in
adults
(
>
30
%
)
are
headache
,
an
##ore
##xia
,
di
##zzi
##ness
,
as
##the
##nia
,
art
##hra
##l
##gia
and
my
##al
##gia
.
[SEP]
[CLS]
In
a
trial
of
patients
with
moderate
re
##nal
imp
##air
##ment
[
see
Clinical
Studies
(
14
.
3
)
]
,
the
mean
serum
phosphate
levels
increased
by
1
.
2
%
,
5
.
0
%
,
and
9
.
3
%
with
place
##bo
,
IN
##VO
##KA
##NA
100
mg
,
and
IN
##VO
##KA
##NA
300
mg
,
respectively
.
[SEP]
[CLS]
Across
the
34
##7
patients
who
were
random
##ized
to
study
treatment
(
34
##3
received
at
least
one
dose
of
study
treatment
)
,
the
median
age
was
50
years
;
14
%
of
patients
were
older
than
65
years
.
[SEP]
[CLS]
Almost
all
these
patients
had
received
treatment
with
a
##za
##thi
##op
##rine
(
A
##Z
##A
)
or
6
-
me
##rca
##pt
##op
##uri
##ne
(
6
-
MP
)
con
##com
##ita
##ntly
with
a
T
##NF
-
block
##er
at
or
prior
to
diagnosis
.
[SEP]
[CLS]
At
##rio
##vent
##ric
##ular
Block
##s
In
##iti
##ation
of
G
##IL
##EN
##Y
##A
treatment
has
resulted
in
trans
##ient
A
##V
conduct
##ion
delays
.
[SEP]
[CLS]
*
B
##ip
##olar
Di
##sor
##der
P
##ediatric
Pat
##ients
(
Mon
##otherapy
)
:
so
##m
##no
##len
##ce
,
di
##zzi
##ness
,
d
##ys
##ge
##us
##ia
,
oral
par
##est
##hesia
,
nausea
,
increased
appetite
,
fatigue
,
increased
weight
.
[SEP]
[CLS]
5
.
3
D
##ys
##pha
##gia
and
B
##reath
##ing
Di
##ff
##ic
##ult
##ies
Treatment
with
D
##Y
##SP
##OR
##T
(
r
)
and
other
b
##ot
##ulin
##um
to
##xin
products
can
result
in
breathing
difficulties
.
[SEP]
[CLS]
The
median
age
of
patients
was
61
years
(
range
27
-
85
)
,
88
%
were
Caucasian
,
and
78
%
were
male
.
[SEP]
[CLS]
Grades
2
to
4
AL
##T
abnormal
##ities
in
he
##pa
##titis
B
and
/
or
C
co
-
infected
compared
with
HIV
mon
##o
-
infected
subjects
receiving
T
##I
##VI
##CA
##Y
were
observed
in
18
%
vs
.
3
%
with
the
50
-
mg
once
-
daily
dose
and
13
%
vs
.
8
%
with
the
50
-
mg
twice
-
daily
dose
.
[SEP]
[CLS]
Laboratory
abnormal
##ities
observed
in
the
FL
##AM
##ING
##O
trial
were
generally
consistent
with
observations
in
SP
##RI
##NG
-
2
and
S
##ING
##LE
.
[SEP]
[CLS]
The
mechanism
and
clinical
significance
are
unknown
.
[SEP]
[CLS]
In
order
to
reduce
the
com
##plication
of
p
##tosis
the
following
steps
should
be
taken
:
*
A
##vo
##id
injection
near
the
le
##vat
##or
p
##al
##pe
##brae
superior
##is
,
particularly
in
patients
with
larger
brow
de
##press
##or
complexes
.
[SEP]
[CLS]
The
most
common
serious
adverse
reactions
were
serious
infections
(
6
.
0
%
and
5
.
2
%
in
the
groups
receiving
B
##EN
##L
##Y
##ST
##A
and
place
##bo
,
respectively
)
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
5
.
11
He
##pa
##tic
To
##xi
##city
and
He
##pa
##tic
F
##ail
##ure
Case
##s
of
he
##pa
##tic
failure
,
including
fatal
cases
,
have
been
reported
(
<
1
%
)
during
treatment
with
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
Pat
##ients
were
random
##ized
in
a
2
:
1
ratio
and
received
al
##g
##lu
##cos
##idas
##e
al
##fa
or
place
##bo
every
other
week
for
78
weeks
(
18
months
)
.
[SEP]
[CLS]
At
screening
,
the
mean
post
##bro
##nch
##od
##ila
##tor
percent
predicted
F
##E
##V
##1
##was
48
%
(
range
:
14
%
to
87
%
)
,
the
mean
post
##bro
##nch
##od
##ila
##tor
F
##E
##V
##1
/
forced
vital
capacity
(
F
##VC
)
ratio
was
47
%
(
range
:
17
%
to
88
%
)
,
and
the
mean
percent
re
##vers
##ibility
was
14
%
(
range
:
-
41
%
to
152
%
)
.
[SEP]
[CLS]
(
5
.
1
)
5
.
1
La
##ryn
##ge
##al
Attack
##s
Given
the
potential
for
air
##way
o
##bs
##truction
during
acute
la
##ryn
##ge
##al
H
##A
##E
attacks
,
patients
should
be
advised
to
seek
medical
attention
in
an
appropriate
healthcare
facility
immediately
in
addition
to
treatment
with
F
##IR
##A
##Z
##Y
##R
.
[SEP]
[CLS]
All
events
resolved
with
continued
treatment
with
IL
##AR
##IS
.
[SEP]
[CLS]
Investigation
##s
-
Weight
increased
,
liver
function
test
abnormal
,
blood
pro
##la
##ct
##in
increased
.
[SEP]
[CLS]
IL
##AR
##IS
should
not
be
administered
to
any
patients
with
known
clinical
h
##yper
##sen
##si
##ti
##vity
to
IL
##AR
##IS
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
All
other
patients
were
eligible
for
these
studies
if
the
plasma
met
##hot
##re
##xa
##te
level
was
greater
than
10
mum
##ol
/
L
more
than
42
hours
after
the
start
of
the
met
##hot
##re
##xa
##te
or
the
plasma
level
was
greater
than
2
standard
de
##viation
##s
above
the
mean
met
##hot
##re
##xa
##te
ex
##cre
##tion
curve
at
least
12
hours
following
met
##hot
##re
##xa
##te
and
the
serum
c
##rea
##tin
##ine
was
greater
than
1
.
5
times
the
upper
limit
of
normal
or
the
c
##rea
##tin
##ine
clearance
was
less
than
60
m
##L
/
min
at
least
12
hours
following
met
##hot
##re
##xa
##te
administration
.
[SEP]
[CLS]
Table
1
:
Ad
##verse
Re
##actions
O
##cc
##ur
##ring
in
>
=
1
%
of
U
##L
##OR
##IC
-
T
##reate
##d
Pat
##ients
and
at
Lea
##st
0
.
5
%
Greater
than
See
##n
in
Pat
##ients
Re
##ceiving
Place
##bo
in
Control
##led
Studies
Ad
##verse
Re
##actions
Place
##bo
U
##L
##OR
##IC
all
##op
##uri
##no
##l
##O
##f
the
subjects
who
received
all
##op
##uri
##no
##l
,
10
received
100
mg
,
145
received
200
mg
,
and
112
##2
received
300
mg
,
based
on
level
of
re
##nal
imp
##air
##ment
.
[SEP]
[CLS]
J
##E
##V
##TA
##NA
is
con
##tra
##ind
##ica
##ted
in
patients
who
have
a
history
of
severe
h
##yper
##sen
##si
##ti
##vity
reactions
to
cab
##azi
##ta
##xe
##l
or
to
other
drugs
formulated
with
p
##oly
##sor
##bate
80
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
,
Con
##tra
##ind
##ica
##tions
(
4
)
,
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
If
T
##AF
##IN
##LA
##R
is
used
in
combination
with
tram
##eti
##ni
##b
,
do
not
modify
the
dose
of
tram
##eti
##ni
##b
.
[SEP]
[CLS]
5
.
5
U
##rina
##ry
T
##rac
##t
In
##fect
##ions
J
##AR
##DI
##AN
##CE
increases
the
risk
for
u
##rina
##ry
tract
infections
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
T
##AN
##Z
##E
##UM
has
not
been
studied
in
patients
with
a
history
of
pan
##cre
##ati
##tis
to
determine
whether
these
patients
are
at
increased
risk
for
pan
##cre
##ati
##tis
.
[SEP]
[CLS]
Ad
##vise
females
of
reproductive
potential
to
use
effective
con
##tra
##ception
during
treatment
with
X
##AL
##KO
##RI
and
for
at
least
45
days
following
the
final
dose
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
,
8
.
3
)
]
.
[SEP]
[CLS]
It
is
unknown
whether
T
##AN
##Z
##E
##UM
causes
thy
##roid
C
-
cell
tumors
,
including
M
##TC
,
in
humans
[
see
Box
##ed
Warning
,
Con
##tra
##ind
##ica
##tions
(
4
.
1
)
]
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
PR
##O
##GR
##ES
##SI
##VE
M
##U
##LT
##IF
##OC
##AL
L
##E
##U
##KO
##EN
##CE
##P
##HA
##L
##OP
##AT
##H
##Y
(
PM
##L
)
WA
##R
##NI
##NG
:
PR
##O
##GR
##ES
##SI
##VE
M
##U
##LT
##IF
##OC
##AL
L
##E
##U
##KO
##EN
##CE
##P
##HA
##L
##OP
##AT
##H
##Y
(
PM
##L
)
J
##C
virus
infection
resulting
in
PM
##L
and
death
can
occur
in
patients
receiving
AD
##CE
##TR
##IS
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
9
)
,
Ad
##verse
Re
##actions
(
6
.
1
)
]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
PR
##O
##GR
##ES
##SI
##VE
M
##U
##LT
##IF
##OC
##AL
L
##E
##U
##KO
##EN
##CE
##P
##HA
##L
##OP
##AT
##H
##Y
(
PM
##L
)
See
Full
Pre
##s
##cribing
Information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
th
##rom
##boe
##mbo
##lic
complications
may
result
from
increases
in
plate
##let
counts
with
PR
##OM
##AC
##TA
.
[SEP]
[CLS]
Do
##se
modifications
Ad
##verse
reactions
that
led
to
dose
delays
in
more
than
5
%
of
patients
in
Studies
1
and
2
were
ne
##ut
##rop
##enia
(
14
%
)
and
peripheral
sensory
ne
##uro
##pathy
(
11
%
)
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
Three
subjects
experienced
severe
or
life
-
threatening
infections
associated
with
ne
##ut
##rop
##enia
,
and
two
subjects
experienced
life
-
threatening
ne
##ut
##rop
##enia
while
receiving
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
.
[SEP]
[CLS]
In
short
-
term
bi
##pol
##ar
man
##ia
adult
trials
,
s
##ync
##ope
was
reported
in
0
.
3
%
(
1
/
37
##9
)
of
patients
treated
with
therapeutic
doses
(
5
mg
or
10
mg
twice
daily
)
of
SA
##P
##H
##RI
##S
,
compared
to
0
%
(
0
/
203
)
of
patients
treated
with
place
##bo
.
[SEP]
[CLS]
The
most
common
serious
adverse
reactions
were
pneumonia
(
4
%
)
,
p
##yre
##xia
(
4
%
)
,
vomit
##ing
(
3
%
)
,
nausea
(
2
%
)
,
he
##pa
##to
##to
##xi
##city
(
2
%
)
and
peripheral
sensory
ne
##uro
##pathy
(
2
%
)
.
[SEP]
[CLS]
Ren
##al
and
hem
##at
##uria
.
[SEP]
[CLS]
Op
##port
##uni
##stic
infections
,
or
other
op
##port
##uni
##stic
path
##ogen
##s
including
as
##per
##gill
##osis
,
blast
##omy
##cos
##is
,
can
##di
##dia
##sis
,
co
##cci
##dio
##ido
##my
##cos
##is
,
his
##top
##las
##mos
##is
,
leg
##ione
##llo
##sis
,
list
##eri
##osis
,
p
##ne
##um
##oc
##ys
##tosis
and
tuberculosis
have
been
reported
with
T
##NF
block
##ers
.
[SEP]
[CLS]
Report
##ed
th
##rom
##boe
##mbo
##lic
complications
and
were
observed
at
low
and
at
normal
plate
##let
counts
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
incidence
of
antibodies
to
AD
##CE
##TR
##IS
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
(
5
.
3
)
*
H
##yper
##sen
##si
##ti
##vity
Re
##actions
:
Disco
##ntin
##ue
T
##AN
##Z
##E
##UM
if
suspected
.
[SEP]
[CLS]
One
of
these
forms
of
con
##tra
##ception
can
be
a
combined
oral
con
##tra
##ceptive
product
containing
at
least
1
mg
of
nor
##eth
##ind
##rone
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
25
%
)
of
X
##AL
##KO
##RI
in
Studies
1
and
2
are
vision
disorders
,
di
##ar
##r
##hea
,
nausea
,
vomit
##ing
,
con
##st
##ip
##ation
,
ed
##ema
,
elevated
trans
##ami
##nas
##es
,
upper
respiratory
infection
,
decreased
appetite
,
and
d
##ys
##ge
##us
##ia
.
[SEP]
[CLS]
Study
1
,
conducted
by
the
National
Cancer
Institute
(
NC
##I
)
,
enrolled
184
patients
;
safety
information
is
available
for
149
patients
.
[SEP]
[CLS]
If
irritation
per
##sist
##s
,
consult
a
physician
.
[SEP]
[CLS]
Treatment
of
CA
##PS
The
data
described
here
##in
reflect
exposure
to
IL
##AR
##IS
in
104
adult
and
p
##ediatric
CA
##PS
patients
,
including
20
FC
##AS
,
72
MW
##S
,
10
MW
##S
/
NO
##MI
##D
(
Neo
##nat
##al
On
##set
Multi
##sy
##ste
##m
In
##f
##lam
##mat
##ory
Di
##sor
##der
)
overlap
,
1
non
-
FC
##AS
non
-
MW
##S
,
and
1
mi
##s
##dia
##gno
##sed
in
place
##bo
-
controlled
(
35
patients
)
and
un
##con
##tro
##lled
trials
.
[SEP]
[CLS]
Co
##rt
##ico
##ster
##oids
may
be
indicated
until
clinical
symptoms
resolve
.
[SEP]
[CLS]
Di
##ar
##r
##hea
,
nausea
,
and
upper
respiratory
tract
infection
were
the
most
commonly
reported
adverse
reactions
.
[SEP]
[CLS]
(
5
.
4
)
5
.
1
Effects
on
Driving
H
##OR
##I
##Z
##AN
##T
may
cause
significant
driving
imp
##air
##ment
[
see
Clinical
Studies
(
14
.
3
)
]
.
[SEP]
[CLS]
Skin
disco
##lora
##tion
has
been
reported
with
higher
frequency
among
em
##tric
##ita
##bine
-
treated
subjects
;
it
was
manifest
##ed
by
h
##yper
##pi
##gment
##ation
on
the
palms
and
was
generally
mild
and
as
##ym
##pt
##oma
##tic
.
[SEP]
[CLS]
5
.
4
F
##ac
##ial
Anatomy
in
the
Treatment
of
G
##la
##bella
##r
Lines
C
##aut
##ion
should
be
exercised
when
administer
##ing
D
##Y
##SP
##OR
##T
(
r
)
to
patients
with
surgical
alterations
to
the
facial
anatomy
,
excessive
weakness
or
at
##rop
##hy
in
the
target
muscle
(
s
)
,
marked
facial
as
##ym
##metry
,
inflammation
at
the
injection
site
(
s
)
,
p
##tosis
,
excessive
der
##mat
##och
##ala
##sis
,
deep
der
##mal
scar
##ring
,
thick
se
##ba
##ce
##ous
skin
[
see
##D
##osa
##ge
and
Administration
(
2
.
3
]
or
the
inability
to
substantially
less
##en
g
##la
##bella
##r
lines
by
physically
spreading
them
apart
[
see
##C
##lini
##cal
Studies
(
14
.
2
)
]
.
[SEP]
[CLS]
P
##sor
##ia
##tic
art
##hr
##itis
:
During
the
0
to
16
week
place
##bo
-
controlled
period
of
the
3
controlled
clinical
trials
,
1
.
0
%
(
10
/
99
##8
)
of
subjects
treated
with
O
##TE
##Z
##LA
reported
depression
or
depressed
mood
compared
to
0
.
8
%
(
4
/
49
##5
)
treated
with
place
##bo
.
[SEP]
[CLS]
The
ma
##li
##gna
##ncies
occurred
after
a
median
of
30
months
(
range
1
to
84
months
)
after
the
first
dose
of
T
##NF
-
block
##er
therapy
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Card
##iac
toxic
##ities
include
cardiac
failure
and
my
##oc
##ard
##ial
in
##far
##ction
with
fatal
outcome
,
and
my
##oc
##ard
##ial
is
##che
##mia
.
[SEP]
[CLS]
Of
the
patients
in
those
trials
,
approximately
95
%
were
between
18
and
60
years
old
,
approximately
50
%
were
male
,
and
approximately
80
%
were
Caucasian
.
[SEP]
[CLS]
*
B
##ip
##olar
Di
##sor
##der
Adults
(
Mon
##otherapy
)
:
so
##m
##no
##len
##ce
,
di
##zzi
##ness
,
extra
##py
##ram
##idal
symptoms
other
than
aka
##thi
##sia
,
increased
weight
.
[SEP]
[CLS]
IN
##L
##Y
##TA
has
not
been
studied
in
patients
with
evidence
of
un
##tre
##ated
brain
meta
##sta
##sis
or
recent
active
gas
##tro
##int
##est
##inal
bleeding
and
should
not
be
used
in
those
patients
.
[SEP]
[CLS]
5
.
4
De
##my
##elin
##ating
Di
##sor
##ders
Use
of
T
##NF
-
block
##ers
,
of
which
S
##IM
##PO
##NI
ARIA
is
a
member
,
has
been
associated
with
rare
cases
of
ex
##ace
##rb
##ation
of
central
nervous
system
(
C
##NS
)
dem
##ye
##lina
##ting
disorders
,
including
multiple
s
##cle
##rosis
(
MS
)
and
peripheral
dem
##ye
##lina
##ting
disorders
,
including
G
##uil
##lain
-
Barr
##e
syndrome
.
[SEP]
[CLS]
The
most
common
adverse
reactions
reported
for
A
##FI
##NI
##TO
##R
(
incidence
>
=
30
%
)
were
s
##tom
##ati
##tis
and
respiratory
tract
infection
.
[SEP]
[CLS]
Consider
su
##sp
##ending
treatment
with
G
##IL
##EN
##Y
##A
if
a
patient
develops
a
serious
infection
,
and
re
##ass
##ess
the
benefits
and
risks
prior
to
re
##ini
##tia
##tion
of
therapy
.
[SEP]
[CLS]
Monitor
blood
pressure
during
and
following
the
treatment
procedure
.
[SEP]
[CLS]
No
new
major
safety
findings
were
reported
from
a
50
-
week
,
open
-
label
,
un
##con
##tro
##lled
safety
trial
.
[SEP]
[CLS]
(
5
.
3
)
*
Tu
##mor
L
##ys
##is
S
##yn
##drome
:
A
##cute
re
##nal
failure
and
death
;
anti
##ci
##pate
and
use
supportive
measures
.
[SEP]
[CLS]
Study
1
Ad
##verse
reactions
and
laboratory
abnormal
##ities
from
the
C
##LL
trial
(
N
=
48
)
using
single
agent
I
##MB
##R
##U
##VI
##CA
420
mg
daily
occurring
at
a
rate
of
>
=
10
%
are
presented
in
Table
##s
3
and
4
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
the
adverse
reaction
rates
observed
can
not
be
directly
compared
with
rates
in
other
clinical
trials
or
experience
with
therapeutic
##s
in
the
same
class
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Basel
##ine
re
##nal
function
was
normal
or
mildly
impaired
in
88
%
of
patients
and
moderately
impaired
in
11
%
of
patients
(
mean
e
##G
##F
##R
82
m
##L
/
min
/
1
.
73
m
2
)
.
[SEP]
[CLS]
5
.
6
Act
##ivation
of
Man
##ia
/
H
##y
##po
##mani
##a
During
all
MD
##D
phase
2
and
phase
3
studies
,
man
##ia
was
reported
for
approximately
0
.
02
%
of
patients
treated
with
PR
##IS
##TI
##Q
.
[SEP]
[CLS]
The
re
##tina
##l
abnormal
##ities
observed
with
P
##OT
##IG
##A
have
been
reported
in
patients
who
were
originally
enrolled
in
clinical
trials
with
P
##OT
##IG
##A
and
who
have
generally
taken
the
drug
for
a
long
period
of
time
in
2
ongoing
extension
trials
.
[SEP]
[CLS]
c
Includes
the
terms
feeling
cold
and
chill
##s
.
[SEP]
[CLS]
Inter
##rup
##t
B
##L
##IN
##C
##Y
##TO
if
the
trans
##ami
##nas
##es
rise
to
greater
than
5
times
the
upper
limit
of
normal
or
if
bi
##li
##ru
##bin
rises
to
more
than
3
times
the
upper
limit
of
normal
.
[SEP]
[CLS]
Table
3
:
Key
Laboratory
A
##b
##nor
##mal
##ities
O
##cc
##ur
##ring
in
>
10
%
(
All
NC
##I
CT
##CA
##E
Grades
)
of
AL
##K
-
Po
##sitive
Pat
##ients
T
##reate
##d
with
Z
##Y
##KA
##DI
##A
in
Study
1
Z
##Y
##KA
##DI
##AN
=
255
All
Grades
Grade
3
-
4
%
%
He
##mo
##g
##lo
##bin
decreased
84
5
AL
##T
)
increased
80
27
AS
##T
)
increased
75
13
C
##rea
##tin
##ine
increased
58
2
G
##lu
##cos
##e
increased
49
13
Ph
##os
##phate
decreased
36
7
Li
##pas
##e
increased
28
10
B
##ili
##ru
##bin
(
total
)
increased
15
1
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Se
##vere
or
Per
##sist
##ent
Gas
##tro
##int
##est
##inal
To
##xi
##city
:
Do
##se
modification
due
to
di
##ar
##r
##hea
,
nausea
,
vomit
##ing
or
abdominal
pain
occurred
in
38
%
of
patients
.
[SEP]
[CLS]
In
##tra
##c
##rani
##al
hem
##or
##r
##hage
included
sub
##du
##ral
bleed
##s
.
[SEP]
[CLS]
Ad
##verse
reaction
information
for
Fe
##rri
##p
##ro
##x
represents
the
pool
##ed
data
collected
from
64
##2
patients
who
participated
in
single
arm
or
active
-
controlled
clinical
studies
.
[SEP]
[CLS]
Do
##se
reduction
due
to
peripheral
ne
##uro
##pathy
was
required
by
3
%
(
14
/
50
##3
)
of
patients
who
received
H
##AL
##AV
##EN
.
[SEP]
[CLS]
N
##eu
##tral
##izing
antibodies
were
ass
##ay
##ed
for
a
subset
of
70
samples
selected
to
be
representative
of
high
and
low
t
##iter
binding
anti
##body
responses
at
week
12
of
treatment
.
[SEP]
